


**CUMULATIVE
SUPPLEMENT 12**
December 2023



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**Cumulative Supplement 12
December 2023**

CONTENTS

	<i>PAGE</i>
Contents	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT	vi
1.3 APPLICANT NAME CHANGES	vii
1.4 LEVOTHYROXINE SODIUM	ix
1.5 AVAILABILITY OF THE EDITION.....	x
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**CUMULATIVE SUPPLEMENT 12
December 2023**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
AKORN OPERATING CO LLC (AKORN)	HIKMA PHARMACEUTICALS USA INC (HIKMA)
AKORN OPERATING CO LLC (AKORN)	RISING PHARMA HOLDINGS INC (RISING)
ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC)
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)

ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBVIE (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EPIC PHARMA INC (EPIC PHARMA)	EPIC PHARMA LLC (EPIC PHARMA LLC)
EPIC PHARMA INC (EPIC PHARMA INC)	EPIC PHARMA LLC (EPIC PHARMA LLC)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MAYNE PHARMA INC (MAYNE PHARMA INC)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA INTL)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA LLC (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
NEXUS PHARMACEUTICALS INC (NEXUS PHARMS)	NEXUS PHARMACEUTICALS LLC (NEXUS)
STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
TORRENT PHARMA INC (TORRENT)	APOZEAL PHARMACEUTICALS INC (APOZEAL PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0 . 3MG	A076187	-	RS
-----	-----------------------------------	-------	---------	---------	---	----

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST **COUNTS CUMULATIVE BY QUARTER**

<u>CATEGORIES</u>	<u>DEC 2022</u>	<u>MAR 2023</u>	<u>JUN 2023</u>	<u>SEP 2023</u>	<u>DEC 2023</u>
DRUG PRODUCTS	21983	22398	22632	22925	23099
LISTED SINGLE SOURCE	2718 (12.4%)	2759 (12.3%)	2779 (12.3%)	2771 (12.1%)	2784 (12.1%)
MULTISOURCE	19265 (87.6%)	19639 (87.7%)	19853 (87.7%)	20154 (87.9%)	20315 (87.9%)
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)	19781 (87.4%)	20083 (87.6%)	20252 (87.7%)

NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)	72 (0.3%)	71 (0.3%)	63 (0.3%)
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	46 (0.2%)	46 (0.2%)	46 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	8	19	11	20	32
NUMBER OF APPLICANTS	1211	1222	1217	1216	1214

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABACAVIR SULFATE

TABLET;ORAL			
ABACAVIR SULFATE			
>D> AB	HETERO LABS LTD III	EQ 300MG BASE	A 091560 001 Sep 13, 2013 Dec CHRS
>A> AB	!	EQ 300MG BASE	A 091560 001 Sep 13, 2013 Dec CHRS
>D>	ZIAGEN		
>D> AB	+! VIIV HLTHCARE	EQ 300MG BASE	N 020977 001 Dec 17, 1998 Dec DISC
>A>	+ @	EQ 300MG BASE	N 020977 001 Dec 17, 1998 Dec DISC

ABACAVIR SULFATE; LAMIVUDINE

>A>	TABLET, FOR SUSPENSION;ORAL		
>A>	ABACAVIR SULFATE AND LAMIVUDINE		
>A>	+! MYLAN LABS LTD	EQ 60MG BASE;30MG	N 204311 001 Dec 22, 2023 Dec NEWA

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL			
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE			
>D> AB	LUPIN LTD	EQ 300MG BASE;150MG;300MG	A 202912 001 Dec 05, 2013 Dec CHRS
>A>	!	EQ 300MG BASE;150MG;300MG	A 202912 001 Dec 05, 2013 Dec CHRS
>D>	TRIZIVIR		
>D> AB	+! VIIV HLTHCARE	EQ 300MG BASE;150MG;300MG	N 021205 001 Nov 14, 2000 Dec DISC
>A>	+ @	EQ 300MG BASE;150MG;300MG	N 021205 001 Nov 14, 2000 Dec DISC

ABIRATERONE ACETATE

TABLET;ORAL			
ABIRATERONE ACETATE			
AB	DR REDDYS	500MG	A 208416 002 Sep 01, 2023 Aug NEWA
AB	FLORIDA	500MG	A 215086 001 Mar 23, 2023 Mar NEWA
AB	TEVA PHARMS USA	500MG	A 210726 001 Jan 26, 2023 Jan NEWA

ABIRATERONE ACETATE; NIRAPARIB TOSYLATE

TABLET;ORAL			
AKEEGA			
+	JANSSEN BIOTECH	500MG;EQ 50MG BASE	N 216793 001 Aug 11, 2023 Aug NEWA
+!		500MG;EQ 100MG BASE	N 216793 002 Aug 11, 2023 Aug NEWA

ACARBOSE

TABLET;ORAL			
ACARBOSE			
@	DASH PHARMS	25MG	A 091053 001 Jan 06, 2011 Feb CAHN
@		50MG	A 091053 002 Jan 06, 2011 Feb CAHN
@		100MG	A 091053 003 Jan 06, 2011 Feb CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS			
ACETAMINOPHEN			
AP	HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	A 215403 001 May 03, 2023 Apr NEWA
AP	INFORLIFE	1GM/100ML (10MG/ML)	A 215403 001 May 03, 2023 Nov CAHN
AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A 205746 001 Apr 18, 2023 Apr NEWA
@	ZYDUS PHARMS	1GM/100ML (10MG/ML)	A 216467 001 Oct 25, 2022 Mar DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL			
APADAZ			
+	@ KVK TECH INC	325MG;EQ 4.08MG BASE	N 208653 002 Jan 04, 2019 Mar DISC
+	@	325MG;EQ 6.12MG BASE	N 208653 001 Feb 23, 2018 Mar DISC
+	@	325MG;EQ 8.16MG BASE	N 208653 003 Jan 04, 2019 Mar DISC
+	@ ZEVRA THERAP	325MG;EQ 4.08MG BASE	N 208653 002 Jan 04, 2019 Jun CAHN
+	@	325MG;EQ 6.12MG BASE	N 208653 001 Feb 23, 2018 Jun CAHN
+	@	325MG;EQ 8.16MG BASE	N 208653 003 Jan 04, 2019 Jun CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL			
BUTALBITAL AND ACETAMINOPHEN			
@	ALVOGEN	300MG;50MG	A 207635 001 Jun 05, 2017 Aug DISC
AA	NE RX PHARMA	300MG;50MG	A 214955 001 Aug 16, 2022 Sep CAHN
AA	SENORES PHARMS	300MG;50MG	A 214088 001 Apr 07, 2022 Jan CAHN
AA		325MG;25MG	A 214088 002 Apr 07, 2022 Jan CAHN
AA		325MG;50MG	A 214088 003 Apr 07, 2022 Jan CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	RISE PHARMA	300MG;50MG;40MG
AA		325MG;50MG;40MG

A214087	001	Aug 13, 2021	Sep CAHN
A214087	002	Aug 13, 2021	Sep CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

@ LARKEN LABS INC	325MG;30MG;16MG
-------------------	-----------------

A204209	001	Sep 30, 2016	Oct DISC
---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	! GENUS LIFESCIENCES	120MG/5ML;12MG/5ML
----	----------------------	--------------------

A087508	001		Sep CAHN
---------	-----	--	----------

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D> AA	EYWA	300MG;15MG
>D> AA		300MG;30MG
>D> AA		300MG;60MG
	@ NOSTRUM LABS INC	300MG;15MG
	@	300MG;30MG
	+ @	300MG;60MG
>A> AA	WES PHARMA INC	300MG;15MG
>A> AA		300MG;30MG
>A> AA		300MG;60MG

A211610	001	Jun 27, 2019	Dec CAHN
A211610	002	Jun 27, 2019	Dec CAHN
A211610	003	Jun 27, 2019	Dec CAHN
A088629	002	Mar 06, 1985	Apr DISC
A088629	003	Mar 06, 1985	Apr DISC
A088629	001	Mar 06, 1985	Apr DISC
A211610	001	Jun 27, 2019	Dec CAHN
A211610	002	Jun 27, 2019	Dec CAHN
A211610	003	Jun 27, 2019	Dec CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D> AA	EYWA	325MG/15ML;7.5MG/15ML
	@ GENUS	325MG/15ML;7.5MG/15ML
	@ VI STAPHARM	325MG/15ML;7.5MG/15ML
>A> AA	WES PHARMA INC	325MG/15ML;7.5MG/15ML

A211023	001	Mar 08, 2019	Dec CAHN
A200343	001	Jan 25, 2012	Nov CAHN
A200343	001	Jan 25, 2012	Aug DISC
A211023	001	Mar 08, 2019	Dec CAHN

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ NOVEL LABS INC	300MG;5MG
	@	300MG;7.5MG
	@	300MG;10MG
	@	325MG;5MG
	@	325MG;7.5MG
	@	325MG;10MG
	@ SUN PHARM IND S INC	325MG;5MG
	@	325MG;7.5MG
	@	325MG;10MG

A206142	001	Nov 14, 2016	Nov DISC
A206142	002	Nov 14, 2016	Nov DISC
A206142	003	Nov 14, 2016	Nov DISC
A206245	001	Dec 01, 2016	Nov DISC
A206245	002	Dec 01, 2016	Nov DISC
A206245	003	Dec 01, 2016	Nov DISC
A090118	001	Dec 23, 2008	Jun DISC
A090118	002	Dec 23, 2008	Jun DISC
A090118	003	Dec 23, 2008	Jun DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

COMBOGESIC

+ @ AFT PHARMS LTD	325MG;97.5MG
+!	325MG;97.5MG

N209471	001	Mar 01, 2023	Aug DISC
N209471	001	Mar 01, 2023	Mar NEWA

ACETAMINOPHEN; IBUPROFEN SODIUM

SOLUTION;INTRAVENOUS

COMBOGESIC IV

+! AFT PHARMS LTD	1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML)
+! HIKMA	1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML)

N215320	001	Oct 17, 2023	Oct NEWA
N215320	001	Oct 17, 2023	Oct CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

	@ DR REDDYS LABS SA	500MG;7.5MG
	@	650MG;10MG
>D> AA	SUN PHARM IND S INC	325MG;2.5MG
>A>	@	325MG;2.5MG
>D> AA		325MG;5MG
>A>	@	325MG;5MG
>D> AA		325MG;7.5MG
>A>	@	325MG;7.5MG
>D> AA		325MG;10MG

A090177	005	Oct 20, 2008	Apr CAHN
A090177	006	Oct 20, 2008	Apr CAHN
A090535	001	Dec 26, 2013	Dec DISC
A090535	001	Dec 26, 2013	Dec DISC
A090535	002	Dec 26, 2013	Dec DISC
A090535	002	Dec 26, 2013	Dec DISC
A090535	003	Dec 26, 2013	Dec DISC
A090535	003	Dec 26, 2013	Dec DISC
A090535	004	Dec 26, 2013	Dec DISC

TABLET;ORAL OXYCODONE AND ACETAMINOPHEN				
>A>	@	325MG;10MG	A 090535	004 Dec 26, 2013 Dec DISC
<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE</u>				
TABLET;ORAL TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN				
AB	! AMNEAL PHARMS	325MG;37.5MG	A 090485	001 Dec 09, 2009 Mar CHRS
	@ CHARTWELL RX	325MG;37.5MG	A 076475	001 Apr 21, 2005 Oct CAHN
<u>ACETAZOLAMIDE</u>				
CAPSULE, EXTENDED RELEASE;ORAL ACETAZOLAMIDE				
AB	INDICUS PHARMA	500MG	A 090779	001 Jul 14, 2011 Feb CMFD
TABLET;ORAL ACETAZOLAMIDE				
AB	AARKISH PHARMS NJ	125MG	A 217197	001 May 09, 2023 Apr NEWA
AB		250MG	A 217197	002 May 09, 2023 Apr NEWA
AB	AJANTA PHARMA LTD	125MG	A 211151	001 Sep 11, 2023 Sep NEWA
AB		250MG	A 211151	002 Sep 11, 2023 Sep NEWA
	@ BRECKENRIDGE	125MG	A 207503	001 Apr 30, 2020 Jan DISC
	@	250MG	A 207503	002 Apr 30, 2020 Jan DISC
AB	NE RX PHARMA	125MG	A 217197	001 May 09, 2023 Sep CAHN
AB		250MG	A 217197	002 May 09, 2023 Sep CAHN
AB	ZYDUS	125MG	A 211069	001 Apr 04, 2023 Mar NEWA
AB		250MG	A 211069	002 Apr 04, 2023 Mar NEWA
<u>ACETIC ACID, GLACIAL</u>				
SOLUTION/DROPS;OTIC ACETIC ACID				
	@ CHARTWELL RX	2%	A 040166	001 Jul 26, 1996 Jan CAHN
VOSOL				
AT	! HIKMA	2%	N 012179	001 Sep CAHN
<u>ACETIC ACID, GLACIAL; HYDROCORTISONE</u>				
SOLUTION/DROPS;OTIC HYDROCORTISONE AND ACETIC ACID				
>D>	@ COSETTE	2%;1%	A 040609	001 Feb 06, 2006 Dec CMFD
>A>	AT	2%;1%	A 040609	001 Feb 06, 2006 Dec CMFD
	@	2%;1%	A 040609	001 Feb 06, 2006 Jun DISC
AT	+! TARO	2%;1%	A 088759	001 Mar 04, 1985 Jun CHRS
AT	+	2%;1%	A 088759	001 Mar 04, 1985 Jun CRLD
	VOSOL HC			
AT	+! SAFTALIS PHARMS	2%;1%	N 012770	001 Oct CAHN
<u>ACETYLCYSTEINE</u>				
INJECTABLE; INTRAVENOUS ACETYLCYSTEINE				
AP	STERISCIENCE	6GM/30ML (200MG/ML)	A 217182	001 Apr 19, 2023 Apr NEWA
SOLUTION; INHALATION, ORAL ACETYLCYSTEINE				
AN	EXELA PHARMA	20%	A 205643	001 Nov 01, 2023 Oct NEWA
<u>ACYCLOVIR</u>				
CAPSULE;ORAL ACYCLOVIR				
AB	@ AUROBINDO PHARMA USA	200MG	A 074727	001 Apr 22, 1997 May CAHN
	INDOCO	200MG	A 075090	001 Jan 26, 1999 Sep CAHN
CREAM;TOPICAL ACYCLOVIR				
AB	ALEMBIC	5%	A 212361	001 Nov 21, 2023 Nov NEWA
AB	ZYDUS LIFESCIENCES	5%	A 206770	001 Feb 28, 2023 Feb NEWA
SUSPENSION;ORAL ACYCLOVIR				
AB	AUROBINDO PHARMA	200MG/5ML	A 216331	001 Mar 31, 2022 Oct CMFD
AB	CHARTWELL RX	200MG/5ML	A 212718	001 Apr 23, 2020 Aug CAHN
AB	MSN	200MG/5ML	A 217393	001 Mar 09, 2023 Mar NEWA
AB	! NOVITIUM PHARMA	200MG/5ML	A 212252	001 Jul 10, 2020 May CHRS
	@ VISTAPHARM	200MG/5ML	A 213951	001 Jan 11, 2021 Oct DISC
	ZOVIRAX			
	+ @ MYLAN	200MG/5ML	N 019909	001 Dec 22, 1989 May DISC

TABLET;BUCCAL SITAVIG			N 203791	001	Apr 12, 2013	Sep CAHN
+!	LNHC	50MG				
TABLET;ORAL ACYCLOVIR			A 075211	001	Sep 28, 1998	Apr CAHN
@	AUROBINDO PHARMA USA	400MG	A 075211	002	Sep 28, 1998	Apr CAHN
@		800MG				
<u>ACYCLOVIR SODIUM</u>						
INJECTABLE; INJECTION ACYCLOVIR SODIUM						
>A>	AP	HAINAN POLY	EQ 50MG BASE/ML		A 218111	001 Jan 08, 2024 Dec NEWA
<u>ADAPALENE</u>						
GEL;TOPICAL ADAPALENE						
AB		ENCUBE ETHICALS	0.3%		A 200298	001 Jun 14, 2012 Apr CMFD
<u>ADAPALENE; BENZOYL PEROXIDE</u>						
GEL;TOPICAL ADAPALENE AND BENZOYL PEROXIDE						
AB		ENCUBE	0.1%;2.5%		A 206164	001 May 23, 2018 Aug CMFD
<u>ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>						
GEL;TOPICAL CABTREO						
+!	BAUSCH	0.15%;3.1%;1.2%			N 216632	001 Oct 20, 2023 Oct NEWA
<u>ADENOSINE</u>						
SOLUTION;INTRAVENOUS ADENOSINE						
>D>	AP	! HONG KONG	60MG/20ML (3MG/ML)		A 077425	001 Aug 29, 2013 Dec CAHN
	AP	!	60MG/20ML (3MG/ML)		A 077425	001 Aug 29, 2013 Sep CAHN
>D>	AP	!	90MG/30ML (3MG/ML)		A 077425	002 Aug 29, 2013 Dec CAHN
	AP	!	90MG/30ML (3MG/ML)		A 077425	002 Aug 29, 2013 Sep CAHN
>A>	AP	! MEITHEAL	60MG/20ML (3MG/ML)		A 077425	001 Aug 29, 2013 Dec CAHN
>A>	AP	!	90MG/30ML (3MG/ML)		A 077425	002 Aug 29, 2013 Dec CAHN
<u>ALBENDAZOLE</u>						
TABLET;ORAL ALBENDAZOLE						
@	CHARTWELL RX	200MG			A 211636	001 Jun 10, 2020 May CAHN
@	CIPLA LTD	200MG			A 210434	001 Sep 21, 2018 Sep DISC
<u>ALBUTEROL SULFATE</u>						
SOLUTION;INHALATION ALBUTEROL SULFATE						
AN	! RITEDOSE CORP	EQ 0.021% BASE			A 214531	001 Dec 28, 2021 Jun CHRS
AN	SENTISS	EQ 0.5% BASE			A 074543	001 Jan 15, 1998 Jul CAHN
TABLET;ORAL ALBUTEROL SULFATE						
AB	DASH PHARMS NATCO	EQ 2MG BASE			A 072894	002 Jan 17, 1991 Feb CAHN
AB	!	EQ 4MG BASE			A 072894	001 Jan 17, 1991 Feb CAHN
<u>ALBUTEROL SULFATE; BUDESONIDE</u>						
AEROSOL, METERED;INHALATION AIRSUPRA						
+!	ASTRAZENECA	EQ 90MCG BASE/INH;80MCG/INH			N 214070	001 Jan 10, 2023 Feb CAHN
+!	BOND	EQ 90MCG BASE/INH;80MCG/INH			N 214070	001 Jan 10, 2023 Jan NEWA
<u>ALENDRONATE SODIUM</u>						
SOLUTION;ORAL ALENDRONATE SODIUM						
AA	! HIKMA	EQ 70MG BASE/75ML			A 090520	001 Feb 25, 2013 May CTEC
AA	NOVITIUM PHARMA	EQ 70MG BASE/75ML			A 214512	001 May 11, 2023 May NEWA
TABLET;ORAL ALENDRONATE SODIUM						
@	ANDA REPOSITORY	EQ 5MG BASE			A 079049	003 Aug 04, 2008 Sep CAHN
@		EQ 10MG BASE			A 079049	004 Aug 04, 2008 Sep CAHN
@		EQ 35MG BASE			A 079049	001 Aug 04, 2008 Sep CAHN
@		EQ 70MG BASE			A 079049	002 Aug 04, 2008 Sep CAHN

TABLET;ORAL

ALENDRONATE SODIUM

@ CHARTWELL RX	EQ 5MG BASE
@	EQ 10MG BASE
@	EQ 35MG BASE
@	EQ 70MG BASE

A079049	003	Aug 04, 2008	Nov CAHN
A079049	004	Aug 04, 2008	Nov CAHN
A079049	001	Aug 04, 2008	Nov CAHN
A079049	002	Aug 04, 2008	Nov CAHN

TABLET, EFFERVESCENT;ORAL

BINOSTO

+! RADIUS	EQ 70MG BASE
-----------	--------------

N202344	001	Mar 12, 2012	Oct CAHN
---------	-----	--------------	----------

ALFENTANIL HYDROCHLORIDEINJECTABLE; INJECTION

ALFENTA

AP	+!	RISING	EQ 0.5MG BASE/ML
----	----	--------	------------------

N019353	001	Dec 29, 1986	Sep CAHN
---------	-----	--------------	----------

ALLOPURINOLTABLET;ORAL

ALLOPURINOL

AB	ACCORD HLTHCARE	300MG	A203154	002	May 06, 2013	Jul CHRS
>A>	@ AIPING PHARM INC	100MG	A070268	001	Dec 31, 1985	Dec CAHN
>D>	@ FOSUN PHARMA	100MG	A070268	001	Dec 31, 1985	Dec CAHN
AB	HETERO LABS LTD V	100MG	A217748	001	Aug 03, 2023	Jul NEWA
AB		300MG	A217748	002	Aug 03, 2023	Jul NEWA
>A> AB	LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Dec NEWA
>A> AB		300MG	A211807	002	Dec 14, 2023	Dec NEWA
AB	! UNICHEM	300MG	A211820	002	Mar 12, 2019	Jul CHRS

ALOSETRON HYDROCHLORIDETABLET;ORAL

ALOSETRON HYDROCHLORIDE

>D> AB	HIKMA	EQ 0.5MG BASE	A200652	001	May 04, 2015	Dec DISC
>A>	@	EQ 0.5MG BASE	A200652	001	May 04, 2015	Dec DISC
>D> AB		EQ 1MG BASE	A200652	002	May 04, 2015	Dec DISC
>A>	@	EQ 1MG BASE	A200652	002	May 04, 2015	Dec DISC

ALPROSTADILINJECTABLE; INJECTION

ALPROSTADIL

>D> AP	HONG KONG	0.5MG/ML	A075196	001	Apr 30, 1999	Dec CAHN
AP		0.5MG/ML	A075196	001	Apr 30, 1999	Sep CAHN
>A> AP	MEITHEAL	0.5MG/ML	A075196	001	Apr 30, 1999	Dec CAHN

ALVIMOPANCAPSULE;ORAL

ALVIMOPAN

AB	HIKMA	12MG	A217753	001	Aug 31, 2023	Aug NEWA
AB	PAR PHARM	12MG	A216843	001	Jan 24, 2023	Jan NEWA
AB	! WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019	Jun CHRS
	ENTEREG					
+ @	CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Jun DISC

AMANTADINE HYDROCHLORIDECAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	RISING	100MG	A210129	001	Mar 02, 2020	Sep CAHN
AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	Feb CTEC

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	! AUROBINDO PHARMA USA	50MG/5ML	A074170	001	Oct 28, 1994	Jul CAHN
AA	ELYSIUM	50MG/5ML	A214178	001	Aug 20, 2021	Sep CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB	ATHEM	100MG	A210215	001	Mar 10, 2020	Sep CAHN
AB	STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Feb CTEC

AMIFOSTINEINJECTABLE; INJECTION

AMIFOSTINE

@ SUN PHARM	500MG/VIAL
ETHYOL	

A077126	001	Mar 14, 2008	Jul DISC
---------	-----	--------------	----------

+! CLINIGEN	500MG/VIAL
-------------	------------

N020221	001	Dec 08, 1995	Jul CTEC
---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>D>	! HIKMA	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Feb CTEC
	@ HONG KONG	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Dec CAHN
	@	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Sep CAHN
>D> AP		EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Dec CAHN
AP		EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Sep CAHN
>A>	@ MEITHEAL	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Dec CAHN
>A> AP		EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Dec CAHN

AMINOCAPROIC ACID

SOLUTION; ORAL

AMICAR

AA	+! HIKMA	0.25GM/ML	N015230	002		Sep CAHN
	AMINOCAPROIC ACID					
>A> AA	SUNNY	0.25GM/ML	A213213	001	Dec 27, 2023	Dec NEWA
AA	TARO	0.25GM/ML	A214458	001	Mar 24, 2023	May CAHN
AA	TARO PHARMS	0.25GM/ML	A214458	001	Mar 24, 2023	Mar NEWA
	@ VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Mar DISC
	TABLET; ORAL					
	AMICAR					
AB	+ HIKMA	500MG	N015197	001		Sep CAHN
AB	+	1GM	N015197	002	Jun 24, 2004	Sep CAHN
	AMINOCAPROIC ACID					
AB	MSN	1GM	A212938	002	Sep 13, 2023	Sep NEWA

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@ CHARTWELL MOLECULAR	100MG	A084588	001		Jul CAHN
@	200MG	A084588	002		Jul CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	CHARTWELL RX	100MG	A077069	003	Oct 04, 2016	Jun CAHN
AB		200MG	A077069	001	Apr 08, 2005	Jun CAHN
AB		400MG	A077069	002	Apr 08, 2005	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CHEMISTRY HLTH	10MG	A216243	001	Jun 06, 2022	Sep CAHN
AB		25MG	A216243	002	Jun 06, 2022	Sep CAHN
AB		50MG	A216243	003	Jun 06, 2022	Sep CAHN
AB		75MG	A216243	004	Jun 06, 2022	Sep CAHN
AB		100MG	A216243	005	Jun 06, 2022	Sep CAHN
AB		150MG	A216243	006	Jun 06, 2022	Sep CAHN
AB	GRAVITI PHARMS	10MG	A217411	001	May 19, 2023	May NEWA
AB		25MG	A217411	002	May 19, 2023	May NEWA
AB		50MG	A217411	003	May 19, 2023	May NEWA
AB		75MG	A217411	004	May 19, 2023	May NEWA
AB		100MG	A217411	005	May 19, 2023	May NEWA
AB		150MG	A217411	006	May 19, 2023	May NEWA
AB	RISING	10MG	A217411	001	May 19, 2023	Aug CAHN
AB		25MG	A217411	002	May 19, 2023	Aug CAHN
AB		50MG	A217411	003	May 19, 2023	Aug CAHN
AB		75MG	A217411	004	May 19, 2023	Aug CAHN
AB		100MG	A217411	005	May 19, 2023	Aug CAHN
AB		150MG	A217411	006	May 19, 2023	Aug CAHN
AB	RUBICON	10MG	A215376	001	May 01, 2023	Apr NEWA
AB		25MG	A215376	002	May 01, 2023	Apr NEWA
AB		50MG	A215376	003	May 01, 2023	Apr NEWA
AB		75MG	A215376	004	May 01, 2023	Apr NEWA
AB		100MG	A215376	005	May 01, 2023	Apr NEWA
AB		150MG	A215376	006	May 01, 2023	Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Sep CAHN
@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Sep CAHN
LIMBITROL					
+ @ CHARTWELL RX	EQ 12.5MG BASE;5MG	N016949	001		Mar CAHN
LIMBITROL DS					
+ @ CHARTWELL RX	EQ 25MG BASE;10MG	N016949	002		Mar CAHN

AMLODIPINE BENZOATE

SUSPENSION;ORAL

AMLODIPINE BENZOATE

@ AMNEAL	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023	Jun DISC
AB	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023	Jun NFTG
KATERZIA					
+! AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jun CTEC
AB	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jun CFTG

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb CAHN
AB		EQ 5MG BASE	A076719	002	May 23, 2007	Feb CAHN
AB		EQ 10MG BASE	A076719	003	May 23, 2007	Feb CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

LOTREL

AB	+ SANDOZ	EQ 2.5MG BASE;10MG	N020364	002	Mar 03, 1995	Sep CAHN
AB	+	EQ 5MG BASE;10MG	N020364	003	Mar 03, 1995	Sep CAHN
AB	+	EQ 5MG BASE;20MG	N020364	004	Mar 03, 1995	Sep CAHN
AB	+	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	Sep CAHN
AB	+	EQ 10MG BASE;20MG	N020364	005	Jun 20, 2002	Sep CAHN
AB	+!	EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	Sep CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

>D> AP	SHERTECH LABS LLC	3.75mCi-260mCi/ML	A204366	001	Sep 19, 2014	Dec DISC
>A>	@	3.75mCi-260mCi/ML	A204366	001	Sep 19, 2014	Dec DISC
	@ SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	May DISC

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

@ CHARTWELL RX	125MG/5ML	A062059	001		Jan CAHN
@	250MG/5ML	A062059	002		Jan CAHN

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PAK

+! PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	Nov CMFD
------------	--------------------------	---------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	DEVA HOLDING AS	250MG/5ML;EQ 62.5MG BASE/5ML	A210374	001	Nov 29, 2023	Nov NEWA
>A> AB		400MG/5ML;EQ 57MG BASE/5ML	A210416	001	Dec 11, 2023	Dec NEWA
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A209351	001	Sep 13, 2023	Sep NEWA

>A> AB	MICRO LABS	600MG/5ML;EQ 42.9MG BASE/5ML	A217805	001	Dec 08, 2023	Dec NEWA
	TABLET;ORAL					

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	DEVA HOLDING AS	500MG;EQ 125MG BASE	A209992	001	Sep 15, 2023	Sep NEWA
		875MG;EQ 125MG BASE	A209991	001	Sep 15, 2023	Sep NEWA

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEBZNA DUAL PAK

+! PHATHOM

500MG;EQ 20MG BASE

N215153 001 May 03, 2022 Nov CMFD

AMPHETAMINETABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
ADZENYS XR-ODT

>D>	AB	+ NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Dec CTEC
>A>		+ AB	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Dec CTEC
		+ AB	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jun CFTG
>D>	AB	+ AB	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Dec CTEC
>A>		+ AB	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Dec CTEC
		+ AB	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jun CFTG
>D>	AB	+ AB	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Dec CTEC
>A>		+ AB	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Dec CTEC
		+ AB	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jun CFTG
>D>	AB	+ AB	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Dec CTEC
>A>		+ AB	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Dec CTEC
		+ AB	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jun CFTG
>D>	AB	+ AB	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Dec CTEC
>A>		+ AB	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Dec CTEC
		+ AB	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jun CFTG
>D>	AB	+ AB	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Dec CTEC
>A>		+ AB	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Dec CTEC
		+ AB	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jun CFTG
>D>		AMPHETAMINE					
>D>	AB	ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Dec DISC
>A>		@ AB	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Dec DISC
		@ AB	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jun NFTG
>D>	AB		EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Dec DISC
>A>		@ AB	EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Dec DISC
		@ AB	EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jun NFTG
>D>	AB		EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Dec DISC
>A>		@ AB	EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Dec DISC
		@ AB	EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jun NFTG
>D>	AB		EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Dec DISC
>A>		@ AB	EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Dec DISC
		@ AB	EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jun NFTG
>D>	AB		EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Dec DISC
>A>		@ AB	EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Dec DISC
		@ AB	EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jun NFTG
>D>	AB		EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Dec DISC
>A>		@ AB	EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Dec DISC
		@ AB	EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jun NFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
AB		1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan NEWA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Feb CTNA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan NEWA
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
AB	@	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CTNA
AB	@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
AB	@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CMFD

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	@	3.75MG;3.75MG;3.75MG;3.75MG 5MG;5MG;5MG;5MG	A214403 003 Nov 26, 2021	Feb CTNA
AB	@	5MG;5MG;5MG;5MG	A214403 004 Nov 26, 2021	Feb CMFD
AB	@	6.25MG;6.25MG;6.25MG;6.25MG	A214403 005 Nov 26, 2021	Feb CTNA
AB	@	6.25MG;6.25MG;6.25MG;6.25MG	A214403 005 Nov 26, 2021	Feb CTNA
AB	@	7.5MG;7.5MG;7.5MG;7.5MG	A214403 006 Nov 26, 2021	Feb CMFD
AB	SPECGX LLC	3.125MG;3.125MG;3.125MG;3.125MG 6.25MG;6.25MG;6.25MG;6.25MG	A211546 001 Aug 31, 2023	Aug NEWA
AB		9.375MG;9.375MG;9.375MG;9.375MG	A211546 002 Aug 31, 2023	Aug NEWA
AB		12.5MG;12.5MG;12.5MG;12.5MG	A211546 003 Aug 31, 2023	Aug NEWA
AB	SUN PHARM INDs INC	3.125MG;3.125MG;3.125MG;3.125MG 6.25MG;6.25MG;6.25MG;6.25MG	A215997 001 Sep 27, 2023	Sep NEWA
AB		9.375MG;9.375MG;9.375MG;9.375MG	A215997 002 Sep 27, 2023	Sep NEWA
AB		12.5MG;12.5MG;12.5MG;12.5MG	A215997 003 Sep 27, 2023	Sep NEWA
AB	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG 6.25MG;6.25MG;6.25MG;6.25MG	A210876 001 Jan 31, 2022	Sep CMFD
AB		9.375MG;9.375MG;9.375MG;9.375MG	A210876 002 Jan 31, 2022	Sep CMFD
AB		12.5MG;12.5MG;12.5MG;12.5MG	A210876 003 Jan 31, 2022	Sep CMFD
	MYDAYIS		A210876 004 Jan 31, 2022	Sep CMFD
AB	+ TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG 6.25MG;6.25MG;6.25MG;6.25MG	N022063 001 Jun 20, 2017	Aug CTEC
AB	+	9.375MG;9.375MG;9.375MG;9.375MG	N022063 002 Jun 20, 2017	Aug CTEC
AB	+!	12.5MG;12.5MG;12.5MG;12.5MG	N022063 003 Jun 20, 2017	Aug CTEC
	N022063 004 Jun 20, 2017	Aug CTEC		

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ALKEM LABS LTD	1.25MG;1.25MG;1.25MG;1.25MG 1.875MG;1.875MG;1.875MG;1.875MG	A217787 001 Oct 06, 2023	Sep NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217787 002 Oct 06, 2023	Sep NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A217787 003 Oct 06, 2023	Sep NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217787 004 Oct 06, 2023	Sep NEWA
AB		5MG;5MG;5MG;5MG	A217787 005 Oct 06, 2023	Sep NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A217787 006 Oct 06, 2023	Sep NEWA
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG 1.875MG;1.875MG;1.875MG;1.875MG	A215565 001 Jul 08, 2022	Feb CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565 002 Jul 08, 2022	Feb CMFD
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565 003 Jul 08, 2022	Feb CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565 004 Jul 08, 2022	Feb CMFD
AB		5MG;5MG;5MG;5MG	A215565 005 Jul 08, 2022	Feb CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565 006 Jul 08, 2022	Feb CMFD
			A215565 007 Jul 08, 2022	Feb CMFD

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	@ STERISCIENCE	EQ 250MG BASE/VIAL	A201025 001 Apr 09, 2014	Jan CAHN
AP	@	EQ 500MG BASE/VIAL	A201025 002 Apr 09, 2014	Jan CAHN
AP		EQ 1GM BASE/VIAL	A201025 003 Apr 09, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL	A201025 004 Apr 09, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL	A202198 001 Apr 07, 2014	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP	STERISCIENCE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024 001 Apr 07, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024 002 Apr 07, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197 001 Apr 07, 2014	Jan CAHN
	UNASYN			
>D> AP	! PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901 002 Feb 27, 1992	Dec DISC
>A>	@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901 002 Feb 27, 1992	Dec DISC
>D> AP	!	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901 001 Nov 23, 1988	Dec DISC
>A>	@	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901 001 Nov 23, 1988	Dec DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

AB	AUROBINDO PHARMA	EQ 250MG BASE	A216554 001 Oct 31, 2023	Oct NEWA
AB		EQ 500MG BASE	A216554 002 Oct 31, 2023	Oct NEWA
AB	! SANDOZ	EQ 500MG BASE	A064082 002 Aug 29, 1995	Oct CTEC

CAPSULE;ORAL
PRINCIPEN '250'
+ @ APOTHECON EQ 250MG BASE N 050056 001 Jul CRLD
PRINCIPEN '500'
+ @ APOTHECON EQ 500MG BASE N 050056 002 Jul CRLD

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL
ANAGRELIDE HYDROCHLORIDE
© NATCO PHARMA USA EQ 0.5MG BASE A 076811 001 Apr 18, 2005 Aug CAHN
© EQ 1MG BASE A 076811 002 Apr 18, 2005 Aug CAHN

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE
© ANDA REPOSITORY 1MG A 090732 001 Jun 28, 2010 Sep CAHN
© CHARTWELL RX 1MG A 090732 001 Jun 28, 2010 Nov CAHN

APATITAMIDE

TABLET;ORAL
ERLEADA
+ JANSSEN BIOTECH 60MG N210951 001 Feb 14, 2018 Feb CHRIS
+ 240MG N210951 002 Feb 17, 2023 Feb NEWA

ARTIKEL

TABLET;ORAL							
APIXABAN							
@ AUROBINDO PHARMA LTD	2.5MG		A210026	001	May 26, 2023	Jun	DISC
	2.5MG		A210026	001	May 26, 2023	May	NEWA
@	5MG		A210026	002	May 26, 2023	Jun	DISC
	5MG		A210026	002	May 26, 2023	May	NEWA
HETERO LABS LTD V	2.5MG		A210066	001	Nov 21, 2023	Nov	NEWA
	5MG		A210066	002	Nov 21, 2023	Nov	NEWA
@ ZYDUS PHARMS	2.5MG		A210185	001	Feb 27, 2023	Jul	DISC
	2.5MG		A210185	001	Feb 27, 2023	Feb	NEWA
@	5MG		A210185	002	Feb 27, 2023	Jul	DISC
	5MG		A210185	002	Feb 27, 2023	Feb	NEWA

APOMORPHINE HYDROCHLORIDE

FILM;SUBLINGUAL
KYNMOBI
+ @ SUMITOMO PHARMA AM 10MG N210875 001 May 21, 2020 Jul CAHN
+ @ 15MG N210875 002 May 21, 2020 Jul CAHN
+ @ 20MG N210875 003 May 21, 2020 Jul CAHN
+ @ 25MG N210875 004 May 21, 2020 Jul CAHN
+ @ 30MG N210875 005 May 21, 2020 Jul CAHN
+ @ SUNOVION PHARMS INC 10MG N210875 001 May 21, 2020 Jul DISC
+ @ 15MG N210875 002 May 21, 2020 Jul DISC
+ @ 20MG N210875 003 May 21, 2020 Jul DISC
+ @ 25MG N210875 004 May 21, 2020 Jul DISC
+ @ 30MG N210875 005 May 21, 2020 Jul DISC

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
 IOPIDINE
 +! HARROW EYE EQ 0.5% BASE N 020258 001 Jul 30, 1993 May CAHN
 +! EQ 1% BASE N 019779 001 Dec 31, 1987 May CAHN

APREMTI LAST

TABLET; ORAL APREMILAST							
ANNORA	10MG		A211878	001	Jul 26, 2023	Jul	NEWA
	20MG		A211878	002	Jul 26, 2023	Jul	NEWA
	30MG		A211878	003	Jul 26, 2023	Jul	NEWA
© AUROBINDO PHARMA LTD	10MG		A211716	001	Jul 19, 2023	Aug	DISC
	10MG		A211716	001	Jul 19, 2023	Jul	NEWA
©	20MG		A211716	002	Jul 19, 2023	Aug	DISC
	20MG		A211716	002	Jul 19, 2023	Jul	NEWA
©	30MG		A211716	003	Jul 19, 2023	Aug	DISC
	30MG		A211716	003	Jul 19, 2023	Jul	NEWA
© DR REDDYS	10MG		A211756	001	Jul 14, 2023	Oct	DISC
	10MG		A211756	001	Jul 14, 2023	Jul	NEWA

TABLET;ORAL
APREMILAST

AB	@	20MG	A211756	002	Jul 14, 2023	Oct DISC
		20MG	A211756	002	Jul 14, 2023	Jul NEWA
AB	@	30MG	A211756	003	Jul 14, 2023	Oct DISC
		30MG	A211756	003	Jul 14, 2023	Jul NEWA
AB	GLENMARK PHARMS LTD	10MG	A211674	001	Oct 16, 2023	Oct NEWA
AB		20MG	A211674	002	Oct 16, 2023	Oct NEWA
AB		30MG	A211674	003	Oct 16, 2023	Oct NEWA
AB	SHILPA	10MG	A211774	001	Apr 07, 2023	Mar NEWA
AB		20MG	A211774	002	Apr 07, 2023	Mar NEWA
AB		30MG	A211774	003	Apr 07, 2023	Mar NEWA
	TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb DISC
	@	20MG	A211897	002	Aug 18, 2022	Feb DISC
	@	30MG	A211897	003	Aug 18, 2022	Feb DISC

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION
ARFORMOTEROL TARTRATE

AN	RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb CMFD
----	---------------	---------------------	---------	-----	--------------	----------

ARGATROBAN

INJECTABLE;INJECTION
ARGATROBAN

AP	GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A217848	001	Jul 31, 2023	Jul NEWA
AP	! HOSPIRA	250MG/2.5ML (100MG/ML)	A204120	001	Sep 21, 2016	Sep CHRS
	+ @ SANDOZ	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Sep DISC
AP	+!	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	May CAHN

ARIPIPRAZOLE

SOLUTION;ORAL
ARIPIPRAZOLE

AA	CHARTWELL RX	1MG/ML	A215595	001	Oct 25, 2022	May CAHN
AA	HETERO LABS LTD III	1MG/ML	A216150	001	Nov 01, 2023	Oct NEWA

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILITY ASIMTUFII

+ OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023	Apr NEWA
+!	960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023	Apr NEWA

TABLET;ORAL
ARIPIPRAZOLE

AB	BRECKENRIDGE	2MG	A091279	001	Jan 09, 2017	Sep CAHN
AB		5MG	A091279	002	Jan 09, 2017	Sep CAHN
AB		10MG	A091279	003	Jan 09, 2017	Sep CAHN
AB		15MG	A091279	004	Jan 09, 2017	Sep CAHN
AB		20MG	A091279	005	Jan 09, 2017	Sep CAHN
AB		30MG	A091279	006	Jan 09, 2017	Sep CAHN
AB	SUNSHINE	2MG	A213037	001	Oct 02, 2023	Sep NEWA
AB		5MG	A213037	002	Oct 02, 2023	Sep NEWA
AB		10MG	A213037	003	Oct 02, 2023	Sep NEWA

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

@ COREPHARMA	50MG	A201514	001	Mar 25, 2019	Feb CAHN
@	150MG	A201514	002	Mar 25, 2019	Feb CAHN
@	250MG	A201514	003	Mar 25, 2019	Feb CAHN

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
ARSENIC TRIOXIDE

AP	ORBICULAR	1MG/ML	A217413	001	Apr 20, 2023	Apr NEWA
AP		2MG/ML	A217413	002	Apr 20, 2023	Apr NEWA
AP	PENN LIFE	1MG/ML	A209873	001	May 06, 2019	May CAHN

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

+ @ ESPERO	162.5MG	N200671	001	Sep 04, 2015	Aug DISC
+ @ HESP	162.5MG	N200671	001	Sep 04, 2015	Oct CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL
CARISOPRODOL AND ASPIRIN
@ CHARTWELL RX 325MG;200MG A089594 001 Mar 31, 1989 Mar CAHN

ASPIRIN; METHOCARBAMOL

TABLET;ORAL
ROBAXISAL
+ @ ROBINS AH 325MG;400MG N012281 001 Mar CRLD

ATAZANAVIR SULFATE

CAPSULE;ORAL
ATAZANAVIR SULFATE
@ CIPLA EQ 100MG BASE A200626 001 Aug 09, 2018 Aug DISC
@ EQ 150MG BASE A200626 002 Aug 09, 2018 Aug DISC
@ EQ 200MG BASE A200626 003 Aug 09, 2018 Aug DISC
@ EQ 300MG BASE A200626 004 Aug 09, 2018 Aug DISC

ATENOLOL

TABLET;ORAL
ATENOLOL
AB TWI PHARMS 25MG A072304 002 Jul 31, 1992 Nov CAHN
AB 50MG A072304 003 Jul 18, 1988 Nov CAHN
AB 100MG A072304 001 Jul 15, 1988 Nov CAHN
TENORMIN
AB + TWI PHARMS 25MG N018240 004 Apr 09, 1990 Nov CAHN
AB + 50MG N018240 001 Nov CAHN
AB +! 100MG N018240 002 Nov CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL
ATENOLOL AND CHLORTHALIDONE
@ AUROBINDO PHARMA USA 50MG;25MG A074203 001 Oct 31, 1993 Apr CAHN
@ 100MG;25MG A074203 002 Oct 31, 1993 Apr CAHN
AB TWI PHARMS 50MG;25MG A072302 002 May 31, 1990 Nov CAHN
AB 100MG;25MG A072302 001 May 31, 1990 Nov CAHN
TENORETIC 100
AB +! TWI PHARMS 100MG;25MG N018760 001 Jun 08, 1984 Nov CAHN
TENORETIC 50
AB + TWI PHARMS 50MG;25MG N018760 002 Jun 08, 1984 Nov CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL
ATOMOXETINE HYDROCHLORIDE
AB ZYDUS PHARMS USA INC 10MG A079017 007 Apr 05, 2023 Mar NEWA

ATORVASTATIN CALCIUM

SUSPENSION;ORAL
ATORVALIQ
+! CMP DEV LLC 20MG/5ML N213260 001 Feb 01, 2023 Feb NEWA

TABLET;ORAL
ATORVASTATIN CALCIUM

>A> AB	ACI	EQ 10MG BASE	A217634	001	Dec 21, 2023	Dec NEWA
>A> AB		EQ 20MG BASE	A217634	002	Dec 21, 2023	Dec NEWA
>A> AB		EQ 40MG BASE	A217634	003	Dec 21, 2023	Dec NEWA
>A> AB		EQ 80MG BASE	A217634	004	Dec 21, 2023	Dec NEWA
AB	BIOCON PHARMA	EQ 10MG BASE	A216436	001	Nov 23, 2022	Sep CMFD
	@	EQ 10MG BASE	A216436	001	Nov 23, 2022	May DISC
AB		EQ 20MG BASE	A216436	002	Nov 23, 2022	Sep CMFD
	@	EQ 20MG BASE	A216436	002	Nov 23, 2022	May DISC
AB		EQ 40MG BASE	A216436	003	Nov 23, 2022	Sep CMFD
	@	EQ 40MG BASE	A216436	003	Nov 23, 2022	May DISC
AB		EQ 80MG BASE	A216436	004	Nov 23, 2022	Sep CMFD
	@	EQ 80MG BASE	A216436	004	Nov 23, 2022	May DISC
AB	CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Oct NEWA
AB		EQ 20MG BASE	A212103	002	Oct 16, 2023	Oct NEWA
AB		EQ 40MG BASE	A212103	003	Oct 16, 2023	Oct NEWA
AB		EQ 80MG BASE	A212103	004	Oct 16, 2023	Oct NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE	A214344	001	Sep 12, 2023	Sep NEWA
AB		EQ 20MG BASE	A214344	002	Sep 12, 2023	Sep NEWA
AB		EQ 40MG BASE	A214344	003	Sep 12, 2023	Sep NEWA

TABLET;ORAL
ATORVASTATIN CALCIUM

AB		EQ 80MG BASE	A214344	004	Sep 12, 2023	Sep NEWA
	@ LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022	Apr DISC
	@	EQ 20MG BASE	A216848	002	Nov 03, 2022	Apr DISC
	@	EQ 40MG BASE	A216848	003	Nov 03, 2022	Apr DISC
	@	EQ 80MG BASE	A216848	004	Nov 03, 2022	Apr DISC
>A> AB	MANKIND PHARMA	EQ 10MG BASE	A217081	001	Jan 05, 2024	Dec NEWA
>A> AB		EQ 20MG BASE	A217081	002	Jan 05, 2024	Dec NEWA
>A> AB		EQ 40MG BASE	A217081	003	Jan 05, 2024	Dec NEWA
>A> AB		EQ 80MG BASE	A217081	004	Jan 05, 2024	Dec NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL
LYPQOZET

>A>	ALTHERA PHARMS	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Dec CAHN
>A>		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Dec CAHN
>A>		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Dec CAHN
>A>	!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Dec CAHN
>D>	SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Dec CAHN
>D>		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Dec CAHN
>D>		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Dec CAHN
>D>	!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Dec CAHN

ATROPINE

SOLUTION;INTRAMUSCULAR
ATROOPEN

+ @ MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May DISC
+ @	EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May DISC
+ @	EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May DISC
+ @	EQ 2MG SULFATE/0.7ML	N017106	001		May DISC

ATROPINE SULFATE

SOLUTION;INTRAVENOUS
ATROPINE SULFATE

AP	AMNEAL	1MG/10ML (0.1MG/ML)	A215342	002	Oct 25, 2023	Oct NEWA
	SOLUTION/DROPS;OPHTHALMIC					
	ATROPINE SULFATE					
AT	+ AKORN	1%	N206289	001	Jul 18, 2014	Jul CHRS
AT	! AMNEAL	1%	A214752	001	Jul 14, 2022	Jul CHRS
>A> AT	MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Dec NEWA
AT	+ RISING	1%	N206289	001	Jul 18, 2014	Sep CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDETABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
@ UPSHER SMITH LABS 0.025MG;2.5MG

A210571 001 Aug 31, 2018 Jun DISC

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	JIANGSU HANSOH PHARM	100MG/VIAL	A215905	001	Jun 28, 2023	Jun NEWA
----	----------------------	------------	---------	-----	--------------	----------

AZELAIC ACID

AEROSOL, FOAM;TOPICAL
FINACEA

+!	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015	Feb CTEC
----	---------------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE

AB	BIONPHARMA	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Jun CAHN
----	------------	---------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATESPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

>D> AB	APOTEX	0.137MG/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Dec CHRS
>A> AB	!	0.137MG/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Dec CHRS
	DYMISTA					
>D> AB	+! MYLAN SPECIALITY LP	0.137MG/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Dec CHRS
>A> AB	+	0.137MG/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Dec CHRS

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	HAINAN POLY	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Jul NEWA
AB		EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Jul NEWA
	INJECTABLE; INJECTION					
	AZITHROMYCIN					
AP	SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A203412	001	Oct 09, 2018	Sep CAHN
	TABLET;ORAL					
	AZITHROMYCIN					
>D>	@ ACI	EQ 250MG BASE	A215772	001	Jul 15, 2022	Dec CMFD
>A> AB		EQ 250MG BASE	A215772	001	Jul 15, 2022	Dec CMFD
	@	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jan DISC
>D>	@	EQ 500MG BASE	A215773	001	Jul 12, 2022	Dec CMFD
>A> AB		EQ 500MG BASE	A215773	001	Jul 12, 2022	Dec CMFD
	@	EQ 500MG BASE	A215773	001	Jul 12, 2022	Jan DISC
	@ AUROBINDO PHARMA USA	EQ 600MG BASE	A065360	001	Jan 08, 2007	May CAHN
	@ ZYDUS PHARMS	EQ 250MG BASE	A213275	001	Apr 11, 2023	Aug DISC
AB		EQ 250MG BASE	A213275	001	Apr 11, 2023	Mar NEWA
	@	EQ 500MG BASE	A213056	001	Apr 07, 2023	Aug DISC
AB		EQ 500MG BASE	A213056	001	Apr 07, 2023	Mar NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

@ AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	Jan DISC
! BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jan CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Jan DISC
---------	--	---------	-----	--------------	----------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Aug NEWA
AP		2MG/ML	A216309	002	Aug 10, 2023	Aug NEWA
AP	RUBICON	0.5MG/ML	A217324	001	Feb 22, 2023	Feb NEWA
AP		1MG/ML	A217324	002	Feb 22, 2023	Feb NEWA
AP		2MG/ML	A217324	003	Feb 22, 2023	Feb NEWA
	SOLUTION;ORAL					
	OZOBAX					
+ @ METACEL PHARMS LLC	5MG/5ML		N208193	001	Sep 18, 2019	Nov DISC
OZOBAX DS						
+! METACEL PHARMS LLC	10MG/5ML		N208193	002	Oct 12, 2023	Nov NEWA
	SUSPENSION;ORAL					
	BACLOFEN					
AB	ANI PHARMS	25MG/5ML	A217252	001	Jun 08, 2023	Aug CAHN
AB	SLAYBACK PHARMA LLC	25MG/5ML	A217252	001	Jun 08, 2023	Jun NFTG
	FLEQSUVY					
AB	+! AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Jun CFTG
	TABLET;ORAL					
	BACLOFEN					
	@ APPCO	10MG	A090334	001	Feb 18, 2010	Nov CAHN
	@	20MG	A090334	002	Feb 18, 2010	Nov CAHN
AB	BEXIMCO PHARMS USA	5MG	A214114	003	Sep 19, 2023	Sep NEWA
>A> AB	GRAVITI PHARMS	10MG	A217788	001	Jan 10, 2024	Dec NEWA
>A> AB		20MG	A217788	002	Jan 10, 2024	Dec NEWA
AB	MICRO LABS	5MG	A217687	001	Nov 08, 2023	Nov NEWA
AB		10MG	A217687	002	Nov 08, 2023	Nov NEWA
AB		20MG	A217687	003	Nov 08, 2023	Nov NEWA
AB	RISING	5MG	A214374	001	Mar 05, 2021	Oct CAHN
AB		10MG	A214374	002	Mar 05, 2021	Oct CAHN
AB		20MG	A214374	003	Mar 05, 2021	Oct CAHN
AB	! RUBICON	5MG	A209102	001	Nov 28, 2017	Nov CHRS
AB	UNICHEM	5MG	A212067	003	Mar 09, 2023	Mar NEWA
	@ UPSHER SMITH LABS	10MG	A090334	001	Feb 18, 2010	Sep CAHN
	@	20MG	A090334	002	Feb 18, 2010	Sep CAHN

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

+ @ GENENTECH INC	20MG
+ @	40MG
+ !	80MG

N210854	001	Oct 24, 2018	Jun DISC
N210854	002	Oct 24, 2018	Jun CHRS
N210854	003	Mar 18, 2021	Jun CHRS

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB @ DASH PHARMS NATCO	750MG	A077807	001	Dec 28, 2007	Feb CAHN
AB ZYDUS	750MG	A217592	001	Jun 08, 2023	Jun NEWA

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

BECONASE AQ

+ @ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY
---------------------	-------------------------

N019389	001	Jul 27, 1987	Nov DISC
---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

>D@ ANI PHARMS	5MG	A076333	001	Feb 11, 2004	Dec CMFD
>A> AB	5MG	A076333	001	Feb 11, 2004	Dec CMFD
>D@	10MG	A076333	002	Feb 11, 2004	Dec CMFD
>A> AB	10MG	A076333	002	Feb 11, 2004	Dec CMFD
>D@	20MG	A076333	003	Feb 11, 2004	Dec CMFD
>A> AB	20MG	A076333	003	Feb 11, 2004	Dec CMFD
>D@	40MG	A076333	004	Feb 11, 2004	Dec CMFD
>A> AB	40MG	A076333	004	Feb 11, 2004	Dec CMFD
AB COREPHARMA	5MG	A077128	001	Mar 08, 2006	Mar CAHN
AB	10MG	A077128	002	Mar 08, 2006	Mar CAHN
AB	20MG	A077128	003	Mar 08, 2006	Mar CAHN
AB	40MG	A077128	004	Mar 08, 2006	Mar CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLORTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLORTHIAZIDE

AB APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014	May CMFD
AB	10MG;12.5MG	A078794	002	Aug 21, 2014	May CMFD
AB	20MG;12.5MG	A078794	003	Aug 21, 2014	May CMFD
AB	20MG;25MG	A078794	004	Aug 21, 2014	May CMFD

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	May NEWA
AP	100MG/VIAL	A204230	002	Jun 05, 2023	May NEWA
AP BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Feb NEWA
AP	100MG/VIAL	A205447	002	Feb 14, 2023	Feb NEWA
AP EUGIA PHARMA	25MG/VIAL	A214739	001	Jun 05, 2023	May NEWA
AP	100MG/VIAL	A214739	002	Jun 05, 2023	May NEWA
AP KINDOS	25MG/VIAL	A211001	001	Jun 05, 2023	May NEWA
AP	100MG/VIAL	A211001	002	Jun 05, 2023	May NEWA
AP @ MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 28, 2023	May DISC
AP	25MG/VIAL	A204104	001	Apr 28, 2023	Apr NEWA
AP @	100MG/VIAL	A204104	002	Apr 28, 2023	May DISC
AP	100MG/VIAL	A204104	002	Apr 28, 2023	Apr NEWA
AP @ NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023	Nov DISC
AP	25MG/VIAL	A206554	001	Jun 07, 2023	May NEWA
AP @	100MG/VIAL	A206554	002	Jun 07, 2023	Nov DISC
AP	100MG/VIAL	A206554	002	Jun 07, 2023	May NEWA

SOLUTION;INTRAVENOUS

BELRAPZO

AP +! EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	Aug CDFR
AP	BENDAMUSTINE HYDROCHLORIDE				
AP +! APOTEX	100MG/4ML (25MG/ML)	N215033	001	Dec 07, 2022	Aug CTEC
AP +! BAXTER HLTHCARE CORP	100MG/4ML (25MG/ML)	N216078	001	Dec 15, 2022	Sep CTEC
+ @ HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022	Jan DISC
+ @	100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022	Jan DISC
+ @	200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022	Jan DISC

SOLUTION;IV (INFUSION)

BELRAPZO

AP +! EAGLE PHARMS 100MG/4ML (25MG/ML) N205580 001 May 15, 2018 Aug CTEC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019	Oct CTEC
	CHARTWELL RX	100MG	A040682	001	Jul 30, 2007	Feb CAHN
	@	100MG	A210562	001	Nov 09, 2018	Oct DISC
	@	150MG	A210562	002	Nov 09, 2018	Oct DISC
AA		200MG	A040682	002	Jul 30, 2007	Feb CAHN
	@	200MG	A210562	003	Nov 09, 2018	Oct DISC
AA	HERITAGE PHARMS LABS	100MG	A040682	001	Jul 30, 2007	Aug CAHN
AA		200MG	A040682	002	Jul 30, 2007	Aug CAHN
AA	! PURACAP PHARM LLC	100MG	A206948	001	Dec 19, 2018	Aug CHRS
AA	!	200MG	A206948	002	Dec 19, 2018	Aug CHRS
	@ THEPHARMANETWORK LLC	100MG	A040627	001	Mar 30, 2007	Aug DISC
	@	150MG	A040627	003	Sep 24, 2014	Aug DISC
	@	200MG	A040627	002	Jul 25, 2007	Aug DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

+ @ BAUSCH	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Feb DISC
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				
@ CHARTWELL RX	5%;1.2%	A203688	001	Aug 25, 2016	Nov CAHN
AB ! GLENMARK PHARMS	5%;EQ 1% BASE	A209252	001	Mar 14, 2019	Feb CHRS
ONEXTON					
AB +! BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug CTEC

BENZTROPIINE MESYLATE

TABLET;ORAL

BENZTROPIINE MESYLATE

>A> AA CHARTWELL RX 0.5MG A081265 003 Nov 29, 2023 Dec NEWA

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT ALEMBIC	1.5%	A214588	001	Apr 05, 2023	Mar NEWA
------------	------	---------	-----	--------------	----------

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB HIKMA	3MG/ML;EQ 3MG BASE/ML	A077838	001	Jan 17, 2023	Jan NEWA
----------	-----------------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

@ SHREE HARI INTL	EQ 0.05% BASE	A070274	001	Aug 12, 1985	Sep CAHN
-------------------	---------------	---------	-----	--------------	----------

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

>D> @ PAI HOLDINGS PHARM	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Dec CAHN
--------------------------	---------------	---------	-----	--------------	----------

@

EQ 0.05% BASE

>A> @ VERTICE	EQ 0.05% BASE	A206389	001	Feb 13, 2018	May DISC
---------------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB GLENMARK PHARMS LTD	0.064%;0.005%	A214688	001	Mar 21, 2023	Mar NFTG
------------------------	---------------	---------	-----	--------------	----------

ENSTILAR

AB +! LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015	Mar CFTG
---------------------	---------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

@ CHARTWELL RX	0.064%;0.005%	A201615	001	Jan 14, 2013	Oct CAHN
----------------	---------------	---------	-----	--------------	----------

@ TOIMAR

0.064%;0.005%

		A201615	001	Jan 14, 2013	Feb DISC
--	--	---------	-----	--------------	----------

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB COSETTE	0.064%;0.005%	A210765	001	May 11, 2020	Feb CAHN
------------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	! TARO	EQ 0.05% BASE;1%	A075673	001	May 29, 2001	May CHRS
	LOTRISONE					
+ @ ORGANON		EQ 0.05% BASE;1%	N018827	001	Jul 10, 1984	May DISC

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB	! TARO	0.12%	A208204	001	May 24, 2017	Aug CHRS
AB	XIROMED	0.12%	A210639	001	Apr 18, 2023	Apr NEWA
	LUXIQ					
+ @ MYLAN		0.12%	N020934	001	Feb 28, 1999	Aug DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ AKORN EQ 0.5% BASE

A075386 001 Jun 30, 2000 Feb DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	CHARTWELL RX	5MG	A040728	002	Oct 26, 2007	May CAHN
AA		10MG	A040728	003	Oct 26, 2007	May CAHN
AA		25MG	A040728	004	Oct 26, 2007	May CAHN
AA		50MG	A040728	001	Oct 26, 2007	May CAHN

BEXAGLIFLOZIN

TABLET;ORAL

BRENZAVVY

+! THERACOSBIO 20MG

N214373 001 Jan 20, 2023 Jan NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	ADAPTIS	50MG	A079089	001	Jul 06, 2009	Sep CAHN
AB	BRECKENRIDGE	50MG	A091011	001	Jun 10, 2015	Sep CAHN
AB	PINNACLE LIFE SCI	50MG	A079089	001	Jul 06, 2009	Jan CAHN

BIMATOPROST

IMPLANT;OPHTHALMIC

DURYSTA

+! ABBVIE 10MCG

N211911 001 Mar 04, 2020 Jan CAHN

SOLUTION/DROPS;OPHTHALMIC

LUMIGAN

+! ABBVIE 0.01%

N022184 001 Aug 31, 2010 Jul CAHN

+ @ 0.03%

N021275 001 Mar 16, 2001 Jul CAHN

>A> BIRCH TRITERPENES

>A> GEL;TOPICAL

>A> FILSUVEZ

>A> +! AMRYT 10%

N215064 001 Dec 18, 2023 Dec NEWA

BISMUTH SUBLIMATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBLIMATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB	PAR PHARM	140MG;125MG;125MG	A205770	001	Mar 06, 2023	Feb NFTG
AB	RICONPHARMA LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Jun NEWA
	PYLERA					
AB	+! ABBVIE	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar CAHN
AB	+! ALLERGAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Feb CFTG
AB	+! LABS JUVISE	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Sep CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

! NOSTRUM LABS INC 262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG

A202584 001 Nov 30, 2018 Aug CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	ALEMBIC	5MG	A204891	001	Jan 11, 2017	Feb CAHN
AB		10MG	A204891	002	Jan 11, 2017	Feb CAHN
	@ DASH PHARMS NATCO	5MG	A075831	001	Dec 14, 2005	Feb CAHN
	@	10MG	A075831	002	Dec 14, 2005	Feb CAHN
AB	PRINSTON INC	5MG	A217368	001	Jul 14, 2023	Jul NEWA
AB		10MG	A217368	002	Jul 14, 2023	Jul NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

AP	SLATE RUN PHARMA	250MG/VIAL	A213078	001	May 28, 2021	Sep CAHN
----	------------------	------------	---------	-----	--------------	----------

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	@ ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Feb DISC
	@ SCINOPHARM TAIWAN	3.5MG/VIAL	A216912	001	Sep 26, 2023	Nov DISC
AP		3.5MG/VIAL	A216912	001	Sep 26, 2023	Sep NEWA
	POWDER;INTRAVENOUS					
	BORTEZOMIB					
	@ DR REDDYS	3.5MG/VIAL	N206927	001	Oct 04, 2019	May DISC
	@ FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017	May DISC
	SOLUTION;INTRAVENOUS					
	BORTEZOMIB					
	+ @ MAIA PHARMS INC	3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022	Oct DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

	@ HIKMA	62.5MG	A208695	001	Apr 26, 2019	Oct DISC
	@	125MG	A208695	002	Apr 26, 2019	Oct DISC
	@ PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr DISC
	@	125MG	A205699	002	Apr 26, 2019	Apr DISC

BOSUTINIB MONOHYDRATE

CAPSULE;ORAL

BOSULIF

+ PF PRISM CV	EQ 50MG BASE	N217729	001	Sep 26, 2023	Oct CHRS
+!	EQ 50MG BASE	N217729	001	Sep 26, 2023	Sep NEWA
+!	EQ 100MG BASE	N217729	002	Sep 26, 2023	Oct CHRS
+	EQ 100MG BASE	N217729	002	Sep 26, 2023	Sep NEWA

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

@ BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Feb DISC
----------------	---------	---------	-----	--------------	----------

BREXPIPRAZOLE

TABLET;ORAL

BREXPIPRAZOLE

	@ AJANTA PHARMA LTD	0.25MG	A213718	001	Feb 03, 2023	Aug DISC
AB		0.25MG	A213718	001	Feb 03, 2023	Jan NEWA
	@	0.5MG	A213718	002	Feb 03, 2023	Aug DISC
AB		0.5MG	A213718	002	Feb 03, 2023	Jan NEWA
	@	1MG	A213718	003	Feb 03, 2023	Aug DISC
AB		1MG	A213718	003	Feb 03, 2023	Jan NEWA
	@	2MG	A213718	004	Feb 03, 2023	Aug DISC
AB		2MG	A213718	004	Feb 03, 2023	Jan NEWA
	@	3MG	A213718	005	Feb 03, 2023	Aug DISC
AB		3MG	A213718	005	Feb 03, 2023	Jan NEWA
	@	4MG	A213718	006	Feb 03, 2023	Aug DISC
AB		4MG	A213718	006	Feb 03, 2023	Jan NEWA
AB	ALKEM LABS LTD	0.25MG	A213782	001	Nov 28, 2023	Nov NEWA
AB		0.5MG	A213782	002	Nov 28, 2023	Nov NEWA
AB		1MG	A213782	003	Nov 28, 2023	Nov NEWA
AB		2MG	A213782	004	Nov 28, 2023	Nov NEWA
AB		3MG	A213782	005	Nov 28, 2023	Nov NEWA
AB		4MG	A213782	006	Nov 28, 2023	Nov NEWA

TABLET;ORAL BREXPIPRAZOLE							
AB	@ AMNEAL	0.25MG	A213562	001	Jan 31, 2023	Mar DISC	
		0.25MG	A213562	001	Jan 31, 2023	Jan NEWA	
AB	@	0.5MG	A213562	002	Jan 31, 2023	Mar DISC	
		0.5MG	A213562	002	Jan 31, 2023	Jan NEWA	
AB	@	1MG	A213562	003	Jan 31, 2023	Mar DISC	
		1MG	A213562	003	Jan 31, 2023	Jan NEWA	
AB	@	2MG	A213562	004	Jan 31, 2023	Mar DISC	
		2MG	A213562	004	Jan 31, 2023	Jan NEWA	
AB	@	3MG	A213562	005	Jan 31, 2023	Mar DISC	
		3MG	A213562	005	Jan 31, 2023	Jan NEWA	
AB	@	4MG	A213562	006	Jan 31, 2023	Mar DISC	
		4MG	A213562	006	Jan 31, 2023	Jan NEWA	
AB	@ AUROBINDO PHARMA LTD	0.25MG	A213659	001	Nov 02, 2023	Nov DISC	
		0.25MG	A213659	001	Nov 02, 2023	Oct NEWA	
AB	@	0.5MG	A213659	002	Nov 02, 2023	Nov DISC	
		0.5MG	A213659	002	Nov 02, 2023	Oct NEWA	
AB	@	1MG	A213659	003	Nov 02, 2023	Nov DISC	
		1MG	A213659	003	Nov 02, 2023	Oct NEWA	
AB	@	2MG	A213659	004	Nov 02, 2023	Nov DISC	
		2MG	A213659	004	Nov 02, 2023	Oct NEWA	
AB	@	3MG	A213659	005	Nov 02, 2023	Nov DISC	
		3MG	A213659	005	Nov 02, 2023	Oct NEWA	
AB	@	4MG	A213659	006	Nov 02, 2023	Nov DISC	
		4MG	A213659	006	Nov 02, 2023	Oct NEWA	
AB	HETERO LABS LTD V	0.25MG	A213669	001	Nov 20, 2023	Nov NEWA	
		0.5MG	A213669	002	Nov 20, 2023	Nov NEWA	
AB		1MG	A213669	003	Nov 20, 2023	Nov NEWA	
AB		2MG	A213669	004	Nov 20, 2023	Nov NEWA	
AB		3MG	A213669	005	Nov 20, 2023	Nov NEWA	
AB		4MG	A213669	006	Nov 20, 2023	Nov NEWA	
AB	@ LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023	May DISC	
		0.25MG	A213512	001	Mar 17, 2023	Mar NEWA	
AB	@	0.5MG	A213512	002	Mar 17, 2023	May DISC	
		0.5MG	A213512	002	Mar 17, 2023	Mar NEWA	
AB	@	1MG	A213512	003	Mar 17, 2023	May DISC	
		1MG	A213512	003	Mar 17, 2023	Mar NEWA	
AB	@	2MG	A213512	004	Mar 17, 2023	May DISC	
		2MG	A213512	004	Mar 17, 2023	Mar NEWA	
AB	@	3MG	A213512	005	Mar 17, 2023	May DISC	
		3MG	A213512	005	Mar 17, 2023	Mar NEWA	
AB	@	4MG	A213512	006	Mar 17, 2023	May DISC	
		4MG	A213512	006	Mar 17, 2023	Mar NEWA	
AB	OPTIMUS	0.25MG	A213758	001	Oct 25, 2023	Oct NEWA	
		0.5MG	A213758	002	Oct 25, 2023	Oct NEWA	
AB		1MG	A213758	003	Oct 25, 2023	Oct NEWA	
AB		2MG	A213758	004	Oct 25, 2023	Oct NEWA	
AB		3MG	A213758	005	Oct 25, 2023	Oct NEWA	
AB		4MG	A213758	006	Oct 25, 2023	Oct NEWA	
AB	@ TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Feb DISC	
		0.5MG	A213692	002	Aug 11, 2022	Feb DISC	
AB	@	1MG	A213692	003	Aug 11, 2022	Feb DISC	
		1MG	A213692	004	Aug 11, 2022	Feb DISC	
AB	@	2MG	A213692	005	Aug 11, 2022	Feb DISC	
		2MG	A213692	006	Aug 11, 2022	Feb DISC	
AB	@	3MG	A213692	001	Jan 10, 2023	Jun DISC	
		3MG	A213692	002	Jan 10, 2023	Jun DISC	
AB	@	4MG	A213692	003	Jan 10, 2023	Jun DISC	
		4MG	A213692	004	Jan 10, 2023	Jun DISC	
		4MG	A213692	005	Jan 10, 2023	Jun DISC	
		4MG	A213692	006	Jan 10, 2023	Jun DISC	
REXULTI							
AB	+ OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Oct CTEC	
	+	0.25MG	N205422	001	Jul 10, 2015	Aug CTEC	
AB	+	0.5MG	N205422	002	Jul 10, 2015	Oct CTEC	
	+	0.5MG	N205422	002	Jul 10, 2015	Aug CTEC	
AB	+	1MG	N205422	003	Jul 10, 2015	Oct CTEC	
	+	1MG	N205422	003	Jul 10, 2015	Aug CTEC	
AB	+	2MG	N205422	004	Jul 10, 2015	Oct CTEC	
	+	2MG	N205422	004	Jul 10, 2015	Aug CTEC	
AB	+	3MG	N205422	005	Jul 10, 2015	Oct CTEC	
	+	3MG	N205422	005	Jul 10, 2015	Aug CTEC	
AB	+	4MG	N205422	006	Jul 10, 2015	Oct CTEC	

TABLET;ORAL

REXULTI

+ 4MG

N205422 006 Jul 10, 2015 Aug CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AB ALEMBIC 0.1%
AT 0.15%
AT MICRO LABS 0.2%A216909 001 Aug 01, 2023 Jul NEWA
A215225 001 Mar 29, 2023 Mar NEWA
A217846 001 Nov 22, 2023 Nov NEWABRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB ALEMBIC 0.2%;EQ 0.5% BASE
AB FLORIDA 0.2%;EQ 0.5% BASE
AB SENTISS 0.2%;EQ 0.5% BASEA215230 001 Aug 25, 2023 Aug NEWA
A201949 001 Oct 04, 2022 Nov CAHN
A091086 001 Oct 31, 2022 Jul CAHNBRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

AZOPT

AB +! SANDOZ 1%
BRINZOLAMIDE
AB PADAGIS US 1%N020816 001 Apr 01, 1998 Sep CAHN
A211914 001 Jul 28, 2023 Jul NEWABRIVARACETAM

TABLET;ORAL

BRIVARACETAM

@ AUROBINDO PHARMA LTD 50MG
@ 100MG
@ LUPIN LTD 10MG
@ 25MG
@ 50MG
@ 75MG
@ 100MGA214848 001 Jan 06, 2023 Mar DISC
A214848 002 Jan 06, 2023 Mar DISC
A214918 001 Dec 20, 2022 Mar DISC
A214918 002 Dec 20, 2022 Mar DISC
A214918 003 Dec 20, 2022 Mar DISC
A214918 004 Dec 20, 2022 Mar DISC
A214918 005 Dec 20, 2022 Mar DISC

BRIVIACT

+ UCB INC 10MG
+ 25MG
+ 50MG
+ 75MG
+! 100MGN205836 001 May 12, 2016 Mar CTEC
N205836 002 May 12, 2016 Mar CTEC
N205836 003 May 12, 2016 Mar CTEC
N205836 004 May 12, 2016 Mar CTEC
N205836 005 May 12, 2016 Mar CTECBROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2 AKORN EQ 0.09% ACID
AT2 ! ALEMBIC EQ 0.09% ACID
AB LUPIN LTD EQ 0.07% ACID
AT2 PROLENSA EQ 0.09% ACID
AT2 SENTISS EQ 0.09% ACID
AB +! BAUSCH AND LOMB EQ 0.07% ACIDA203395 001 Jan 22, 2014 Jun CHRS
A210560 001 Jun 21, 2019 Jun CHRS
A206027 001 Nov 22, 2023 Nov NFTG
A202903 001 Aug 15, 2023 Aug NEWA
A203395 001 Jan 22, 2014 Jul CAHN
N203168 001 Apr 05, 2013 Nov CFTGBROMOCRIPTINE MESYLATE

CAPSULE;ORAL

PARLODEL

>A> AB + SS PHARMA EQ 5MG BASE
>D> AB + VALIDUS PHARMS EQ 5MG BASEN017962 002 Mar 01, 1982 Dec CAHN
N017962 002 Mar 01, 1982 Dec CAHN

TABLET;ORAL

BROMOCRIPTINE MESYLATE

@ AUROBINDO PHARMA USA EQ 2.5MG BASE
PARLODEL

A076962 001 Sep 24, 2004 Apr CAHN

>A> AB + SS PHARMA EQ 2.5MG BASE
>D> AB + VALIDUS PHARMS EQ 2.5MG BASEN017962 001 Dec CAHN
N017962 001 Dec CAHNBROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA + WOCKHARDT BIO AG 2MG/5ML;10MG/5ML;30MG/5ML
AA +! 2MG/5ML;10MG/5ML;30MG/5MLA088811 001 Jun 07, 1985 Jun CHRS
A088811 001 Jun 07, 1985 Jun CRLD

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
© BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jun CAHN
© BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jan DISC
>D> AA EYWA	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Dec CAHN
AA ! PADAGIS US	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun CHRS
>A> AA WES PHARMA INC	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Dec CAHN

BUDESONIDE

AEROSOL, FOAM;RECTAL					
BUDESONIDE					
AB PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Mar NFTG
UCERIS					
AB +! SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar CFTG
CAPSULE, DELAYED RELEASE;ORAL					
ORTIKOS					
+ © SUN PHARM INDs INC	6MG	N211929	001	Jun 13, 2019	Oct DISC
+ ©	9MG	N211929	002	Jun 13, 2019	Oct DISC
SUSPENSION;INHALATION					
BUDESONIDE					
AN EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	Nov NEWA

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION					
SYMBICORT AEROSPHERE					
+! ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023	Apr NEWA

BUMETANIDE

INJECTABLE;INJECTION					
BUMETANIDE					
AP SAGENT	0.25MG/ML	A074441	001	Jan 27, 1995	Aug CAHN
TABLET;ORAL					
BUMETANIDE					
AB TARO	0.5MG	A213458	001	Jul 24, 2023	Jul NEWA
AB	1MG	A213458	002	Jul 24, 2023	Jul NEWA
AB	2MG	A213458	003	Jul 24, 2023	Jul NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
BUPIVACAINE HYDROCHLORIDE					
AP KINDOS	0.25%	A216039	001	Jun 23, 2023	Jun NEWA
>A> AP	0.25%	A216040	001	Dec 27, 2023	Dec NEWA
AP	0.5%	A216039	002	Jun 23, 2023	Jun NEWA
>A> AP	0.5%	A216040	002	Dec 27, 2023	Dec NEWA
>A> AP	0.75%	A216040	003	Dec 27, 2023	Dec NEWA
AP SOMERSET	0.25%	A217792	001	Nov 20, 2023	Nov NEWA
AP	0.5%	A217792	002	Nov 20, 2023	Nov NEWA
AP STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Jun CMFD
AP	0.5%	A091503	002	Oct 18, 2011	Jun CMFD
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
AP STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Jun CMFD
AP	0.5%	A091487	001	Oct 18, 2011	Jun CMFD
AP	0.75%	A091487	003	Oct 18, 2011	Jun CMFD
INJECTABLE;SPINAL					
BUPIVACAINE HYDROCHLORIDE					
© BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016	Aug DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL					
BUPRENORPHINE					
AB © ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Sep DISC
	7.5MCG/HR	A207490	005	Mar 21, 2023	Mar NEWA
SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS					
BRIXADI					
+ BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	May NEWA
+	16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	May NEWA
+	24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	May NEWA
+	32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	May NEWA
+	64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	May NEWA
+	96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	May NEWA
+!	128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023	May NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP ! PAR STERILE PRODUCTS EQ 0.3MG BASE/ML A206586 001 Jul 28, 2015 Jul CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>D> AB3	@ ANCHEN PHARMS	150MG	A077284	001	Dec 14, 2006	Sep DISC
		300MG	A077284	002	Dec 14, 2006	Dec DISC
>A>	@	300MG	A077284	002	Dec 14, 2006	Dec DISC
AB1	ANNORA PHARMA	100MG	A216800	001	May 31, 2023	May NEWA
AB1		150MG	A216800	002	May 31, 2023	May NEWA
AB1		200MG	A216800	003	May 31, 2023	May NEWA
AB3	SCINOPHARM TAIWAN	150MG	A210081	001	Nov 03, 2017	Sep CAHN
AB3		300MG	A210081	002	Nov 03, 2017	Sep CAHN
>D> AB1	SUN PHARM	100MG	A078866	001	Apr 06, 2010	Dec DISC
>A>	@	100MG	A078866	001	Apr 06, 2010	Dec DISC
	FORFIVO XL					
+!	TWI PHARMS	450MG	N022497	001	Nov 10, 2011	Nov CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@ GRAVITI PHARMS	5MG	A075413	001	Mar 19, 2002	Feb CAHN	
@	10MG	A075413	002	Mar 19, 2002	Feb CAHN	
@	15MG	A075413	003	Mar 19, 2002	Feb CAHN	
@ RISING	5MG	A075413	001	Mar 19, 2002	Aug CAHN	
@	10MG	A075413	002	Mar 19, 2002	Aug CAHN	
@	15MG	A075413	003	Mar 19, 2002	Aug CAHN	
AB	ZYDUS PHARMS	7.5MG	A078888	005	Mar 21, 2023	Mar NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

@ AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Jan DISC
@ ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018	Mar DISC
TABLET; ORAL					
MYLERAN					
+! WAYLIS THERAP	2MG	N009386	001		Sep CAHN

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+ @ MYLAN 1% N020524 001 Oct 18, 1996 Jul DISC

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

+! ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb CMFD
@ APOTEX	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Aug DISC
AP	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Feb NEWA
AP	60MG/1.5ML (40MG/ML)	A207718	001	Feb 10, 2023	Feb NEWA
@ MYLAN LABS LTD	60MG/1.5ML (40MG/ML)	A207381	001	Jul 05, 2023	Jul DISC
AP	60MG/1.5ML (40MG/ML)	A207381	001	Jul 05, 2023	Jun NEWA

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

+ EXELIXIS EQ 20MG BASE N203756 001 Nov 29, 2012 Jun CHRS
+! EQ 80MG BASE N203756 002 Nov 29, 2012 Jun CHRSCALCIPOURIENE

CREAM; TOPICAL

CALCIPOURIENE

@ CHARTWELL RX	0.005%	A200935	001	May 30, 2012	Oct CAHN
@ TOLMAR	0.005%	A200935	001	May 30, 2012	Feb DISC
SOLUTION; TOPICAL					
CALCIPOURIENE					
AT CHARTWELL RX	0.005%	A207163	001	Dec 26, 2017	Jul CAHN
AT ! COSETTE	0.005%	A078468	001	Mar 24, 2011	Feb CHRS

CALCITRIOL

	CAPSULE;ORAL						
	CALCITRIOL						
AB	! STRIDES PHARMA	0.5MCG		A091356	002	Dec 12, 2014	May CHRS
	ROCALTROL						
>A> AB	+ SS PHARMA	0.25MCG		N018044	001		Dec CAHN
>A> AB	+	0.5MCG		N018044	002		Dec CAHN
>D> AB	+ VALIDUS PHARMS	0.25MCG		N018044	001		Dec CAHN
>D> AB	+	0.5MCG		N018044	002		Dec CAHN
AB	+	0.5MCG		N018044	002		May CHRS
	INJECTABLE;INJECTION						
	CALCITRIOL						
AP	! LONG GROVE PHARMS	0.001MG/ML		A078066	001	Jan 29, 2008	Aug CAHN
	@	0.002MG/ML		A078066	002	Jan 29, 2008	Aug CAHN
	SOLUTION;ORAL						
	CALCITRIOL						
AA	PATRIN	1MCG/ML		A203973	001	Jul 28, 2023	Jul NEWA
AA	RISING	1MCG/ML		A209798	001	Nov 21, 2018	Jul CAHN
	ROCALTROL						
>A> AA	+! SS PHARMA	1MCG/ML		N021068	001	Nov 20, 1998	Dec CAHN
>D> AA	+! VALIDUS PHARMS	1MCG/ML		N021068	001	Nov 20, 1998	Dec CAHN

CALCIUM ACETATE

	CAPSULE;ORAL						
	CALCIUM ACETATE						
>D>	@ SQUARE PHARMS	667MG		A217205	001	Mar 13, 2023	Dec CMFD
>A> AB		667MG		A217205	001	Mar 13, 2023	Dec CMFD
	@	667MG		A217205	001	Mar 13, 2023	Sep DISC
AB		667MG		A217205	001	Mar 13, 2023	Mar NEWA
	SOLUTION;ORAL						
	PHOSLYRA						
	+ @ FRESENIUS MEDCL	667MG/5ML		N022581	001	Apr 18, 2011	Jun DISC

CALCIUM GLUCONATE

	SOLUTION;INTRAVENOUS						
	CALCIUM GLUCONATE						
AP	B BRAUN MEDICAL INC	10GM/100ML (100MG/ML)		A216541	001	Aug 21, 2023	Aug NFTG
AP	+! FRESENIUS KABI USA	5GM/50ML (100MG/ML)		N208418	002	Jun 15, 2017	Oct CFTG
AP	+!	10GM/100ML (100MG/ML)		N208418	003	Jun 15, 2017	Aug CFTG
AP	NIVAGEN PHARMS INC	5GM/50ML (100MG/ML)		A213071	002	Oct 19, 2023	Oct NFTG
AP	SOMERSET	5GM/50ML (100MG/ML)		A217689	001	Oct 19, 2023	Oct NFTG
AP		10GM/100ML (100MG/ML)		A217689	002	Oct 19, 2023	Oct NEWA
	CALCIUM GLUCONATE IN SODIUM CHLORIDE						
AP	AMNEAL	1GM/50ML (20MG/ML)		A217174	001	Sep 05, 2023	Aug NFTG
AP		2GM/100ML (20MG/ML)		A217174	002	Sep 05, 2023	Aug NFTG
AP	+! FRESENIUS KABI USA	1GM/50ML (20MG/ML)		N208418	004	Jun 17, 2021	Aug CFTG
AP	+	2GM/100ML (20MG/ML)		N208418	005	Jun 17, 2021	Aug CFTG

CANDESARTAN CILEXETIL

	TABLET;ORAL						
	CANDESARTAN CILEXETIL						
AB	PRINSTON INC	8MG		A206233	001	Aug 21, 2023	Aug NEWA
AB		16MG		A206233	002	Aug 21, 2023	Aug NEWA
AB		32MG		A206233	003	Aug 21, 2023	Aug NEWA
AB	ZYDUS LIFESCIENCES	4MG		A091390	001	Aug 23, 2017	May CAHN
AB		8MG		A091390	002	Aug 23, 2017	May CAHN
AB		16MG		A091390	003	Aug 23, 2017	May CAHN
AB		32MG		A091390	004	Aug 23, 2017	May CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

	TABLET;ORAL						
	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE						
AB	ZYDUS LIFESCIENCES	16MG;12.5MG		A203466	001	Nov 27, 2017	May CAHN
AB		32MG;12.5MG		A203466	002	Nov 27, 2017	May CAHN
AB		32MG;25MG		A203466	003	Nov 27, 2017	May CAHN

CANNABIDIOL

SOLUTION;ORAL

EPIDIOLEX

>D>	+!	GW RES LTD	100MG/ML	N210365	001	Sep 28, 2018	Dec CAHN
>A>	+!	JAZZ PHARMS RES	100MG/ML	N210365	001	Sep 28, 2018	Dec CAHN

CANTHARIDIN

SOLUTION;TOPICAL

YCANTH

+! VERRICA PHARMS 0.7%

N212905 001 Jul 21, 2023 Jul NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		TEYRO LABS	150MG	A217237	001	Oct 23, 2023	Oct NEWA
AB			500MG	A217237	002	Oct 23, 2023	Oct NEWA
		XELODA					
AB	+	CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Apr CAHN
AB	+		500MG	N020896	002	Apr 30, 1998	Apr CAHN

CAPIVASERTIB

TABLET;ORAL

TRUQAP

+ ASTRAZENECA 160MG
+! 200MGN218197 001 Nov 16, 2023 Nov NEWA
N218197 002 Nov 16, 2023 Nov NEWACAPTOPRIL

TABLET;ORAL

Captopril

@	AUROBINDO PHARMA USA	12.5MG	A074434	001	Feb 13, 1996	May CAHN
@		25MG	A074434	002	Feb 13, 1996	May CAHN
@		50MG	A074434	003	Feb 13, 1996	May CAHN
@		100MG	A074434	004	Feb 13, 1996	May CAHN
AB	CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023	Jan NEWA
AB		25MG	A214442	002	Jan 27, 2023	Jan NEWA
AB		50MG	A214442	003	Jan 27, 2023	Jan NEWA
AB		100MG	A214442	004	Jan 27, 2023	Jan NEWA
AB	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Mar CAHN
AB		25MG	A074737	002	Oct 28, 1998	Mar CAHN
AB		50MG	A074737	003	Oct 28, 1998	Mar CAHN
AB		100MG	A074737	004	Oct 28, 1998	Mar CAHN
AB	KENTON	12.5MG	A074677	004	May 30, 1997	Sep CAHN
AB		25MG	A074677	002	May 30, 1997	Sep CAHN
AB		50MG	A074677	001	May 30, 1997	Sep CAHN
AB		100MG	A074677	003	May 30, 1997	Sep CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

Captopril And Hydrochlorothiazide

RISING 25MG;15MG
! 25MG;25MG
! 50MG;15MG
50MG;25MGA074896 001 Dec 29, 1997 May CMFD
A074896 002 Dec 29, 1997 May CMFD
A074896 004 Dec 29, 1997 May CMFD
A074896 003 Dec 29, 1997 May CMFDCARBAMAZEPINE

SUSPENSION;ORAL

CARBAMAZEPINE

AB	CHARTWELL RX	100MG/5ML	A075714	001	Jun 05, 2002	Jan CAHN
	TABLET;ORAL					
	CARBAMAZEPINE					
	@ RK PHARMA	200MG	A214328	001	Aug 16, 2021	Jun CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	CARBAMAZEPINE					
AB	@ AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023	Sep DISC
		100MG	A216193	001	Mar 24, 2023	Mar NEWA
AB	@	200MG	A216193	002	Mar 24, 2023	Sep DISC
AB	@	200MG	A216193	002	Mar 24, 2023	Mar NEWA
AB	@	400MG	A216193	003	Mar 24, 2023	Sep DISC
AB		400MG	A216193	003	Mar 24, 2023	Mar NEWA
AB	AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Sep NEWA
AB		200MG	A212704	002	Sep 22, 2023	Sep NEWA

**TABLET, EXTENDED RELEASE;ORAL
CARBAMAZEPINE**

AB		400MG	A212704	003	Sep 22, 2023	Sep NEWA
AB	RICONPHARMA LLC	100MG	A216404	001	Dec 02, 2022	Jun CMFD
AB		200MG	A216404	002	Dec 02, 2022	Jun CMFD
AB		400MG	A216404	003	Dec 02, 2022	Jun CMFD
AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb NEWA
AB		200MG	A216235	002	Mar 02, 2023	Feb NEWA
AB		400MG	A216235	003	Mar 02, 2023	Feb NEWA

CARBIDOPA

**TABLET;ORAL
CARBIDOPA**

>A>	AB	BEXIMCO PHARMS USA	25MG	A217961	001	Dec 11, 2023	Dec NEWA
-----	----	--------------------	------	---------	-----	--------------	----------

CARBIDOPA; LEVODOPA

**TABLET;ORAL
CARBIDOPA AND LEVODOPA**

AB	@ ZYDUS PHARMS	10MG;100MG	A215999	001	Apr 04, 2023	Aug DISC
AB	@	10MG;100MG	A215999	001	Apr 04, 2023	Mar NEWA
AB	@	25MG;100MG	A215999	002	Apr 04, 2023	Aug DISC
AB	@	25MG;100MG	A215999	002	Apr 04, 2023	Mar NEWA
AB	@	25MG;250MG	A215999	003	Apr 04, 2023	Aug DISC
AB		25MG;250MG	A215999	003	Apr 04, 2023	Mar NEWA

**TABLET, EXTENDED RELEASE;ORAL
CARBIDOPA AND LEVODOPA**

AB	! SCIEGEN PHARMS INC	50MG;200MG	A214091	002	Oct 05, 2021	May CHRS
AB	SUN PHARM IND	50MG;200MG	A077828	002	Aug 23, 2007	May CHRS

**TABLET, ORALLY DISINTEGRATING;ORAL
CARBIDOPA AND LEVODOPA**

SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009	Apr CTEC
	25MG;100MG	A078690	002	Jul 31, 2009	Apr CTEC

CARBINOXAMINE MALEATE

**SOLUTION;ORAL
CARBINOXAMINE MALEATE**

!	GENUS	4MG/5ML	A040458	001	Apr 25, 2003	Sep CAHN
---	-------	---------	---------	-----	--------------	----------

**TABLET;ORAL
CARBINOXAMINE MALEATE**

AA	! GENUS	4MG	A040442	001	Mar 19, 2003	Sep CAHN
----	---------	-----	---------	-----	--------------	----------

CARBOPLATIN

**INJECTABLE;INJECTION
CARBOPLATIN**

>D>	@ MYLAN LABS LTD	50MG/VIAL	A091510	001	May 29, 2012	Dec CAHN
>D>	@	150MG/VIAL	A091510	002	May 29, 2012	Dec CAHN
>D>	@	450MG/VIAL	A091510	003	May 29, 2012	Dec CAHN
>A>	@ NATCO PHARMA USA	50MG/VIAL	A091510	001	May 29, 2012	Dec CAHN
>A>	@	150MG/VIAL	A091510	002	May 29, 2012	Dec CAHN
>A>	@	450MG/VIAL	A091510	003	May 29, 2012	Dec CAHN

**INJECTABLE;INTRAVENOUS
CARBOPLATIN**

AP	EPIC PHARMA LLC	600MG/60ML (10MG/ML)	A091268	002	Jul 28, 2010	Oct CAHN
AP	NOVAST LABS	450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CMFD
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CMFD

CARBOPROST TROMETHAMINE

**INJECTABLE;INJECTION
CARBOPROST TROMETHAMINE**

AP	ALEMBIC	EQ 0.25MG BASE/ML	A217198	001	Jun 15, 2023	Jun NEWA
AP	CAPLIN	EQ 0.25MG BASE/ML	A216882	001	Feb 13, 2023	Feb NEWA
AP	EUGIA PHARMA	EQ 0.25MG BASE/ML	A216939	001	May 25, 2023	May NEWA
AP	GLAND PHARMA LTD	EQ 0.25MG BASE/ML	A217657	001	Aug 07, 2023	Jul NEWA
AP	SOLA PHARMS	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	Jun CAHN
AP	STERISCIENCE	EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Jul NEWA
AP	WELDING	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	May NEWA

CARFILZOMIB

	POWDER; INTRAVENOUS						
	KYPROLIS						
AP	+ ONYX PHARMS AMGEN	10MG/VIAL	N 202714	003	Jun 07, 2018	Jun CAHN	
	+ !	30MG/VIAL	N 202714	002	Jun 03, 2016	Jun CAHN	
		60MG/VIAL	N 202714	001	Jul 20, 2012	Jun CAHN	

CARI普拉齐NE HYDROCHLORIDE

	CAPSULE; ORAL						
	CARI普拉齐NE HYDROCHLORIDE						
	@ ZYDUS	EQ 1.5MG BASE	A 213984	001	Sep 09, 2022	May CAHN	
	@	EQ 3MG BASE	A 213984	002	Sep 09, 2022	May CAHN	
	@	EQ 4.5MG BASE	A 213984	003	Sep 09, 2022	May CAHN	
	@	EQ 6MG BASE	A 213984	004	Sep 09, 2022	May CAHN	
	VRAYLAR						
	+! ABBVIE	EQ 1.5MG BASE	N 204370	001	Sep 17, 2015	Jan CAHN	
	+	EQ 3MG BASE	N 204370	002	Sep 17, 2015	Jan CAHN	
	+	EQ 4.5MG BASE	N 204370	003	Sep 17, 2015	Jan CAHN	
	+	EQ 6MG BASE	N 204370	004	Sep 17, 2015	Jan CAHN	

CARMUSTINE

	INJECTABLE; INJECTION						
	CARMUSTINE						
AP	@ ACCORD HLTHCARE	100MG/VIAL	A 214117	001	Dec 27, 2022	Jul DISC	
AP		100MG/VIAL	A 214117	001	Dec 27, 2022	Mar CTNA	
AP	ALEMBIC	100MG/VIAL	A 215730	001	Oct 20, 2023	Oct NEWA	
AP	MSN	100MG/VIAL	A 214814	001	May 11, 2023	May NEWA	
	@ MYLAN LABS LTD	100MG/VIAL	A 215368	001	Mar 03, 2023	Mar DISC	
AP		100MG/VIAL	A 215368	001	Mar 03, 2023	Feb NEWA	
AP	PENN LIFE	100MG/VIAL	A 209278	001	Apr 02, 2019	May CAHN	

CEFACLOR

	CAPSULE; ORAL						
	CEFACLOR						
>D> AB	HIKMA	EQ 250MG BASE	A 065350	001	Apr 03, 2007	Dec DISC	
>A>	@	EQ 250MG BASE	A 065350	001	Apr 03, 2007	Dec DISC	
>D> AB	!	EQ 500MG BASE	A 065350	002	Apr 03, 2007	Dec DISC	
>A>	@	EQ 500MG BASE	A 065350	002	Apr 03, 2007	Dec DISC	
>D> AB	YUNG SHIN PHARM	EQ 250MG BASE	A 065146	001	Jan 22, 2004	Dec CTEC	
>A>		EQ 250MG BASE	A 065146	001	Jan 22, 2004	Dec CTEC	
>D> AB		EQ 500MG BASE	A 065146	002	Jan 22, 2004	Dec CTEC	
>A>	!	EQ 500MG BASE	A 065146	002	Jan 22, 2004	Dec CTEC	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

	CAPSULE; ORAL						
	CEFADROXIL						
>D> AB	HIKMA	EQ 500MG BASE	A 065311	001	Feb 07, 2006	Dec DISC	
>A>	@	EQ 500MG BASE	A 065311	001	Feb 07, 2006	Dec DISC	
	FOR SUSPENSION; ORAL						
	CEFADROXIL						
>D> AB	HIKMA PHARMS	EQ 250MG BASE/5ML	A 091036	001	Nov 28, 2012	Dec DISC	
>A>	@	EQ 250MG BASE/5ML	A 091036	001	Nov 28, 2012	Dec DISC	
>D> AB		EQ 500MG BASE/5ML	A 091036	002	Nov 28, 2012	Dec DISC	
>A>	@	EQ 500MG BASE/5ML	A 091036	002	Nov 28, 2012	Dec DISC	
	TABLET; ORAL						
	CEFADROXIL						
>D> AB	HIKMA	EQ 1GM BASE	A 065260	001	Mar 30, 2006	Dec DISC	
>A>	@	EQ 1GM BASE	A 065260	001	Mar 30, 2006	Dec DISC	
>D> AB	! TEVA PHARMS	EQ 1GM BASE	A 062774	001	Apr 08, 1987	Dec CTEC	
>A>	!	EQ 1GM BASE	A 062774	001	Apr 08, 1987	Dec CTEC	

CEFAZOLIN SODIUM

	INJECTABLE; INJECTION						
	ANCEF IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	EQ 20MG BASE/ML	A 063002	002	Mar 28, 1991	Oct DISC	
	POWDER; INTRAVENOUS						
	CEFAZOLIN SODIUM						
+!	HQ SPCLT PHARMA	EQ 2GM BASE/VIAL	N 211413	001	May 08, 2023	May NEWA	

CEFDINIR

CAPSULE;ORAL	CEFDINIR						
AB ANDA REPOSITORY FOR SUSPENSION;ORAL	300MG	A065418	001	Jul 18, 2007	Sep CAHN		
CEFDINIR							
AB ANDA REPOSITORY	125MG/5ML	A065429	001	Jul 18, 2007	Sep CAHN		
	250MG/5ML	A065429	002	Jul 18, 2007	Sep CAHN		

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION	CEFEPIME HYDROCHLORIDE						
>D> AP QILU	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Dec CTEC		
>A> !	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Dec CTEC		
>D> AP	EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Dec CHRS		
>A> AP !	EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Dec CHRS		
>D> AP	EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Dec CHRS		
>A> AP !	EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Dec CHRS		
MAXIPIME							
>D> AP +! HOSPIRA INC	EQ 500MG BASE/VIAL	N050679	001	Jan 18, 1996	Dec DISC		
>A> + @	EQ 500MG BASE/VIAL	N050679	001	Jan 18, 1996	Dec DISC		
>D> AP +!	EQ 1GM BASE/VIAL	N050679	002	Jan 18, 1996	Dec DISC		
>A> + @	EQ 1GM BASE/VIAL	N050679	002	Jan 18, 1996	Dec DISC		
>D> AP +!	EQ 2GM BASE/VIAL	N050679	003	Jan 18, 1996	Dec DISC		
>A> + @	EQ 2GM BASE/VIAL	N050679	003	Jan 18, 1996	Dec DISC		

CEFOTAXIME SODIUM

INJECTABLE; INJECTION	CEFOTAXIME						
@ HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC		
@	EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC		
@	EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC		
@	EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC		

CEFOTETAN DISODIUM

INJECTABLE; INJECTION	CEFOTAN						
+ @ PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	May DISC		
+ @	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	May DISC		
CEFOTETAN							
! FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	May CTEC		
!	EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	May CTEC		

CEFPODOXIME PROXETIL

TABLET; ORAL	CEFPODOXIME PROXETIL						
AB ANDA REPOSITORY	EQ 100MG BASE	A065388	001	Nov 14, 2007	Sep CAHN		
AB	EQ 200MG BASE	A065388	002	Nov 14, 2007	Sep CAHN		

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS	TEFLARO						
+! ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	May CAHN		
+	600MG/VIAL	N200327	002	Oct 29, 2010	May CAHN		

CEFTAZIDIME

INJECTABLE; INJECTION	CEFTAZIDIME						
AP ! ACS DOBFAR	1GM/VIAL	A062640	002	Nov 20, 1985	May CHRS		
AP !	2GM/VIAL	A062640	003	Nov 20, 1985	May CHRS		
AP !	6GM/VIAL	A062640	004	Feb 03, 1992	May CHRS		
FORTAZ							
+ @ PAI HOLDINGS PHARM	500MG/VIAL	N050578	001	Jul 19, 1985	May DISC		
+ @	1GM/VIAL	N050578	002	Jul 19, 1985	May DISC		
+ @	2GM/VIAL	N050578	003	Jul 19, 1985	May DISC		
+ @	6GM/VIAL	N050578	004	Jul 19, 1985	May DISC		
TAZICEF							
@ HOSPIRA	500MG/VIAL	A062662	001	Mar 06, 1986	May DISC		
	500MG/VIAL	A062662	001	Mar 06, 1986	May CTEC		

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE SODIUM

AP ANDA REPOSITORY EQ 10GM BASE/VIAL A091117 001 Jan 20, 2017 Sep CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB ANDA REPOSITORY EQ 125MG BASE A065359 001 Feb 15, 2008 Sep CAHN
AB EQ 250MG BASE A065359 002 Feb 15, 2008 Sep CAHN
AB EQ 500MG BASE A065359 003 Feb 15, 2008 Sep CAHNCEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

+ @ B BRAUN EQ 750MG BASE/VIAL N050780 001 Feb 21, 2001 Jun DISC
+ ! EQ 750MG BASE/VIAL N050780 001 Feb 21, 2001 May CTEC
+ @ EQ 1.5GM BASE/VIAL N050780 002 Feb 21, 2001 Jun DISC
CEFUROXIME SODIUM
@ ACS DOBFAR SPA EQ 7.5GM BASE/VIAL A064124 001 May 30, 1997 Jun DISC
AP ! HIKMA EQ 1.5GM BASE/VIAL A065048 002 Jan 09, 2004 Jun CHRS
@ EQ 7.5GM BASE/VIAL A065046 001 Jan 09, 2004 Jun DISC
ZINACEF
+ @ PAI HOLDINGS PHARM EQ 1.5GM BASE/VIAL N050558 003 Oct 19, 1983 Jun DISC
+ @ EQ 7.5GM BASE/VIAL N050558 004 Oct 23, 1986 Jun DISC
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUM
AB ! HIKMA EQ 750MG BASE/VIAL A065048 001 Jan 09, 2004 Jun CHRS
ZINACEF
+ @ PAI HOLDINGS PHARM EQ 750MG BASE/VIAL N050558 002 Oct 19, 1983 Jun DISCCELECOXIB

CAPSULE; ORAL

CELECOXIB

@ MYLAN 50MG A078857 001 May 30, 2014 Jun DISC
@ 100MG A078857 002 Feb 11, 2015 Mar DISC
@ 200MG A078857 003 Feb 11, 2015 Jun DISC
@ 400MG A078857 004 Feb 11, 2015 Jun DISC
AB @ YABAO PHARM 100MG A212564 001 Apr 10, 2023 Sep DISC
100MG A212564 001 Apr 10, 2023 Mar NEWA
AB @ 200MG A212564 002 Apr 10, 2023 Sep DISC
200MG A212564 002 Apr 10, 2023 Mar NEWA
AB @ 400MG A212564 003 Apr 10, 2023 Sep DISC
400MG A212564 003 Apr 10, 2023 Mar NEWA
SOLUTION; ORAL
ELYXYB
+! SCILEX HLDG 25MG/ML N212157 001 May 05, 2020 Nov CMFD
+ @ 25MG/ML N212157 001 May 05, 2020 Feb CAHNCEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB ! ALKEM LABS LTD EQ 750MG BASE A090836 004 Mar 29, 2013 Nov CTEC
AB ANDA REPOSITORY EQ 250MG BASE A065248 001 Jun 28, 2005 Sep CAHN
AB EQ 500MG BASE A065248 002 Jun 28, 2005 Sep CAHN
AB AUROBINDO PHARMA EQ 750MG BASE A065253 003 Dec 06, 2023 Nov NEWA
>D> AB HIKMA EQ 250MG BASE A065215 001 Jan 24, 2006 Dec DISC
>A> @ EQ 250MG BASE A065215 001 Jan 24, 2006 Dec DISC
>D> AB EQ 500MG BASE A065215 002 Jan 24, 2006 Dec DISC
>A> @ EQ 500MG BASE A065215 002 Jan 24, 2006 Dec DISCCETIRIZINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ZERVIAZE

+! HARROW EYE EQ 0.24% BASE N208694 001 May 30, 2017 Oct CAHN

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA BIONPHARMA 5MG/5ML A078488 001 Oct 06, 2008 Jun CAHN

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS

CETRORELIX ACETATE

AP TEVA PHARMS INC EQ 0.25MG BASE/VIAL A215737 001 Aug 12, 2022 Jul CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB AUROBINDO PHARMA 30MG A215056 001 Apr 18, 2023 Apr NEWA
AB BIONPHARMA 30MG A218290 001 Nov 08, 2023 Nov NEWA
AB RUBICON 30MG A216682 001 Apr 06, 2023 Mar NEWACHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+! WAYLIS THERAP 2MG N010669 002 Sep CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB ALEMBIC 5MG;2.5MG A216969 001 Sep 15, 2023 Sep NEWA
AB AUROBINDO PHARMA LTD 5MG;2.5MG A216419 001 Sep 14, 2023 Sep NEWA
>A> @ TORRENT 5MG;2.5MG A217385 001 Dec 14, 2023 Dec DISCCHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT CHARTWELL RX 0.12% A075006 001 Mar 03, 2004 Jan CAHN

CHLOROPROCAINE HYDROCHLORIDE

SOLUTION; INTRATHECAL

CLOROTEKAL

+ @ B BRAUN MEDICAL INC 50MG/5ML (10MG/ML) N208791 001 Sep 26, 2017 Sep DISC

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

+ @ RISING 250MG N011145 004 Sep CAHN

+ @ 500MG N011145 002 Sep CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

>D> AP SAGENT PHARMS INC EQ 500MG BASE/VIAL A202462 001 May 29, 2015 Dec CHRS
>A> AP ! EQ 500MG BASE/VIAL A202462 001 May 29, 2015 Dec CHRS
>D> DIURIL
>D> AP +! RISING EQ 500MG BASE/VIAL N011145 005 Dec DISC
>A> + @ EQ 500MG BASE/VIAL N011145 005 Dec DISC
AP +! EQ 500MG BASE/VIAL N011145 005 Sep CAHNCHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB ALEMBIC 10MG A217350 001 Jul 18, 2023 Jul NEWA
AB 25MG A217350 002 Jul 18, 2023 Jul NEWA
AB 50MG A217350 003 Jul 18, 2023 Jul NEWA
AB 100MG A217350 004 Jul 18, 2023 Jul NEWA
AB 200MG A217350 005 Jul 18, 2023 Jul NEWA
AB AMNEAL PHARMS CO 10MG A209755 001 Sep 10, 2018 Apr CTEC
AB 25MG A209755 002 Sep 10, 2018 Apr CTEC
AB 50MG A209755 003 Sep 10, 2018 Apr CTEC
AB 100MG A209755 004 Sep 10, 2018 Apr CTEC
AB 200MG A209755 005 Sep 10, 2018 Apr CTEC
AB APPCO 10MG A213590 001 Aug 31, 2020 Jul CMFD
AB 25MG A213590 002 Aug 31, 2020 Jul CMFD
AB 50MG A213590 003 Aug 31, 2020 Jul CMFD
AB 100MG A213590 004 Aug 31, 2020 Jul CMFD
AB 200MG A213590 005 Aug 31, 2020 Jul CMFD
AB CHARTWELL RX 10MG A212630 001 Nov 29, 2021 Sep CAHN
AB 25MG A212630 002 Nov 29, 2021 Sep CAHN
AB 50MG A212630 003 Nov 29, 2021 Sep CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		100MG	A212630	004	Nov 29, 2021	Sep CAHN
AB		200MG	A212630	005	Nov 29, 2021	Sep CAHN
AB	LUPIN	10MG	A213327	001	Jul 13, 2023	Jul NEWA
AB		25MG	A213327	002	Jul 13, 2023	Jul NEWA
AB		50MG	A213327	003	Jul 13, 2023	Jul NEWA
AB		100MG	A213327	004	Jul 13, 2023	Jul NEWA
AB		200MG	A213327	005	Jul 13, 2023	Jul NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA	@ ACME LABS	500MG	A214365	001	Apr 27, 2023	Nov DISC
AB	APPCO	375MG	A214365	001	Apr 27, 2023	Apr NEWA
AB		750MG	A212047	001	Jan 27, 2023	Jan NEWA
AB	APTAPHARMA INC	375MG	A212047	002	Jan 27, 2023	Jan NEWA
AB		750MG	A212053	001	Sep 14, 2020	Sep CAHN
AB	AUROBINDO PHARMA LTD	375MG	A212053	002	Sep 14, 2020	Sep CAHN
AB		750MG	A089853	002	Aug 17, 2023	Aug NEWA
AA	BELCHER	250MG	A089853	003	Aug 17, 2023	Aug NEWA
AA	COREPHARMA	250MG	A215540	001	Jan 24, 2023	Jan NEWA
AA	GRAVITI PHARMS	250MG	A214702	001	Apr 10, 2023	Mar NEWA
AA	RISE PHARMA	250MG	A216925	001	Aug 09, 2023	Jul NEWA
AB	UPSHER SMITH LABS	375MG	A215158	001	Jul 29, 2021	Sep CAHN
AB		750MG	A212047	001	Jan 27, 2023	Sep CAHN
			A212047	002	Jan 27, 2023	Sep CAHN

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

@ ANI PHARMS

EQ 4GM RESIN/PACKET

@

EQ 4GM RESIN/SCOOPFUL

A074554 001 Oct 02, 1996 Aug DISC

A074554 002 Oct 02, 1996 Aug DISC

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

+ MIRUM

50MG

N205750 001 Mar 17, 2015 Sep CAHN

+!

250MG

N205750 002 Mar 17, 2015 Sep CAHN

CHOLINE FENOFOBIRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFOBIRIC ACID

AB	SCINOPHARM TAIWAN	EQ 45MG FENOFOBIRIC ACID	A210469	001	Jul 05, 2019	Sep CAHN
AB		EQ 135MG FENOFOBIRIC ACID	A210469	002	Jul 05, 2019	Sep CAHN

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

>D>	@ PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	Dec CAHN
	@	1%	A209975	001	Apr 05, 2018	May DISC
>A>	@ VERTICE	1%	A209975	001	Apr 05, 2018	Dec CAHN
	SOLUTION;TOPICAL					
	CICLOPIROX					
AT	ENCUBE	8%	A077687	001	Sep 18, 2007	Oct CMFD
AT	! PADAGIS US	8%	A077623	001	Sep 18, 2007	Jan CHRS

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

@ AUROBINDO PHARMA USA

50MG

A077019 001 Nov 23, 2004 Apr CAHN

@

100MG

A077019 002 Nov 23, 2004 Apr CAHN

@ CASI PHARMS INC

50MG

A077310 001 Nov 08, 2005 Nov DISC

@

100MG

A077021 001 Nov 23, 2004 Nov DISC

AB	EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005	Jun CMFD
AB		100MG	A077022	001	Nov 23, 2004	Jun CMFD

CIMETIDINE

TABLET;ORAL
CIMETIDINE
@ PLIVA 800MG A074566 001 Feb 27, 1997 Sep DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE
AA ! PAI HOLDINGS PHARM EQ 300MG BASE/5ML A074664 001 Oct 28, 1997 Oct CAHN
@ PHARMOBEDIENT CNSLTG EQ 300MG BASE/5ML A074757 001 Oct 17, 1997 Sep CAHN
@ XTTRIUM LABS INC EQ 300MG BASE/5ML A074757 001 Oct 17, 1997 Jul DISC
AA EQ 300MG BASE/5ML A074757 001 Oct 17, 1997 Mar CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL
CINACALCET HYDROCHLORIDE
>D> @ AMNEAL PHARMS 30MG A204364 001 Dec 02, 2021 Dec CAHN
>D> @ 60MG A204364 002 Dec 02, 2021 Dec CAHN
>D> @ 90MG A204364 003 Dec 02, 2021 Dec CAHN
AB CHARTWELL RX EQ 30MG BASE A213325 001 May 18, 2020 Jun CAHN
AB EQ 60MG BASE A213325 002 May 18, 2020 Jun CAHN
AB EQ 90MG BASE A213325 003 May 18, 2020 Jun CAHN
AB SLATE RUN PHARMA EQ 30MG BASE A210207 001 Aug 01, 2018 Sep CAHN
AB EQ 60MG BASE A210207 002 Aug 01, 2018 Sep CAHN
AB EQ 90MG BASE A210207 003 Aug 01, 2018 Sep CAHN
>A> @ STEVENS J 30MG A204364 001 Dec 02, 2021 Dec CAHN
>A> @ 60MG A204364 002 Dec 02, 2021 Dec CAHN
>A> @ 90MG A204364 003 Dec 02, 2021 Dec CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL
CIPRO
AB + BAYER HLTHCARE 250MG/5ML N020780 001 Sep 26, 1997 May CTEC
AB +! 500MG/5ML N020780 002 Sep 26, 1997 May CTEC
CIPROFLOXACIN
AB CHARTWELL 250MG/5ML A200563 001 Mar 05, 2014 May CMFD
AB 500MG/5ML A200563 002 Mar 05, 2014 May CMFD
INJECTABLE, SUSPENSION;OTIC
OTIPIRIO
+ @ ALK ABELLO 6% (60MG/ML) N207986 001 Dec 10, 2015 Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC
CILOXAN
+! SANDOZ EQ 0.3% BASE N020369 001 Mar 30, 1998 Sep CAHN
SOLUTION/DROPS;OPHTHALMIC
CILOXAN
AT +! SANDOZ EQ 0.3% BASE N019992 001 Dec 31, 1990 Sep CAHN
CIPROFLOXACIN HYDROCHLORIDE
@ AKORN EQ 0.3% BASE A076555 001 Dec 11, 2008 Feb DISC
@ PAI HOLDINGS PHARM EQ 0.3% BASE A076754 001 Jun 09, 2004 Aug DISC
AT RUBICON EQ 0.3% BASE A075928 001 Jun 09, 2004 Aug CMFD
TABLET;ORAL
CIPROFLOXACIN HYDROCHLORIDE
AB AMNEAL EQ 250MG BASE A075939 002 Jun 09, 2004 Jun CMFD
AB EQ 500MG BASE A075939 003 Jun 09, 2004 Jun CMFD
AB EQ 750MG BASE A075939 004 Jun 09, 2004 Jun CMFD
@ TARO EQ 250MG BASE A076912 002 Oct 06, 2004 Aug DISC
@ EQ 500MG BASE A076912 003 Oct 06, 2004 Aug DISC
@ EQ 750MG BASE A076912 004 Oct 06, 2004 Aug DISC

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC
CIPRO HC
+! SANDOZ EQ 0.2% BASE;1% N020805 001 Feb 10, 1998 Sep CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ RISING	212.6MG;EQ 287.5MG BASE
@	425.2MG;EQ 574.9MG BASE

A078183	001	Mar 22, 2007	Jun CAHN
A078183	002	Mar 22, 2007	Jun CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

AB	+! SANDOZ	0.3%;0.1%	N021537	001	Jul 18, 2003	Sep CAHN
AB	AKORN	0.3%;0.1%	A215768	001	Jun 09, 2023	Jun NEWA
AB	SENTISS	0.3%;0.1%	A215768	001	Jun 09, 2023	Aug CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Jun NEWA
AP		EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Jun NEWA
>A> AP	HIKMA	EQ 2MG BASE/ML	A203078	001	Jun 28, 2022	Dec CPOT
AP		EQ 2MG BASE/ML	A203079	001	Apr 19, 2023	Apr NEWA
>D> AP		EQ 10MG BASE/ML	A203078	001	Jun 28, 2022	Dec CPOT
>A> AP		EQ 10MG BASE/ML	A203078	002	Dec 18, 2023	Dec NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+	ABBVIE	EQ 10MG BASE	N020822	001	Apr 27, 2000	Feb CAHN
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Feb CAHN
AB	+!		EQ 40MG BASE	N020822	003	Jul 17, 1998	Feb CAHN
	@		EQ 60MG BASE	N020822	004	Jul 17, 1998	Feb CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

SANDOZ	125MG/5ML	A065283	002	Sep 04, 2007	May CTEC
!	250MG/5ML	A065283	003	Sep 04, 2007	May CTEC

TABLET;ORAL

CLARITHROMYCIN

@ TEVA	250MG	A065155	001	May 31, 2005	Sep DISC
@	500MG	A065155	002	May 31, 2005	Sep DISC

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB	NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016	Sep CMFD
----	------------------	-------	---------	-----	--------------	----------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	EQ 75MG BASE	A216957	001	Mar 10, 2023	Mar NEWA
AB		EQ 150MG BASE	A216957	002	Mar 10, 2023	Mar NEWA
AB		EQ 300MG BASE	A216957	003	Mar 10, 2023	Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	CHARTWELL RX	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Feb CAHN
----	--------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	! PADAGIS ISRAEL	1%	A090785	001	Mar 31, 2010	Jun CHRS
+	@ MYLAN	1%	N050801	001	Oct 22, 2004	Jun DISC

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1	ZYDUS LIFESCIENCES	EQ 1% BASE	A216587	001	Sep 19, 2023	Sep NEWA
		INJECTABLE; INJECTION				

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP	HIKMA	EQ 6MG BASE/ML	A214401	001	Apr 05, 2023	Mar NEWA
AP		EQ 12MG BASE/ML	A214401	002	Apr 05, 2023	Mar NEWA

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP		EQ 18MG BASE/ML	A214401	003	Apr 05, 2023	Mar NEWA
	SOLUTION;TOPICAL					
	CLINDAMYCIN PHOSPHATE					
AT	CHARTWELL RX	EQ 1% BASE	A209846	001	Feb 08, 2018	May CAHN
	@ PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016	Aug DISC
	@ XTTRIUM LABS INC	EQ 1% BASE	A063304	001	Jul 15, 1997	Jan CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB2	ENCUBE	1.2%;0.025%	A216943	001	Sep 01, 2023	Aug NEWA
-----	--------	-------------	---------	-----	--------------	----------

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

@ ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022	Mar DISC
@ MYLAN	2.5MG/ML	A211259	001	Oct 22, 2018	Nov DISC
@ UPSHER SMITH LABS	2.5MG/ML	A210569	001	Oct 22, 2018	Mar DISC
@ VISTAPHARM	2.5MG/ML	A210746	001	Jul 10, 2019	Oct DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2	@ NOVAST LABS	0.05%	A206805	001	Jul 31, 2017	Sep CAHN
AB1	! PADAGIS ISRAEL	0.05%	A201402	001	Aug 14, 2012	Nov CHRS
AB1	! TARO OLUX	0.05%	A208779	001	Oct 04, 2018	Nov CHRS
	+ @ MYLAN OLUX E	0.05%	N021142	001	May 26, 2000	Nov DISC
	+ @ MYLAN	0.05%	N022013	001	Jan 12, 2007	Nov DISC

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	@ CHARTWELL RX	0.05%	A211207	001	Mar 26, 2021	May CAHN
AB1	! ENCUBE	0.05%	A212982	001	Aug 28, 2020	Jun CHRS
	@ PAI HOLDINGS PHARM	0.05%	A209974	001	Apr 17, 2018	Aug DISC
	@ TORRENT	0.05%	A211836	001	Dec 30, 2019	Feb DISC
	CLOBETASOL PROPIONATE (EMOLlient)					

@ ANI PHARMS

@ PAI HOLDINGS PHARM

GEL;TOPICAL

CLOBETASOL PROPIONATE

	@ PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017	Aug DISC
	LOTION;TOPICAL					
	CLOBETASOL PROPIONATE					
	@ PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016	Aug DISC
	IMPEKLO					

+ @ MYLAN

0.05%

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

>A> AB	MACLEODS PHARMS LTD	0.05%	A215990	001	Dec 28, 2023	Dec NEWA
	@ PAI HOLDINGS PHARM	0.05%	A208589	001	Jan 23, 2019	Aug DISC
	SHAMPOO;TOPICAL					
	CLOBETASOL PROPIONATE					

@ ACTAVIS MID ATLANTIC

0.05%

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT	! TARO	0.05%	A078854	001	Jun 07, 2011	Sep DISC
	OINTMENT;TOPICAL					

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

@ EUGIA PHARMA 20MG/20ML (1MG/ML)

A212457 001 Oct 03, 2022 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	AUROBINDO PHARMA	25MG	A216440	001	Mar 20, 2023	Mar NEWA
AB		50MG	A216440	002	Mar 20, 2023	Mar NEWA
AB		75MG	A216440	003	Mar 20, 2023	Mar NEWA

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	CHEMISTRY HLTH	25MG	A211364	001	Feb 07, 2020	Sep CAHN
AB		50MG	A211364	002	Feb 07, 2020	Sep CAHN
AB		75MG	A211364	003	Feb 07, 2020	Sep CAHN
AB	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Jun CAHN
AB		50MG	A213221	002	Jun 22, 2020	Jun CAHN
AB		75MG	A213221	003	Jun 22, 2020	Jun CAHN

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB	AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998	Jan CMFD
AB		1MG	A075150	002	Oct 05, 1998	Jan CMFD
AB		2MG	A075150	003	Oct 05, 1998	Jan CMFD
@	CHARTWELL RX	0.5MG	A074925	001	Sep 30, 1997	Sep CAHN
@		1MG	A074925	002	Sep 30, 1997	Sep CAHN
@		2MG	A074925	003	Sep 30, 1997	Sep CAHN

CLONIDINE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

>D> AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Dec DISC
>A>	@	0.1MG	A202792	001	May 15, 2015	Dec DISC
>D> AB1	AJANTA PHARMA LTD	0.1MG	A209686	001	Nov 20, 2017	Dec CHRS
>A> AB1	!	0.1MG	A209686	001	Nov 20, 2017	Dec CHRS
@	AMNEAL PHARMS NY	0.1MG	A210052	001	Nov 20, 2017	Oct DISC
>D>	KAPVAY					
>D> AB1	+! CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Dec DISC
>A>	+ @	0.1MG	N022331	003	Sep 28, 2010	Dec DISC

CLOPIDOGREL BISULFATETABLET;ORAL
CLOPIDOGREL BISULFATE

>A> AB	ALKEM LABS LTD	EQ 75MG BASE	A203632	001	Dec 08, 2023	Dec NEWA
@	CHARTWELL RX	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jun CAHN
@		EQ 300MG BASE	A202266	002	Nov 20, 2012	Jun CAHN
AB	HETERO LABS LTD V	EQ 75MG BASE	A205345	001	Aug 04, 2023	Aug NEWA
AB		EQ 300MG BASE	A205345	002	Aug 04, 2023	Aug NEWA
AB	RISING	EQ 75MG BASE	A204359	001	Feb 02, 2017	Aug CAHN
@	SUN PHARM	EQ 75MG BASE	A090494	001	May 17, 2012	Sep DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@	DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987	Feb CAHN
@		7.5MG	A071510	001	Oct 19, 1987	Feb CAHN
@		15MG	A071511	001	Oct 19, 1987	Feb CAHN
	TRANXENE					
>A>	+ @ AJENAT PHARMS	3.75MG	N017105	001		Dec CAHN
>A>	+ @	7.5MG	N017105	002		Dec CAHN
>A>	+ @	15MG	N017105	003		Dec CAHN
>D>	+ @ KEY THERAP	3.75MG	N017105	001		Dec CAHN
>D>	+ @	7.5MG	N017105	002		Dec CAHN
>D>	+ @	15MG	N017105	003		Dec CAHN

TABLET;ORAL

TRANXENE

>A>	+ @ AJENAT PHARMS	3.75MG	N017105	006		Dec CAHN
>A> AB	+	7.5MG	N017105	007		Dec CAHN
>A>	+ @	15MG	N017105	008		Dec CAHN
>D>	+ @ KEY THERAP	3.75MG	N017105	006		Dec CAHN
>D> AB	+	7.5MG	N017105	007		Dec CAHN
>D>	+ @	15MG	N017105	008		Dec CAHN
	TRANXENE SD					
>A>	+ @ AJENAT PHARMS	11.25MG	N017105	005		Dec CAHN
>A>	+ @	22.5MG	N017105	004		Dec CAHN
>D>	+ @ KEY THERAP	11.25MG	N017105	005		Dec CAHN
>D>	+ @	22.5MG	N017105	004		Dec CAHN

CLOTRIMAZOLE

CREAM;TOPICAL
LOTRIMIN
+ @ SCHERING PLOUGH 1% N017619 001 Sep CRLD
SOLUTION;TOPICAL
CLOTRIMAZOLE
AT SCIEGEN PHARMS INC 1% A216569 001 Oct 16, 2023 Oct NEWA

CLOZAPINE

TABLET;ORAL
CLOZAPINE
@ DR REDDYS LABS SA 25MG A203807 001 Sep 17, 2015 Apr CAHN
@ 50MG A203807 003 Aug 22, 2017 Apr CAHN
@ 100MG A203807 002 Sep 17, 2015 Apr CAHN
@ 200MG A203807 004 Aug 22, 2017 Apr CAHN
@ MAYNE PHARMA 25MG A203807 001 Sep 17, 2015 Apr DISC
@ 50MG A203807 003 Aug 22, 2017 Apr DISC
@ 100MG A203807 002 Sep 17, 2015 Apr DISC
@ 200MG A203807 004 Aug 22, 2017 Apr DISC
TABLET, ORALLY DISINTEGRATING;ORAL
CLOZAPINE
AB MYLAN 150MG A201824 004 Aug 07, 2023 Jul NEWA
AB 200MG A201824 005 Aug 07, 2023 Jul NEWA
AB TEVA PHARMS USA 150MG A203039 001 Nov 25, 2015 Jul CTEC
AB 200MG A203039 002 Nov 25, 2015 Jul CTEC

COCAINE HYDROCHLORIDE

SOLUTION;NASAL
NUMBRINO
+! OMNIVIUM PHARMS 4% N209575 001 Jan 10, 2020 Aug CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE
+ @ ACTAVIS MID ATLANTIC 10MG/5ML; 6.25MG/5ML A088763 001 Oct 31, 1984 Sep DISC
AA ! TRIS PHARMA INC 10MG/5ML; 6.25MG/5ML A200386 001 Jun 29, 2012 Sep CHRS

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL
TRIACIN-C
! ANIMA 10MG/5ML; 30MG/5ML; 1.25MG/5ML A088704 001 Mar 22, 1985 Mar CAHN

COLCHICINE

CAPSULE;ORAL
COLCHICINE
AB PAR PHARM INC 0.6MG A208678 001 Nov 29, 2018 Jun CMFD
MITIGARE
AB +! HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014 Jun CTEC
TABLET;ORAL
LODOC
+! AGEPHA PHARMA FZ 0.5MG N215727 001 Jun 16, 2023 Jun NEWA

COLCHICINE; PROBENECID

TABLET;ORAL
PROBENECID AND COLCHICINE
AB RISING 0.5MG;500MG A217030 001 Oct 24, 2023 Oct NEWA

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL
COLESEVELAM HYDROCHLORIDE
AB IMPAX 3.75GM/PACKET A212886 001 Jan 18, 2023 Jan NEWA
TABLET;ORAL
COLESEVELAM HYDROCHLORIDE
@ CHARTWELL RX 625MG A201354 001 Dec 17, 2020 May CAHN
@ UNITED RES LABS 625MG A213456 001 Jan 21, 2022 Sep DISC
AB 625MG A213456 001 Jan 21, 2022 Sep CAHN

COLESTIPOL HYDROCHLORIDE

TABLET;ORAL

COLESTIPOL HYDROCHLORIDE

AB	ANI PHARMS	1GM	A216517	001	Mar 10, 2023	Apr CAHN
AB	PRAZGEN	1GM	A216517	001	Mar 10, 2023	Mar NEWA

>D> COPANLISIB DIHYDROCHLORIDE

>D> POWDER; INTRAVENOUS

>D> ALIQOPA

>D>	+! BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017	Dec DISC
>A>	+ @	60MG/VIAL	N209936	001	Sep 14, 2017	Dec DISC

CORTISONE ACETATE

TABLET;ORAL

CORTISONE ACETATE

@ HIKMA INTL PHARMS	25MG	A080776	002		Jul DISC
---------------------	------	---------	-----	--	----------

CRIZOTINIB

CAPSULE, PELLETS;ORAL

XALKORI

+ PF PRISM CV	20MG	N217581	001	Sep 07, 2023	Sep NEWA
+	50MG	N217581	002	Sep 07, 2023	Sep NEWA
+!	150MG	N217581	003	Sep 07, 2023	Sep NEWA

CROMOLYN SODIUM

SOLUTION;INHALATION

CROMOLYN SODIUM

AN	@ EUGIA PHARMA	10MG/ML	A074209	001	Apr 26, 1994	May CAHN
	VIRTUS	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN

SOLUTION/DROPS;OPHTHALMIC

CROMOLYN SODIUM

@ AKORN	4%	A074706	001	Apr 29, 1998	Feb DISC
! SANDOZ	4%	A075282	001	Jun 16, 1999	Feb CTEC
AT ! SANDOZ INC	4%	A075282	001	Jun 16, 1999	Feb CHRS

CROTAMITON

LOTION;TOPICAL

CROTAN

>A> AT	LEGACY PHARMA	10%	A087204	001		Dec CAHN
>D> AT	MARNEL PHARMS	10%	A087204	001		Dec CAHN

CYANOCOBALAMIN

SPRAY, METERED;NASAL

CYANOCOBALAMIN

AB	LUPIN	0.5MG/SPRAY	A210629	001	Jun 30, 2023	Jun NEWA
AB	PADAGIS ISRAEL	0.5MG/SPRAY	A212458	001	Sep 09, 2020	Nov CMFD
AB	NASCOBAL					
AB	+! ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Jun CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

@ APOTEX	15MG	A206703	001	Jul 24, 2018	Mar DISC
@	30MG	A206703	002	Jul 24, 2018	Mar DISC

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	CHARTWELL RX	5MG	A078218	002	Jun 19, 2015	Feb CAHN
AB		7.5MG	A078218	003	Nov 03, 2020	Feb CAHN
AB		10MG	A078218	001	Apr 18, 2008	Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOGYL

+! ALCON LABS INC	0.5%	A084109	001		Feb CTEC
@ AKORN	0.5%	A205937	001	Dec 09, 2015	Feb DISC

CYCLOPHOSPHAMIDE

	CAPSULE;ORAL						
	CYCLOPHOSPHAMIDE						
>A> AB	ZYDUS LIFESCIENCES	25MG	A211552	001	Dec 13, 2023	Dec CAHN	
>A> AB		50MG	A211552	002	Dec 13, 2023	Dec CAHN	
	INJECTABLE;INJECTION						
	CYCLOPHOSPHAMIDE						
>A> AP	RK PHARMA	500MG/VIAL	A216958	001	Dec 18, 2023	Dec NEWA	
>A> AP		1GM/VIAL	A216958	002	Dec 18, 2023	Dec NEWA	
>A> AP		2GM/VIAL	A216958	003	Dec 18, 2023	Dec NEWA	
AP	SAGENT PHARMS INC	500MG/VIAL	A214529	001	Jul 17, 2023	Jul NEWA	
AP		1GM/VIAL	A214529	002	Jul 17, 2023	Jul NEWA	
AP		2GM/VIAL	A214529	003	Jul 17, 2023	Jul NEWA	
AP	SUNNY	500MG/VIAL	A215089	001	Oct 26, 2023	Oct NEWA	
AP		1GM/VIAL	A215089	002	Oct 26, 2023	Oct NEWA	
AP		2GM/VIAL	A215089	003	Oct 26, 2023	Oct NEWA	
AP	XGEN PHARMS	500MG/VIAL	A211757	001	Oct 18, 2022	May CAHN	
AP		1GM/VIAL	A211757	002	Oct 18, 2022	May CAHN	
AP		2GM/VIAL	A211757	003	Oct 18, 2022	May CAHN	
	SOLUTION;INTRAVENOUS						
	CYCLOPHOSPHAMIDE						
+!	DR REDDYS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun NEWA	
+!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun NEWA	
+!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun NEWA	
+!	EUGIA PHARMA SPECLTS	2GM/10ML (200MG/ML)	N210735	003	Nov 20, 2023	Nov NEWA	
+ @	NEVAKAR INJECTABLES	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Aug DISC	
+!		500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jun NEWA	
+ @		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Aug DISC	
+!		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jun NEWA	
+!	SANDOZ	500MG/5ML (100MG/ML)	N217150	001	Sep 12, 2023	Sep NEWA	
+!		1GM/10ML (100MG/ML)	N217150	002	Sep 12, 2023	Sep NEWA	
+!		2GM/20ML (100MG/ML)	N217150	003	Sep 12, 2023	Sep NEWA	

CYCLOSPORINE

	EMULSION;OPHTHALMIC						
	CYCLOSPORINE						
AB	APOTEX	0.05%	A207606	001	Jan 12, 2023	Jan NEWA	
>A> AB	TEVA PHARMS USA INC	0.05%	A203880	001	Dec 14, 2023	Dec NEWA	
	VERKAZIA						
+!	HARROW EYE	0.1%	N214965	001	Jun 23, 2021	Oct CAHN	
	SOLUTION;OPHTHALMIC						
	VEVYE						
+!	HARROW EYE	0.1%	N217469	001	May 30, 2023	Sep CAHN	
+!	NOVALIQ GMBH	0.1%	N217469	001	May 30, 2023	May NEWA	
	SOLUTION;ORAL						
	CYCLOSPORINE						
@	PHARMOBEDIENT CNSLTG	100MG/ML	A065133	001	Sep 17, 2004	Sep CAHN	
@	XTTRIUM LABS INC	100MG/ML	A065133	001	Sep 17, 2004	Jul DISC	
AB2		100MG/ML	A065133	001	Sep 17, 2004	Jan CAHN	
	SANDIMMUNE						
+!	NOVARTIS	100MG/ML	N050574	001	Nov 14, 1983	Jul CTEC	

CYPROHEPTADINE HYDROCHLORIDE

	SYRUP;ORAL						
	CYPROHEPTADINE HYDROCHLORIDE						
AA	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN	
	TABLET;ORAL						
	CYPROHEPTADINE HYDROCHLORIDE						
AA	CHARTWELL RX	4MG	A088212	001	May 26, 1983	Mar CMFD	
+ @	HERITAGE PHARMA	4MG	A087056	001		Nov DISC	
AA	KENTON	4MG	A040644	001	May 30, 2006	Sep CAHN	
AA	RISING	4MG	A207555	001	Jan 31, 2017	Aug CAHN	
@		4MG	A207783	001	Dec 29, 2016	May DISC	
AA	! ZYDUS PHARMS	4MG	A208938	001	May 19, 2017	Nov CHRS	

CYSTEINE HYDROCHLORIDE

	SOLUTION;INTRAVENOUS						
	ELCYS						
>A>	+! EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Dec NEWA	

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

>A> AB	APOTEX	EQ 75MG BASE	A208070	001	Dec 15, 2023	Dec NEWA
>A> AB		EQ 110MG BASE	A208070	002	Dec 15, 2023	Dec NFTG
>A> AB		EQ 150MG BASE	A208070	003	Dec 15, 2023	Dec NEWA
	PRADAXA					
>D>	+ BOEHRINGER INGELHEIM	EQ 110MG BASE	N022512	003	Nov 20, 2015	Dec CFTG
>A> AB	+ BOEHRINGER INGELHEIM	EQ 110MG BASE	N022512	003	Nov 20, 2015	Dec CFTG

DABRAFENIB MESYLATE

TABLET, FOR SUSPENSION;ORAL

TAFINLAR

+! NOVARTIS

EQ 10MG BASE

N217514 001 Mar 16, 2023 Mar NEWA

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

>D> AP	HONG KONG	200MG/VIAL	A075259	002	Aug 27, 1998	Dec CAHN
	AP	200MG/VIAL	A075259	002	Aug 27, 1998	Nov CAHN
>D> AP	!	500MG/VIAL	A075259	001	Sep 22, 2000	Dec CAHN
	AP	500MG/VIAL	A075259	001	Sep 22, 2000	Nov CAHN
>A> AP	MEITHEAL	200MG/VIAL	A075259	002	Aug 27, 1998	Dec CAHN
>A> AP	!	500MG/VIAL	A075259	001	Sep 22, 2000	Dec CAHN

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

DALVANCE

+! ABBVIE

EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jun CAHN

DAPRODUSTAT

TABLET;ORAL

JESDUVROQ

+	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	Feb NEWA
+		2MG	N216951	002	Feb 01, 2023	Feb NEWA
+		4MG	N216951	003	Feb 01, 2023	Feb NEWA
+		6MG	N216951	004	Feb 01, 2023	Feb NEWA
+!		8MG	N216951	005	Feb 01, 2023	Feb NEWA

DAPSONE

GEL;TOPICAL

ACZONE

AB	+! ABBVIE	5%	N021794	001	Jul 07, 2005	Jun CAHN
	DAPSONE					
AB	ACRUX DDS	5%	A213907	001	Jun 06, 2023	May NEWA
AB	ALEMPLIC	7.5%	A215718	001	Oct 27, 2023	Oct NEWA
AB	AMNEAL	5%	A209890	001	Oct 19, 2023	Oct NEWA
AB		7.5%	A212701	001	May 31, 2023	May NEWA
AB	BELOTECA	5%	A213907	001	Jun 06, 2023	Sep CAHN
AB	ENCUBE	5%	A212383	001	Oct 13, 2023	Oct NEWA
AB	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Oct NEWA
AB		7.5%	A212657	001	Nov 01, 2023	Oct NEWA

TABLET;ORAL

DAPSONE

>D> AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Dec DISC
>A>	@	25MG	A205429	001	Jan 07, 2016	Dec DISC
>D> AB		100MG	A205429	002	Jan 07, 2016	Dec DISC
>A>	@	100MG	A205429	002	Jan 07, 2016	Dec DISC
	@ CHARTWELL RX	25MG	A204074	001	May 10, 2016	Sep CAHN
	@	100MG	A204074	002	May 10, 2016	Sep CAHN
AB	+ EVEREST LIFE SCI	100MG	A086842	001		Jun CHRS
AB	! NOVITIUM PHARMA	100MG	A206505	002	Dec 01, 2016	Jun CHRS
AB	RISING	25MG	A207165	002	Jul 20, 2023	Jul NEWA
	@ VIRTUS	25MG	A204074	001	May 10, 2016	Sep CAHN
	@	100MG	A204074	002	May 10, 2016	Sep CAHN

DAPTO MYCIN

POWDER; INTRAVENOUS

DAPTO MYCIN

AP	HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022	Sep CMFD
@		500MG/VIAL	A215890	001	Aug 18, 2022	Feb DISC
>D>	@ HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021	Dec CMFD
>A>	AP	500MG/VIAL	A212250	001	Apr 21, 2021	Dec CMFD
AP	MYLAN	500MG/VIAL	A213966	001	Aug 07, 2023	Jul NEWA
AP	! QILU PHARM HAINAN	500MG/VIAL	A215316	001	Aug 24, 2021	May CHRS
+!	XELLIA PHARMS APS	350MG/VIAL	N217415	001	Jan 30, 2023	Jan NEWA
+!		500MG/VIAL	N217415	002	Jan 30, 2023	Jan NEWA
SOLUTION; INTRAVENOUS						
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE						
+!	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N213645	002	Feb 27, 2023	Mar NEWA
+!		500MG/50ML (10MG/ML)	N213645	003	Feb 27, 2023	Mar NEWA
+!		700MG/100ML (7MG/ML)	N213645	004	Feb 27, 2023	Mar NEWA
+!		1GM/100ML (10MG/ML)	N213645	005	Feb 27, 2023	Mar NEWA

DARUNAVIR

TABLET; ORAL

DARU NAVTR

>A>	AB	AMNEAL	600MG	A212493	001	Dec 08, 2023	Dec NEWA
>A>	AB		800MG	A212493	002	Dec 08, 2023	Dec NEWA
	AB	AUROBINDO PHARMA LTD	600MG	A210677	001	Nov 28, 2023	Nov NEWA
	AB		800MG	A210677	002	Nov 28, 2023	Nov NEWA
	AB	CIPILA	600MG	A206288	001	Nov 28, 2023	Nov NEWA
	AB		800MG	A206288	002	Nov 28, 2023	Nov NEWA
	AB	DR REDDYS	600MG	A211578	001	Nov 28, 2023	Nov NEWA
	AB		800MG	A211578	002	Nov 28, 2023	Nov NEWA
		HETERO LABS LTD III	400MG	A202083	001	Sep 14, 2023	Sep NEWA
	AB		600MG	A202083	002	Sep 14, 2023	Sep NEWA
	AB	MSN	600MG	A215389	001	Nov 28, 2023	Nov NEWA
	AB		800MG	A215389	002	Nov 28, 2023	Nov NEWA
>A>	AB	ZYDUS PHARMS	600MG	A214085	001	Dec 13, 2023	Dec NEWA
>A>	AB		800MG	A214085	002	Dec 13, 2023	Dec NEWA

DASATINIB

TABLET; ORAL

PHYRAGO

>A>	+	NANOCOPOEIA	20MG	N216099	001	Dec 05, 2023	Dec NEWA
>A>	+		50MG	N216099	002	Dec 05, 2023	Dec NEWA
>A>	+		70MG	N216099	003	Dec 05, 2023	Dec NEWA
>A>	+		80MG	N216099	004	Dec 05, 2023	Dec NEWA
>A>	+!		100MG	N216099	005	Dec 05, 2023	Dec NEWA
>A>	+		140MG	N216099	006	Dec 05, 2023	Dec NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE: INJECTION

DAUNOBUBTCIN HYDROCHLORIDE

>D>	AP	HONG KONG	EQ	5MG	BASE/ML	A065035	001	Jan 24,	2000	Dec CAHN
	AP		EQ	5MG	BASE/ML	A065035	001	Jan 24,	2000	Oct CAHN
>A>	AP	MEITHEAL	EQ	5MG	BASE/ML	A065035	001	Jan 24,	2000	Dec CAHN

DEFERASIROX

GRANULE; ORAL

DEFFERASTROX

AB	ANNORA PHARMA	90MG	A216229	003	Mar 16, 2023	Mar NEWA
	TABLET;ORAL					
	DEFERASIROX					
>D>	@ AMNEAL	90MG	A210727	001	Dec 27, 2019	Dec CAHN
>D>	@	180MG	A210727	003	Jun 15, 2020	Dec CAHN
>D>	@	360MG	A210727	002	Dec 27, 2019	Dec CAHN
AB	AUROBINDO PHARMA LTD	90MG	A214474	001	Oct 16, 2023	Oct NEWA
AB		180MG	A214474	002	Oct 16, 2023	Oct NEWA
AB		360MG	A214474	003	Oct 16, 2023	Oct NEWA
AB	CHARTWELL RX	90MG	A212669	001	May 27, 2021	Mar CAHN
AB		180MG	A212669	002	May 27, 2021	Mar CAHN
AB		360MG	A212669	003	May 27, 2021	Mar CAHN
	@ CIPLA	90MG	A211852	001	Feb 11, 2020	Mar DISC
	@	180MG	A211852	003	Jun 15, 2020	Mar DISC
	@	360MG	A211852	002	Feb 11, 2020	Mar DISC
>A>	@ STEVENS J	90MG	A210727	001	Dec 27, 2019	Dec CAHN

TABLET;ORAL
DEFERASIROX

>A>	@	180MG	A210727	003	Jun 15, 2020	Dec CAHN
>A>	@	360MG	A210727	002	Dec 27, 2019	Dec CAHN
TABLET, FOR SUSPENSION;ORAL						
DEFERASIROX						
	@ TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Mar DISC
	@	250MG	A207124	002	Sep 23, 2022	Mar DISC
	@	500MG	A207124	003	Sep 23, 2022	Mar DISC

DEFERIPRONE

TABLET;ORAL
DEFERIPRONE

AB	! HIKMA	1GM	A213239	002	Feb 08, 2022	May CHRS
AB	TARO	1GM	A208800	002	Nov 22, 2023	Nov NEWA
FERRIPROX						
AB	+ CHIESI	1GM	N021825	002	Jul 25, 2019	May CHRS

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

AB	SANDOZ	10MG	A072103	002	May 24, 1988	Oct CMS1
AB		25MG	A072103	003	May 24, 1988	Oct CMS1
AB		50MG	A072103	004	May 24, 1988	Oct CMS1
AB		75MG	A072103	005	Jun 20, 1988	Oct CMS1
AB		150MG	A072103	006	Jun 20, 1988	Oct CMS1

DESLOTRADATINE

TABLET;ORAL
DESLOTRADATINE
@ DASH PHARMS

5MG	A078351	001	Feb 10, 2012	Feb CAHN
-----	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION
DESMOPRESSIN ACETATE

@ AM REGENT	0.004MG/ML	A091374	001	Feb 14, 2019	Oct DISC
AP GLAND	0.004MG/ML	A216904	001	Mar 20, 2023	Mar NEWA
>D> AP HONG KONG	0.004MG/ML	A074888	001	Oct 15, 1997	Dec CAHN
AP	0.004MG/ML	A074888	001	Oct 15, 1997	Sep CAHN
>A> AP METHEAL	0.004MG/ML	A074888	001	Oct 15, 1997	Dec CAHN

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB ! APOTEX	0.01MG/SPRAY	A076703	001	Jan 27, 2005	Aug CHRS
@ SUN PHARM	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Aug DISC

TABLET;ORAL

DESMOPRESSIN ACETATE

>D> @ MYLAN	0.1MG	A200653	001	Jun 27, 2014	Dec CAHN
>D> @	0.2MG	A200653	002	Jun 27, 2014	Dec CAHN
>A> @ NATCO PHARMA USA	0.1MG	A200653	001	Jun 27, 2014	Dec CAHN
>A> @	0.2MG	A200653	002	Jun 27, 2014	Dec CAHN

TABLET;SUBLINGUAL

NOCDURNA

+ @ FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018	Oct DISC
+ @	0.0553MG	N022517	002	Jun 21, 2018	Oct DISC

DESONIDE

AEROSOL, FOAM;TOPICAL
VERDESO

+ @ ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Sep DISC
--------------	-------	---------	-----	--------------	----------

LOTION;TOPICAL

DESONIDE

@ PAI HOLDINGS PHARM	0.05%	A207855	001	Sep 28, 2017	May DISC
----------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

DESONIDE

@ PAI HOLDINGS PHARM	0.05%	A212002	001	Mar 12, 2019	Aug DISC
----------------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

OINTMENT;TOPICAL
DESOXIMETASONE
@ PAI HOLDINGS PHARM 0.25% A208101 001 Feb 25, 2016 Aug DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE
>A> AB RUBICON EQ 25MG BASE A204028 003 Dec 07, 2023 Dec NEWA

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR
+ TEVA 6MG N216354 001 Feb 17, 2023 Feb NEWA
+ 12MG N216354 002 Feb 17, 2023 Feb NEWA
+! 24MG N216354 003 Feb 17, 2023 Feb NEWA

DEXAMETHASONE

ELIXIR;ORAL
DEXAMETHASONE
+ @ PHARMOBEDIENT CNSLTG 0.5MG/5ML A088254 001 Jul 27, 1983 Sep CAHN
+ @ XTTRIUM LABS INC 0.5MG/5ML A088254 001 Jul 27, 1983 Jan CAHN
SUSPENSION/DROPS;OPHTHALMIC
MAXIDEX
+! HARROW EYE 0.1% N013422 001 May CAHN

TABLET;ORAL
DEXAMETHASONE

AB	ALVOGEN	4MG	A088481	004	Apr 28, 1983	Apr CTEC
AB		6MG	A088481	001	Nov 28, 1983	Apr CTEC
AB	APOTEX	0.5MG	A217695	001	Aug 23, 2023	Nov CTEC
BP		0.5MG	A217695	001	Aug 23, 2023	Aug NEWA
AB		0.75MG	A217695	002	Aug 23, 2023	Nov CTEC
BP		0.75MG	A217695	002	Aug 23, 2023	Aug NEWA
AB		1MG	A217695	003	Aug 23, 2023	Nov CTEC
BP		1MG	A217695	003	Aug 23, 2023	Aug NEWA
AB		1.5MG	A217695	004	Aug 23, 2023	Aug NEWA
AB		2MG	A217695	005	Aug 23, 2023	Aug NEWA
AB		4MG	A217695	006	Aug 23, 2023	Aug NEWA
AB		6MG	A217695	007	Aug 23, 2023	Aug NEWA
AB	BIONPHARMA	2MG	A217538	001	Apr 26, 2023	Apr NEWA
AB		4MG	A217001	001	Apr 19, 2023	Apr NEWA
AB		6MG	A217001	002	Apr 19, 2023	Apr NEWA
AB	+ HIKMA	0.5MG	A084611	001		Nov CTEC
AB	+!	0.75MG	A084613	001		Nov CTEC
AB	+!	1MG	A088306	001	Sep 15, 1983	Nov CTEC
AB	NOVITIUM PHARMA	0.5MG	A215604	004	Oct 05, 2023	Nov NEWA
AB		0.75MG	A215604	005	Oct 05, 2023	Nov NEWA
AB		2MG	A217696	001	May 09, 2023	Apr NEWA
AB	PRASCO	4MG	A080399	002	Apr 20, 2022	Apr CMFD
@		4MG	A080399	002	Apr 20, 2022	Feb DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
AP GENEYORK PHARMS EQ 10MG PHOSPHATE/ML A214890 001 Jul 07, 2023 Jun NEWA
AP GLAND PHARMA LTD EQ 10MG PHOSPHATE/ML A215654 002 Sep 25, 2023 Sep NEWA
AP HIKMA EQ 4MG PHOSPHATE/ML A211451 001 Aug 01, 2023 Jul NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
MAXITROL
AT +! SANDOZ 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM N050065 002 Sep CAHN
SUSPENSION/DROPS;OPHTHALMIC
MAXITROL
AT +! HARROW EYE 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N050023 002 May CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

AB	+! SANDOZ	0.1%;0.3%	N050592	001	Aug 18, 1988	Sep CAHN
	TOBRADEX ST					
	+! HARROW EYE	0.05%;0.3%	N050818	001	Feb 13, 2009	Oct CAHN

TOBRAMYCIN AND DEXAMETHASONE

@ AMNEAL

0.1%;0.3%

A212991 001 Jul 15, 2021 Jun DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	AMNEAL	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A216604	001	May 15, 2023	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A216604	002	May 15, 2023	May NEWA
AP	MILLA PHARMS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A217308	001	Jun 07, 2023	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A217308	002	Jun 07, 2023	May NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
FOCALIN XR

AB	+ SANDOZ	5MG	N021802	001	May 26, 2005	Sep CAHN
AB	+ SANDOZ	10MG	N021802	002	May 26, 2005	Sep CAHN
AB	+ SANDOZ	15MG	N021802	004	Aug 01, 2006	Sep CAHN
AB	+ SANDOZ	20MG	N021802	003	May 26, 2005	Sep CAHN
AB	+ SANDOZ	25MG	N021802	008	Apr 21, 2011	Sep CAHN
AB	+ SANDOZ	30MG	N021802	005	Oct 23, 2009	Sep CAHN
AB	+ SANDOZ	35MG	N021802	007	Apr 21, 2011	Sep CAHN
AB	+! SANDOZ	40MG	N021802	006	Aug 11, 2010	Sep CAHN
	TABLET; ORAL FOCALIN					
AB	+ SANDOZ	2.5MG	N021278	001	Nov 13, 2001	Sep CAHN
AB	+ SANDOZ	5MG	N021278	002	Nov 13, 2001	Sep CAHN
AB	+! SANDOZ	10MG	N021278	003	Nov 13, 2001	Sep CAHN

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

AA	! PRASCO	5MG/5ML	A040776	001	Jan 29, 2008	Mar CAHN
	TABLET; ORAL DEXTROAMPHETAMINE SULFATE					
AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan CTEC
AA		7.5MG	A090533	003	Oct 25, 2011	Jan CTEC
AA		15MG	A090533	005	Oct 25, 2011	Jan CTEC
AA		20MG	A090533	006	Oct 25, 2011	Jan CTEC
AA		30MG	A090533	007	Oct 25, 2011	Jan CTEC
AA	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan CMFD
AA		5MG	A212160	002	Jun 07, 2021	Jan CMFD
AA		7.5MG	A212160	003	Jun 07, 2021	Jan CMFD
AA		10MG	A212160	004	Jun 07, 2021	Jan CMFD
AA		15MG	A212160	005	Jun 07, 2021	Jan CMFD
AA		20MG	A212160	006	Jun 07, 2021	Jan CMFD
AA		30MG	A212160	007	Jun 07, 2021	Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Mar CMFD
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Mar CMFD
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Mar CMFD
AP	+! ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CHRS
AP	+ FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CTEC
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Mar CMFD
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Mar CMFD

INJECTABLE; INJECTION

AP	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%	FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Mar CMFD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL	DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM						
AA	ANDA REPOSITORY	66%;10%		A214201	001	Jun 27, 2022	Sep CAHN
AA	ANNORA PHARMA	66%;10%		A215049	001	Nov 17, 2023	Nov NEWA

DIAZEPAM

GEL;RECTAL	DIASTAT ACUDIAL						
AB	+! BAUSCH	10MG/2ML (5MG/ML)		N020648	007	Sep 15, 2005	May CFTG
AB	+!	20MG/4ML (5MG/ML)		N020648	006	Sep 15, 2005	May CFTG
	DIAZEPAM						
AB	NOVEL LABS INC	10MG/2ML (5MG/ML)		A091076	001	May 30, 2023	May NFTG
AB		20MG/4ML (5MG/ML)		A091076	002	May 30, 2023	May NFTG
	TABLET;ORAL						
	DIAZEPAM						
>D>	@ AIPING PHARM INC	2MG		A070302	001	Dec 20, 1985	Dec CAHN
	@	2MG		A070302	001	Dec 20, 1985	Oct CAHN
>D>	@	5MG		A070303	001	Dec 20, 1985	Dec CAHN
	@	5MG		A070303	001	Dec 20, 1985	Oct CAHN
>D>	@	10MG		A070304	001	Dec 20, 1985	Dec CAHN
	@	10MG		A070304	001	Dec 20, 1985	Oct CAHN
>A> AB	AUROBINDO PHARMA LTD	2MG		A217843	001	Dec 14, 2023	Dec NEWA
>A> AB		5MG		A217843	002	Dec 14, 2023	Dec NEWA
>A> AB		10MG		A217843	003	Dec 14, 2023	Dec NEWA
>A>	@ CHARTWELL RX	2MG		A070302	001	Dec 20, 1985	Dec CAHN
>A>	@	5MG		A070303	001	Dec 20, 1985	Dec CAHN
>A>	@	10MG		A070304	001	Dec 20, 1985	Dec CAHN
AB	NUVO PHARM	10MG		A070464	001	Feb 25, 1986	Nov CMFD

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL	FLECTOR						
+! IBSA	1.3%			N021234	001	Jan 31, 2007	Aug CAHN

DICLOFENAC POTASSIUM

TABLET;ORAL	DICLOFENAC POTASSIUM						
@ CHARTWELL RX	50MG			A075582	001	Feb 23, 2001	May CAHN
AB SENORES PHARMS	25MG			A215787	002	Nov 09, 2023	Nov NEWA
AB	50MG			A215787	001	Mar 15, 2023	Mar NEWA

DICLOFENAC SODIUM

GEL;TOPICAL	DICLOFENAC SODIUM						
AB AMNEAL	3%			A200936	001	Oct 28, 2013	Feb CAHN
	SOLUTION;TOPICAL						
	DICLOFENAC SODIUM						
AB AUROLIFE PHARMA LLC	2%			A213040	001	Feb 03, 2023	Jan NEWA
AB @ PAI HOLDINGS PHARM	1.5%			A202769	001	Jul 08, 2015	Aug DISC
	SOLUTION/DROPS;OPHTHALMIC						
	DICLOFENAC SODIUM						
AT RUBICON	0.1%			A077600	001	Nov 13, 2008	Aug CMFD
	TABLET, DELAYED RELEASE;ORAL						
	DICLOFENAC SODIUM						
AB RUBICON	25MG			A216548	001	May 11, 2023	May NEWA
AB	50MG			A216548	002	May 11, 2023	May NEWA
AB	75MG			A216548	003	May 11, 2023	May NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	DICLOFENAC SODIUM						
@ AUROBINDO PHARMA USA	100MG			A076152	001	Dec 13, 2001	Apr CAHN

DICLOFENAC SODIUM; MISOPROSTOL

	TABLET, DELAYED RELEASE;ORAL					
	DICLOFENAC SODIUM AND MISOPROSTOL					
AB	@ ZYDUS PHARMS	50MG;0.2MG	A206771	001	Jun 12, 2023	Oct DISC
		50MG;0.2MG	A206771	001	Jun 12, 2023	Jun NEWA
AB	@	75MG;0.2MG	A206771	002	Jun 12, 2023	Oct DISC
		75MG;0.2MG	A206771	002	Jun 12, 2023	Jun NEWA

DICYCLOMINE HYDROCHLORIDE

	CAPSULE;ORAL					
	DICYCLOMINE HYDROCHLORIDE					
AB	COREPHARMA	10MG	A216639	001	Mar 24, 2023	Mar NEWA
AB	PRINSTON INC	10MG	A217531	001	Aug 30, 2023	Aug NEWA
	INJECTABLE; INJECTION					
	BENTYL					
AP	+! ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Feb CAHN
	BENTYL PRESERVATIVE FREE					
AP	+! ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Feb CAHN
	DICYCLOMINE HYDROCHLORIDE					
AP	OAK TREE PHARMA	10MG/ML	A207084	001	May 04, 2018	Aug CAHN
	@ PRAZGEN PHARMS	10MG/ML	A212058	001	Apr 26, 2019	Jul CAHN
	@ RENEW PHARMS	10MG/ML	A207084	001	May 04, 2018	Sep DISC
AP		10MG/ML	A207084	001	May 04, 2018	Aug CAHN
	TABLET;ORAL					
	DICYCLOMINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Feb CMFD
AB	BIONPHARMA	20MG	A217916	001	Aug 04, 2023	Jul NEWA
AB	TWI PHARMS	20MG	A216782	001	Jun 01, 2023	May NEWA

DIETHYLPROMION HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL					
	DIETHYLPROMION HYDROCHLORIDE					
!	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Feb CTEC

DIFLORASONE DIACETATE

	CREAM;TOPICAL					
	DIFLORASONE DIACETATE					
AB	@ AVONDALE PHARMS	0.05%	A075187	001	Mar 30, 1998	May CAHN
	OINTMENT;TOPICAL					
	DIFLORASONE DIACETATE					
AB	AVONDALE PHARMS	0.05%	A075374	001	Apr 27, 1999	May CAHN

DIFLUPREDNATE

	EMULSION;OPHTHALMIC					
	DUREZOL					
AB	+! SANDOZ	0.05%	N022212	001	Jun 23, 2008	Sep CAHN

DIHYDROERGOTAMINE MESYLATE

	INJECTABLE; INJECTION					
	DIHYDROERGOTAMINE MESYLATE					
AP	GLAND PHARMA LTD	1MG/ML	A215623	001	Aug 18, 2023	Aug NEWA
	SPRAY, METERED;NASAL					
	DIHYDROERGOTAMINE MESYLATE					
AB	AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Apr CMFD
AB	RUBICON	0.5MG/SPRAY	A216881	001	Jun 22, 2023	Jun NEWA

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL					
	DILTIAZEM HYDROCHLORIDE					
AB1	TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb NEWA
AB1		90MG	A217377	002	Mar 01, 2023	Feb NEWA
AB1		120MG	A217377	003	Mar 01, 2023	Feb NEWA
	INJECTABLE; INJECTION					
	DILTIAZEM HYDROCHLORIDE					
AP	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Mar NEWA
AP	! SAGENT	5MG/ML	A074617	001	Feb 28, 1996	Aug CAHN
	TABLET;ORAL					
	DILTIAZEM HYDROCHLORIDE					
AB	@ EDENBRIDGE PHARMS	30MG	A211596	001	Nov 18, 2019	Aug DISC
	@	60MG	A211596	002	Nov 18, 2019	Aug DISC

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

@	90MG
@	120MG

A211596	003	Nov 18, 2019	Aug DISC
A211596	004	Nov 18, 2019	Aug DISC

TABLET, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB	AMTA	120MG
AB		180MG
AB		240MG
AB		300MG
AB		360MG
AB		420MG
AB	SCIEGEN PHARMS INC	120MG
AB		180MG
AB		240MG
AB		300MG
AB		360MG
AB		420MG

A216439	001	Mar 07, 2023	Feb NEWA
A216439	002	Mar 07, 2023	Feb NEWA
A216439	003	Mar 07, 2023	Feb NEWA
A216439	004	Mar 07, 2023	Feb NEWA
A216439	005	Mar 07, 2023	Feb NEWA
A216439	006	Mar 07, 2023	Feb NEWA
A216327	001	Apr 06, 2023	Mar NEWA
A216327	002	Apr 06, 2023	Mar NEWA
A216327	003	Apr 06, 2023	Mar NEWA
A216327	004	Apr 06, 2023	Mar NEWA
A216327	005	Apr 06, 2023	Mar NEWA
A216327	006	Apr 06, 2023	Mar NEWA

DIMERCAFROL

INJECTABLE;INJECTION

BAL

+!	PROVEPHARM SAS	10%
----	----------------	-----

N005939	001		Aug CAHN
---------	-----	--	----------

DIMETHYL FUMARATECAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

AB	SOLA PHARMS	120MG
AB		240MG

A210436	001	Mar 26, 2021	Feb CMFD
A210436	002	Mar 26, 2021	Feb CMFD

DIPHENHYDRAMINE HYDROCHLORIDEELIXIR;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

+!	PHARM ASSOC	12.5MG/5ML
----	-------------	------------

A087513	001	Feb 10, 1982	Apr CRLD
---------	-----	--------------	----------

DIPYRIDAMOLEINJECTABLE;INJECTION
DIPYRIDAMOLE

@	FRESENIUS KABI USA	5MG/ML
---	--------------------	--------

A074956	001	Sep 30, 1998	Jun DISC
---------	-----	--------------	----------

TABLET;ORAL
DIPYRIDAMOLE

@	ANI PHARMS	25MG
@		50MG
@		75MG

A086944	002	Apr 16, 1991	Apr DISC
A086944	001	Feb 25, 1992	Apr DISC
A086944	003	Feb 25, 1992	Apr DISC

AB	RISING	25MG
AB		50MG
AB		75MG

A040733	001	Feb 13, 2007	Sep CAHN
A040733	002	Feb 13, 2007	Sep CAHN
A040733	003	Feb 13, 2007	Sep CAHN

DISULFIRAMTABLET;ORAL
DISULFIRAM

AB	! CHARTWELL MOLECULES	500MG
	@ DASH PHARMS	250MG
	@	500MG

>D> AB HIKMA 250MG

>A> @ 250MG

>D> AB 500MG

>A> @ 500MG

AB 500MG

A091563	002	Dec 31, 2012	Aug CHRS
A203916	001	Mar 04, 2015	Feb CAHN
A203916	002	Mar 04, 2015	Feb CAHN

A202652 001 Feb 05, 2014 Dec DISC

A202652 001 Feb 05, 2014 Dec DISC

A202652 002 Feb 05, 2014 Dec DISC

A202652 002 Feb 05, 2014 Dec DISC

A202652 002 Feb 05, 2014 Aug CHRS

DIVALPROEX SODIUMTABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

@	ACTAVIS LABS FL INC	EQ 500MG VALPROIC ACID
AB	CHARTWELL RX	EQ 125MG VALPROIC ACID
AB		EQ 250MG VALPROIC ACID
AB		EQ 500MG VALPROIC ACID

A079080	001	Feb 25, 2011	Sep DISC
A077296	001	Jul 31, 2008	Jun CAHN
A077296	002	Jul 31, 2008	Jun CAHN
A077296	003	Jul 31, 2008	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
DEPAKOTE ER

AB	+ ABBVIE	EQ 500MG VALPROIC ACID
AB	DIVALPROEX SODIUM	
AB	! AMNEAL PHARMS	EQ 500MG VALPROIC ACID

N021168	001	Aug 04, 2000	Aug CHRS
A203730	002	May 29, 2015	Aug CHRS

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB	ANNORA PHARMA	EQ 250MG VALPROIC ACID	A215527	001	Sep 26, 2023	Sep NEWA
AB		EQ 500MG VALPROIC ACID	A215527	002	Sep 26, 2023	Sep NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ALEMBIC	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb NEWA
AP		80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb NEWA
AP		160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb NEWA
@	MYLAN LABS LTD	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Sep DISC
AP		20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Apr NEWA
@		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Sep DISC
AP		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Apr NEWA
@	NOVAST LABS	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Sep CAHN
AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Sep CAHN
AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Sep CAHN
SOLUTION; INTRAVENOUS						
DOCETAXEL						
+ @	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jul CAHN
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jul CAHN
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jul CAHN
+ @	MERIDIAN LABS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	May DISC
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	May DISC
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	May DISC

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

@	RK PHARMA	0.125MG	A215323	001	Apr 14, 2022	Jun CAHN
@		0.25MG	A215323	002	Apr 14, 2022	Jun CAHN
@		0.5MG	A215323	003	Apr 14, 2022	Jun CAHN

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

+ @	EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004	Jun CRLD
-----	-----------	---------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>A>	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE					
>A> AB	ANI PHARMS	10MG;21MG	A208237	001	Dec 15, 2023	Dec NFTG
	NAMZARIC					
>D>	+ ABBVIE	10MG;21MG	N206439	004	Jul 18, 2016	Dec CFTG
>A> AB	+	10MG;21MG	N206439	004	Jul 18, 2016	Dec CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CMFD
----	---------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

AT1	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	May CTEC
AT2	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	May CTEC
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE					
AT1	AKORN	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	May CTEC
AT1		EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	May CTEC
AT1	ALEMBIC	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	May CTEC
AT1	BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009	May CTEC
AT1	EPIC PHARMA LLC	EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	Oct CAHN
AT1	EUGIA PHARMA	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	May CTEC
AT1	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	May CTEC
AT1	GLAND PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	May CTEC
AT1	HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Sep CAHN
AT1	INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May CTEC
AT2	INGENUS PHARMS LLC	EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	May CTEC
AT		EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	Apr NEWA

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT1	MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	May CTEC
AT1	SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008	May CTEC
AT1		EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	May CTEC
AT1	SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	May CTEC
	@ TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	Sep DISC
AT1		EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	May CTEC

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Sep CTEC
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Sep CTEC
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Sep CTEC
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Sep CTEC
AB	MLV	EQ 1MG BASE	A212727	001	Mar 15, 2022	Aug CAHN
AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Aug CAHN
AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Aug CAHN
AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Aug CAHN
	@ PLIVA	EQ 1MG BASE	A075750	001	Jun 08, 2001	Sep DISC
	@	EQ 2MG BASE	A075750	002	Jun 08, 2001	Sep DISC
	@	EQ 4MG BASE	A075750	003	Jun 08, 2001	Sep DISC
	@	EQ 8MG BASE	A075750	004	Jun 08, 2001	Sep DISC
AB	RISING	EQ 1MG BASE	A212727	001	Mar 15, 2022	Sep CAHN
AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Sep CAHN
AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Sep CAHN
AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Sep CAHN
>A> AB	UNICHEM	EQ 1MG BASE	A212329	001	Jan 10, 2024	Dec NEWA
>A> AB		EQ 2MG BASE	A212329	002	Jan 10, 2024	Dec NEWA
>A> AB		EQ 4MG BASE	A212329	003	Jan 10, 2024	Dec NEWA
>A> AB		EQ 8MG BASE	A212329	004	Jan 10, 2024	Dec NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	CHEMISTRY HLTH	EQ 10MG BASE	A211619	001	Mar 09, 2021	Oct CAHN
AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Oct CAHN
AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Oct CAHN
AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Oct CAHN
AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Oct CAHN
AB	MICRO LABS	EQ 10MG BASE	A217688	001	Jun 27, 2023	Jun NEWA
AB		EQ 25MG BASE	A217688	002	Jun 27, 2023	Jun NEWA
AB		EQ 50MG BASE	A217688	003	Jun 27, 2023	Jun NEWA
AB		EQ 75MG BASE	A217688	004	Jun 27, 2023	Jun NEWA
AB		EQ 100MG BASE	A217688	005	Jun 27, 2023	Jun NEWA
AB	UNIQUE PHARM	EQ 10MG BASE	A217975	001	Aug 21, 2023	Aug NEWA
AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Aug NEWA
AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Aug NEWA
AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Aug NEWA
AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Aug NEWA
AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CAHN
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CAHN
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CAHN
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CAHN
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CAHN
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CAHN
AB	ZYDUS PHARMS	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar NEWA
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar NEWA
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar NEWA
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar NEWA
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar NEWA
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar NEWA

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

!	LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	Jul CTEC
@	PHARMOBEDIENT CNSLTG	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Sep CAHN
@	XTTRIUM LABS INC	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Jul DISC

CREAM;TOPICAL

DOXEPIN HYDROCHLORIDE

AB	AMNEAL	5%	A212357	001	Aug 16, 2023	Aug NEWA
AB	TEVA PHARMS	5%	A215408	001	Feb 17, 2023	Feb NFTG

	CREAM;TOPICAL ZONALON						
AB	+! MYLAN	5%		N 020126	001	Apr 01, 1994	Feb CFTG
	TABLET;ORAL DOXEPEPIN HYDROCHLORIDE						
AB	MSN	EQ 3MG BASE		A 214823	001	Apr 03, 2023	Mar NEWA
AB		EQ 6MG BASE		A 214823	002	Apr 03, 2023	Mar NEWA
>D> AB	ZYDUS PHARMS	EQ 3MG BASE		A 202761	001	Aug 16, 2023	Dec DISC
>A>	@	EQ 3MG BASE		A 202761	001	Aug 16, 2023	Dec DISC
AB		EQ 3MG BASE		A 202761	001	Aug 16, 2023	Aug NEWA
>D> AB		EQ 6MG BASE		A 202761	002	Aug 16, 2023	Dec DISC
>A>	@	EQ 6MG BASE		A 202761	002	Aug 16, 2023	Dec DISC
AB		EQ 6MG BASE		A 202761	002	Aug 16, 2023	Aug NEWA
	<u>DOXERCALCIFEROL</u>						
	INJECTABLE;INJECTION DOXERCALCIFEROL						
AP	ALEMBIC	4MCG/2ML (2MCG/ML)		A 215810	001	Jun 15, 2023	Jun NEWA
	@ EPIC PHARMA LLC	2MCG/ML (2MCG/ML)		A 203929	002	Mar 28, 2016	Oct CAHN
	@	4MCG/2ML (2MCG/ML)		A 203929	001	May 07, 2015	Oct CAHN
	<u>DOXORUBICIN HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION DOXORUBICIN HYDROCHLORIDE						
!	HIKMA	10MG/VIAL		A 062921	001	Mar 17, 1989	Sep CTEC
@	PHARMACHEMIE BV	2MG/ML		A 063336	001	Feb 28, 1995	Sep DISC
@		10MG/VIAL		A 063097	001	May 21, 1990	Sep DISC
@		20MG/VIAL		A 063097	002	May 21, 1990	Sep DISC
@		50MG/VIAL		A 063097	003	May 21, 1990	Sep DISC
@		200MG/100ML		A 063336	004	Feb 28, 1995	Sep DISC
	INJECTABLE, LIPOSOMAL;INJECTION DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)						
AB	BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)		A 212219	001	Oct 19, 2022	Sep CAHN
AB		50MG/25ML (2MG/ML)		A 212219	002	Oct 19, 2022	Sep CAHN
	<u>DOXYCYCLINE</u>						
	TABLET;ORAL DOXYCYCLINE						
@	APPCO	EQ 50MG BASE		A 065377	001	Nov 07, 2006	Nov CAHN
@		EQ 75MG BASE		A 065377	002	Nov 07, 2006	Nov CAHN
@		EQ 100MG BASE		A 065377	003	Nov 07, 2006	Nov CAHN
@		EQ 150MG BASE		A 065427	001	Jun 07, 2007	Nov CAHN
@	UPSHER SMITH LABS	EQ 50MG BASE		A 065377	001	Nov 07, 2006	Sep CAHN
@		EQ 75MG BASE		A 065377	002	Nov 07, 2006	Sep CAHN
@		EQ 100MG BASE		A 065377	003	Nov 07, 2006	Sep CAHN
@		EQ 150MG BASE		A 065427	001	Jun 07, 2007	Sep CAHN
	<u>DOXYCYCLINE HYCLATE</u>						
	INJECTABLE;INJECTION DOXYCYCLINE						
AP	@ HIKMA	EQ 100MG BASE/VIAL		A 062569	001	Mar 09, 1988	Aug DISC
!	ZYDUS PHARMS	EQ 100MG BASE/VIAL		A 207757	001	Sep 28, 2017	Aug CHRS
	DOXYCYCLINE HYCLATE						
AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL		A 215583	001	Apr 12, 2023	Mar NEWA
	@ PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL		A 216690	001	Dec 07, 2022	Jun DISC
	TABLET;ORAL DOXYCYCLINE HYCLATE						
AB	MYLAN	EQ 100MG BASE		A 062432	001	Feb 15, 1983	Sep CMFD
@	ORYZA PHARMS SHENZHN	EQ 100MG BASE		A 213475	001	Mar 10, 2021	Feb CAHN
@	PHARMOBEDIENT	EQ 100MG BASE		A 213475	001	Mar 10, 2021	Aug CAHN
	TABLET, DELAYED RELEASE;ORAL DORYX						
AB	+ @ MAYNE PHARMA	EQ 50MG BASE		N 050795	006	Dec 19, 2014	Jun DISC
+		EQ 80MG BASE		N 050795	004	Apr 11, 2013	Aug CTEC
AB	+	EQ 80MG BASE		N 050795	004	Apr 11, 2013	Aug CFTG
+	@	EQ 100MG BASE		N 050795	002	May 06, 2005	Jun DISC
AB	+	EQ 200MG BASE		N 050795	005	Apr 11, 2013	Jul CHRS
	DORYX MPC						
AB	+ MAYNE PHARMA	EQ 60MG BASE		N 050795	007	May 20, 2016	Aug CTEC
+		EQ 60MG BASE		N 050795	007	May 20, 2016	Aug CFTG
AB	+ @	EQ 120MG BASE		N 050795	008	May 20, 2016	Jun DISC

TABLET, DELAYED RELEASE;ORALDOXYCYCLINE HYCLATE

AB	@ AUROBINDO PHARMA USA	EQ 150MG BASE	A091052	001	Feb 08, 2012	May CAHN
AB	! HERITAGE PHARMS	EQ 200MG BASE	A200856	004	Nov 13, 2018	Jul CHRS
AB	@ LUPIN	EQ 50MG BASE	A208741	001	Aug 11, 2023	Aug DISC
AB		EQ 50MG BASE	A208741	001	Aug 11, 2023	Aug NEWA
AB	@	EQ 60MG BASE	A208741	002	Aug 11, 2023	Aug DISC
AB	@	EQ 75MG BASE	A208741	003	Aug 11, 2023	Aug DISC
AB	@	EQ 75MG BASE	A208741	003	Aug 11, 2023	Aug NEWA
AB	@	EQ 80MG BASE	A208741	004	Aug 11, 2023	Aug DISC
AB	@	EQ 80MG BASE	A208741	004	Aug 11, 2023	Aug NEWA
AB	@	EQ 100MG BASE	A208741	005	Aug 11, 2023	Aug DISC
AB	@	EQ 100MG BASE	A208741	005	Aug 11, 2023	Aug NEWA
AB	@	EQ 120MG BASE	A208741	006	Aug 11, 2023	Aug DISC
AB	@	EQ 120MG BASE	A208741	006	Aug 11, 2023	Aug NEWA
AB	@	EQ 150MG BASE	A208741	007	Aug 11, 2023	Aug DISC
AB	@	EQ 200MG BASE	A208741	007	Aug 11, 2023	Aug NEWA
AB		EQ 200MG BASE	A208741	008	Aug 11, 2023	Aug DISC
			A208741	008	Aug 11, 2023	Aug NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDETABLET, DELAYED RELEASE;ORALDOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB	BIONPHARMA	10MG;10MG	A217000	001	Aug 04, 2023	Jul NEWA
----	------------	-----------	---------	-----	--------------	----------

DROPERIDOLINJECTABLE;INJECTIONDROPERIDOL

AP	! AM REGENT	2.5MG/ML	A072123	001	Oct 24, 1988	Jul CTEC
AP	! HIKMA	2.5MG/ML	A072123	001	Oct 24, 1988	Jul CHRS
AP	@ HOSPIRA	2.5MG/ML	A208197	001	Dec 14, 2017	Jul DISC
	INAPSINE	2.5MG/ML	A208197	001	Dec 14, 2017	May CAHN
+ @ AKORN		2.5MG/ML	A071981	001	Feb 29, 1988	Jul DISC
+ @ RISING		2.5MG/ML	N016796	001		Sep CAHN
			N016796	001		

DROPERIDOL; FENTANYL CITRATEINJECTABLE;INJECTIONINNOVAR

@ EPIC PHARMA LLC	2.5MG/ML; EQ 0.05MG BASE/ML	N016049	001			Nov CAHN
-------------------	-----------------------------	---------	-----	--	--	----------

DROSPIRENONONETABLET, CHEWABLE;ORALDROSPIRENONONE

+ @ EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022	Jun DISC
---------------------	-------	---------	-----	--------------	----------

DROSPIRENONONE; ETHINYLEDIENODRUGONETABLET;ORALDROSPIRENONONE AND ETHINYLEDIENODRUGONE

@ BARR	3MG;0.02MG	A078515	001	Mar 30, 2009	Sep DISC
--------	------------	---------	-----	--------------	----------

TABLET;ORAL-28DROSPIRENONONE AND ETHINYLEDIENODRUGONE

@ BARR	3MG;0.03MG	A077527	001	May 09, 2008	Sep DISC
--------	------------	---------	-----	--------------	----------

DROXIDOPACAPSULE;ORALDROXIDOPA

>A> AB	BLUEPHARMA INDUSTRIA	100MG	A214543	001	May 05, 2021	Dec CAHN
>A> AB		200MG	A214543	002	May 05, 2021	Dec CAHN
>A> AB		300MG	A214543	003	May 05, 2021	Dec CAHN
	@ CHARTWELL RX	100MG	A214217	001	May 05, 2022	May CAHN
	@	200MG	A214217	002	May 05, 2022	May CAHN
	@	300MG	A214217	003	May 05, 2022	May CAHN
>D> AB	HIKMA	100MG	A212835	001	Feb 18, 2021	Dec DISC
>A>	@	100MG	A212835	001	Feb 18, 2021	Dec DISC
>D> AB		200MG	A212835	002	Feb 18, 2021	Dec DISC
>A>	@	200MG	A212835	002	Feb 18, 2021	Dec DISC
>D> AB		300MG	A212835	003	Feb 18, 2021	Dec DISC
>A>	@	300MG	A212835	003	Feb 18, 2021	Dec DISC
>D> AB	TRIS PHARMA INC	100MG	A214543	001	May 05, 2021	Dec CAHN

	CAPSULE;ORAL DROXIDOPA						
>D>	AB	200MG	A214543	002	May 05, 2021	Dec CAHN	
>D>	AB	300MG	A214543	003	May 05, 2021	Dec CAHN	
DULOXETINE HYDROCHLORIDE							
CAPSULE, DELAYED REL PELLETS;ORAL DRIZALMA SPRINKLE							
+ @	SUN PHARM	EQ 30MG BASE	N212516	002	Jul 19, 2019	Mar DISC	
+ @		EQ 40MG BASE	N212516	003	Jul 19, 2019	Jan DISC	
+ @		EQ 60MG BASE	N212516	004	Jul 19, 2019	Mar DISC	
DULOXETINE HYDROCHLORIDE							
@	APOTEX	EQ 20MG BASE	A202045	001	Jun 11, 2014	Nov DISC	
@		EQ 30MG BASE	A202045	002	Jun 11, 2014	Nov DISC	
@		EQ 60MG BASE	A202045	003	Jun 11, 2014	Nov DISC	
AB	ZYDUS HLTHCARE	EQ 40MG BASE	A090739	004	Apr 18, 2023	Apr NEWA	
DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM							
POWDER; INTRAVENOUS XACDURO (COPACKAGED)							
+!	ENTASIS THERAP	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL	N216974	001	May 23, 2023	Jun CMS1	
+!		EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL	N216974	001	May 24, 2023	May NEWA	
DUTASTERIDE							
CAPSULE;ORAL DUTASTERIDE							
AB	ADAPTIS	0.5MG	A204376	001	Apr 07, 2017	Sep CAHN	
DYCLONINE HYDROCHLORIDE							
SOLUTION;TOPICAL DYCLOPRO							
! SEPTODONT		0.5%	A200480	001	Nov 20, 2018	May CAHN	
!		1%	A200480	002	Nov 20, 2018	May CAHN	
ECONAZOLE NITRATE							
CREAM;TOPICAL ECONAZOLE NITRATE							
>D>	@ AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Apr CAHN	
	@ PAI HOLDINGS PHARM	1%	A076574	001	Dec 17, 2004	Dec CAHN	
>A>	@ VERTICE	1%	A076574	001	Dec 17, 2004	May DISC	
			A076574	001	Dec 17, 2004	Dec CAHN	
EDETA TE CALCIUM DISODIUM							
INJECTABLE;INJECTION EDETA TE CALCIUM DISODIUM							
!	CASPER PHARMA LLC	200MG/ML 200MG/ML	A216435	001	May 03, 2023	Apr NFTG	
			A216435	001	May 03, 2023	Apr NFTG	
EFAVIRENZ							
CAPSULE;ORAL EFAVIRENZ							
AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017	Mar CTEC		
!	200MG	A078064	003	Dec 15, 2017	Mar CHRS		
	200MG	A078064	003	Dec 15, 2017	Mar CTEC		
SUSTIVA							
+ @ BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Mar DISC		
+ @	200MG	N020972	003	Sep 17, 1998	Mar DISC		
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE							
TABLET;ORAL EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE							
AB	STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Sep NEWA	
EFLORNITHINE HYDROCHLORIDE							
TABLET;ORAL IWILFIN							
>A>							
>A>	+! USWM	EQ 192MG BASE	N215500	001	Dec 13, 2023	Dec NEWA	

ELACESTRANT DIHYDROCHLORIDE

TABLET;ORAL						
ORSERDU						
+ STEMLINE THERAP	EQ 86MG BASE		N217639	001	Jan 27, 2023	Jan NEWA
+!	EQ 345MG BASE		N217639	002	Jan 27, 2023	Jan NEWA

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL						
ELETRIPTAN HYDROBROMIDE						
>D>	@ AMNEAL PHARMS CO	EQ 20MG BASE	A206787	001	May 25, 2018	Dec CAHN
>D>	@	EQ 40MG BASE	A206787	002	May 25, 2018	Dec CAHN
>A>	@ STEVENS J	EQ 20MG BASE	A206787	001	May 25, 2018	Dec CAHN
>A>	@	EQ 40MG BASE	A206787	002	May 25, 2018	Dec CAHN

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR, IVACAFTOR

GRANULES;ORAL						
TRIKAFTA (COPACKAGED)						
+ VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG		N217660	001	Apr 26, 2023	Apr NEWA
+!	100MG, 75MG, 50MG;75MG		N217660	002	Apr 26, 2023	Apr NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL						
ELIGLUSTAT TARTRATE						
AB UPSHER SMITH LABS	EQ 84MG BASE		A212420	001	May 02, 2023	Sep CAHN
AB ZENARA	EQ 84MG BASE		A212420	001	May 02, 2023	Apr NEWA

ELTROMEOFAG CHOLINE

TABLET;ORAL						
ALVAIZ						
+ TEVA PHARMS INC	EQ 9MG BASE		N216774	001	Nov 29, 2023	Nov NEWA
+	EQ 18MG BASE		N216774	002	Nov 29, 2023	Nov NEWA
+	EQ 36MG BASE		N216774	003	Nov 29, 2023	Nov NEWA
+!	EQ 54MG BASE		N216774	004	Nov 29, 2023	Nov NEWA

EMPAGLIFLOZIN

TABLET;ORAL						
EMPAGLIFLOZIN						
@ ZYDUS PHARMS	10MG		A212138	001	Aug 03, 2022	Jan DISC
@	25MG		A212138	002	Aug 03, 2022	Jan DISC
JARDIANCE						
+ BOEHRINGER INGELHEIM	10MG		N204629	001	Aug 01, 2014	Jan CTEC
+!	25MG		N204629	002	Aug 01, 2014	Jan CTEC

EMTRICITABINE

CAPSULE;ORAL						
EMTRICITABINE						
AB AUROBINDO PHARMA LTD	200MG		A079188	001	Mar 15, 2023	Mar NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL						
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
@ APOTEX	200MG;300MG		A208740	001	Jun 16, 2021	Apr DISC
@ AUROBINDO PHARMA LTD	100MG;150MG		A211640	001	Mar 09, 2023	Dec CMFD
	100MG;150MG		A211640	001	Mar 09, 2023	Dec CMFD
AB @	100MG;150MG		A211640	001	Mar 09, 2023	Sep DISC
AB	100MG;150MG		A211640	001	Mar 09, 2023	Mar NEWA
>D>	@	133MG;200MG	A211640	002	Mar 09, 2023	Dec CMFD
>A> AB		133MG;200MG	A211640	002	Mar 09, 2023	Dec CMFD
AB	@	133MG;200MG	A211640	002	Mar 09, 2023	Sep DISC
AB		133MG;200MG	A211640	002	Mar 09, 2023	Mar NEWA
>D>	@	167MG;250MG	A211640	003	Mar 09, 2023	Dec CMFD
>A> AB		167MG;250MG	A211640	003	Mar 09, 2023	Dec CMFD
AB	@	167MG;250MG	A211640	003	Mar 09, 2023	Sep DISC
AB		167MG;250MG	A211640	003	Mar 09, 2023	Mar NEWA
	CIPLA	200MG;300MG	A090958	001	Apr 02, 2021	Sep DISC

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

>A>	AB	AUROBINDO PHARMA	1MG/ML	A216458	001	Jan 08, 2024	Dec NEWA
		TABLET;ORAL					
		ENALAPRIL MALEATE					
	@	CHARTWELL RX	2.5MG	A075048	001	Aug 22, 2000	May CAHN
	@		5MG	A075048	002	Aug 22, 2000	May CAHN
	@		10MG	A075048	003	Aug 22, 2000	May CAHN
	@		20MG	A075048	004	Aug 22, 2000	May CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	Apr CMFD
----	-----------	-----------	---------	-----	--------------	----------

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	BE PHARMS	30MG/0.3ML (100MG/ML)	A214646	001	Jun 06, 2023	May NEWA
AP		40MG/0.4ML (100MG/ML)	A214646	002	Jun 06, 2023	May NEWA
AP		60MG/0.6ML (100MG/ML)	A214646	003	Jun 06, 2023	May NEWA
AP		80MG/0.8ML (100MG/ML)	A214646	004	Jun 06, 2023	May NEWA
AP		100MG/ML (100MG/ML)	A214646	005	Jun 06, 2023	May NEWA
AP		120MG/0.8ML (150MG/ML)	A214646	006	Jun 06, 2023	May NEWA
AP		150MG/ML (150MG/ML)	A214646	007	Jun 06, 2023	May NEWA
AP	GLAND	30MG/0.3ML (100MG/ML)	A078990	001	Sep 28, 2018	Jun CAHN
AP		40MG/0.4ML (100MG/ML)	A078990	002	Sep 28, 2018	Jun CAHN
AP		60MG/0.6ML (100MG/ML)	A078990	003	Sep 28, 2018	Jun CAHN
AP		80MG/0.8ML (100MG/ML)	A078990	004	Sep 28, 2018	Jun CAHN
AP		100MG/ML (100MG/ML)	A078990	005	Sep 28, 2018	Jun CAHN
AP		120MG/0.8ML (150MG/ML)	A078990	006	Sep 28, 2018	Jun CAHN
AP		150MG/ML (150MG/ML)	A078990	007	Sep 28, 2018	Jun CAHN
AP	SHENZHEN TECHDOW	30MG/0.3ML (100MG/ML)	A205660	001	Mar 15, 2023	Mar NEWA
AP		40MG/0.4ML (100MG/ML)	A205660	002	Mar 15, 2023	Mar NEWA
AP		60MG/0.6ML (100MG/ML)	A205660	003	Mar 15, 2023	Mar NEWA
AP		80MG/0.8ML (100MG/ML)	A205660	004	Mar 15, 2023	Mar NEWA
AP		100MG/ML (100MG/ML)	A205660	005	Mar 15, 2023	Mar NEWA
AP		120MG/0.8ML (150MG/ML)	A205660	006	Mar 15, 2023	Mar NEWA
AP		150MG/ML (150MG/ML)	A205660	007	Mar 15, 2023	Mar NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB	CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017	Nov DISC
	@	1MG	A206672	002	May 11, 2017	Nov DISC
AB	VITRUVIAS	0.5MG	A212106	001	Aug 10, 2020	Sep CAHN
AB		1MG	A212106	002	Aug 10, 2020	Sep CAHN

ENTRECTINIB

PELLETS;ORAL

ROZLYTREK

+! GENENTECH INC

50MG/PACKET

N218550 001 Oct 20, 2023 Oct NEWA

EPHEDRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

REZIPRES

>A>	+!	DR REDDYS LABS SA	47MG/10ML (4.7MG/ML)	N213536	004	Dec 07, 2023	Dec NEWA
-----	----	-------------------	----------------------	---------	-----	--------------	----------

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EPHEDRINE SULFATE

AP	OAK TREE PHARMA	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Aug CAHN	
	+!	OPERAND PHARMS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Jun CAHN
	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Jun CAHN
	@	RENEW PHARMS	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Nov DISC
AP			50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Aug CAHN
AP	SAGENT PHARMS INC	50MG/ML (50MG/ML)	A214528	001	Mar 09, 2023	Feb NEWA	
	@ ZYDUS PHARMS	50MG/ML (50MG/ML)	A217276	001	May 16, 2023	Sep DISC	
AP		50MG/ML (50MG/ML)	A217276	001	May 16, 2023	May NEWA	

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE
@ EPIC PHARMA LLC 0.05% A204055 001 May 05, 2017 Oct CAHN

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ADRENALIN
+! PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML) N204200 001 Dec 07, 2012 Sep CTEC
EPINEPHRINE
@ AM REGENT EQ 1MG BASE/ML (EQ 1MG BASE/ML) A207568 001 Jul 06, 2018 Sep DISC
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
SYMJEPI
+ @ ADAMIS PHARMS CORP 0.15MG/0.3ML (0.15MG/0.3ML) N207534 002 Sep 27, 2018 Oct DISC
SOLUTION;INTRAVENOUS
ADRENALIN
+! PAR STERILE PRODUCTS 2MG/250ML (8MCG/ML) N215875 001 Apr 21, 2023 Oct CTNA
+! 2MG/250ML (8MCG/ML) N215875 001 Apr 21, 2023 Apr NEWA
+! 4MG/250ML (16MCG/ML) N215875 002 Apr 21, 2023 Oct CTNA
+! 4MG/250ML (16MCG/ML) N215875 002 Apr 21, 2023 Apr NEWA
+! 5MG/250ML (20MCG/ML) N215875 003 Apr 21, 2023 Oct CTNA
+! 5MG/250ML (20MCG/ML) N215875 003 Apr 21, 2023 Apr NEWA
+! 8MG/250ML (32MCG/ML) N215875 004 Apr 21, 2023 Oct CTNA
+! 8MG/250ML (32MCG/ML) N215875 004 Apr 21, 2023 Apr NEWA
+! 10MG/250ML (40MCG/ML) N215875 005 Apr 21, 2023 Oct CTNA
+! 10MG/250ML (40MCG/ML) N215875 005 Apr 21, 2023 Apr NEWA
EPINEPHRINE
+! BPI LABS 1MG/ML (1MG/ML) N205029 003 May 12, 2023 Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
! HOSPIRA 0.01MG/ML;2% A089646 001 Jun 21, 1988 Apr CTEC
XYLOCAINE W/ EPINEPHRINE
+! FRESENIUS KABI USA 0.02MG/ML;2% N006488 005 May CTEC

EPLERENONE

TABLET;ORAL
EPLERENONE
AB ANNORA PHARMA 25MG A213812 001 Jun 02, 2023 May NEWA
AB 50MG A213812 002 Jun 02, 2023 May NEWA
AB RISING 25MG A214663 001 Mar 23, 2022 Oct CAHN
AB 50MG A214663 002 Mar 23, 2022 Oct CAHN

>A > EPLONTERSEN SODIUM

>A > SOLUTION;SUBCUTANEOUS
>A > WAINUA
>A > +! IONIS PHARMS INC EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) N217388 001 Dec 21, 2023 Dec NEWA

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION
EPOPROSTENOL SODIUM
AP2 ! SUN PHARM VELETRI EQ 0.5MG BASE/VIAL A210473 001 Jan 15, 2021 Feb CHRS
AP2 + ACTELION EQ 0.5MG BASE/VIAL N022260 002 Jun 28, 2012 Feb CHRS

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE
AP SLATE RUN PHARMA 2MG/ML A209864 001 Jan 25, 2019 Sep CAHN
AP 75MG/100ML A209864 002 Jan 25, 2019 Sep CAHN

ERGOCALCIFEROL

CAPSULE;ORAL
DRISDOL
>A > AA + SS PHARMA 50,000 IU N003444 001 Dec CAHN
>D > AA + VALIDUS PHARMS 50,000 IU N003444 001 Dec CAHN
AA + 50,000 IU N003444 001 Feb CHRS

	CAPSULE;ORAL ERGOCALCIFEROL						
AA	CHARTWELL RX	50,000 IU	A040833	001	May 20, 2009	Feb CAHN	
AA	! STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Feb CHRS	
>D> AA	SUN PHARM INDS INC	50,000 IU	A040865	001	Dec 29, 2009	Dec DISC	
>A>	@	50,000 IU	A040865	001	Dec 29, 2009	Dec DISC	
<u>ERLOTINIB HYDROCHLORIDE</u>							
	TABLET;ORAL ERTOLTINIB HYDROCHLORIDE						
AB	! ZYDUS PHARMS TARCEVA	EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr CHRS	
	+ @ OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Apr DISC	
	+ @	EQ 100MG BASE	N021743	002	Nov 18, 2004	Apr DISC	
	+ @	EQ 150MG BASE	N021743	003	Nov 18, 2004	Apr DISC	
<u>ERTUGLIFLOZIN</u>							
	TABLET;ORAL ERTUGLIFLOZIN						
AB	@ AUROBINDO PHARMA LTD	5MG	A216947	001	Jul 13, 2023	Jul DISC	
		5MG	A216947	001	Jul 13, 2023	Jul NFTG	
AB	@	15MG	A216947	002	Jul 13, 2023	Jul DISC	
		15MG	A216947	002	Jul 13, 2023	Jul NFTG	
	STEGLATRO						
AB	+ MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jul CTEC	
	+	5MG	N209803	001	Dec 19, 2017	Jul CFTG	
	+!	15MG	N209803	002	Dec 19, 2017	Jul CTEC	
AB	+!	15MG	N209803	002	Dec 19, 2017	Jul CFTG	
<u>ERYTHROMYCIN</u>							
	GEL;TOPICAL ERYTHROMYCIN						
>D>	@ PAI HOLDINGS PHARM	2%	A208154	001	Jul 19, 2017	Dec CAHN	
	@	2%	A208154	001	Jul 19, 2017	May DISC	
>A>	@ VERTICE	2%	A208154	001	Jul 19, 2017	Dec CAHN	
	OINTMENT;OPHTHALMIC ERYTHROMYCIN						
AT	SENTISS	0.5%	A064030	001	Jul 18, 1996	Aug CAHN	
	SOLUTION;TOPICAL ERYTHROMYCIN						
	@ PAI HOLDINGS PHARM	2%	A208100	001	Nov 20, 2017	Aug DISC	
	@ PHARMOBEDIENT CNSLTG	2%	A062825	001	Oct 23, 1987	Sep CAHN	
	@ XTTRIUM LABS INC	2%	A062825	001	Oct 23, 1987	Jul DISC	
	TABLET;ORAL ERYTHROMYCIN						
AB	ALEMBIC	250MG	A215661	001	Aug 24, 2023	Aug NEWA	
AB		500MG	A215661	002	Aug 24, 2023	Aug NEWA	
AB	ARBOR PHARMS LLC	500MG	A061621	002		Jan CHRS	
AB	! CADILA PHARMS LTD	500MG	A213628	002	Jun 28, 2021	Jan CHRS	
AB	ZYDUS	250MG	A212693	001	Mar 07, 2023	Feb NEWA	
AB		500MG	A212693	002	Mar 07, 2023	Feb NEWA	
>D> AB	ZYDUS PHARMS	250MG	A215440	001	Aug 31, 2023	Dec DISC	
>A>	@	250MG	A215440	001	Aug 31, 2023	Dec DISC	
AB		250MG	A215440	001	Aug 31, 2023	Aug NEWA	
>D> AB		500MG	A215440	002	Aug 31, 2023	Dec DISC	
>A>	@	500MG	A215440	002	Aug 31, 2023	Dec DISC	
AB		500MG	A215440	002	Aug 31, 2023	Aug NEWA	
<u>ERYTHROMYCIN ETHYLSUCCINATE</u>							
	TABLET;ORAL ERYTHROMYCIN ETHYLSUCCINATE						
	@ AUROBINDO PHARMA USA	EQ 400MG BASE	A062847	001	Sep 14, 1988	Apr CAHN	
<u>ERYTHROMYCIN LACTOBIONATE</u>							
	INJECTABLE;INJECTION ERYTHROMYCIN LACTOBIONATE						
	@ EXELA PHARMA	EQ 500MG BASE/VIAL	A211086	001	Sep 17, 2020	May DISC	

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA	CHARTWELL MOLECULAR LEXAPRO	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	Jul CAHN
+ @ ABBVIE		EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan CAHN
TABLET;ORAL						
	ESCITALOPRAM OXALATE					
@ DASH PHARMS	EQ 5MG BASE	A077550	001	May 14, 2015	Feb CAHN	
@	EQ 10MG BASE	A077550	002	May 14, 2015	Feb CAHN	
@	EQ 20MG BASE	A077550	003	May 14, 2015	Feb CAHN	
AB	JUBILANT CADISTA	EQ 5MG BASE	A202280	001	Sep 12, 2012	May CAHN
AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	May CAHN
AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	May CAHN
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210	001	Sep 11, 2012	Nov CMFD
AB		EQ 10MG BASE	A202210	002	Sep 11, 2012	Nov CMFD
AB		EQ 20MG BASE	A202210	003	Sep 11, 2012	Nov CMFD
	LEXAPRO					
AB	+ ABBVIE	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan CAHN
AB	+	EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan CAHN
AB	+	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan CAHN

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTOIM

AB	+ SUMITOMO PHARMA AM	200MG	N022416	001	Nov 08, 2013	Jul CAHN
AB	+	400MG	N022416	002	Nov 08, 2013	Jul CAHN
AB	+	600MG	N022416	003	Nov 08, 2013	Jul CAHN
AB	+!	800MG	N022416	004	Nov 08, 2013	Jul CAHN
	ESLICARBAZEPINE ACETATE					
AB	ALKEM LABS LTD	200MG	A211199	001	Oct 06, 2023	Sep NEWA
AB		400MG	A211199	002	Oct 06, 2023	Sep NEWA
AB		600MG	A211199	003	Oct 06, 2023	Sep NEWA
AB		800MG	A211199	004	Oct 06, 2023	Sep NEWA
>A> AB	APOTEX	200MG	A211236	001	Dec 07, 2023	Dec NEWA
>A> AB		400MG	A211236	002	Dec 07, 2023	Dec NEWA
>A> AB		600MG	A211236	003	Dec 07, 2023	Dec NEWA
>A> AB		800MG	A211236	004	Dec 07, 2023	Dec NEWA
AB	HETERO LABS LTD V	200MG	A211186	001	Aug 03, 2023	Jul NEWA
AB		400MG	A211186	002	Aug 03, 2023	Jul NEWA
AB		600MG	A211186	003	Aug 03, 2023	Jul NEWA
AB		800MG	A211186	004	Aug 03, 2023	Jul NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jan CTEC
	BREVIBLOC IN PLASTIC CONTAINER					
AP	+! BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jan CTEC
	ESMOLOL HYDROCHLORIDE					
AP	AMNEAL	1GM/100ML	A216603	001	Dec 13, 2022	Jan CPOT
AP		2GM/100ML	A216603	002	Dec 13, 2022	Jan CPOT
AP	EUGIA PHARMA	1GM/100ML	A216244	001	Mar 21, 2022	Jan CPOT
AP		2GM/100ML	A216244	002	Mar 21, 2022	Jan CPOT
	@ FRESENIUS KABI USA	10MG/ML	A076573	001	May 02, 2005	Oct DISC
	@	20MG/ML	A076573	002	Aug 23, 2023	Oct DISC
		20MG/ML	A076573	002	Aug 23, 2023	Aug NEWA
AP	HQ SPCLT PHARMA	1GM/100ML	A214172	001	Dec 02, 2022	Jan CPOT
AP		2GM/100ML	A214172	002	Dec 02, 2022	Jan CPOT
AP	MYLAN LABS LTD	1GM/100ML	A206608	001	Jun 08, 2018	Jan CPOT
AP		2GM/100ML	A206608	002	Jun 08, 2018	Jan CPOT
AP	SAGENT PHARMS INC	1GM/100ML	A207107	001	Jun 08, 2018	Jan CPOT
AP		2GM/100ML	A207107	002	Jun 08, 2018	Jan CPOT

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	GRANULES	EQ 20MG BASE	A217427	001	Oct 18, 2023	Oct NEWA
AB		EQ 40MG BASE	A217427	002	Oct 18, 2023	Oct NEWA
AB	GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Aug CMFD
AB		EQ 40MG BASE	A213859	002	Nov 18, 2020	Aug CMFD
AB	PRINSTON INC	EQ 20MG BASE	A214920	001	Mar 28, 2023	Mar NEWA

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB		EQ 40MG BASE	A214920	002	Mar 28, 2023	Mar NEWA
	@ TORRENT	EQ 20MG BASE	A203636	001	Oct 19, 2015	Aug DISC
	@	EQ 40MG BASE	A203636	002	Oct 19, 2015	Aug DISC
>A> AB	ZHEJIANG YONGTAI	EQ 20MG BASE	A217022	001	Dec 27, 2023	Dec NEWA
>A> AB		EQ 40MG BASE	A217022	002	Dec 27, 2023	Dec NEWA

FOR SUSPENSION, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

AB	ZYDUS PHARMS	EQ 20MG BASE/PACKET	A206055	001	Jun 07, 2023	May NEWA
AB		EQ 40MG BASE/PACKET	A206055	002	Jun 07, 2023	May NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	@ ACTAVIS LABS FL INC	EQ 20MG BASE;375MG	A204470	001	Aug 24, 2022	Feb DISC
	@	EQ 20MG BASE;500MG	A204470	002	Aug 24, 2022	Feb DISC
AB	! DR REDDYS	EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Aug CHRS
	@ MYLAN	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Oct DISC
	@	EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Oct DISC
AB	SCIEGEN PHARMS INC	EQ 20MG BASE;375MG	A217738	001	Oct 11, 2023	Sep NEWA
AB		EQ 20MG BASE;500MG	A217738	002	Oct 11, 2023	Sep NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jan CHRS
	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Apr CTEC

ESTRADIOL

CREAM; VAGINAL
ESTRADIOL

AB	PRASCO	0.01%	A212313	001	Jul 15, 2021	Jun CAHN
	FILM, EXTENDED RELEASE; TRANSDERMAL					
	ALORA					
	@ ABBVIE	0.025MG/24HR	N020655	004	Apr 05, 2002	Oct CAHN
	@	0.05MG/24HR	N020655	001	Dec 20, 1996	Oct CAHN
	@	0.075MG/24HR	N020655	002	Dec 20, 1996	Oct CAHN
	@	0.1MG/24HR	N020655	003	Dec 20, 1996	Oct CAHN
	ESTRADIOL					

AB2	ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA
AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Mar NEWA
	@ ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Jul DISC
AB2		0.025MG/24HR	A202985	001	Mar 29, 2023	Apr CAHN
	@	0.0375MG/24HR	A202985	002	Mar 29, 2023	Jul DISC
AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Apr CAHN
	@	0.05MG/24HR	A202985	003	Mar 29, 2023	Jul DISC
AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Apr CAHN
	@	0.06MG/24HR	A202985	004	Mar 29, 2023	Jul DISC
AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Apr CAHN
	@	0.075MG/24HR	A202985	005	Mar 29, 2023	Jul DISC
AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Apr CAHN
	@	0.1MG/24HR	A202985	006	Mar 29, 2023	Jul DISC
AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Apr CAHN

GEL; TRANSDERMAL
ESTRADIOL

AB	NOVITIUM PHARMA	0.1%	A217610	001	Aug 24, 2023	Aug NEWA
AB	PADAGIS ISRAEL	0.1%	A216524	001	Nov 14, 2023	Nov NEWA

INSERT; VAGINAL
IMVEXXY

+ MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018	Jan CAHN
+!	0.01MG	N208564	002	May 29, 2018	Jan CAHN

SYSTEM; TRANSDERMAL
ESTRADIOL

AB	ZYDUS NOVELTECH INC	0.014MG/24HR	A204379	001	Apr 17, 2023	Apr NFTG
AB	ZYDUS PHARMS	0.014MG/24HR	A204379	001	Apr 17, 2023	May CAHN
AB1		0.025MG/24HR	A206241	001	Dec 01, 2022	May CAHN
AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	May CAHN

SYSTEM; TRANSDERMAL
ESTRADIOL

AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	May CAHN
AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	May CAHN
AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	May CAHN
	MENOSTAR					
AB	+! BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004	Apr CFTG
	VIVELLE					
	@ SANDOZ	0.025MG/24HR	N020323	005	Aug 16, 2000	May CAHN
	@	0.0375MG/24HR	N020323	001	Oct 28, 1994	May CAHN
	@	0.05MG/24HR	N020323	002	Oct 28, 1994	May CAHN
	@	0.075MG/24HR	N020323	003	Oct 28, 1994	May CAHN
	@	0.1MG/24HR	N020323	004	Oct 28, 1994	May CAHN
	VIVELLE-DOT					
AB1	+ SANDOZ	0.025MG/24HR	N020538	009	May 03, 2002	May CAHN
AB1	+	0.0375MG/24HR	N020538	005	Jan 08, 1999	May CAHN
AB1	+	0.05MG/24HR	N020538	006	Jan 08, 1999	May CAHN
AB1	+	0.075MG/24HR	N020538	007	Jan 08, 1999	May CAHN
AB1	+	0.1MG/24HR	N020538	008	Jan 08, 1999	May CAHN
	TABLET; ORAL					
	ESTRADIOL					
AB	NOVITIUM PHARMA	0.5MG	A217334	001	Sep 06, 2023	Aug NEWA
AB		1MG	A217334	002	Sep 06, 2023	Aug NEWA
AB		2MG	A217334	003	Sep 06, 2023	Aug NEWA

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

AO	XIROMED	10MG/ML	A216656	001	Apr 28, 2023	Apr NEWA
AO		20MG/ML	A216656	002	Apr 28, 2023	Apr NEWA
AO		40MG/ML	A216656	003	Apr 28, 2023	Apr NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

>D> AB	AUROBINDO PHARMA LTD	0.5MG; 0.1MG	A214729	001	Jun 30, 2023	Dec DISC
AB		0.5MG; 0.1MG	A214729	001	Jun 30, 2023	Jun NEWA
>D> AB		1MG; 0.5MG	A214729	002	Jun 30, 2023	Dec DISC
AB		1MG; 0.5MG	A214729	002	Jun 30, 2023	Jun NEWA
	ETYQA					
>A>	@ AUROBINDO PHARMA LTD	0.5MG; 0.1MG	A214729	001	Jun 30, 2023	Dec DISC
>A>	@	1MG; 0.5MG	A214729	002	Jun 30, 2023	Dec DISC

ESTRADIOL; PROGESTERONE

CAPSULE; ORAL
BIJUVA

>D>	+ @ MAYNE PHARMA	0.5MG; 100MG	N210132	002	Dec 28, 2021	Dec CMFD
>A>	+	0.5MG; 100MG	N210132	002	Dec 28, 2021	Dec CMFD

ESZOPICLONE

TABLET; ORAL
ESZOPICLONE

>A> AB	HETERO LABS LTD V	1MG	A205504	001	Jan 04, 2024	Dec NEWA
>A> AB		2MG	A205504	002	Jan 04, 2024	Dec NEWA
>A> AB		3MG	A205504	003	Jan 04, 2024	Dec NEWA
>A> AB	IPCA LABS LTD	1MG	A206222	001	Dec 29, 2023	Dec NEWA
>A> AB		2MG	A206222	002	Dec 29, 2023	Dec NEWA
>A> AB		3MG	A206222	003	Dec 29, 2023	Dec NEWA

ETHACRYNIC ACID

TABLET; ORAL
ETHACRYNIC ACID

>D> AB	HIKMA	25MG	A207262	001	Feb 23, 2017	Dec DISC
>A>	@	25MG	A207262	001	Feb 23, 2017	Dec DISC

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL
ENILLORING

AB	XIROMED	0.015MG/24HR; 0.12MG/24HR	A211157	001	Jun 29, 2023	Jun NEWA
----	---------	---------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

	TABLET;ORAL BALCOLTRA						
AB3	+! AVION PHARMS	0.02MG;0.1MG		N208612	001	Jan 09, 2018	Aug CFTG
	LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB3	XIROMED	0.02MG;0.1MG		A214640	001	Aug 16, 2023	Aug NFTG
	TABLET;ORAL-28						
	LEVONORGESTREL AND ETHINYL ESTRADIOL						
	@ AMNEAL PHARMS	0.02MG;0.1MG		A201108	001	Feb 05, 2014	Jan DISC
	@	0.03MG;0.15MG		A201095	001	Dec 08, 2014	Jan DISC
AB1	HETERO LABS	0.02MG;0.1MG		A212298	001	Feb 13, 2023	Feb NEWA
AB	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075M G,0.125MG		A200248	001	Nov 19, 2015	Jan CTEC

ETHINYL ESTRADIOL; NORELGESTROMIN

	FILM, EXTENDED RELEASE;TRANSDERMAL						
	ETHINYL ESTRADIOL AND NORELGESTROMIN						
AB	ZYDUS NOVELTECH INC	0.035MG/24HR;0.15MG/24HR		A214594	001	Sep 14, 2023	Sep NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET;ORAL-28						
	RHUZDAH						
	@ AUROBINDO PHARMA	0.035MG;0.4MG		A207585	001	Oct 11, 2022	Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL						
	HAILEY 24 FE						
AB	! GLENMARK PHARMS LTD	0.02MG;1MG		A204847	001	Nov 17, 2017	Feb CTNA
	MINASTRIN 24 FE						
	+ @ APIL	0.02MG;1MG		N203667	001	May 08, 2013	Apr DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	! GLENMARK PHARMS LTD	0.02MG;1MG		A210369	001	Dec 26, 2017	Apr CHRS
	OISHI						
AB	AUROBINDO PHARMA	0.02MG;1MG		A216558	001	Dec 06, 2023	Nov NEWA
	TABLET;ORAL-21						
	TRI-LEGEST 21						
	@ BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG		A076405	001	Oct 26, 2007	Sep DISC

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET;ORAL-28						
	NORGESTIMATE AND ETHINYL ESTRADIOL						
	@ AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.2 15MG,0.25MG		A203870	001	Nov 12, 2015	Jan DISC
	@	0.035MG;0.25MG		A203865	001	Oct 27, 2015	Jun DISC

ETHINYL ESTRADIOL; NORGESTREL

	TABLET;ORAL-28						
	TURQOZ						
AB	LUPIN LTD	0.03MG;0.3MG		A202980	001	Jul 31, 2023	Jul NEWA

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

	RING;VAGINAL						
	ANNOVERA						
	+! MAYNE PHARMA	0.013MG/24HR;0.15MG/24HR		N209627	001	Aug 10, 2018	Jan CAHN

ETODOLAC

	TABLET;ORAL						
	ETODOLAC						
	@ EDENBRIDGE PHARMS	400MG		A209888	001	Nov 30, 2018	Aug DISC
	@	500MG		A209888	002	Nov 30, 2018	Aug DISC
	@ SHREE HARI INTL	400MG		A074839	001	Jul 11, 1997	Sep CAHN
	@	400MG		A074846	001	Feb 28, 1997	Sep CAHN

ETOMIDATE

	INJECTABLE;INJECTION						
	ETOMIDATE						
	@ AVET LIFESCIENCES	2MG/ML		A204618	001	Aug 13, 2014	Sep DISC

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+! ORGANON

68MG/IMPLANT

N021529 002 May 13, 2011 Nov CMS1

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

@ DASH PHARMS

20MG/ML

A204927 001 Oct 31, 2017 Mar CAHN

@ DASH PHARMS NATCO

20MG/ML

A203507 001 Nov 20, 2017 Feb CAHN

>D> AP HONG KONG

20MG/ML

A074529 001 Jul 24, 1996 Dec CAHN

AP 20MG/ML

A074529 001 Jul 24, 1996 Oct CAHN

>A> AP MEITHEAL

20MG/ML

A074529 001 Jul 24, 1996 Dec CAHN

ETRASIMOD ARGinine

TABLET; ORAL

VELSIPITY

+! PFIZER

EQ 2MG BASE

N216956 001 Oct 12, 2023 Oct NEWA

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

AB TEVA PHARMS USA

10MG

A210050 004 Dec 09, 2019 Apr CMFD

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ ALVOGEN

25MG

A200898 001 Jul 28, 2014 Feb DISC

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB ORIENT PHARMA

10MG

A215693 001 Sep 13, 2022 Nov CMFD

@

10MG

A215693 001 Sep 13, 2022 Mar DISC

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB AJANTA PHARMA LTD

40MG/5ML

A217529 001 Sep 18, 2023 Sep NEWA

AB ALKEM LABS LTD

40MG/5ML

A216400 001 May 15, 2023 May NEWA

AB ANNORA PHARMA

40MG/5ML

A217330 001 Aug 17, 2023 Aug NEWA

AB APPCO

40MG/5ML

A217655 001 Jun 16, 2023 Jun NEWA

AB CARNEGIE

40MG/5ML

A217137 001 Jul 07, 2023 Jun NEWA

AB LUPIN LTD

40MG/5ML

A090440 001 Jun 29, 2010 Jun CHRS

AB MICRO LABS

40MG/5ML

A217842 001 Sep 14, 2023 Sep NEWA

AB ! NOVITIUM PHARMA

40MG/5ML

A215043 001 Apr 20, 2021 Jun CHRS

AB UPSHER SMITH LABS

40MG/5ML

A217655 001 Jun 16, 2023 Sep CAHN

INJECTABLE; INJECTION

FAMOTIDINE

AP SAGENT

10MG/ML

A075651 001 Apr 16, 2001 Aug CAHN

AP 10MG/ML

10MG/ML

A075684 001 Apr 16, 2001 Oct CAHN

@ ZYDUS PHARMS

10MG/ML

A215828 001 Nov 22, 2022 Apr DISC

FAMOTIDINE PRESERVATIVE FREE

AP SAGENT

10MG/ML

A075622 001 Apr 16, 2001 Aug CAHN

AP 10MG/ML

10MG/ML

A075825 001 Apr 17, 2001 Aug CAHN

TABLET; ORAL

FAMOTIDINE

AB ALKEM LABS LTD

20MG

A215630 001 Jan 07, 2022 Sep CAHN

AB 20MG

20MG

A217375 001 Apr 24, 2023 Apr NEWA

AB 40MG

40MG

A215630 002 Jan 07, 2022 Sep CAHN

AB 40MG

40MG

A217375 002 Apr 24, 2023 Apr NEWA

>D> AB CELLTRION

20MG

A075786 001 Apr 16, 2001 Dec CAHN

>D> AB 40MG

40MG

A075786 002 Apr 16, 2001 Dec CAHN

>A> AB CHARTWELL RX

20MG

A075786 001 Apr 16, 2001 Dec CAHN

AB 20MG

20MG

A215630 001 Jan 07, 2022 Aug CAHN

>A> AB 40MG

40MG

A075786 002 Apr 16, 2001 Dec CAHN

AB 40MG

40MG

A215630 002 Jan 07, 2022 Aug CAHN

>A> AB CONTRACT PHARMACAL

20MG

A217669 001 Dec 20, 2023 Dec NEWA

>A> AB 40MG

40MG

A217669 002 Dec 20, 2023 Dec NEWA

>A> AB GRAVITI PHARMS

20MG

A218181 001 Dec 22, 2023 Dec NEWA

>A> AB 40MG

40MG

A218181 002 Dec 22, 2023 Dec NEWA

TABLET;ORAL

FAMOTIDINE

AB	MANKIND PHARMA	20MG	A075302	001	Apr 16, 2001	Oct CMFD
AB		40MG	A075302	002	Apr 16, 2001	Oct CMFD
AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB	ASCENT PHARMS INC	26.6MG;800MG	A216814	001	Mar 15, 2023	Mar NEWA
----	-------------------	--------------	---------	-----	--------------	----------

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB	AUROBINDO PHARMA LTD	40MG	A210741	001	Oct 25, 2023	Oct NEWA
AB		80MG	A210741	002	Oct 25, 2023	Oct NEWA
AB	MACLEODS PHARMS LTD	40MG	A207293	001	Sep 28, 2023	Sep NEWA
AB		80MG	A207293	002	Sep 28, 2023	Sep NEWA
	@ MYLAN	40MG	A205385	001	Jul 01, 2019	Oct DISC
	@	80MG	A205385	002	Jul 01, 2019	Jun DISC
>A>	@ TORRENT	40MG	A211837	001	Dec 19, 2023	Dec DISC
>A>	@	80MG	A211837	002	Dec 19, 2023	Dec DISC
AB	ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan CAHN
AB		80MG	A205443	002	Jan 09, 2023	Jan CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

>D> AB	SUN PHARM INDUSTRIES	2.5MG	A075896	001	Nov 02, 2004	Dec DISC
>A>	@	2.5MG	A075896	001	Nov 02, 2004	Dec DISC
>D> AB		5MG	A075896	002	Nov 02, 2004	Dec DISC
>A>	@	5MG	A075896	002	Nov 02, 2004	Dec DISC
>D> AB		10MG	A075896	003	Nov 02, 2004	Dec DISC
>A>	@	10MG	A075896	003	Nov 02, 2004	Dec DISC

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

+!	UCB INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun CAHN
----	---------	------------------	---------	-----	--------------	----------

FENOFOBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

+ @ LUPIN		90MG	N021695	005	Oct 18, 2013	Jun DISC
	TABLET;ORAL					
	FENOFOBRATE					
AB	CHARTWELL RX	54MG	A209660	001	Feb 11, 2019	Feb CAHN
AB		160MG	A209660	002	Feb 11, 2019	Feb CAHN
AB	CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Sep NEWA
AB		120MG	A217732	002	Sep 07, 2023	Sep NEWA

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AB	MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	May NEWA
		EQ 300MG BASE	A215548	002	May 16, 2023	May NEWA
AB		EQ 400MG BASE	A215548	003	May 16, 2023	May NEWA
	NALFON					
AB	+ XSPIRE PHARMA	EQ 200MG BASE	N017604	003		May CTEC
	TABLET;ORAL					
	NALFON					
AB	+ @ DISTA	EQ 600MG BASE	N017710	001		Oct CRLD

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	100MCG/HR	A209655	008	Jan 24, 2023	Jan NEWA
	@ ZYDUS PHARMS	100MCG/HR	A209655	008	Jan 24, 2023	Jun DISC
AB		100MCG/HR	A209655	008	Jan 24, 2023	May CAHN

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jul CMFD
AB	ZYDUS NOVELTECH INC	12.5MCG/HR	A209655	001	Jan 24, 2023	Jan NEWA
@	ZYDUS PHARMS	12.5MCG/HR	A209655	001	Jan 24, 2023	Jun DISC
AB		12.5MCG/HR	A209655	001	Jan 24, 2023	May CAHN
	FENTANYL-25					
AB	AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	25MCG/HR	A209655	002	Jan 24, 2023	Jan NEWA
@	ZYDUS PHARMS	25MCG/HR	A209655	002	Jan 24, 2023	Jun DISC
AB		25MCG/HR	A209655	002	Jan 24, 2023	May CAHN
	FENTANYL-37					
AB	AVEVA	37.5MCG/HR	A077449	006	Dec 06, 2017	Jul CMFD
AB	ZYDUS NOVELTECH INC	37.5MCG/HR	A209655	003	Jan 24, 2023	Jan NEWA
@	ZYDUS PHARMS	37.5MCG/HR	A209655	003	Jan 24, 2023	Jun DISC
AB		37.5MCG/HR	A209655	003	Jan 24, 2023	May CAHN
	FENTANYL-50					
AB	AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	50MCG/HR	A209655	004	Jan 24, 2023	Jan NEWA
@	ZYDUS PHARMS	50MCG/HR	A209655	004	Jan 24, 2023	Jun DISC
AB		50MCG/HR	A209655	004	Jan 24, 2023	May CAHN
	FENTANYL-62					
AB	AVEVA	62.5MCG/HR	A077449	007	Dec 06, 2017	Jul CMFD
AB	ZYDUS NOVELTECH INC	62.5MCG/HR	A209655	005	Jan 24, 2023	Jan NEWA
@	ZYDUS PHARMS	62.5MCG/HR	A209655	005	Jan 24, 2023	Jun DISC
AB		62.5MCG/HR	A209655	005	Jan 24, 2023	May CAHN
	FENTANYL-75					
AB	AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	75MCG/HR	A209655	006	Jan 24, 2023	Jan NEWA
@	ZYDUS PHARMS	75MCG/HR	A209655	006	Jan 24, 2023	Jun DISC
AB		75MCG/HR	A209655	006	Jan 24, 2023	May CAHN
	FENTANYL-87					
AB	AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017	Jul CMFD
AB	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Jul CTEC
		87.5MCG/HR	A076258	008	Dec 29, 2014	Jun CTEC
AB		87.5MCG/HR	A076258	008	Dec 29, 2014	Jan CTEC
AB	ZYDUS NOVELTECH INC	87.5MCG/HR	A209655	007	Jan 24, 2023	Jan NEWA
@	ZYDUS PHARMS	87.5MCG/HR	A209655	007	Jan 24, 2023	Jun DISC
AB		87.5MCG/HR	A209655	007	Jan 24, 2023	May CAHN

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

	+! HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023	Jan NEWA
AP	+!	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jan CTNA
	SUBLIMAZE PRESERVATIVE FREE					
AP	+! RISING	EQ 0.05MG BASE/ML	N016619	001		Sep CAHN
	SOLUTION; INTRAVENOUS					
	FENTANYL CITRATE					
	+ @ EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	May DISC
	+!	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	Feb NEWA
	+ @	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	May DISC
	+!	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	Feb NEWA

TABLET; BUCCAL, SUBLINGUAL

FENTORA

>D>	+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Dec CAHN
>A>	+		EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Dec CAHN
>D>	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Dec CAHN
>A>	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Dec CAHN
>D>	+	@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Dec CAHN
>A>	+	@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Dec CAHN
>D>	+	!	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Dec CAHN
>A>	+	!	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Dec CAHN
>D>	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Dec CAHN
>A>	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Dec CAHN
>D>	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Dec CAHN
>A>	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Dec CAHN

TROCHE/LOZENGE; TRANSMUCOSALACTIQ

+ CEPHALON	EQ 0.2MG BASE	N 020747	001	Nov 04, 1998	Oct CAHN
+ CEPHALON	EQ 0.2MG BASE	N 020747	001	Nov 04, 1998	Sep CTEC
+! CEPHALON	EQ 0.4MG BASE	N 020747	002	Nov 04, 1998	Oct CAHN
+! CEPHALON	EQ 0.4MG BASE	N 020747	002	Nov 04, 1998	Sep CTEC
+ CEPHALON	EQ 0.6MG BASE	N 020747	003	Nov 04, 1998	Oct CAHN
+ CEPHALON	EQ 0.6MG BASE	N 020747	003	Nov 04, 1998	Sep CTEC
+ CEPHALON	EQ 0.8MG BASE	N 020747	004	Nov 04, 1998	Oct CAHN
+ CEPHALON	EQ 0.8MG BASE	N 020747	004	Nov 04, 1998	Sep CTEC
+ CEPHALON	EQ 1.2MG BASE	N 020747	005	Nov 04, 1998	Oct CAHN
+ CEPHALON	EQ 1.2MG BASE	N 020747	005	Nov 04, 1998	Sep CTEC
+ CEPHALON	EQ 1.6MG BASE	N 020747	006	Nov 04, 1998	Oct CAHN
+ CEPHALON	EQ 1.6MG BASE	N 020747	006	Nov 04, 1998	Sep CTEC
FENTANYL CITRATE					
@ SPECGX LLC	EQ 0.2MG BASE	A 078907	001	Oct 30, 2009	Sep DISC
@ SPECGX LLC	EQ 0.4MG BASE	A 078907	002	Oct 30, 2009	Sep DISC
@ SPECGX LLC	EQ 0.6MG BASE	A 078907	003	Oct 30, 2009	Sep DISC
@ SPECGX LLC	EQ 0.8MG BASE	A 078907	004	Oct 30, 2009	Sep DISC
@ SPECGX LLC	EQ 1.2MG BASE	A 078907	005	Oct 30, 2009	Sep DISC
@ SPECGX LLC	EQ 1.6MG BASE	A 078907	006	Oct 30, 2009	Sep DISC

FERRIC PYROPHOSPHATE CITRATEPOWDER; INTRAVENOUSTRIFERIC

+ @ ROCKWELL MEDICAL INC 272MG IRON/PACKET

N 208551 001 Apr 25, 2016 Oct CDFR

FESOTERODINE FUMARATETABLET, EXTENDED RELEASE; ORAL
FESOTERODINE FUMARATE

@ ACCORD HLTHCARE	4MG	A 205012	001	Jan 04, 2023	Jul DISC
@ ACTAVIS LABS FL INC	8MG	A 205012	002	Jan 04, 2023	Jul DISC
@ ACTAVIS LABS FL INC	4MG	A 204868	001	Jan 04, 2023	Jul DISC
@ ACTAVIS LABS FL INC	8MG	A 204868	002	Jan 04, 2023	Jul DISC
>A> AB HETERO LABS LTD V	4MG	A 204792	001	Jan 09, 2024	Dec NEWA
>A> AB	8MG	A 204792	002	Jan 09, 2024	Dec NEWA
@ LUPIN LTD	4MG	A 204983	001	Jan 05, 2023	Feb DISC
@ LUPIN LTD	8MG	A 204983	002	Jan 05, 2023	Feb DISC

FEZOLINETANTTABLET; ORALVEOZAH

+! ASTELLAS 45MG

N 216578 001 May 12, 2023 May NEWA

FINAFLOXACINSUSPENSION/DROPS; OTICXTORO

+ @ FONSECA BIOSCIENCES 0.3%

N 206307 001 Dec 17, 2014 Jan CAHN

FINASTERIDE; TADALAFILCAPSULE; ORALENTADFI

+! BLUE WATER BIOTECH 5MG;5MG

N 215423 001 Dec 09, 2021 Jul CAHN

FINGOLIMOD HYDROCHLORIDECAPSULE; ORALFINGOLIMOD HYDROCHLORIDE

@ BIOCON LTD	EQ 0.5MG BASE	A 207979	001	Dec 04, 2019	Sep DISC
AB BIONPHARMA	EQ 0.5MG BASE	A 207979	001	Dec 04, 2019	Jan CMFD
AB EZRA VENTURES	EQ 0.5MG BASE	A 210252	001	May 24, 2023	May NEWA
>D> @ TEVA PHARMS USA	EQ 0.5MG BASE	A 207945	001	Dec 06, 2023	Nov NEWA
>A> AB	EQ 0.5MG BASE	A 208008	001	Jul 02, 2020	Dec CMFD
	EQ 0.5MG BASE	A 208008	001	Jul 02, 2020	Dec CMFD

FINGOLIMOD LAURYL SULFATETABLET, ORALLY DISINTEGRATING; ORALTASCENSO ODT+ CYCLE EQ 0.25MG BASE
+! CYCLE EQ 0.5MG BASEN 214962 001 Dec 23, 2021 Jan CAHN
N 214962 002 Dec 09, 2022 Jan CAHN

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+ @ AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)
+!	10-100ML (13.5-51mCi/ML)
+ @	10-30ML (13.5-51mCi/ML)

N202008 001	Apr 06, 2012	Nov CRLD
N202008 004	Oct 13, 2023	Nov NEWA
N202008 002	Apr 06, 2012	Nov DISC

FLOTUFOLASTAT F-18 GALLIUM

SOLUTION; INTRAVENOUS

POSOLUMA

+! BLUE EARTH	25ML (8-158mCi/ML)
+!	50ML (8-158mCi/ML)

N216023 001	May 25, 2023	Aug CPOT
N216023 001	May 25, 2023	May NEWA

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

AB HAINAN POLY 200MG/5ML

A215738 001 Sep 21, 2023 Sep NEWA

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

@ BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)
@	400MG/200ML (2MG/ML)

A077947 001	May 26, 2010	Aug DISC
A077947 002	May 26, 2010	Aug DISC

TABLET; ORAL

FLUCONAZOLE

>D> AB LUPIN LTD	50MG	A209146 001 Oct 20, 2023 Dec DISC
>A> @	50MG	A209146 001 Oct 20, 2023 Dec DISC
AB	50MG	A209146 001 Oct 20, 2023 Oct NEWA
>D> AB	100MG	A209146 002 Oct 20, 2023 Dec DISC
>A> @	100MG	A209146 002 Oct 20, 2023 Dec DISC
AB	100MG	A209146 002 Oct 20, 2023 Oct NEWA
>D> AB	150MG	A209146 003 Oct 20, 2023 Dec DISC
>A> @	150MG	A209146 003 Oct 20, 2023 Dec DISC
AB	150MG	A209146 003 Oct 20, 2023 Oct NEWA
>D> AB	200MG	A209146 004 Oct 20, 2023 Dec DISC
>A> @	200MG	A209146 004 Oct 20, 2023 Dec DISC
AB	200MG	A209146 004 Oct 20, 2023 Oct NEWA

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

>D> AB HIKMA	250MG	A206550 001 Oct 17, 2017 Dec DISC
>A> @	250MG	A206550 001 Oct 17, 2017 Dec DISC
>D> AB	500MG	A206550 002 Oct 17, 2017 Dec DISC
>A> @	500MG	A206550 002 Oct 17, 2017 Dec DISC

A206550 001	Oct 17, 2017	Dec DISC
A206550 001	Oct 17, 2017	Dec DISC
A206550 002	Oct 17, 2017	Dec DISC
A206550 002	Oct 17, 2017	Dec DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

@ ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738 001 Feb 28, 2017 Jun DISC
AP2	50MG/2ML (25MG/ML)	A203738 001 Feb 28, 2017 Jan CTEC
AP1	50MG/2ML (25MG/ML)	A090724 001 Sep 27, 2010 Jan CTEC
AP1	50MG/2ML (25MG/ML)	A078393 001 Oct 15, 2007 Jan CTEC
AP	50MG/2ML (25MG/ML)	A078393 001 Oct 15, 2007 Jan CHRS
AP1	50MG/2ML (25MG/ML)	A076661 001 Apr 28, 2004 Jan CTEC
+ @ SANDOZ	50MG/2ML (25MG/ML)	N022137 001 Sep 21, 2007 Jun DISC
AP2 +!	50MG/2ML (25MG/ML)	N022137 001 Sep 21, 2007 Jan CTEC

A203738 001	Feb 28, 2017	Jun DISC
A203738 001	Feb 28, 2017	Jan CTEC
A090724 001	Sep 27, 2010	Jan CTEC
A078393 001	Oct 15, 2007	Jan CTEC
A078393 001	Oct 15, 2007	Jan CHRS
A076661 001	Apr 28, 2004	Jan CTEC
N022137 001	Sep 21, 2007	Jun DISC
N022137 001	Sep 21, 2007	Jan CTEC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

>A> AP PHARMALOGIC	20-300mCi/ML	A204264 001 Dec 18, 2014 Dec CAHN
>D> AP SHERTECH LABS LLC	20-300mCi/ML	A204264 001 Dec 18, 2014 Dec CAHN

A204264 001	Dec 18, 2014	Dec CAHN
A204264 001	Dec 18, 2014	Dec CAHN

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

@ HIKMA 0.1MG

A216013 001 Oct 27, 2022 Apr DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL
 FLUOCINOLONE ACETONIDE
 @ INVATECH 0.025% A088045 001 Dec 16, 1982 Mar CAHN
 IMPLANT;INTRAVITREAL
 YUTIQ
 +! ALIMERA SCIENCES INC 0.18MG N210331 001 Oct 12, 2018 Jun CAHN
 OIL;TOPICAL
 FLUOCINOLONE ACETONIDE
 AT NOVEL LABS INC 0.01% A207345 001 Jul 31, 2023 Jul NEWA
 AT 0.01% A207347 001 Aug 07, 2023 Jul NEWA
 OIL/DROPS;OTIC
 FLAC
 AT PATRIN 0.01% A210736 001 Apr 11, 2018 Sep CAHN
 SOLUTION;TOPICAL
 FLUOCINOLONE ACETONIDE
 AT CHARTWELL RX 0.01% A209596 001 Dec 26, 2017 May CAHN

FLUOCINONIDE

CREAM;TOPICAL
 FLUOCINONIDE
 AB1 ! AMNEAL 0.05% A210554 001 Aug 21, 2018 Feb CHRS
 @ ENCUBE 0.05% A211410 001 Oct 16, 2018 Oct CAHN
 @ PAI HOLDINGS PHARM 0.1% A211758 001 Apr 03, 2019 Aug DISC
 OINTMENT;TOPICAL
 FLUOCINONIDE
 AB CHARTWELL RX 0.05% A207538 001 Jul 31, 2017 Apr CAHN
 @ PAI HOLDINGS PHARM 0.05% A207680 001 Sep 28, 2018 Aug DISC
 SOLUTION;TOPICAL
 FLUOCINONIDE
 AT CHARTWELL RX 0.05% A209118 001 Apr 23, 2018 May CAHN
 @ PAI HOLDINGS PHARM 0.05% A207554 001 Mar 18, 2019 May DISC
 LIDEX
 + @ ALVOGEN 0.05% N018849 001 Apr 06, 1984 Nov DISC

FLUORESCIN SODIUM

INJECTABLE;INTRAVENOUS
 AK-FLUOR 10%
 AP +! LONG GROVE PHARMS EQ 500MG BASE/5ML (EQ 100MG
 BASE/ML) N022186 001 Aug 08, 2008 Nov CHRS
 AP + EQ 500MG BASE/5ML (EQ 100MG
 BASE/ML)
 AK-FLUOR 25%
 AP +! LONG GROVE PHARMS EQ 500MG BASE/2ML (EQ 250MG
 BASE/ML) N022186 002 Aug 08, 2008 Sep CFTG
 +!
 EQ 500MG BASE/2ML (EQ 250MG
 BASE/ML)
 FLUORESCIN SODIUM
 AP NEXUS PHARMS EQ 500MG BASE/5ML (EQ 100MG
 BASE/ML) A215709 001 Sep 25, 2023 Sep NEWA
 AP EQ 500MG BASE/2ML (EQ 250MG
 BASE/ML) A215709 002 Sep 25, 2023 Sep NFTG

FLUOROESTRADIOL F-18

SOLUTION;INTRAVENOUS
 CERIANNA
 +! GE HEALTHCARE 50ML (4-100mCi/ML) N212155 001 May 20, 2020 Aug CAHN

FLUOROMETHOLONE

SUSPENSION/DROPS;OPHTHALMIC
 >A> FLUOROMETHOLONE
 >A> AB AMNEAL 0.1% A216348 001 Jan 09, 2024 Dec NEWA
 FML
 >D> +! ABBVIE 0.1% N016851 002 Jul 28, 1982 Dec CTEC
 >A> AB +! 0.1% N016851 002 Jul 28, 1982 Dec CTEC
 +!
 FML FORTE
 +! ABBVIE 0.25% N019216 001 Apr 23, 1986 Jan CAHN

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

FLAREX

+! HARROW EYE 0.1%

N019079 001 Feb 11, 1986 Oct CAHN

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRASONE

@ HARROW EYE 0.1%;0.3%

N050628 001 Jul 21, 1989 Oct CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP ALEMBIC 2.5GM/50ML (50MG/ML)
AP 5GM/100ML (50MG/ML)A217295 001 Mar 03, 2023 Feb NEWA
A217676 001 Oct 18, 2023 Oct NEWA

SOLUTION;TOPICAL

FLUOROURACIL

AT ENCUBE 5%
AT ! TARO 5%A215612 001 Nov 02, 2023 Oct NEWA
A076526 002 Nov 05, 2003 Oct CTECFLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

>D> @ MYLAN EQ 10MG BASE
>D> @ EQ 20MG BASE
>A> @ NATCO PHARMA USA EQ 10MG BASE
>A> @ EQ 20MG BASEA078045 001 Nov 17, 2008 Dec CAHN
A078045 002 Nov 17, 2008 Dec CAHN
A078045 001 Nov 17, 2008 Dec CAHN
A078045 002 Nov 17, 2008 Dec CAHN

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA @ CHARTWELL MOLECULAR EQ 20MG BASE/5ML
AA NOSTRUM LABS INC EQ 20MG BASE/5ML
AA @ PHARMOBEDIENT CNSLTG EQ 20MG BASE/5ML
AA @ XTTRIUM LABS INC EQ 20MG BASE/5ML
AA EQ 20MG BASE/5MLA076458 001 May 14, 2004 Jul CAHN
A075292 001 Feb 07, 2002 Mar CMFD
A075514 001 Aug 29, 2002 Sep CAHN
A075514 001 Aug 29, 2002 Jul DISC
A075514 001 Aug 29, 2002 Jan CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB @ PIRAMAL HLTHCARE UK EQ 10MG BASE
@ EQ 20MG BASE
@ SLATE RUN PHARMA EQ 10MG BASE
@ EQ 20MG BASE
AB +! TWI PHARMS EQ 60MG BASEA211444 001 Sep 13, 2022 Mar DISC
A211444 002 Sep 13, 2022 Mar DISC
A211444 001 Sep 13, 2022 Sep CAHN
A211444 002 Sep 13, 2022 Sep CAHN
N202133 001 Oct 06, 2011 Nov CAHNFLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO GLAND PHARMA LTD 25MG/ML
AO MSN 25MG/MLA215509 001 Mar 30, 2023 Mar NEWA
A215365 001 Nov 02, 2023 Oct NEWAFLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB AJANTA PHARMA LTD 1MG
@ 1MG
AB 2.5MG
@ 2.5MG
AB 5MG
@ 5MG
AB 10MG
@ 10MG
AB AUROBINDO PHARMA LTD 1MG
AB 2.5MG
AB 5MG
AB 10MG
AB CHARTWELL RX 1MG
AB 2.5MG
AB 5MG
AB 10MG
AB DR REDDYS 1MG
AB 2.5MG
AB 5MG
AB 10MGA217410 001 Jan 05, 2023 Sep CMFD
A217410 001 Jan 05, 2023 Jun DISC
A217410 002 Jan 05, 2023 Sep CMFD
A217410 002 Jan 05, 2023 Jun DISC
A217410 003 Jan 05, 2023 Sep CMFD
A217410 003 Jan 05, 2023 Jun DISC
A217410 004 Jan 05, 2023 Sep CMFD
A217410 004 Jan 05, 2023 Jun DISC
A218055 001 Aug 18, 2023 Aug NEWA
A218055 002 Aug 18, 2023 Aug NEWA
A218055 003 Aug 18, 2023 Aug NEWA
A218055 004 Aug 18, 2023 Aug NEWA
A215141 001 Oct 20, 2021 Sep CAHN
A215141 002 Oct 20, 2021 Sep CAHN
A215141 003 Oct 20, 2021 Sep CAHN
A215141 004 Oct 20, 2021 Sep CAHN
A214534 001 Jan 07, 2021 Sep CAHN
A214534 002 Jan 07, 2021 Sep CAHN
A214534 003 Jan 07, 2021 Sep CAHN
A214534 004 Jan 07, 2021 Sep CAHN

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	1MG	A216350	001	Nov 06, 2023	Oct NEWA
AB		2.5MG	A216350	002	Nov 06, 2023	Oct NEWA
AB		5MG	A216350	003	Nov 06, 2023	Oct NEWA
AB		10MG	A216350	004	Nov 06, 2023	Oct NEWA
AB	MSN	1MG	A217189	001	Sep 11, 2023	Sep NEWA
AB		2.5MG	A217189	002	Sep 11, 2023	Sep NEWA
AB		5MG	A217189	003	Sep 11, 2023	Sep NEWA
AB		10MG	A217189	004	Sep 11, 2023	Sep NEWA
@	PRASCO	1MG	A089804	002	Aug 12, 1988	Apr DISC
@		2.5MG	A089804	003	Aug 12, 1988	Apr DISC
@		5MG	A089804	004	Aug 12, 1988	Apr DISC
@		10MG	A089804	001	Aug 12, 1988	Apr DISC

FLURANDRENOLIDE

CREAM;TOPICAL

FLURANDRENOLIDE

	@ CHARTWELL RX	0.05%	A205342	001	Apr 13, 2016	Aug CAHN
	LOTION;TOPICAL					
	CORDRAN					
+ @	ALMIRALL FLURANDRENOLIDE	0.05%	N013790	001		May DISC
@	CHARTWELL RX	0.05%	A205343	001	Dec 22, 2016	Aug CAHN
!	PADAGIS ISRAEL	0.05%	A207133	001	Aug 30, 2016	May CTEC
AT	!	0.05%	A207133	001	Aug 30, 2016	May CHRS
	OINTMENT;TOPICAL					
	CORDRAN					
+ @	ALMIRALL FLURANDRENOLIDE	0.05%	N012806	001		May DISC
!	TELIGENT	0.05%	A207851	001	Dec 30, 2016	May CTEC
AT	!	0.05%	A207851	001	Dec 30, 2016	May CHRS

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

>D>	@ CHARTWELL RX	15MG	A072368	001	Mar 30, 1989	Dec CMFD
>A> AB		15MG	A072368	001	Mar 30, 1989	Dec CMFD
>D>	@	30MG	A072369	001	Mar 30, 1989	Dec CMFD
>A> AB		30MG	A072369	001	Mar 30, 1989	Dec CMFD
>D>	RISING	15MG	A070345	002	Nov 27, 1985	Dec CTEC
>A> AB		15MG	A070345	002	Nov 27, 1985	Dec CTEC
>D>	!	30MG	A070345	001	Nov 27, 1985	Dec CTEC
>A> AB	!	30MG	A070345	001	Nov 27, 1985	Dec CTEC

FLURBIPROFEN

TABLET;ORAL

ANSAID

+ @	PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988	Oct CRLD
+ @		100MG	N018766	003	Oct 31, 1988	Oct CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

+ @	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023	May NEWA
-----	---------------	--------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

OINTMENT;TOPICAL

FLUTICASONE PROPIONATE

AB	@ BRIGHT	0.005%	A215343	001	Sep 01, 2023	Nov DISC
		0.005%	A215343	001	Sep 01, 2023	Aug NEWA
	SPRAY, METERED;NASAL					
	FLUTICASONE PROPIONATE					
AB	CHARTWELL RX	0.05MG/SPRAY	A078492	001	Jan 09, 2012	Sep CAHN

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

>A> AB	HIKMA	0.5MG/INH;EQ 0.05MG BASE/INH	A203433	003	Dec 19, 2023	Dec NEWA
--------	-------	------------------------------	---------	-----	--------------	----------

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

LESCOL XL

AB +! SANDOZ EQ 80MG BASE N021192 001 Oct 06, 2000 Sep CAHN

FLUVOXAMINE MALEATE

TABLET;ORAL

LUVOX

AB + ANI PHARMS 25MG N021519 001 Dec 20, 2007 Jan CRLD
AB + 50MG N021519 002 Dec 20, 2007 Jan CRLD
AB + 100MG N021519 003 Dec 20, 2007 Jan CRLDFOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP GLAND PHARMA LTD 1.5GM/1.5ML (1GM/ML) A216791 001 Jul 06, 2023 Jun NEWA

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN MANKIND PHARMA 0.02MG/2ML A215883 001 Mar 22, 2023 Mar NEWA

FOSAMPRENAVIR CALCIUM

>D> SUSPENSION;ORAL

>D> LEXIVA

>D> +! VII V HLTHCARE EQ 50MG BASE/ML N022116 001 Jun 14, 2007 Dec DISC
>A> + @ EQ 50MG BASE/ML N022116 001 Jun 14, 2007 Dec DISCFOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP PIRAMAL CRITICAL EQ 150MG BASE/VIAL A214683 001 May 16, 2023 May NEWA

SOLUTION;INTRAVENOUS

FOCINVEZ

+! SPES PHARMS EQ 150MG BASE/50ML (EQ 3MG BASE/ML) N216686 001 Aug 22, 2023 Aug NEWA

+! STERISCIENCE EQ 150MG BASE/50ML (EQ 3MG BASE/ML) N216686 001 Aug 22, 2023 Oct CAHN

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP AVET LIFESCIENCES 2.4GM/100ML A213807 001 Jun 05, 2023 May NEWA
AP BEIJING 2.4GM/100ML A213987 001 Nov 29, 2023 Nov NEWAFOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS

AKYNZEO

+ @ HELSINN HLTHCARE EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL N210493 001 Apr 19, 2018 Sep DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP GLAND PHARMA LTD EQ 50MG PHENYTOIN NA/ML A214926 001 Oct 13, 2023 Oct NEWA
@ MYLAN LABS LTD EQ 50MG PHENYTOIN NA/ML A078736 001 Jun 08, 2010 Apr DISCFROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

@ MYLAN

EQ 2.5MG BASE

A202931 001 Aug 28, 2014 Apr DISC

FRUQUINTINIB

CAPSULE;ORAL

FRUZAQLA

+ TAKEDA PHARMS USA 1MG N217564 001 Nov 08, 2023 Nov NEWA
+! 5MG N217564 002 Nov 08, 2023 Nov NEWA

FULVESTRANT

SOLUTION; INTRAMUSCULAR

FULVESTRANT

AO EUGIA PHARMA 250MG/5ML (50MG/ML) A215169 001 Jun 30, 2023 Jun NEWA

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP AMNEAL PHARMS CO 10MG/ML A207552 001 Jul 20, 2016 Aug CMFD

AP SAGENT 10MG/ML A214766 001 Jan 27, 2021 Aug CAHN

SOLUTION; ORAL

FUROSEMIDE

@ PHARMOBEDIENT CNSLTG 10MG/ML A070655 001 Oct 02, 1987 Sep CAHN

@ XTTRIUM LABS INC 10MG/ML A070655 001 Oct 02, 1987 Jan CAHN

TABLET; ORAL

FUROSEMIDE

@ CHARTWELL RX 20MG N018413 001 Nov 30, 1983 Mar CAHN

@ 40MG N018413 002 Nov 30, 1983 Mar CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB IPCA LABS LTD 100MG A208928 001 Nov 20, 2023 Nov NEWA

AB 300MG A208928 002 Nov 20, 2023 Nov NEWA

AB 400MG A208928 003 Nov 20, 2023 Nov NEWA

AB LAURUS 100MG A217546 001 May 12, 2023 May NEWA

AB 300MG A217546 002 May 12, 2023 May NEWA

AB 400MG A217546 003 May 12, 2023 May NEWA

SOLUTION; ORAL

GABAPENTIN

AA MISSION PHARMACAL 250MG/5ML A078974 001 Feb 18, 2011 Aug CAHN

AA RUBICON 250MG/5ML A216492 001 Jan 18, 2023 Jan NEWA

TABLET; ORAL

GABAPENTIN

@ CHARTWELL RX 600MG A076120 001 Jan 27, 2006 May CAHN

@ 800MG A076120 002 Jan 27, 2006 May CAHN

AB GRANULES 600MG A217116 001 Mar 28, 2023 Mar NEWA

AB 800MG A217116 002 Mar 28, 2023 Mar NEWA

AB GRAVITI PHARMS 600MG A217995 001 Jul 19, 2023 Jul NEWA

AB 800MG A217995 002 Jul 19, 2023 Jul NEWA

AB RISING 600MG A217995 001 Jul 19, 2023 Aug CAHN

AB 800MG A217995 002 Jul 19, 2023 Aug CAHN

GRALISE

+ ALMATICA 450MG N022544 003 Apr 18, 2023 Aug NEWA

+ 750MG N022544 004 Apr 18, 2023 Aug NEWA

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

AP +! BAYER HLTHCARE 18.1416GM/30ML (604.72MG/ML) N201277 004 Mar 14, 2011 Sep CFTG

AP +! GADOBUTROL 39.3068GM/65ML (604.72MG/ML) N201277 005 Mar 14, 2011 Sep CFTG

AP HAINAN POLY PHARM 4.5354GM/7.5ML (604.72MG/ML) A217480 001 Mar 15, 2023 Nov CMFD

@ 4.5354GM/7.5ML (604.72MG/ML) A217480 001 Mar 15, 2023 Sep DISC

AP 4.5354GM/7.5ML (604.72MG/ML) A217480 001 Mar 15, 2023 Mar NEWA

AP 9.0708GM/15ML (604.72MG/ML) A217480 002 Mar 15, 2023 Nov CMFD

@ 9.0708GM/15ML (604.72MG/ML) A217480 002 Mar 15, 2023 Sep DISC

AP 9.0708GM/15ML (604.72MG/ML) A217480 002 Mar 15, 2023 Mar NEWA

AP HENGRIU PHARMA 18.1416GM/30ML (604.72MG/ML) A216081 001 Sep 08, 2023 Sep NFTG

AP 39.3068GM/65ML (604.72MG/ML) A216081 002 Sep 08, 2023 Sep NFTG

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

GADOTERATE MEGLUMINE

AP HENGRIU PHARMA 37.69GM/100ML (376.9MG/ML) A215304 005 Apr 15, 2022 Feb CMS1

<u>GALANTAMINE HYDROBROMIDE</u>					
CAPSULE, EXTENDED RELEASE;ORAL GALANTAMINE HYDROBROMIDE					
AB	! AUROBINDO PHARMA	EQ 8MG BASE	A204895	001 Aug 05, 2016	Jul CHRS
<u>GALLIUM CITRATE GA-67</u>					
INJECTABLE;INJECTION GALLIUM CITRATE GA 67					
	@ LANTHEUS MEDCL	2mCi/ML	N017478	001	Sep DISC
<u>GALLIUM GA-68 DOTATOC</u>					
SOLUTION;INTRAVENOUS GALLIUM GA 68 EDOTREOTIDE					
+!	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001 Aug 21, 2019	Aug CTNA
<u>GALLIUM GA-68 EDOTREOTIDE</u>					
SOLUTION;INTRAVENOUS GALLIUM GA 68 EDOTREOTIDE					
+!	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001 Aug 21, 2019	Aug CAIN
<u>GALLIUM GA-68 GOZETOTIDE</u>					
POWDER;INTRAVENOUS LOCAMETZ					
+!	NOVARTIS	N/A	N215841	001 Mar 23, 2022	Nov CAHN
<u>GANCICLOVIR SODIUM</u>					
INJECTABLE;INJECTION GANCICLOVIR SODIUM					
AP	SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A204204	001 Nov 08, 2018	Sep CAHN
<u>GANIRELIX ACETATE</u>					
INJECTABLE;INJECTION GANIRELIX ACETATE					
AP	GLAND PHARMA LTD	250MCG/0.5ML	A215658	001 Feb 28, 2023	Feb NEWA
AP	LUPIN LTD	250MCG/0.5ML	A216075	001 Nov 16, 2023	Nov NEWA
AP	+! ORGANON USA ORGANON	250MCG/0.5ML	N021057	001 Jul 29, 1999	May CAHN
<u>GATIFLOXACIN</u>					
SOLUTION/DROPS;OPHTHALMIC ZYMAR					
+ @	ALLERGAN ZYMAXID	0.3%	N021493	001 Mar 28, 2003	Mar DISC
AT	+! ABBVIE	0.5%	N022548	001 May 18, 2010	Jan CAHN
<u>GEFITINIB</u>					
TABLET;ORAL GEFITINIB					
AB	ACTAVIS LABS FL INC	250MG	A208913	001 Apr 26, 2023	Apr NEWA
AB	NATCO	250MG	A212827	001 May 31, 2023	May NEWA
AB	QILU PHARM HAINAN	250MG	A211591	001 Feb 13, 2023	Feb NEWA
<u>GEMCITABINE HYDROCHLORIDE</u>					
INJECTABLE;INJECTION GEMCITABINE HYDROCHLORIDE					
AP	HIKMA	200MG/5.26ML (38MG/ML)	A213175	001 Mar 07, 2023	Feb NEWA
AP		1GM/26.3ML (38MG/ML)	A213175	002 Mar 07, 2023	Feb NEWA
AP		2GM/52.6ML (38MG/ML)	A213175	003 Mar 07, 2023	Feb NEWA
AP	NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001 Feb 14, 2019	Jun CMFD
AP		1GM/26.3ML (38MG/ML)	A210383	002 Feb 14, 2019	Jun CMFD
AP		2GM/52.6ML (38MG/ML)	A210383	003 Feb 14, 2019	Jun CMFD
SOLUTION;INTRAVENOUS INFUGEM					
+ @	SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001 Jul 16, 2018	Jul DISC
+ @		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002 Jul 16, 2018	Jul DISC
+ @		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003 Jul 16, 2018	Jul DISC
+ @		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004 Jul 16, 2018	Jul DISC
+ @		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005 Jul 16, 2018	Jul DISC

**SOLUTION; INTRAVENOUS
INFUGEM**

+ @	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313 006 Jul 16, 2018	Jul DISC
+ @	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313 007 Jul 16, 2018	Jul DISC
+ @	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313 008 Jul 16, 2018	Jul DISC
+ @	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313 009 Jul 16, 2018	Jul DISC
+ @	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313 010 Jul 16, 2018	Jul DISC

GENTAMICIN SULFATE

**INJECTABLE; INJECTION
GENTAMICIN SULFATE**

>A> AP	EUGIA PHARMA	EQ 10MG BASE/ML	A215236 001 Jan 08, 2024	Dec NEWA
>A> AP		EQ 40MG BASE/ML	A215237 001 Jan 08, 2024	Dec NEWA
AP	HIKMA	EQ 10MG BASE/ML	A062251 002	Sep CMFD
AP		EQ 40MG BASE/ML	A062251 001	Sep CMFD

**OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE**

@ AKORN	EQ 0.3% BASE	A064093 001 Aug 31, 1995	Feb DISC
! FERA PHARMS LLC	EQ 0.3% BASE	A065024 001 Jul 30, 2004	Feb CTEC
AT !	EQ 0.3% BASE	A065024 001 Jul 30, 2004	Feb CHRS

**OINTMENT; TOPICAL
GENTAMICIN SULFATE**

>D>	@ PAI HOLDINGS PHARM	EQ 0.1% BASE	A209233 001 Dec 31, 2018	Dec CAHN
@ A>	@ VERTICE	EQ 0.1% BASE	A209233 001 Dec 31, 2018	May DISC
			A209233 001 Dec 31, 2018	Dec CAHN

**SOLUTION/DROPS; OPHTHALMIC
GENOPTIC**

@ ALLERGAN	EQ 0.3% BASE	A062452 001 Oct 10, 1984	Feb DISC
GENTAK			
@ AKORN	EQ 0.3% BASE	A064163 001 Oct 12, 2001	Feb DISC

AT !	SANDOZ	EQ 0.3% BASE	A062196 001	Feb CHRS
------	--------	--------------	-------------	----------

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC PRED-G				
+ @ ALLERGAN	EQ 0.3% BASE; 0.6%	N050612 001 Dec 01, 1989	Jan DISC	

GEPIRONE HYDROCHLORIDE

**TABLET, EXTENDED RELEASE; ORAL
EXXUA**

+ FABRE KRAMER	EQ 18.2MG BASE	N021164 001 Sep 22, 2023	Sep NEWA
+	EQ 36.3MG BASE	N021164 002 Sep 22, 2023	Sep NEWA
+	EQ 54.5MG BASE	N021164 003 Sep 22, 2023	Sep NEWA
+!	EQ 72.6MG BASE	N021164 004 Sep 22, 2023	Sep NEWA

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS COPAXONE				
+ @ TEVA PHARMS USA	20MG/VIAL	N020622 001 Dec 20, 1996	Jun CRLD	

GLIPIZIDE

**TABLET; ORAL
GLIPIZIDE**

RUBICON	2.5MG	A214874 001 Oct 03, 2023	Sep NFTG
	5MG	A214874 002 Oct 03, 2023	Sep NEWA
	10MG	A214874 003 Oct 03, 2023	Sep NEWA
@ SUN PHARM INDNS INC	5MG	A077820 001 Jul 11, 2006	Nov DISC
@	10MG	A077820 002 Jul 11, 2006	Nov DISC
GLUCOTROL			
+ @ PFIZER	2.5MG	N017783 003 May 11, 1993	Sep CFTG
+ @	5MG	N017783 001 May 08, 1984	Sep CFTG
+ @	10MG	N017783 002 May 08, 1984	Sep CFTG

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE
 @ DASH PHARMS 2.5MG;250MG
 @ 2.5MG;500MG
 @ 5MG;500MG

A078083 001 Apr 12, 2007 Feb CAHN
 A078083 002 Apr 12, 2007 Feb CAHN
 A078083 003 Apr 12, 2007 Feb CAHN

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

AP	! AMPHASTAR PHARMS INC	1MG/VIAL	A208086 001 Dec 28, 2020 Oct CTEC
	!	1MG/VIAL	A208086 001 Dec 28, 2020 Oct CHRS
	+ @ LILLY	1MG/VIAL	N020928 001 Sep 11, 1998 Oct DISC
	POWDER;NASAL		
	BAQSIMI		
	+! AMPHASTAR PHARMS INC	3MG	N210134 001 Jul 24, 2019 Sep CAHN
	SOLUTION;SUBCUTANEOUS		
	GVOKE KIT		
	+! XERIS	1MG/0.2ML (1MG/0.2ML)	N212097 005 Aug 20, 2021 May NEWA
	GVOKE PFS		
	+ @ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097 001 Sep 10, 2019 Jan DISC

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

@ HIKMA 1.5MG
 @ 3MG
 @ 6MG

A075890 001 Jul 31, 2003 Nov DISC
 A075890 002 Jul 31, 2003 Nov DISC
 A075890 003 Jul 31, 2003 Nov DISC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+! HORIZON THERAP US 1.1GM/ML

N203284 001 Feb 01, 2013 Jan CAHN

GLCOPYRROLATE

INJECTABLE;INJECTION

GLCOPYRROLATE

AP	@ LUPIN LTD	0.2MG/ML	A213655 001 Feb 07, 2023 Apr DISC
		0.2MG/ML	A213655 001 Feb 07, 2023 Jan NEWA
AP	@ MANKIND PHARMA	0.2MG/ML	A217354 001 Feb 27, 2023 Aug DISC
AP	SAGENT	0.2MG/ML	A217354 001 Feb 27, 2023 Feb NEWA
AP	UMEDICA	0.2MG/ML	A210083 001 Feb 21, 2020 Aug CAHN
	SOLUTION;INHALATION		
	LONHALA MAGNAIR KIT		
	+ @ SUMITOMO PHARMA AM	25MCG/ML	N208437 001 Dec 05, 2017 Jul CAHN
	+ @ SUNOVION RESP	25MCG/ML	N208437 001 Dec 05, 2017 Jul DISC

	TABLET;ORAL		
	GLCOPYRROLATE		
AA	ALEMBIC	1MG	A203657 001 Nov 30, 2018 Feb CAHN
AA		2MG	A203657 002 Nov 30, 2018 Feb CAHN
AA	AUROBINDO PHARMA	1MG	A202675 001 Apr 15, 2013 Jan CAHN
AA		2MG	A202675 002 Oct 30, 2018 Jan CAHN
AA	INDOCO	1MG	A091182 001 Feb 03, 2014 Sep CAHN
AA		2MG	A091182 002 Feb 03, 2014 Sep CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

DARTISLA ODT

@ EDENBRIDGE PHARMS 0.85MG
 0.85MG
 + @ 1.7MG

N215019 002 Oct 11, 2023 Nov DISC
 N215019 002 Oct 11, 2023 Nov NEWA
 N215019 001 Dec 16, 2021 Jun DISC

GLCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

+! SLAYBACK PHARMA LLC 0.6MG/3ML (0.2MG/ML);3MG/3ML
 (1MG/ML)

N216903 001 Feb 23, 2023 Feb NEWA

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL
SANCUSO
+! CUMBERLAND 3.1MG/24HR

N022198 001 Sep 12, 2008 Sep CAHN

GRANISETRON HYDROCHLORIDE

TABLET;ORAL
GRANISETRON HYDROCHLORIDE

>D> AB	@ AUROBINDO PHARMA USA	EQ 1MG BASE	A078725	001	Jan 30, 2008	May CAHN
>A>	! HIKMA	EQ 1MG BASE	A077842	001	Dec 31, 2007	Dec DISC
>D> AB	@	EQ 1MG BASE	A077842	001	Dec 31, 2007	Dec DISC
>D> AB	ORBION PHARMS	EQ 1MG BASE	A078678	001	Feb 13, 2008	Dec CHRS
>A> AB	!	EQ 1MG BASE	A078678	001	Feb 13, 2008	Dec CHRS

GUANFACINE HYDROCHLORIDE

TABLET;ORAL
GUANFACINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 1MG BASE	A217293	001	Apr 27, 2023	Apr NEWA
AB		EQ 2MG BASE	A217293	002	Apr 27, 2023	Apr NEWA
AB	AUROBINDO PHARMA USA	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jul CMFD
AB		EQ 2MG BASE	A074796	002	Jan 27, 1997	Jul CMFD
AB	I 3 PHARMS	EQ 1MG BASE	A216828	001	Oct 05, 2023	Sep NEWA
AB		EQ 2MG BASE	A216828	002	Oct 05, 2023	Sep NEWA
AB	RUBICON	EQ 1MG BASE	A216762	001	Oct 17, 2023	Oct NEWA
AB		EQ 2MG BASE	A216762	002	Oct 17, 2023	Oct NEWA

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

AB	ALEMBIC	EQ 1MG BASE	A217269	001	Aug 07, 2023	Jul NEWA
AB		EQ 2MG BASE	A217269	002	Aug 07, 2023	Jul NEWA
AB		EQ 3MG BASE	A217269	003	Aug 07, 2023	Jul NEWA
AB		EQ 4MG BASE	A217269	004	Aug 07, 2023	Jul NEWA

HALCINONIDE

CREAM;TOPICAL
HALCINONIDE

AB	CHARTWELL RX	0.1%	A214723	001	Sep 08, 2021	May CAHN
----	--------------	------	---------	-----	--------------	----------

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL
HALOBETASOL PROPIONATE

AB	PADAGIS ISRAEL LEXETTE	0.05%	A215266	001	Aug 11, 2023	Aug NFTG
AB	+! MAYNE PHARMA OINTMENT;TOPICAL	0.05%	N210566	001	May 24, 2018	Aug CFTG
>D>	HALOBETASOL PROPIONATE					
>D>	@ PAI HOLDINGS PHARM	0.05%	A209978	001	Mar 20, 2018	Dec CAHN
	@	0.05%	A209978	001	Mar 20, 2018	May DISC
>A>	@ VERTICE	0.05%	A209978	001	Mar 20, 2018	Dec CAHN

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

	@ ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jan DISC
	@	1MG	A200854	002	Jul 01, 2022	Jan DISC
	@	2MG	A200854	003	Jul 01, 2022	Jan DISC
	@	5MG	A200854	004	Jul 01, 2022	Jan DISC
	@	10MG	A200854	005	Jul 01, 2022	Jan DISC
	@	20MG	A200854	006	Jul 01, 2022	Jan DISC
	@ AIPING PHARM INC	0.5MG	A071128	001	Feb 17, 1987	Aug CAHN
	@	1MG	A071129	001	Feb 17, 1987	Aug CAHN
AB		2MG	A071130	001	Feb 17, 1987	Aug CAHN
AB		5MG	A071131	001	Feb 17, 1987	Aug CAHN
AB		10MG	A071132	001	May 12, 1987	Aug CAHN
	@	20MG	A071133	001	May 12, 1987	Aug CAHN
AB	SCIEGEN PHARMS INC	2MG	A071130	001	Feb 17, 1987	Sep CAHN
AB		5MG	A071131	001	Feb 17, 1987	Sep CAHN
AB		10MG	A071132	001	May 12, 1987	Sep CAHN
AB	ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023	Jan NEWA
AB		1MG	A077580	002	Jan 17, 2023	Jan NEWA
AB		2MG	A077580	006	Jan 17, 2023	Jan NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023	May NEWA
AO		EQ 100MG BASE/ML	A216730	002	May 23, 2023	May NEWA

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL
@ EPIC PHARMA LLC EQ 5MG BASE/ML

A204849 001 Sep 06, 2017 Oct CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

A208827 001 Nov 19, 2018 Nov CTEC

AP	B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	N017486	001	Oct CAHN
	@ EPIC PHARMA LLC	1,000 UNITS/ML	N017486	002	Oct CAHN
	@	5,000 UNITS/ML	N017486	003	Oct CAHN
	@	10,000 UNITS/ML	N017486	004	Oct CAHN
	@	20,000 UNITS/ML	N017486	005	Oct CAHN
	@	40,000 UNITS/ML			
AP	HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986 Nov CMFD
AP	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020 Feb CMFD
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
>A>	+! B BRAUN	200 UNITS/100ML	N019953	002	Dec 15, 2023 Dec NEWA
	HEPARIN SODIUM PRESERVATIVE FREE				
AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020 Feb CMFD

HEPARIN SODIUM; TAUROLIDINE

N214520 001 Nov 15, 2023 Dec CDFR

>D>	SOLUTION; INJECTION		N214520	001	Nov 15, 2023	Dec CDFR
>D>	DEFENCATH					
>D>	+! CORMEDIX	3,000 UNITS/3ML (1,000 UNITS/ML); 40.5MG/3ML (13.5MG/ML)	N214520	001	Nov 15, 2023	Nov NEWA
	+!	3,000 UNITS/3ML (1,000 UNITS/ML); 40.5MG/3ML (13.5MG/ML)	N214520	002	Nov 15, 2023	Dec CDFR
>D>	+!	5,000 UNITS/5ML (1,000 UNITS/ML); 67.5MG/5ML (13.5MG/ML)	N214520	002	Nov 15, 2023	Nov NEWA
	+!	5,000 UNITS/5ML (1,000 UNITS/ML); 67.5MG/5ML (13.5MG/ML)	N214520	002	Nov 15, 2023	Dec CDFR

N214520 001 Nov 15, 2023 Dec CDFR

N214520 002 Nov 15, 2023 Dec CDFR

N214520 001 Nov 15, 2023 Dec CDFR

N214520 002 Nov 15, 2023 Dec CDFR

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

A040613 001 Feb 08, 2008 Oct CAHN

SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	! PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML
----	----------------------	--------------------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

A215147 001 Feb 13, 2023 Feb NEWA

A204680 001 Apr 28, 2016 May DISC

A209251 001 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Nov CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Nov CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Nov CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Nov CAHN

A040858 001 Feb 26, 2010 May CMFD

A040858 002 Feb 26, 2010 May CMFD

A040858 003 Feb 26, 2010 May CMFD

A040858 004 Feb 26, 2010 May CMFD

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

A209251 003 Jul 09, 2018 Dec CAHN

A209251 004 Jul 09, 2018 Dec CAHN

A209251 001 Jul 09, 2018 Dec CAHN

A209251 002 Jul 09, 2018 Dec CAHN

TABLET;ORAL HYDRALAZINE HYDROCHLORIDE					
>A>	@ 100MG		A209251	004	Jul 09, 2018 Dec CAHN
	<u>HYDROCHLOROTHIAZIDE</u>				
	CAPSULE;ORAL HYDROCHLOROTHIAZIDE		A090651	001	Apr 07, 2014 Sep DISC
	@ SUN PHARM IND'S INC 12.5MG				
	TABLET;ORAL HYDROCHLOROTHIAZIDE		A085182	003	May 02, 2023 Apr NEWA
AB	HERITAGE PHARMS 12.5MG				
	<u>HYDROCHLOROTHIAZIDE; LISINOPRIL</u>				
	TABLET;ORAL LISINOPRIL AND HYDROCHLOROTHIAZIDE				
AB	! INVAGEN PHARMS 12.5MG;20MG		A204058	002	May 23, 2017 Jun CHRS
AB	! 25MG;20MG		A204058	003	May 23, 2017 Jun CHRS
	ZESTORETIC				
AB	+ ALMATICA 12.5MG;20MG		N019888	001	Sep 20, 1990 Jun CHRS
AB	+ 25MG;20MG		N019888	002	Jul 20, 1989 Jun CHRS
	<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM</u>				
	TABLET;ORAL LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE				
AB	GRANULES 12.5MG;50MG		A218015	001	Sep 29, 2023 Sep NEWA
AB	12.5MG;100MG		A218015	002	Sep 29, 2023 Sep NEWA
AB	25MG;100MG		A218015	003	Sep 29, 2023 Sep NEWA
	<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL</u>				
	TABLET;ORAL OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE				
AB	MACLEODS PHARMS LTD 12.5MG;20MG		A204801	001	Jun 01, 2023 May NEWA
AB	12.5MG;40MG		A204801	002	Jun 01, 2023 May NEWA
AB	25MG;40MG		A204801	003	Jun 01, 2023 May NEWA
>D>	@ MYLAN 12.5MG;20MG		A078827	001	Oct 26, 2016 Dec CAHN
>D>	@ 12.5MG;40MG		A078827	002	Oct 26, 2016 Dec CAHN
>D>	@ 25MG;40MG		A078827	003	Oct 26, 2016 Dec CAHN
>A>	@ NATCO PHARMA USA 12.5MG;20MG		A078827	001	Oct 26, 2016 Dec CAHN
>A>	@ 12.5MG;40MG		A078827	002	Oct 26, 2016 Dec CAHN
>A>	@ 25MG;40MG		A078827	003	Oct 26, 2016 Dec CAHN
	@ TORRENT 12.5MG;20MG		A206515	001	May 03, 2017 Aug DISC
	@ 12.5MG;40MG		A206515	002	May 03, 2017 Aug DISC
	@ 25MG;40MG		A206515	003	May 03, 2017 Aug DISC
	@ ZYDUS PHARMS 12.5MG;20MG		A206377	001	Feb 24, 2023 Jul DISC
AB	12.5MG;20MG		A206377	001	Feb 24, 2023 Feb NEWA
AB	@ 12.5MG;40MG		A206377	002	Feb 24, 2023 Jul DISC
AB	12.5MG;40MG		A206377	002	Feb 24, 2023 Feb NEWA
AB	@ 25MG;40MG		A206377	003	Feb 24, 2023 Jul DISC
AB	25MG;40MG		A206377	003	Feb 24, 2023 Feb NEWA
	<u>HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE</u>				
	TABLET;ORAL QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
AB	APOTEX 12.5MG;EQ 10MG BASE		A091524	001	Mar 12, 2013 Jan CAHN
AB	12.5MG;EQ 20MG BASE		A091524	002	Mar 12, 2013 Jan CAHN
AB	25MG;EQ 20MG BASE		A091524	003	Mar 12, 2013 Jan CAHN
	@ CHARTWELL RX 12.5MG;EQ 10MG BASE		A076374	001	Mar 31, 2004 Apr CAHN
	@ 12.5MG;EQ 20MG BASE		A076374	002	Mar 31, 2004 Apr CAHN
	@ 25MG;EQ 20MG BASE		A076374	003	Mar 31, 2004 Apr CAHN
	<u>HYDROCHLOROTHIAZIDE; SPIRONOLACTONE</u>				
	TABLET;ORAL ALDACTAZIDE				
+ @ PFIZER 50MG;50MG			N012616	005	Dec 30, 1982 Sep DISC
	<u>HYDROCHLOROTHIAZIDE; VALSARTAN</u>				
	TABLET;ORAL VALSARTAN AND HYDROCHLOROTHIAZIDE				
AB	AMNEAL PHARMS 12.5MG;80MG		A204382	001	Aug 11, 2023 Aug NEWA
AB	12.5MG;160MG		A204382	002	Aug 11, 2023 Aug NEWA
AB	12.5MG;320MG		A204382	004	Aug 11, 2023 Aug NEWA
AB	25MG;160MG		A204382	003	Aug 11, 2023 Aug NEWA

	TABLET;ORAL VALSARTAN AND HYDROCHLOROTHIAZIDE	25MG;320MG	A204382	005	Aug 11, 2023	Aug NEWA
<u>HYDROCORTISONE</u>						
AB	CREAM;TOPICAL HYDROCORTISONE	@ ENCUBE 2.5%	A203810	001	Jul 23, 2018	Oct CAHN
<u>LOTION;TOPICAL ALA-SCALP</u>						
>D>	DERM RX 2%	A083231	001			Dec CAHN
>A>	LEGACY PHARMA 2%	A083231	001			Dec CAHN
<u>HYDROCORTISONE</u>						
>D>	@ PAI HOLDINGS PHARM 2.5%	A203804	001	Jul 27, 2018	Dec CAHN	
>A>	@ VERTICE 2.5%	A203804	001	Jul 27, 2018	Dec CAHN	
<u>TABLET;ORAL HYDROCORTISONE</u>						
AB	AUROBINDO PHARMA LTD 5MG	A214649	001	Jul 17, 2023	Jul NEWA	
AB	10MG	A214649	002	Jul 17, 2023	Jul NEWA	
AB	20MG	A214649	003	Jul 17, 2023	Jul NEWA	
<u>HYDROCORTISONE ACETATE</u>						
INJECTABLE;INJECTION HYDROCORTISONE ACETATE						
	@ EPIC PHARMA LLC 25MG/ML	N009637	001			Nov CAHN
	@ 50MG/ML	N009637	002			Nov CAHN
<u>HYDROCORTISONE ACETATE; NEOMYCIN SULFATE</u>						
SUSPENSION/DROPS;OPHTHALMIC COR-OTICIN						
	@ EPIC PHARMA LLC 1.5%;EQ 3.5MG BASE/ML	A060188	001			Oct CAHN
<u>HYDROMORPHONE HYDROCHLORIDE</u>						
INJECTABLE;INJECTION HYDROMORPHONE HYDROCHLORIDE						
AP	HIKMA 2MG/ML	A202159	001	Apr 27, 2018	May CAHN	
	HOSPIRA INC 0.25MG/0.5ML	N200403	005	Mar 03, 2023	Mar NEWA	
	4MG/ML	N200403	003	Dec 01, 2011	Apr CTNA	
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS HYDROMORPHONE HYDROCHLORIDE						
>A>	+! HIKMA 40MG/20ML (2MG/ML)	N217812	001	Dec 14, 2023	Dec NEWA	
<u>HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE</u>						
SOLUTION/DROPS;OPHTHALMIC PAREMYD						
	+ @ AKORN 1%;0.25%	N019261	001	Jan 30, 1992	Feb DISC	
	+ @ EPIC PHARMA LLC 1%;0.25%	N019261	001	Jan 30, 1992	Nov CAHN	
<u>HYDROXYCHLOROQUINE SULFATE</u>						
TABLET;ORAL HYDROXYCHLOROQUINE SULFATE						
AB	CHARTWELL RX 200MG	A210543	001	Jul 06, 2018	May CAHN	
	@ TEVA PHARMS 200MG	A040081	001	Sep 30, 1994	Sep DISC	
	SOVUNA					
	+ NOVITIUM PHARMA 200MG	N214581	001	Jan 14, 2022	Sep CTNA	
	+! 300MG	N214581	002	Jan 14, 2022	Sep CTNA	
<u>HYDROXYPROGESTERONE CAPROATE</u>						
INJECTABLE;INJECTION HYDROXYPROGESTERONE CAPROATE						
	@ EPIC PHARMA LLC 125MG/ML	N018004	001			Nov CAHN
<u>HYDROXYPROPYL CELLULOSE</u>						
INSERT;OPHTHALMIC LACRISERT						
	+! BAUSCH 5MG	N018771	001			Jan CAHN
	+! BAUSCH AND LOMB INC 5MG	N018771	001			Jan CAHN

HYDROXYUREA

TABLET;ORAL					
SIKLOS					
+ THERAVIA	100MG		N 208843	001	Dec 21, 2017
+!	1GM		N 208843	002	Dec 21, 2017

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION					
HYDROXYZINE HYDROCHLORIDE					
+! AM REGENT	25MG/ML		A 087408	001	Feb CRLD
+!	50MG/ML		A 087408	002	Feb CRLD
SYRUP;ORAL					
HYDROXYZINE HYDROCHLORIDE					
AA +! CHARTWELL RX	10MG/5ML		A 087294	001	Apr 12, 1982
TABLET;ORAL					
HYDROXYZINE HYDROCHLORIDE					
AB CHARTWELL RX	10MG		A 040804	001	Jun 30, 2008
AB	25MG		A 040804	002	Jun 30, 2008
AB	50MG		A 040804	003	Jun 30, 2008
AB GRAVITI PHARMS	10MG		A 217652	001	Aug 17, 2023
AB	25MG		A 217652	002	Aug 17, 2023
AB	50MG		A 217652	003	Aug 17, 2023

HYDROXYZINE PAMOATE

CAPSULE;ORAL					
HYDROXYZINE PAMOATE					
AB HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE		A 201507	001	Jun 03, 2013
	EQ 50MG HYDROCHLORIDE		A 201507	002	Jun 03, 2013

IBRUTINIB

CAPSULE;ORAL					
IMBRUVICA					
+ PHARMACYCLICS LLC	70MG		N 205552	002	Dec 20, 2017
+!	140MG		N 205552	001	Nov 13, 2013
SUSPENSION;ORAL					
IMBRUVICA					
+! PHARMACYCLICS LLC	70MG/ML		N 217003	001	Aug 24, 2022
TABLET;ORAL					
IMBRUVICA					
+ PHARMACYCLICS LLC	140MG		N 210563	001	Feb 16, 2018
+	280MG		N 210563	002	Feb 16, 2018
+	420MG		N 210563	003	Feb 16, 2018
+ @	560MG		N 210563	004	Feb 16, 2018
+!	560MG		N 210563	004	Feb 16, 2018

IBUPROFEN

SUSPENSION;ORAL					
IBUPROFEN					
@ PAJ HOLDINGS PHARM	100MG/5ML		A 205647	001	Nov 03, 2016
AB STRIDES PHARMA	100MG/5ML		A 215311	001	May 27, 2022

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS					
ICATIBANT ACETATE					
AP EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A 213521	001	Aug 14, 2023

ICOSAPENT ETHYL

CAPSULE;ORAL					
ICOSAPENT ETHYL					
>A> AB ASCENT PHARMS INC	500MG		A 216811	001	Dec 07, 2023
AB DR REDDYS	500MG		A 209499	002	Mar 08, 2023
AB HIKMA	500MG		A 209457	002	Mar 08, 2023
>A> AB HUMANWELL PURACAP	500MG		A 217919	001	Dec 22, 2023
>A> AB	1GM		A 217919	002	Dec 22, 2023
AB STRIDES PHARMA	500MG		A 217844	001	Sep 22, 2023
AB	1GM		A 217844	002	Sep 22, 2023
AB ZYDUS	500MG		A 217656	001	Apr 20, 2023
AB	1GM		A 217656	002	Apr 20, 2023

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

>D>	AP	HONG KONG	1MG/ML	A065036	001	May 01, 2002	Dec CAHN
	AP		1MG/ML	A065036	001	May 01, 2002	Nov CTNA
	AP		1MG/ML	A065036	001	May 01, 2002	Sep CAHN
>A>	AP	MEITHEAL	1MG/ML	A065036	001	May 01, 2002	Dec CAHN

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

>D>	AP	! HONG KONG	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	Dec CAHN
	AP	!	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	Sep CAHN
>D>	AP	!	3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	Dec CAHN
	AP	!	3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	Sep CAHN
>A>	AP	! MEITHEAL	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	Dec CAHN
>A>	AP	!	3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	Dec CAHN

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

		@ BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Mar DISC
		@	EQ 400MG BASE	A205990	002	Feb 08, 2019	Jun DISC
AB		CHARTWELL RX	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan CAHN
AB			EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan CAHN
>D>	AB	HIKMA	EQ 100MG BASE	A207586	001	Jul 13, 2018	Dec DISC
>A>		@	EQ 100MG BASE	A207586	001	Jul 13, 2018	Dec DISC
>D>	AB		EQ 400MG BASE	A207586	002	Jul 13, 2018	Dec DISC
>A>		@	EQ 400MG BASE	A207586	002	Jul 13, 2018	Dec DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ SUN PHARM INDUSTRIES 10MG

A081048 001 Jun 05, 1990 Nov DISC

IMIQUIMOD

CREAM; TOPICAL

ALDARA

+ @ BAUSCH IMIQUIMOD

AB ! GLENMARK GENERICS 5%

N020723 001 Feb 27, 1997 Feb DISC

A201994 001 Mar 06, 2012 Feb CHRS

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

		@ AUROBINDO PHARMA USA	1.25MG	A075105	001	Jul 23, 1998	Apr CAHN
		@	2.5MG	A075105	002	Jul 23, 1998	Apr CAHN
AB		RISING	1.25MG	A074461	002	Mar 26, 1997	Jul CMFD
AB			2.5MG	A074461	001	Mar 27, 1996	Jul CMFD

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

		@ OAK TREE PHARMA	10MG/VIAL	N011525	003		Aug CAHN
		+!	25MG/VIAL	N011525	001		Aug CAHN
		@	40MG/VIAL	N011525	004		Aug CAHN
		@	50MG/VIAL	N011525	002		Aug CAHN
		@ RENEW PHARMS	10MG/VIAL	N011525	003		Aug CAHN
		+ @	25MG/VIAL	N011525	001		Sep DISC
AP		+!	25MG/VIAL	N011525	001		Aug CAHN
		@	40MG/VIAL	N011525	004		Aug CAHN
		@	50MG/VIAL	N011525	002		Aug CAHN
		INDOCYANINE GREEN					
		! RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	Sep CTEC
AP		!	25MG/VIAL	A040811	001	Nov 21, 2007	Sep CHRS

INDOMETHACIN

CAPSULE;ORAL
INDOCIN
+ @ ZYLA LIFE SCIENCES 25MG N016059 001 Sep CAHN
+ @ 50MG N016059 002 Sep CAHN
INDOMETHACIN
AB CHARTWELL MOLECULES 25MG N018829 002 Aug 06, 1984 Feb CMFD
AB 50MG N018829 001 Aug 06, 1984 Feb CMFD
CAPSULE, EXTENDED RELEASE;ORAL
INDOCIN SR
+ @ ZYLA 75MG N018185 001 Feb 23, 1982 Sep CAHN
INDOMETHACIN
>D> AB HETERO LABS LTD III 75MG A201807 001 Sep 28, 2012 Dec CHRS
>A> AB ! 75MG A201807 001 Sep 28, 2012 Dec CHRS
>D> AB ! SANDOZ 75MG A074464 001 May 28, 1998 Dec DISC
>A> @ 75MG A074464 001 May 28, 1998 Dec DISC
SUPPOSITORY;RECTAL
INDOCIN
+ @ ZYLA LIFE SCIENCES 50MG N017814 001 Aug 13, 1984 Jul CAHN
INDOMETHACIN
AB ! COSETTE 50MG A073314 001 Aug 31, 1992 Jul CTEC
AB ZYDUS 50MG A216184 001 Aug 02, 2023 Jul NEWA
SUSPENSION;ORAL
INDOCIN
+! ZYLA 25MG/5ML N018332 001 Oct 10, 1985 Jun CAHN

INFIGRATINIB PHOSPHATE

CAPSULE;ORAL
TRUSELTIQ
+ @ HELSINN HLTHCARE 25MG N214622 001 May 28, 2021 Apr DISC
+ @ 100MG N214622 002 May 28, 2021 Apr DISC

IOPAMIDOL

INJECTABLE;INJECTION
IOPAMIDOL
AP1 HAINAN POLY 41% A215382 001 Feb 27, 2023 Sep CTEC
AP 41% A215382 001 Feb 27, 2023 Feb NEWA
AP2 41% A217134 001 Sep 27, 2023 Sep NFTG
AP 61% A215382 002 Feb 27, 2023 Feb NEWA
ISOVUE-200
AP2 +! BRACCO 41% N018735 006 Jul 07, 1987 Sep CFTG
ISOVUE-250
+ @ BRACCO 51% N020327 002 Oct 12, 1994 Jun DISC
ISOVUE-M 200
AP1 +! BRACCO 41% N018735 001 Dec 31, 1985 Sep CTEC
AP +! 41% N018735 001 Dec 31, 1985 Feb CTEC
ISOVUE-M 300
AP +! BRACCO 61% N018735 004 Dec 31, 1985 Feb CTEC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL
IPRATROPIUM BROMIDE
@ AUROBINDO PHARMA USA 0.021MG/SPRAY A075552 001 Mar 31, 2003 Apr CAHN
@ 0.042MG/SPRAY A075553 001 Mar 31, 2003 Apr CAHN

>A> IPTACOPAN HYDROCHLORIDE

>A> CAPSULE;ORAL
>A> FABHALTA
>A> +! NOVARTIS EQ 200MG BASE N218276 001 Dec 05, 2023 Dec NEWA

IRBESARTAN

TABLET;ORAL
IRBESARTAN
@ ANDA REPOSITORY 75MG A203161 001 Sep 27, 2012 Sep CAHN
@ 150MG A203161 002 Sep 27, 2012 Sep CAHN
@ 300MG A203161 003 Sep 27, 2012 Sep CAHN
@ CHARTWELL RX 75MG A203161 001 Sep 27, 2012 Nov CAHN
@ 150MG A203161 002 Sep 27, 2012 Nov CAHN
@ 300MG A203161 003 Sep 27, 2012 Nov CAHN
AB UNICHEM 75MG A203020 001 Dec 07, 2015 Jun CMFD
AB 150MG A203020 002 Dec 07, 2015 Jun CMFD

TABLET;ORAL
IRBESARTAN

AB		300MG	A203020	003	Dec 07, 2015	Jun CMFD
@	UPSHER SMITH LABS	75MG	A200461	001	Sep 27, 2012	Sep CAHN
@		150MG	A200461	002	Sep 27, 2012	Sep CAHN
@		300MG	A200461	003	Sep 27, 2012	Sep CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

@ ANDA REPOSITORY	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	Sep CAHN
@	100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	Sep CAHN
@ CHARTWELL RX	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	Nov CAHN
@	100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	Nov CAHN

ISONIAZID

TABLET;ORAL

ISONIAZID

>D> AA	GENUS LIFESCIENCES	100MG	A040090	001	Jun 26, 1997	Dec CAHN
AA		100MG	A040090	001	Jun 26, 1997	Sep CAHN
>D> AA		300MG	A040090	002	Jun 26, 1997	Dec CAHN
AA		300MG	A040090	002	Jun 26, 1997	Sep CAHN
>A> AA	OMNIVIUM PHARMS	100MG	A040090	001	Jun 26, 1997	Dec CAHN
>A> AA		300MG	A040090	002	Jun 26, 1997	Dec CAHN
	LANIAZID					
	@ CHARTWELL MOLECULAR	50MG	A080140	001		Feb CAHN
	@	100MG	A080140	002		Feb CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

@ AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022	Apr DISC
AP HIKMA	0.2MG/ML	A211703	001	Apr 26, 2023	Apr NEWA
@ MYLAN LABS LTD	0.2MG/ML	A212573	001	Sep 06, 2022	Jul DISC
AP PENN LIFE	0.2MG/ML	A215542	001	Sep 20, 2022	May CAHN
@ ZYDUS PHARMS	0.2MG/ML	A215557	001	Apr 14, 2023	Aug DISC
AP ISUPREL	0.2MG/ML	A215557	001	Apr 14, 2023	Apr NEWA
+ @ BAUSCH	0.2MG/ML	N010515	001		Jun DISC

ISOSORBIDE DINITRATE

>D>	TABLET, EXTENDED RELEASE;ORAL					
>D>	ISOSORBIDE DINITRATE					
>D>	! SUN PHARM INDs INC	40MG	A040009	001	Dec 30, 1998	Dec DISC
>A>	@	40MG	A040009	001	Dec 30, 1998	Dec DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

@ SHANDONG	120MG	A214115	001	Apr 29, 2022	May DISC
------------	-------	---------	-----	--------------	----------

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP AM REGENT	1%	A210294	001	May 17, 2023	May NEWA
--------------	----	---------	-----	--------------	----------

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

AB1 ZYDUS PHARMS	10MG	A211568	001	Aug 29, 2023	Aug NEWA
AB1	20MG	A211568	002	Aug 29, 2023	Aug NEWA
AB1	30MG	A211568	003	Aug 29, 2023	Aug NEWA
AB1	40MG	A211568	004	Aug 29, 2023	Aug NEWA

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

@ PAR PHARM INC	100MG	A205724	001	Dec 13, 2016	Nov DISC
-----------------	-------	---------	-----	--------------	----------

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

IVABRADINE HYDROCHLORIDE

AB	ZYDUS PHARMS	EQ 5MG BASE	A213442	001	Nov 29, 2023	Nov NEWA
AB		EQ 7.5MG BASE	A213442	002	Nov 29, 2023	Nov NEWA

IVACAFTOR

GRANULE; ORAL

KALYDECO

+ VERTEX PHARMS INC	5.8MG/PACKET	N207925	004	May 03, 2023	May NEWA
+ @	13.4MG/PACKET	N207925	005	May 03, 2023	May NEWA

IVERMECTIN

CREAM; TOPICAL

IVERMECTIN

AB	PADAGIS ISRAEL	1%	A210225	001	Apr 13, 2020	Nov CMFD
AB	ZYDUS	1%	A215210	001	Aug 02, 2022	Jul CMFD
@		1%	A215210	001	Aug 02, 2022	Jan DISC

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HYDROCHLORIDE

AP	@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jul DISC
	@	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan NEWA
AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jul DISC
AP	GLAND PHARMA LTD	EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan NEWA
AP		EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan NEWA
		EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan NEWA

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

AB	@ AUROBINDO PHARMA USA	200MG	A075597	001	Dec 23, 1999	May CAHN
	RISE PHARMA	200MG	A075912	001	Jan 10, 2002	Sep CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	ASPIRO	15MG/ML	A217166	001	Jun 20, 2023	Jun NEWA
AP		30MG/ML	A217166	002	Jun 20, 2023	Jun NEWA
AP	CAPLIN	15MG/ML	A217789	001	May 10, 2023	Apr NEWA
AP		30MG/ML	A217789	002	May 10, 2023	Apr NEWA

SOLUTION/DROPS; OPHTHALMIC

ACULAR

AT	+! ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan CAHN
	KETOROLAC TROMETHAMINE					
	@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan DISC
	@ CHARTWELL RX	0.5%	A078434	001	Nov 05, 2009	Sep CAHN

TABLET; ORAL

KETOROLAC TROMETHAMINE

AB	@ AIPING PHARM INC	10MG	A074790	001	Jun 26, 1997	Aug CAHN
		10MG	A210616	001	Aug 16, 2018	Aug CAHN
AB	BIONPHARMA	10MG	A216759	001	Feb 23, 2023	Feb NEWA
	@ CHARTWELL RX	10MG	A074790	001	Jun 26, 1997	Sep CAHN
AB		10MG	A210616	001	Aug 16, 2018	Sep CAHN
AB	LEADING	10MG	A215745	001	Feb 23, 2023	Feb NEWA

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS; OPHTHALMIC

ACUVUE THERAVISION WITH KETOTIFEN

+ @ JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	May DISC
--------------------------	---------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

TABLET; ORAL

TRANDATE

+ @ ALVOGEN	200MG	N018716	002	Aug 01, 1984	Nov DISC
+ @	300MG	N018716	003	Aug 01, 1984	Nov DISC

LACOSAMIDE

CAPSULE, EXTENDED RELEASE;ORAL MOTPOLY XR								
+ AUCTA	100MG	N 216185	001	May 04,	2023	May	NEWA	
+	150MG	N 216185	002	May 04,	2023	May	NEWA	
+!	200MG	N 216185	003	May 04,	2023	May	NEWA	
SOLUTION; INTRAVENOUS LACOSAMIDE								
AP AP	APOTEX	200MG/20ML (10MG/ML)	A 216670	001	Nov 13,	2023	Nov	NEWA
AP	MSN	200MG/20ML (10MG/ML)	A 215979	001	Feb 09,	2023	Feb	NEWA
SOLUTION;ORAL LACOSAMIDE								
AA AA >A> AA	LEADING PHARMA	10MG/ML	A 216461	001	Feb 06,	2023	Aug	CAHN
	MEDLEY PHARMS	10MG/ML	A 216461	001	Feb 06,	2023	Jan	NEWA
	MSN	10MG/ML	A 215379	001	Dec 22,	2023	Dec	NEWA
TABLET;ORAL LACOSAMIDE								
@ ACCORD HLTHCARE	50MG	A 205011	001	Jul 12,	2022	Jan	DISC	
@	100MG	A 205011	002	Jul 12,	2022	Jan	DISC	
@	150MG	A 205011	003	Jul 12,	2022	Jan	DISC	
@	200MG	A 205011	004	Jul 12,	2022	Jan	DISC	
@ ACTAVIS LABS FL INC	50MG	A 204855	001	Jan 05,	2023	Jul	DISC	
@	100MG	A 204855	002	Jan 05,	2023	Jul	DISC	
@	150MG	A 204855	003	Jan 05,	2023	Jul	DISC	
@	200MG	A 204855	004	Jan 05,	2023	Jul	DISC	
@ APOTEX	50MG	A 214567	001	Sep 23,	2022	Mar	DISC	
@	100MG	A 214567	002	Sep 23,	2022	Mar	DISC	
@	150MG	A 214567	003	Sep 23,	2022	Mar	DISC	
@	200MG	A 214567	004	Sep 23,	2022	Mar	DISC	
>A> AB	ZYDUS PHARMS	50MG	A 204947	001	Dec 15,	2023	Dec	NEWA
>A> AB		100MG	A 204947	002	Dec 15,	2023	Dec	NEWA
>A> AB		150MG	A 204947	003	Dec 15,	2023	Dec	NEWA
>A> AB		200MG	A 204947	004	Dec 15,	2023	Dec	NEWA

LACTULOSE

SOLUTION;ORAL LACTULOSE								
AA	AUROBINDO PHARMA LTD	10GM/15ML	A 074602	001	Nov 14,	1996	Sep	CAHN
@ VISTAPHARM		10GM/15ML	A 074138	001	Sep 30,	1992	Sep	DISC
AA XTRIUM LABS INC		10GM/15ML	A 075911	001	Feb 21,	2002	Mar	CMFD
SOLUTION;ORAL, RECTAL LACTULOSE								
AA BAJAJ		10GM/15ML	A 076645	001	Jul 28,	2003	Feb	CMFD
AA PAI HOLDINGS PHARM		10GM/15ML	A 074077	001	Jul 03,	1995	Oct	CAHN

LAMIVUDINE

SOLUTION;ORAL LAMIVUDINE								
AA	CHARTWELL MOLECULAR	10MG/ML	A 203564	001	Oct 31,	2014	Jul	CAHN
AA	HETERO LABS LTD III	10MG/ML	A 091475	001	Oct 06,	2023	Sep	NEWA
TABLET;ORAL LAMIVUDINE								
@ AUROBINDO PHARMA USA	100MG	A 204002	001	Dec 31,	2014	May	CAHN	

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL TEMIXYS							
+ @ CHARTWELL RX	300MG;300MG	N 211284	001	Nov 16,	2018	Mar	CAHN

LAMOTRIGINE

TABLET;ORAL LAMOTRIGINE							
@ CHARTWELL MOLECULAR	25MG	A 077783	001	Nov 01,	2010	Jan	CAHN
@	100MG	A 077783	002	Nov 01,	2010	Jan	CAHN
@	150MG	A 077783	003	Nov 01,	2010	Jan	CAHN
@	200MG	A 077783	004	Nov 01,	2010	Jan	CAHN

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB	AUROBINDO PHARMA LTD	15MG	A207167	001	Mar 28, 2023	Mar NEWA
AB		30MG	A207167	002	Mar 28, 2023	Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

>A > AT	@ AKORN	0.005%	A090887	001	Jul 19, 2011	Jan DISC
>D > AT	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Dec CAHN
	DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11, 2013	Dec CAHN
	@ EPIC PHARMA LLC	0.005%	A090887	001	Jul 19, 2011	Oct CAHN

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC
ROCKLATAN

+! ALCON LABS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	May CAHN
-------------------	----------------------	---------	-----	--------------	----------

LEFAMULIN ACETATE

>D>	SOLUTION;INTRAVENOUS					
>D>	XENLETA					
>D>	+! NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Dec DISC
>A>	+ @	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Dec DISC

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

AB	APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb NEWA
AB		20MG	A211022	006	Mar 07, 2023	Feb NEWA
AB	ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb NEWA
AB		20MG	A201452	006	Mar 06, 2023	Feb NEWA
AB	CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb NEWA
AB		20MG	A210435	005	Mar 06, 2023	Feb NEWA
AB	EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb NEWA
AB		5MG	A213885	002	Mar 06, 2023	Feb NEWA
AB		10MG	A213885	003	Mar 06, 2023	Feb NEWA
AB		15MG	A213885	004	Mar 06, 2023	Feb NEWA
AB		20MG	A213885	005	Mar 06, 2023	Feb NEWA
AB		25MG	A213885	006	Mar 06, 2023	Feb NEWA
AB	HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023	May NEWA
AB		5MG	A212414	002	May 11, 2023	May NEWA
AB		10MG	A212414	003	May 11, 2023	May NEWA
AB		15MG	A212414	004	May 11, 2023	May NEWA
AB		20MG	A212414	005	May 11, 2023	May NEWA
AB		25MG	A212414	006	May 11, 2023	May NEWA
AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210480	006	Mar 06, 2023	Feb NEWA
AB	MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb NEWA
AB		20MG	A213912	006	Mar 06, 2023	Feb NEWA
AB	SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb NEWA
AB		5MG	A211846	001	Feb 08, 2023	Jan NEWA
AB		10MG	A211846	002	Feb 08, 2023	Jan NEWA
AB		15MG	A211846	003	Feb 08, 2023	Jan NEWA
AB		20MG	A211846	006	Mar 06, 2023	Feb NEWA
AB		25MG	A211846	004	Feb 08, 2023	Jan NEWA
	@ TORRENT	10MG	A213405	001	Feb 17, 2023	Aug DISC
AB		10MG	A213405	001	Feb 17, 2023	Feb NEWA
	@	20MG	A213405	003	Aug 03, 2023	Aug DISC
AB		20MG	A213405	003	Aug 03, 2023	Jul NEWA
	@	25MG	A213405	002	Feb 17, 2023	Aug DISC
AB		25MG	A213405	002	Feb 17, 2023	Feb NEWA
AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210154	006	Mar 06, 2023	Feb NEWA
	REVLIMID					
AB	+ BRISTOL MYERS SQUIBB	2.5MG	N021880	005	Dec 21, 2011	Sep CAHN
AB	+	5MG	N021880	001	Dec 27, 2005	Sep CAHN
AB	+	10MG	N021880	002	Dec 27, 2005	Sep CAHN
AB	+	15MG	N021880	003	Jun 29, 2006	Sep CAHN
AB	+	20MG	N021880	006	Jun 05, 2013	Sep CAHN

	CAPSULE;ORAL REVLIMID						
AB	+!	25MG		N 021880	004	Jun 29, 2006	Sep CAHN
<u>LENIOLISIB PHOSPHATE</u>							
	TABLET;ORAL JOENJA			N 217759	001	Mar 24, 2023	Mar NEWA
<u>LETROZOLE</u>							
	TABLET;ORAL LETROZOLE						
>A> AB	CARNEGIE	2.5MG		A 091191	001	Jun 03, 2011	Dec CAHN
	@ CHARTWELL RX	2.5MG		A 202716	001	May 16, 2013	Feb CAHN
>D> AB	DR REDDYS LABS LTD	2.5MG		A 091191	001	Jun 03, 2011	Dec CAHN
<u>LEUCOVORIN CALCIUM</u>							
	INJECTABLE;INJECTION LEUCOVORIN CALCIUM			A 207226	001	Jul 27, 2018	Apr CHRS
	! FRESENIUS KABI USA	EQ 10MG BASE/ML		A 207226	001	Jul 27, 2018	Apr CTEC
	!	EQ 10MG BASE/ML		A 207241	001	Mar 14, 2018	Apr CHRS
AP	HAINAN POLY	EQ 50MG BASE/VIAL		A 217021	001	Jul 10, 2023	Jun NEWA
AP		EQ 100MG BASE/VIAL		A 217021	002	Jul 10, 2023	Jun NEWA
AP		EQ 200MG BASE/VIAL		A 217021	003	Jul 10, 2023	Jun NEWA
AP		EQ 500MG BASE/VIAL		A 217021	004	Jul 10, 2023	Jun NEWA
AP	KINDOS	EQ 50MG BASE/VIAL		A 216590	001	Jul 19, 2023	Jul NEWA
AP		EQ 100MG BASE/VIAL		A 216590	002	Jul 19, 2023	Jul NEWA
AP		EQ 200MG BASE/VIAL		A 216590	003	Jul 19, 2023	Jul NEWA
AP		EQ 350MG BASE/VIAL		A 216590	004	Jul 19, 2023	Jul NEWA
AP		EQ 500MG BASE/VIAL		A 216590	005	Jul 19, 2023	Jul NEWA
	@ TEVA PHARMS USA	EQ 100MG BASE/VIAL		A 081277	001	Sep 28, 1993	Nov DISC
	@	EQ 350MG BASE/VIAL		A 040174	001	Jun 12, 1997	Nov DISC
	LEUCOVORIN CALCIUM PRESERVATIVE FREE			A 040347	001	Apr 25, 2000	Apr DISC
	@ HIKMA	EQ 10MG BASE/ML					
<u>LEUPROLIDE ACETATE</u>							
	FOR SUSPENSION;INTRAMUSCULAR						
>A>	LEUPROLIDE ACETATE FOR DEPOT SUSPENSION						
>A>	+! INVAGEN PHARMS	22.5MG/VIAL		N 205054	001	Aug 28, 2018	Dec CTNA
>D>	LUTRATE DEPOT KIT						
>D>	+! INVAGEN PHARMS	22.5MG/VIAL		N 205054	001	Aug 28, 2018	Dec CTNA
	INJECTABLE;INJECTION LEUPROLIDE ACETATE						
>D> AP	HONG KONG	1MG/0.2ML		A 075471	001	Oct 25, 2000	Dec CAHN
AP		1MG/0.2ML		A 075471	001	Oct 25, 2000	Sep CAHN
>A> AP	MEITHEAL	1MG/0.2ML		A 075471	001	Oct 25, 2000	Dec CAHN
AP	RK PHARMA	1MG/0.2ML		A 213829	001	Aug 13, 2021	Jun CAHN
	LUPRON DEPOT						
	+! ABBVIE ENDOCRINE INC	7.5MG		N 019732	001	Jan 26, 1989	Jul CPOT
	+!	11.25MG		N 020708	001	Mar 07, 1997	Jul CPOT
	+	22.5MG		N 020517	001	Dec 22, 1995	Jul CPOT
	+!	30MG		N 020517	002	May 30, 1997	Jul CPOT
	+!	45MG		N 020517	003	Jun 17, 2011	Jul CPOT
	POWDER;INTRAMUSCULAR						
	LUPRON DEPOT-PED KIT						
	+! ABBVIE ENDOCRINE INC	45MG		N 020263	009	Apr 14, 2023	Apr NEWA
	POWDER;SUBCUTANEOUS ELIGARD KIT						
	+! TOLMAR	7.5MG		N 021343	001	Jan 23, 2002	Feb CAHN
	+!	22.5MG		N 021379	001	Jul 24, 2002	Feb CAHN
	+!	30MG		N 021488	001	Feb 13, 2003	Feb CAHN
	+!	45MG		N 021731	001	Dec 14, 2004	Feb CAHN
<u>LEVALBUTEROL HYDROCHLORIDE</u>							
	SOLUTION;INHALATION XOPENEX						
AN	+! HIKMA	EQ 0.0103% BASE		N 020837	003	Jan 30, 2002	Sep CAHN
AN	+!	EQ 0.021% BASE		N 020837	001	Mar 25, 1999	Sep CAHN
AN	+!	EQ 0.042% BASE		N 020837	002	Mar 25, 1999	Sep CAHN
AN	+!	EQ 0.25% BASE		N 020837	004	Jul 18, 2003	Sep CAHN

LEVAMLODIPINE MALEATE

TABLET;ORAL

CONJUPRI

+ @ CSPC OUYI

+ @

EQ 2.5MG BASE

EQ 5MG BASE

N212895 002 Dec 19, 2019 Sep DISC

N212895 003 Dec 19, 2019 Sep DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

AP	BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Sep NEWA
AP		1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Sep NEWA
AP		1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Sep NEWA
	LEVETIRACETAM IN SODIUM CHLORIDE					
AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan NEWA
AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA	ALEMBIC	100MG/ML	A203067	001	May 09, 2013	Feb CAHN
AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	Jun CAHN
@	PHARMOBEDIENT CNSLTG	100MG/ML	A090028	001	Mar 03, 2010	Sep CAHN
AA	QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Oct CAHN
AA		100MG/ML	A090079	001	Apr 11, 2012	Feb CAHN
AA	SCIEGEN PHARMS INC	100MG/ML	A090079	001	Apr 11, 2012	Sep CAHN
AA	STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023	Nov NEWA
@	XTRIUM LABS INC	100MG/ML	A090028	001	Mar 03, 2010	Mar CAHN

TABLET;ORAL

LEVETIRACETAM

AB	GRANULES	250MG	A217878	001	Jun 13, 2023	Jun NEWA
AB		500MG	A217878	002	Jun 13, 2023	Jun NEWA
AB		750MG	A217878	003	Jun 13, 2023	Jun NEWA
AB		1GM	A217878	004	Jun 13, 2023	Jun NEWA
@	MYLAN	250MG	A076919	001	Nov 04, 2008	Apr DISC
>A> AB	RISING	250MG	A090767	001	Jul 28, 2010	Dec CAHN
>A> AB		500MG	A090767	002	Jul 28, 2010	Dec CAHN
>A> AB		750MG	A090767	003	Jul 28, 2010	Dec CAHN
>A> AB		1GM	A090767	004	Jul 28, 2010	Dec CAHN
>D> AB	VKT PHARMA	250MG	A090767	001	Jul 28, 2010	Dec CAHN
>D> AB		500MG	A090767	002	Jul 28, 2010	Dec CAHN
>D> AB		750MG	A090767	003	Jul 28, 2010	Dec CAHN
>D> AB		1GM	A090767	004	Jul 28, 2010	Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

+ @	TRIPOINT	1GM	N204417	001	Dec 20, 2018	Sep DISC
+ @		1.5GM	N204417	002	Dec 20, 2018	Sep DISC
	LEVETIRACETAM					
@	AUROBINDO PHARMA USA	500MG	A200475	001	Dec 19, 2011	Apr CAHN
@		750MG	A200475	002	Dec 19, 2011	Apr CAHN
@		1GM	A200475	003	Dec 07, 2015	Apr CAHN
@	CHARTWELL RX	500MG	A091291	001	Sep 12, 2011	Sep CAHN
@		750MG	A091291	002	Sep 12, 2011	Sep CAHN
AB	OVERSEAS	500MG	A212688	002	May 05, 2023	Apr NEWA
@	SUN PHARM	500MG	A203059	001	Sep 09, 2013	Aug DISC
@		750MG	A203059	002	Sep 09, 2013	Aug DISC

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

@ EPIC PHARMA LLC

0.25%

A074779 001 Oct 29, 1996 Oct CAHN

LEVOFLOXACIN

SOLUTION;ORAL

LEVOFLOXACIN

AA	! NOVITIUM PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug CAHN
	SOLUTION/DROPS;OPHTHALMIC					
	LEVOFLOXACIN					
@	AKORN	0.5%	A090268	001	Dec 20, 2010	Jan DISC
!	RISING	0.5%	A077700	001	Dec 20, 2010	Jan CTEC

LEVOLEUCOVORIN

POWDER; INTRAVENOUS
KHPZORY
+ @ ACROTECH BIOPHARMA 300MG/VIAL N211226 002 Oct 19, 2018 Aug DISC

LEVOLEUCOVORIN CALCIUM

SOLUTION; INTRAVENOUS	LEVOLEUCOVORIN CALCIUM				
@ AILEX PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Sep CAHN
AP ! GLAND PHARMA LTD	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	May CTEC
AP HAINAN POLY PHARM	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A217314	001	May 22, 2023	May NEWA
AP	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A217314	002	May 22, 2023	May NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL	FETZIMA				
+ ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar CTEC
AB +	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
+ +	EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar CTEC
AB +	EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
+ +	EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar CTEC
AB +	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
+ ! +!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar CTEC
AB +!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN
LEVOMILNACIPRAN HYDROCHLORIDE					
@ AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar DISC
@	EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar DISC
@	EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar DISC
@	EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar DISC
AB PRINSTON INC	EQ 20MG BASE	A210771	001	Mar 20, 2023	Mar NEWA
AB	EQ 40MG BASE	A210771	002	Mar 20, 2023	Mar NEWA
AB	EQ 80MG BASE	A210771	003	Mar 20, 2023	Mar NEWA
AB	EQ 120MG BASE	A210771	004	Mar 20, 2023	Mar NEWA

LEVONORDERFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
SCANDONEST L
@ DEPROCO 0.05MG/ML; 2% A088388 001 Oct 10, 1984 Sep DISC

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVORPHANOL TARTRATE

AB HIKMA	2MG	A074278	001	Mar 31, 2000	Jan CMFD
AB ! NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Apr CTEC
AB SUN PHARM IND'S INC	3MG	A213906	002	Apr 25, 2023	Apr NEWA

LEVOTHYROXINE SODIUM

CAPSULE; ORAL
LEVOTHYROXINE SODIUM

AB @ TEVA PHARMS USA INC	0.137MG	A211369	005	May 02, 2023	May DISC
	0.137MG	A211369	005	May 02, 2023	Apr NFTG
AB @	0.175MG	A211369	006	May 02, 2023	May DISC
	0.175MG	A211369	006	May 02, 2023	Apr NFTG
AB @	0.2MG	A211369	004	Nov 09, 2022	May DISC
TIROSINT					
+ IBSA	0.013MG	N021924	013	Aug 01, 2007	Aug CAHN
+	0.025MG	N021924	002	Oct 13, 2006	Aug CAHN
+	0.0375MG	N021924	014	Jun 22, 2022	Aug CAHN
+	0.044MG	N021924	015	Jun 22, 2022	Aug CAHN
+	0.05MG	N021924	003	Oct 13, 2006	Aug CAHN
+	0.0625MG	N021924	016	Jun 22, 2022	Aug CAHN
+	0.075MG	N021924	004	Oct 13, 2006	Aug CAHN
+	0.088MG	N021924	010	Oct 02, 2009	Aug CAHN
+	0.1MG	N021924	005	Oct 13, 2006	Aug CAHN
+	0.112MG	N021924	008	Oct 02, 2009	Aug CAHN
+	0.125MG	N021924	006	Oct 13, 2006	Aug CAHN
+	0.137MG	N021924	009	Oct 02, 2009	Aug CAHN
+	0.15MG	N021924	007	Oct 13, 2006	Aug CAHN

	CAPSULE;ORAL TIROSINT							
	+ 0.175MG	N 021924	011	Apr 25, 2017	Aug CAHN			
	+! 0.2MG	N 021924	012	Apr 25, 2017	Aug CAHN			
	+ INSTITUT BIOCHIMIQUE 0.137MG	N 021924	009	Oct 02, 2009	May CTEC			
AB	+ 0.137MG	N 021924	009	Oct 02, 2009	Apr CFTG			
	+ 0.175MG	N 021924	011	Apr 25, 2017	May CTEC			
AB	+ 0.175MG	N 021924	011	Apr 25, 2017	Apr CFTG			
	+! 0.2MG	N 021924	012	Apr 25, 2017	May CTEC			
	POWDER;INTRAVENOUS LEVOTHYROXINE SODIUM							
AP	ZYDUS PHARMS 100MCG/VIAL	A217066	001	Mar 24, 2023	Mar NEWA			
AP	200MCG/VIAL	A217066	002	Mar 24, 2023	Mar NEWA			
AP	500MCG/VIAL	A217066	003	Mar 24, 2023	Mar NEWA			
	SOLUTION;ORAL TIROSINT-SOL							
	+ IBSA 13MCG/ML	N 206977	001	Dec 15, 2016	Aug CAHN			
	+ 25MCG/ML	N 206977	002	Dec 15, 2016	Aug CAHN			
	+ 37.5MCG/ML	N 206977	013	Jan 13, 2021	Aug CAHN			
	+ 44MCG/ML	N 206977	014	Jan 13, 2021	Aug CAHN			
	+ 50MCG/ML	N 206977	003	Dec 15, 2016	Aug CAHN			
	+ 62.5MCG/ML	N 206977	015	Jan 13, 2021	Aug CAHN			
	+ 75MCG/ML	N 206977	004	Dec 15, 2016	Aug CAHN			
	+ 88MCG/ML	N 206977	005	Dec 15, 2016	Aug CAHN			
	+ 100MCG/ML	N 206977	006	Dec 15, 2016	Aug CAHN			
	+ 112MCG/ML	N 206977	007	Dec 15, 2016	Aug CAHN			
	+ 125MCG/ML	N 206977	008	Dec 15, 2016	Aug CAHN			
	+ 137MCG/ML	N 206977	009	Dec 15, 2016	Aug CAHN			
	+ 150MCG/ML	N 206977	010	Dec 15, 2016	Aug CAHN			
	+ 175MCG/ML	N 206977	011	Dec 15, 2016	Aug CAHN			
	+! 200MCG/ML	N 206977	012	Dec 15, 2016	Aug CAHN			

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

	TABLET;ORAL LEVOTHYROXINE SODIUM							
AB4	ASCENT PHARMS INC 0.025MG	A215259	001	Jan 18, 2023	Jan NEWA			
AB4	0.05MG	A215259	002	Jan 18, 2023	Jan NEWA			
AB4	0.075MG	A215259	003	Jan 18, 2023	Jan NEWA			
AB4	0.088MG	A215259	004	Jan 18, 2023	Jan NEWA			
AB4	0.1MG	A215259	005	Jan 18, 2023	Jan NEWA			
AB4	0.112MG	A215259	006	Jan 18, 2023	Jan NEWA			
AB4	0.125MG	A215259	007	Jan 18, 2023	Jan NEWA			
AB4	0.137MG	A215259	008	Jan 18, 2023	Jan NEWA			
AB4	0.15MG	A215259	009	Jan 18, 2023	Jan NEWA			
AB4	0.175MG	A215259	010	Jan 18, 2023	Jan NEWA			
AB4	0.2MG	A215259	011	Jan 18, 2023	Jan NEWA			
AB4	0.3MG	A215259	012	Jan 18, 2023	Jan NEWA			
AB2	MACLEODS PHARMS LTD 0.025MG	A211417	001	Dec 21, 2022	Jan CTEC			
AB2	0.05MG	A211417	002	Dec 21, 2022	Jan CTEC			
AB2	0.075MG	A211417	003	Dec 21, 2022	Jan CTEC			
AB2	0.088MG	A211417	004	Dec 21, 2022	Jan CTEC			
AB2	0.1MG	A211417	005	Dec 21, 2022	Jan CTEC			
AB2	0.112MG	A211417	006	Dec 21, 2022	Jan CTEC			
AB2	0.125MG	A211417	007	Dec 21, 2022	Jan CTEC			
AB2	0.137MG	A211417	008	Dec 21, 2022	Jan CTEC			
AB2	0.15MG	A211417	009	Dec 21, 2022	Jan CTEC			
AB2	0.175MG	A211417	010	Dec 21, 2022	Jan CTEC			
AB2	0.2MG	A211417	011	Dec 21, 2022	Jan CTEC			
AB2	0.3MG	A211417	012	Dec 21, 2022	Jan CTEC			

LIDOCAINE

	OINTMENT;TOPICAL LIDOCAINE							
>D>	@ AILEX PHARMS LLC 5%	A212486	001	Oct 17, 2019	Sep CAHN			
	@ PAI HOLDINGS PHARM 5%	A205318	001	Feb 01, 2016	Dec CAHN			
	@ 5%	A205318	001	Feb 01, 2016	May DISC			
>A>	@ VERTICE 5%	A205318	001	Feb 01, 2016	Dec CAHN			
	@ VITRUVIAS THERAP 5%	A208822	001	Sep 25, 2017	Oct DISC			
	PATCH;TOPICAL LIDOCAINE							
AB	IBSA 5%	A209190	001	Apr 30, 2020	Aug CAHN			
AB	INST BIOCHIMIQUE SA 5%	A209190	001	Apr 30, 2020	Apr CAHN			

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>A>	AP	ASPIRO	2%	A214336	002	Dec 13, 2023	Dec NEWA
	AP	+! HOSPIRA	1%	A083158	001	Aug CRLD	
	AP	+!	2%	A083158	002	Aug CRLD	
	AP	HUONS	2%	A212821	002	Jun 15, 2023	Jun NEWA
	AP	MANKIND PHARMA	1%	A217692	001	Jun 16, 2023	Jun NEWA
	AP		1%	A217692	003	Nov 29, 2023	Nov NEWA
	AP		1%	A217693	001	Jul 11, 2023	Jun NEWA
	AP		2%	A217692	002	Jun 16, 2023	Jun NEWA
	AP		2%	A217693	002	Jul 11, 2023	Jun NEWA
		JELLY;TOPICAL					
		GLYDO					
AT	!	SAGENT PHARMS INC	2%	A201094	001	Apr 28, 2014	Apr CHRS
		LIDOCAINE HYDROCHLORIDE					
AT		AKORN	2%	A040433	001	Feb 12, 2003	Apr CHRS
AT		SENTISSION	2%	A040433	001	Feb 12, 2003	Aug CAHN
		XYLOCAINE					
	+ @	EPIC PHARMA LLC	2%	N008816	001		Sep CAHN
		SOLUTION;ORAL					
		LIDOCAINE HYDROCHLORIDE					
		@ HIKMA	2%	A040014	001	Jul 10, 1995	Nov DISC
AT	!	RUBICON	2%	A216780	001	Mar 28, 2023	Nov CHRS
AT			2%	A216780	001	Mar 28, 2023	Mar NEWA
		LIDOCAINE HYDROCHLORIDE VISCOSUS					
AT		CHARTWELL MOLECULAR	2%	A040708	001	Feb 27, 2007	Jul CAHN
		SOLUTION;TOPICAL					
		LIDOCAINE HYDROCHLORIDE					
>A>	AT	TARO	4%	A218182	001	Dec 07, 2023	Dec NEWA

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

AB	!	FOUGERA PHARMS	2.5%;2.5%	A076453	001	Aug 18, 2003	Oct CHRS
AB		HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Oct CHRS
	@	PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	May DISC

LIDOCAINE; TETRACAIN

CREAM;TOPICAL

PLIAGLIS

+ @ TARO

7%;7%

N021717 001 Jun 29, 2006 Aug DISC

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

LIFITEGRAST

AB		EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	Oct NEWA
----	--	--------------	----	---------	-----	--------------	----------

LINACLOTIDE

CAPSULE;ORAL

LINACLOTIDE

AB		@ AUROBINDO PHARMA	145MCG	A209611	001	Feb 07, 2023	Mar DISC
			145MCG	A209611	001	Feb 07, 2023	Jan NEWA
		@	290MCG	A209611	002	Feb 07, 2023	Mar DISC
AB			290MCG	A209611	002	Feb 07, 2023	Jan NEWA
		LINZESS					
	+!	ABBVIE	145MCG	N202811	001	Aug 30, 2012	Mar CTEC
	+		290MCG	N202811	002	Aug 30, 2012	Mar CTEC
AB	+!	ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Jan CTEC
AB	+		290MCG	N202811	002	Aug 30, 2012	Jan CTEC

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

AB		@ ZYDUS PHARMS	5MG	A208448	001	Mar 30, 2023	Jul DISC
			5MG	A208448	001	Mar 30, 2023	Mar NEWA

LINAGLITZTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

LINAGLITZTIN AND METFORMIN HYDROCHLORIDE

AB	@ ZYDUS PHARMS	2.5MG;500MG 2.5MG;500MG	A208449 001 Mar 30, 2023 A208449 001 Mar 30, 2023	Jul DISC Mar NEWA
AB	@	2.5MG;850MG 2.5MG;850MG	A208449 002 Mar 30, 2023 A208449 002 Mar 30, 2023	Jul DISC Mar NEWA
AB	@	2.5MG;1GM 2.5MG;1GM	A208449 003 Mar 30, 2023 A208449 003 Mar 30, 2023	Jul DISC Mar NEWA
AB				

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

@ GENEYORK PHARMS	EQ 300MG BASE/ML	A212770 001 Mar 12, 2021	Sep CAHN
@ HAINAN POLY	EQ 300MG BASE/ML	A216662 001 Dec 21, 2022	Jun DISC
@ PRAZGEN PHARMS	EQ 300MG BASE/ML	A212770 001 Mar 12, 2021	Jul CAHN
@ SLATE RUN PHARMA	EQ 300MG BASE/ML	A216662 001 Dec 21, 2022	Sep CAHN

LINEZOLID

SOLUTION;INTRAVENOUS

LINEZOLID

AP	HIKMA	600MG/300ML (2MG/ML)	A206454 001 Aug 22, 2022	Sep CAHN
	TABLET;ORAL			
	LINEZOLID			
AB	CHARTWELL RX	600MG	A210702 001 Apr 25, 2019	Mar CAHN

>D> @ RISING 600MG A078845 001 Dec 21, 2015 Dec CMFD

>A> AB 600MG A078845 001 Dec 21, 2015 Dec CMFD

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

LIOTHYRONINE SODIUM

! XGEN PHARMS	EQ 0.01MG BASE/ML EQ 0.01MG BASE/ML	A076923 001 Aug 17, 2005 A076923 001 Aug 17, 2005	Jun CHRS Jun CTEC
+ @ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105 001 Dec 31, 1991	Jun DISC

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	ACTAVIS ELIZABETH	10MG 20MG 30MG 40MG 50MG 60MG 70MG	A202802 001 Aug 25, 2023 A202802 002 Aug 25, 2023 A202802 003 Aug 25, 2023 A202802 004 Aug 25, 2023 A202802 005 Aug 25, 2023 A202802 006 Aug 25, 2023 A202802 007 Aug 25, 2023	Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG
AB	ALKEM LABS LTD	10MG 20MG 30MG 40MG 50MG 60MG 70MG	A217194 001 Aug 25, 2023 A217194 002 Aug 25, 2023 A217194 003 Aug 25, 2023 A217194 004 Aug 25, 2023 A217194 005 Aug 25, 2023 A217194 006 Aug 25, 2023 A217194 007 Aug 25, 2023	Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG
AB	AMNEAL	20MG 30MG 40MG 50MG 60MG 70MG	A202830 001 Aug 25, 2023 A202830 002 Aug 25, 2023 A202830 003 Aug 25, 2023 A202830 004 Aug 25, 2023 A202830 005 Aug 25, 2023 A202830 006 Aug 25, 2023 A202830 007 Aug 25, 2023	Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG
AB	APOTEX	10MG 20MG 30MG 40MG 50MG 60MG 70MG	A216944 001 Aug 25, 2023 A216944 002 Aug 25, 2023 A216944 003 Aug 25, 2023 A216944 004 Aug 25, 2023 A216944 005 Aug 25, 2023 A216944 006 Aug 25, 2023 A216944 007 Aug 25, 2023	Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG
AB	ASCENT PHARMS INC	10MG 20MG 30MG 40MG 50MG 60MG 70MG	A217442 001 Aug 25, 2023 A217442 002 Aug 25, 2023 A217442 003 Aug 25, 2023 A217442 004 Aug 25, 2023 A217442 005 Aug 25, 2023 A217442 006 Aug 25, 2023 A217442 007 Aug 25, 2023	Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG Aug NFTG

CAPSULE;ORAL

LISDEXAMFETAMINE Dimesylate

AB		70MG	A217442	007	Aug 25, 2023	Aug NFTG
AB	HIKMA	20MG	A202827	001	Aug 25, 2023	Aug NFTG
AB		30MG	A202827	002	Aug 25, 2023	Aug NFTG
AB		40MG	A202827	003	Aug 25, 2023	Aug NFTG
AB		50MG	A202827	004	Aug 25, 2023	Aug NFTG
AB		60MG	A202827	005	Aug 25, 2023	Aug NFTG
AB		70MG	A202827	006	Aug 25, 2023	Aug NFTG
AB	LANNETT CO INC	10MG	A215802	001	Aug 25, 2023	Aug NFTG
AB		20MG	A215802	002	Aug 25, 2023	Aug NFTG
AB		30MG	A215802	003	Aug 25, 2023	Aug NFTG
AB		40MG	A215802	004	Aug 25, 2023	Aug NFTG
AB		50MG	A215802	005	Aug 25, 2023	Aug NFTG
AB		60MG	A215802	006	Aug 25, 2023	Aug NFTG
AB		70MG	A215802	007	Aug 25, 2023	Aug NFTG
AB	MYLAN	10MG	A202835	001	Aug 25, 2023	Aug NFTG
AB		20MG	A202835	002	Aug 25, 2023	Aug NFTG
AB		30MG	A202835	003	Aug 25, 2023	Aug NFTG
AB		40MG	A202835	004	Aug 25, 2023	Aug NFTG
AB		50MG	A202835	005	Aug 25, 2023	Aug NFTG
AB		60MG	A202835	006	Aug 25, 2023	Aug NFTG
AB		70MG	A202835	007	Aug 25, 2023	Aug NFTG
AB	NORWICH	10MG	A214547	001	Aug 25, 2023	Aug NFTG
AB		20MG	A214547	002	Aug 25, 2023	Aug NFTG
AB		30MG	A214547	003	Aug 25, 2023	Aug NFTG
AB		40MG	A214547	004	Aug 25, 2023	Aug NFTG
AB		50MG	A214547	005	Aug 25, 2023	Aug NFTG
AB		60MG	A214547	006	Aug 25, 2023	Aug NFTG
AB		70MG	A214547	007	Aug 25, 2023	Aug NFTG
AB	PRINSTON INC	10MG	A216266	001	Aug 25, 2023	Aug NFTG
AB		20MG	A216266	002	Aug 25, 2023	Aug NFTG
AB		30MG	A216266	003	Aug 25, 2023	Aug NFTG
AB		40MG	A216266	004	Aug 25, 2023	Aug NFTG
AB		50MG	A216266	005	Aug 25, 2023	Aug NFTG
AB		60MG	A216266	006	Aug 25, 2023	Aug NFTG
AB		70MG	A216266	007	Aug 25, 2023	Aug NFTG
AB	RHODES PHARMS	10MG	A215330	001	Aug 25, 2023	Aug NFTG
AB		20MG	A215330	002	Aug 25, 2023	Aug NFTG
AB		30MG	A215330	003	Aug 25, 2023	Aug NFTG
AB		40MG	A215330	004	Aug 25, 2023	Aug NFTG
AB		50MG	A215330	005	Aug 25, 2023	Aug NFTG
AB		60MG	A215330	006	Aug 25, 2023	Aug NFTG
AB		70MG	A215330	007	Aug 25, 2023	Aug NFTG
AB	SPECGX LLC	10MG	A211840	001	Aug 25, 2023	Aug NFTG
AB		20MG	A211840	002	Aug 25, 2023	Aug NFTG
AB		30MG	A211840	003	Aug 25, 2023	Aug NFTG
AB		40MG	A211840	004	Aug 25, 2023	Aug NFTG
AB		50MG	A211840	005	Aug 25, 2023	Aug NFTG
AB		60MG	A211840	006	Aug 25, 2023	Aug NFTG
AB		70MG	A211840	007	Aug 25, 2023	Aug NFTG
AB	SUN PHARM INDs INC	10MG	A214484	001	Aug 25, 2023	Aug NFTG
AB		20MG	A214484	002	Aug 25, 2023	Aug NFTG
AB		30MG	A214484	003	Aug 25, 2023	Aug NFTG
AB		40MG	A214484	004	Aug 25, 2023	Aug NFTG
AB		50MG	A214484	005	Aug 25, 2023	Aug NFTG
AB		60MG	A214484	006	Aug 25, 2023	Aug NFTG
AB		70MG	A214484	007	Aug 25, 2023	Aug NFTG
VYVANSE						
AB	+ TAKEDA PHARMS USA	10MG	N021977	007	Oct 30, 2014	Aug CFTG
AB	+	20MG	N021977	004	Dec 10, 2007	Aug CFTG
AB	+	30MG	N021977	001	Feb 23, 2007	Aug CFTG
AB	+	40MG	N021977	005	Dec 10, 2007	Aug CFTG
AB	+	50MG	N021977	002	Feb 23, 2007	Aug CFTG
AB	+	60MG	N021977	006	Dec 10, 2007	Aug CFTG
AB	!+	70MG	N021977	003	Feb 23, 2007	Aug CFTG
TABLET, CHEWABLE;ORAL						
LISDEXAMFETAMINE Dimesylate						
AB	ASCENT PHARMS INC	10MG	A217068	001	Aug 25, 2023	Aug NFTG
AB		20MG	A217068	002	Aug 25, 2023	Aug NFTG
AB		30MG	A217068	003	Aug 25, 2023	Aug NFTG
AB		40MG	A217068	004	Aug 25, 2023	Aug NFTG
AB		50MG	A217068	005	Aug 25, 2023	Aug NFTG
AB		60MG	A217068	006	Aug 25, 2023	Aug NFTG

TABLET, CHEWABLE;ORALLISDEXAMFETAMINE Dimesylate

AB	SUN PHARM INDS INC	10MG	A214134	001	Aug 25, 2023	Aug NFTG
AB		20MG	A214134	002	Aug 25, 2023	Aug NFTG
AB		30MG	A214134	003	Aug 25, 2023	Aug NFTG
AB		40MG	A214134	004	Aug 25, 2023	Aug NFTG
AB		50MG	A214134	005	Aug 25, 2023	Aug NFTG
AB		60MG	A214134	006	Aug 25, 2023	Aug NFTG
AB	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Aug NFTG
AB		20MG	A215415	002	Aug 25, 2023	Aug NFTG
AB		30MG	A215415	003	Aug 25, 2023	Aug NFTG
AB		40MG	A215415	004	Aug 25, 2023	Aug NFTG
AB		50MG	A215415	005	Aug 25, 2023	Aug NFTG
AB		60MG	A215415	006	Aug 25, 2023	Aug NFTG
	VYVANSE					
AB	+ TAKEDA PHARMS USA	10MG	N208510	001	Jan 28, 2017	Aug CFTG
AB	+	20MG	N208510	002	Jan 28, 2017	Aug CFTG
AB	+	30MG	N208510	003	Jan 28, 2017	Aug CFTG
AB	+	40MG	N208510	004	Jan 28, 2017	Aug CFTG
AB	+	50MG	N208510	005	Jan 28, 2017	Aug CFTG
AB	+ !	60MG	N208510	006	Jan 28, 2017	Aug CFTG

LISINOPRILTABLET;ORALLISINOPRIL

AB	@ HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug DISC
AB	@	2.5MG	A075752	001	Jul 01, 2002	Mar CMFD
AB	@	5MG	A075752	002	Jul 01, 2002	Aug DISC
AB	@	5MG	A075752	002	Jul 01, 2002	Mar CMFD
AB	@	10MG	A075752	003	Jul 01, 2002	Aug DISC
AB	@	10MG	A075752	003	Jul 01, 2002	Mar CMFD
AB	@	20MG	A075752	004	Jul 01, 2002	Aug DISC
AB	@	20MG	A075752	004	Jul 01, 2002	Mar CMFD
AB	@	30MG	A075752	005	Jul 01, 2002	Aug DISC
AB	@	30MG	A075752	005	Jul 01, 2002	Mar CMFD
AB	@	40MG	A075752	006	Jul 01, 2002	Aug DISC
AB	@ RISING	2.5MG	A075999	001	Jul 01, 2002	Aug CAHN
AB	@	5MG	A075999	002	Jul 01, 2002	Aug CAHN
AB	@	10MG	A075999	003	Jul 01, 2002	Aug CAHN
AB	@	20MG	A075999	004	Jul 01, 2002	Aug CAHN
AB	@	30MG	A075999	005	Jul 01, 2002	Aug CAHN
AB	@	40MG	A075999	006	Jul 01, 2002	Aug CAHN
AB	SCIEGEN PHARMS INC	2.5MG	A212041	001	Sep 15, 2020	Nov CAHN
AB		5MG	A212041	002	Sep 15, 2020	Nov CAHN
AB		10MG	A212041	003	Sep 15, 2020	Nov CAHN
AB		20MG	A208920	001	Mar 04, 2021	Nov CAHN
AB		30MG	A208920	002	Mar 04, 2021	Nov CAHN
AB		40MG	A208920	003	Mar 04, 2021	Nov CAHN
	ZESTRIL					
AB	+ TWI PHARMS	2.5MG	N019777	005	Apr 29, 1993	Nov CAHN
AB	+	5MG	N019777	001	May 19, 1988	Nov CAHN
AB	+	10MG	N019777	002	May 19, 1988	Nov CAHN
AB	+	20MG	N019777	003	May 19, 1988	Nov CAHN
AB	+	30MG	N019777	006	Jan 20, 1999	Nov CAHN
AB	+ !	40MG	N019777	004	May 19, 1988	Nov CAHN

LITHIUM CITRATESYRUP;ORALLITHIUM CITRATE

AA	! PAJ HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Aug CTEC
AA	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Aug NEWA

LOPERAMIDE HYDROCHLORIDECAPSULE;ORALLOPERAMIDE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	2MG	A218122	001	Sep 05, 2023	Aug NEWA
AB	JUBILANT CADISTA	2MG	A217840	001	Jul 05, 2023	Jun NEWA
AB	RUBICON	2MG	A216876	001	Jan 26, 2023	Jan NEWA
AB	ZYDUS LIFESCIENCES	2MG	A217471	001	Mar 23, 2023	Apr CAHN
AB	ZYDUS PHARMS	2MG	A217471	001	Mar 23, 2023	Mar NEWA

LORAZEPAM

TABLET;ORAL

LORAZEPAM

@	AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010	May DISC
@		1MG	A078826	002	Jun 23, 2010	May DISC
@		2MG	A078826	003	Jun 23, 2010	May DISC
AB	SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Sep CMFD
AB		1MG	A076045	002	Aug 29, 2001	Sep CMFD
AB		2MG	A076045	003	Aug 29, 2001	Sep CMFD

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB	GRANULES	25MG	A215959	001	Feb 23, 2023	Feb NEWA
AB		50MG	A215959	002	Feb 23, 2023	Feb NEWA
AB		100MG	A215959	003	Feb 23, 2023	Feb NEWA
AB	MSN	25MG	A217396	001	Aug 14, 2023	Aug NEWA
AB		50MG	A217396	002	Aug 14, 2023	Aug NEWA
AB		100MG	A217396	003	Aug 14, 2023	Aug NEWA

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

AB	SENTISS	0.5%	A212080	001	Feb 10, 2021	Aug CAHN
AB	SLAYBACK PHARMA LLC	0.5%	A213956	001	Nov 29, 2023	Nov NEWA
AB	SUN PHARM	0.5%	A215384	001	Aug 09, 2023	Jul NEWA
	SUSPENSION/DROPS;OPHTHALMIC					
	ALREX					
AB	+! BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998	Mar CFTG
	LOTEPREDNOL ETABONATE					
AB	AKORN	0.2%	A215933	001	Apr 12, 2023	Mar NFTG
>A> AB	LUPIN LTD	0.2%	A215550	001	Dec 26, 2023	Dec NEWA
AB	SENTISS	0.2%	A215933	001	Apr 12, 2023	Aug CAHN
AB		0.5%	A207609	001	Apr 17, 2019	Jul CAHN

LOTILANER

SOLUTION/DROPS;OPHTHALMIC

XDEMVY

+! TARSUS

0.25%

N217603 001 Jul 24, 2023 Jul NEWA

LOVASTATIN

TABLET;ORAL

LOVASTATIN

@	AUROBINDO PHARMA USA	10MG	A075451	001	Dec 17, 2001	May CAHN
@		10MG	A075935	001	Dec 17, 2001	Apr CAHN
@		20MG	A075451	002	Dec 17, 2001	May CAHN
@		20MG	A075935	002	Dec 17, 2001	Apr CAHN
@		40MG	A075451	003	Dec 17, 2001	May CAHN
@		40MG	A075935	003	Dec 17, 2001	Apr CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB		24MCG	A209450	002	Nov 30, 2021	Jan CMFD
AB	ZYDUS PHARMS	8MCG	A214131	001	Mar 23, 2023	Mar NEWA
AB		24MCG	A214131	002	Mar 23, 2023	Mar NEWA

LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

>A>	@ LEES PHARM HK	8.5ML	N021746	001	Mar 06, 2012	Dec CAHN
>D>	@ WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012	Dec CAHN

LUMASIRAN SODIUM

SOLUTION;SUBCUTANEOUS

OXLUMO

+!	ALNYLAM PHARMS INC	EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)	N214103	001	Nov 23, 2020	Aug CPOT
----	--------------------	--	---------	-----	--------------	----------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208002	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208002	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208002	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208002	005	Jan 03, 2019	Feb CMFD
AB	AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar NEWA
AB		40MG	A208045	002	Mar 10, 2023	Mar NEWA
AB		60MG	A208045	003	Mar 10, 2023	Mar NEWA
AB		80MG	A208045	004	Mar 10, 2023	Mar NEWA
AB		120MG	A208045	005	Mar 10, 2023	Mar NEWA
AB	AVET LIFESCIENCES	20MG	A208058	001	Sep 04, 2019	Sep CMFD
AB		40MG	A208058	002	Sep 04, 2019	Sep CMFD
AB		60MG	A208058	003	Sep 04, 2019	Sep CMFD
AB		80MG	A208058	004	Sep 04, 2019	Sep CMFD
AB		120MG	A208058	005	Feb 28, 2023	Sep CMFD
	@	120MG	A208058	005	Feb 28, 2023	Mar DISC
AB		120MG	A208058	005	Feb 28, 2023	Feb NEWA
AB	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208031	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208031	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208031	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208031	005	Jan 03, 2019	Feb CMFD
AB	MACLEODS PHARMS LTD	20MG	A212124	001	Jun 09, 2023	Jun NEWA
AB		40MG	A212124	002	Jun 09, 2023	Jun NEWA
AB		60MG	A212124	003	Jun 09, 2023	Jun NEWA
AB		80MG	A212124	004	Jun 09, 2023	Jun NEWA
AB		120MG	A212124	005	Jun 09, 2023	Jun NEWA
AB	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb CMFD
AB		40MG	A212091	002	Dec 28, 2020	Feb CMFD
AB		60MG	A212091	003	Dec 28, 2020	Feb CMFD
AB		80MG	A212091	004	Dec 28, 2020	Feb CMFD
AB		120MG	A212091	005	Dec 28, 2020	Feb CMFD
AB	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208055	002	Jan 03, 2019	Feb CMFD
AB		80MG	A208055	003	Jan 03, 2019	Feb CMFD
AB		120MG	A208055	004	Jan 03, 2019	Feb CMFD

LUSUTROMBOPAG

TABLET; ORAL

MULPLETA

>D>	+!	SHIONOGI INC	3MG	N210923	001	Jul 31, 2018	Dec CAHN
>A>	+!	VANCOCIN ITALIA	3MG	N210923	001	Jul 31, 2018	Dec CAHN

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

SOLUTION; INTRAVENOUS

PLUVICTO

+!	NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022	Nov CAHN
----	----------	----------	---------	-----	--------------	----------

MACIMORELIN ACETATE

FOR SOLUTION; ORAL

MACRILEN

+ @ NOVO	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May DISC
----------	--------------------	---------	-----	--------------	----------

MACITENTAN

TABLET; ORAL

MACITENTAN

>A> AB	APOTEX	10MG	A211195	001	Jan 09, 2024	Dec NEWA	
	@ AUROBINDO PHARMA LTD	10MG	A211198	001	Apr 18, 2023	Apr DISC	
AB		10MG	A211198	001	Apr 18, 2023	Apr NEWA	
	OPSUMIT						
>D>	+!	ACTELION	10MG	N204410	001	Oct 18, 2013	Dec CTEC
>A> AB	+!		10MG	N204410	001	Oct 18, 2013	Dec CTEC
	+!		10MG	N204410	001	Oct 18, 2013	Apr CTEC
AB	+!		10MG	N204410	001	Oct 18, 2013	Apr CFTG

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

@ NOVAST LABS

5%

A206716 001 Jul 31, 2017 May DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

AP FRESENIUS KABI USA 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML A215370 001 Jun 29, 2022 Mar CMFD

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

AP FRESENIUS KABI USA 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML A215371 001 Jun 08, 2022 Mar CMFD

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP +! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N017378 001 Mar CTEC

PLASMA-LYTE A IN PLASTIC CONTAINER

AP +! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N017378 002 Nov 22, 1982 Mar CTEC

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP AMNEAL 2GM/50ML (40MG/ML) A216597 001 Feb 15, 2023 Feb NEWA

AP AMNEAL 4GM/100ML (40MG/ML) A216597 002 Feb 15, 2023 Feb NEWA

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

SUFLAVE

+! BRAINTREE LABS 0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0 5GM/BOT;7.3GM/BOT N215344 001 Jun 15, 2023 Jun NEWA

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

>A> AA ALKEM LABS LTD 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT A213924 001 Dec 29, 2023 Dec NEWA

AA STRIDES PHARMA 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT A215469 001 Nov 22, 2023 Nov NEWA

MANNITOL

POWDER;INHALATION

ARIDOL KIT

+! ARNA PHARMA

N/A,5MG,10MG,20MG,40MG

N022368 001 Oct 05, 2010 Nov CAHN

MARAVIROC

TABLET;ORAL

MARAVIROC

AB I 3 PHARMS 150MG A217114 001 Aug 17, 2023 Aug NEWA

AB I 3 PHARMS 300MG A217114 002 Aug 17, 2023 Aug NEWA

MAVACAMTEN

CAPSULE;ORAL

CAMZYOS

+! BRISTOL

5MG

N214998 002 Apr 28, 2022 Sep CHRS

+

15MG

N214998 004 Apr 28, 2022 Sep CHRS

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@ ANI PHARMS 12.5MG

A084657 002 Aug DISC

@

25MG

A084657 001 Aug DISC

AA AUROBINDO PHARMA USA 12.5MG A202640 001 Sep 17, 2012 Sep CMFD

AA 25MG A202640 002 Sep 17, 2012 Sep CMFD

AA 50MG A202640 003 Sep 17, 2012 Sep CMFD

AA WILSHIRE PHARMS INC 12.5MG A205136 001 Feb 22, 2019 May CAHN

AA 25MG A205136 002 Feb 22, 2019 May CAHN

AA 50MG A205136 003 Feb 22, 2019 May CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

@ CHARTWELL RX	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
@	EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB	AMNEAL	150MG/ML	A215397	001	Jun 07, 2023	May NEWA
@ HIKMA	150MG/ML	A214309	001	Jan 05, 2023	Jul DISC	
>D> AB	HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Dec CAHN
AB		150MG/ML	A076553	001	Jul 28, 2004	Oct CAHN
>A> AB	MEITHEAL	150MG/ML	A076553	001	Jul 28, 2004	Dec CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

@ BIONPHARMA	125MG/ML	A204688	001	Dec 01, 2017	Jun CAHN
@ BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jan DISC
@ NOVITIUM PHARMA	40MG/ML	A077404	001	Feb 16, 2006	Nov CAHN
@ XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jul DISC
AB	40MG/ML	A076721	001	Nov 01, 2004	Jan CAHN

MELOXICAM

TABLET;ORAL

MELOXICAM

AB	ASCENT PHARMS INC	7.5MG	A217579	001	Jun 07, 2023	May NEWA
AB		15MG	A217579	002	Jun 07, 2023	May NEWA
AB	COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
AB		15MG	A077882	002	Jul 20, 2006	Feb CAHN
@ SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006	Sep CAHN	
@	15MG	A077920	002	Jul 19, 2006	Sep CAHN	

MELPHALAN HYDROCHLORIDE

POWDER;INTRA-ARTERIAL

HEPZATO

+! DELCATH SYSTEMS INC EQ 50MG BASE/VIAL

N201848 001 Aug 14, 2023 Aug NEWA

SOLUTION;INTRAVENOUS

MELPHALAN HYDROCHLORIDE

+! APOTEX EQ 90MG BASE/ML (EQ 90MG BASE/ML)

N217110 001 Aug 18, 2023 Aug NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

@ ANI PHARMS	28MG	A205365	004	Feb 28, 2020	Feb DISC	
AB	XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Nov CMFD
@		7MG	A213985	001	Oct 11, 2022	Apr DISC
AB		14MG	A213985	002	Oct 11, 2022	Nov CMFD
@		14MG	A213985	002	Oct 11, 2022	Apr DISC
AB		28MG	A213985	003	Oct 11, 2022	Nov CMFD
@		28MG	A213985	003	Oct 11, 2022	Apr DISC
NAMENDA XR						
+ @ ABBVIE	7MG	N022525	001	Jun 21, 2010	Aug DISC	
AB	+	7MG	N022525	001	Jun 21, 2010	Feb CAHN
AB	+	14MG	N022525	002	Jun 21, 2010	Feb CAHN
AB	+	21MG	N022525	003	Jun 21, 2010	Feb CAHN
AB	+!	28MG	N022525	004	Jun 21, 2010	Feb CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

@ HIKMA	5MG	A208173	001	Feb 28, 2020	Oct DISC	
@	10MG	A208173	002	Feb 28, 2020	Oct DISC	
AB	WESTMINSTER PHARMS	5MG	A209527	001	May 07, 2018	Aug CAHN
AB		10MG	A209527	002	May 07, 2018	Aug CAHN
@ YILING	5MG	A212947	001	Apr 03, 2020	Mar CAHN	
@	10MG	A212947	002	Apr 03, 2020	Mar CAHN	
NAMENDA						
AB	+ ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb CAHN
AB	+!	10MG	N021487	002	Oct 16, 2003	Feb CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST PLAIN

! DEPROCO

3%

A088387 001 Oct 10, 1984 May CTEC

MEROPENEM

INJECTABLE; INJECTION

MEROPELEM

AP	BROOKS STERISCIENCE	500MG/VIAL
	@	500MG/VIAL
AP		1GM/VIAL
	@	1GM/VIAL
	POWDER; INTRAVENOUS	
	MEROPELEM	
+!	HQ SPCLT PHARMA	2GM/VIAL

A216154	001	Aug 18, 2022	Jul CMFD
A216154	001	Aug 18, 2022	Mar DISC
A216154	002	Aug 18, 2022	Jul CMFD
A216154	002	Aug 18, 2022	Mar DISC
N215212	001	Jul 26, 2023	Jul NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

AB	+! ABBVIE	400MG
	CAPSULE, EXTENDED RELEASE; ORAL	
	APRISO	
AB	+! SALIX	375MG
	MESALAMINE	
AB	AMTA	375MG
AB	AUROBINDO PHARMA LTD	375MG
	ENEMA; RECTAL	
	MESALAMINE	
AB	ENCUBE	4GM/60ML
	SUPPOSITORY; RECTAL	
	CANASA	
	@ ABBVIE	500MG
AB	+!	1GM
	MESALAMINE	
AB	PHARM SOURCING	1GM
AB	RISING	1GM
	TABLET, DELAYED RELEASE; ORAL	
	MESALAMINE	
AB	SINOATHERAPEUTICS INC	1.2GM

N204412	001	Feb 01, 2013	Feb CAHN
N022301	001	Oct 31, 2008	Sep CAHN
A217533	001	Jun 06, 2023	May NEWA
A214477	001	Mar 31, 2023	Mar NEWA
A216941	001	May 30, 2023	May NEWA
N021252	001	Jan 05, 2001	Feb CAHN
N021252	002	Nov 05, 2004	Feb CAHN
A207448	001	Apr 19, 2019	Oct CAHN
A207448	001	Apr 19, 2019	Sep CAHN
A217337	001	May 12, 2023	May NEWA

METAXALONE

TABLET; ORAL

METAXALONE

AB	! AMNEAL PHARMS	800MG
+ @ PRIMUS PHARMS	640MG	
+!	640MG	
	SKELAXIN	
+ @ KING PHARMS	800MG	

A203399	001	Jun 21, 2013	Jul CHRS
N022503	001	Jun 01, 2015	Jun DISC
N022503	001	Jun 01, 2015	Feb CMFD
N013217	003	Aug 30, 2002	Jul DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

@ SUN PHARM INDs INC	500MG	
@	850MG	
@	1GM	
	TABLET, EXTENDED RELEASE; ORAL	
	METFORMIN HYDROCHLORIDE	
AB1	LAURUS	500MG
AB		750MG
AB3	RK PHARMA	500MG
AB3		1GM
AB3	VGYAAN	500MG
AB3		1GM

A075967	001	Jan 29, 2002	Sep DISC
A075967	002	Jan 29, 2002	Sep DISC
A075967	003	Jan 29, 2002	Sep DISC
A217631	001	Oct 05, 2023	Sep NEWA
A217631	002	Oct 05, 2023	Sep NEWA
A215629	001	Jun 20, 2023	Jun CAHN
A215629	002	Jun 20, 2023	Jun CAHN
A215629	001	Jun 20, 2023	Jun NEWA
A215629	002	Jun 20, 2023	Jun NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

AB	+ @ ASTRAZENECA AB	500MG; EQ 5MG BASE
+ @	500MG; EQ 5MG BASE	
+ @	1GM; EQ 2.5MG BASE	

N200678	001	Nov 05, 2010	Oct DISC
N200678	001	Nov 05, 2010	Jul CFTG
N200678	003	Nov 05, 2010	Oct DISC

TABLET, EXTENDED RELEASE;ORAL
KOMBIGLYZE XR

AB	+	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Jul CFTG
	+ @	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Oct DISC
AB	+!	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Jul CFTG
	METFORMIN HYDROCHLORIDE; SAXagliptin Hydrochloride					
AB	DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jul NEWA
AB		1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jul NEWA
AB	!	1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Oct CHRS
AB		1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jul NEWA
	SAXagliptin AND METFORMIN HYDROCHLORIDE					
AB	MYLAN	500MG;EQ 5MG BASE	A205981	001	Jul 31, 2023	Jul NFTG
AB		1GM;EQ 2.5MG BASE	A205981	002	Jul 31, 2023	Jul NFTG
AB		1GM;EQ 5MG BASE	A205981	003	Jul 31, 2023	Jul NFTG
AB	SUN PHARM	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul NFTG
AB		1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul NFTG
AB		1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul NFTG

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

TABLET; ORAL

ZITUVIMET

+ ZYDUS 500MG;50MG N 216743 001 Nov 03, 2023 Nov NEWA
+! 1GM;50MG N 216743 002 Nov 03, 2023 Nov NEWA

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

+ MSD SUB MERCK 500MG;EQ 50MG BASE N022044 001 Mar 30, 2007 Mar CAHN
+! 1GM;EQ 50MG BASE N022044 002 Mar 30, 2007 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

+ MSD SUB MERCK 500MG;EQ 50MG BASE N202270 001 Feb 02, 2012 Sep CAHN
+ 1GM;EQ 50MG BASE N202270 002 Feb 02, 2012 Sep CAHN
+! 1GM;EQ 100MG BASE N202270 003 Feb 02, 2012 Sep CAHN

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

AP LONG GROVE PHARMS 10MG/ML A 208306 001 Oct 27, 2017 Aug CAHN

TABLET; ORAL

METHADONE

@ SUN PHARM INDUSTRIES 5MG A208305 001 Mar 30, 2018 Sep DISC
@ 10MG A208305 002 Mar 30, 2018 Sep DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

>A> AA +! AJENAT PHARMS 5MG N005378 002 Dec CAHN
>D> AA +! KEY THERAP 5MG N005378 002 Dec CAHN
TABLET, EXTENDED RELEASE;ORAL

DESOXYN

© ANTENA

>A> @ 10MG N 005378 003 Dec CAHN
>A> @ 15MG N 005378 005 Dec CAHN
>D> @ KEY THERAP 5MG N 005378 004 Dec CAHN
>D> @ 10MG N 005378 003 Dec CAHN
>D> @ 15MG N 005378 005 Dec CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

>A> AB	+	SS PHARMA	1GM	N 017681	001	Dec CAHN
>D> AB	+	VALIDUS PHARMS	1GM	N 017681	001	Dec CAHN
		METHENAMINE HIPPURATE				
	AB	LYRUS LIFE SCIENCES	1GM	A 217675	001	Dec 01, 2023
						Nov NEWA

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	BIONPHARMA	5MG	A218149	001	Sep 25, 2023	Sep NEWA
AB		10MG	A218149	002	Sep 25, 2023	Sep NEWA
AB	MACLEODS PHARMS LTD	5MG	A209827	001	May 24, 2023	May NEWA
AB		10MG	A209827	002	May 24, 2023	May NEWA
AB	QINGDAO BAHEAL PHARM	5MG	A040547	001	Feb 18, 2005	Sep CAHN
AB		10MG	A040547	002	Feb 18, 2005	Sep CAHN
	@	20MG	A040547	004	Feb 18, 2005	Sep CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP	@ BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Feb DISC
	SLATE RUN PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Sep CAHN
	TABLET;ORAL					
	METHOCARBAMOL					
AA	ACME LABS	500MG	A203550	001	Feb 08, 2017	Sep CAHN
AA		750MG	A203550	002	Feb 08, 2017	Sep CAHN
AA	AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb NEWA
AA		750MG	A213967	001	Aug 12, 2020	Feb CMFD
AB	! AUSTARPHARMA LLC	1GM	A200958	003	Dec 06, 2021	Jun CTEC
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN
AB	MIKART	1GM	A212707	001	Jun 12, 2023	Jun NEWA

METHOTREXATE

SOLUTION;ORAL

JYILAMVO

+!	SHORLA	2MG/ML	N212479	001	Nov 29, 2022	Oct CAHN
+!	THERAKIND	2MG/ML	N212479	001	Nov 29, 2022	Oct CMFD
+ @		2MG/ML	N212479	001	Nov 29, 2022	May DISC
	SOLUTION;SUBCUTANEOUS					
	REDITREX					
+ @	NORDIC GRP	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Aug DISC
+ @		20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Aug DISC
+ @		25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Aug DISC

METHOTREXATE SODIUM

TABLET;ORAL

METHOTREXATE SODIUM

AB	DAITO	EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Jul NEWA
----	-------	---------------	---------	-----	--------------	----------

METHSUXIMIDE

CAPSULE;ORAL

CELONTIN

AB	+! PARKE DAVIS	300MG	N010596	008		Apr CFTG
AB	NOVITIUM PHARMA	300MG	A217213	001	May 01, 2023	Apr NFTG

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

AP	ZYDUS	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Nov NFTG
AP		50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Nov NFTG
	PROVAYBLUE					
AP	+! PROVEPHARM SAS	10MG/2ML (5MG/ML)	N204630	002	Jul 18, 2019	Nov CFTG
AP	+!	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Nov CFTG

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	! CHARTWELL RX	0.2MG	A091577	001	May 02, 2011	Jun CAHN
----	----------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

RITALIN LA

AB1	+	SANDOZ	10MG	N021284	004	Apr 10, 2004	Sep CAHN
AB1	+		20MG	N021284	001	Jun 05, 2002	Sep CAHN
AB1	+		30MG	N021284	002	Jun 05, 2002	Sep CAHN

CAPSULE, EXTENDED RELEASE;ORAL
RITALIN LA

AB1	+	40MG	N 021284	003	Jun 05, 2002	Sep CAHN
	+	60MG	N 021284	005	Oct 27, 2014	Sep CAHN
SOLUTION;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE					
>D> AA	EYWA	5MG/5ML	A 210139	001	Oct 03, 2018	Dec CAHN
>D> AA		10MG/5ML	A 210139	002	Oct 03, 2018	Dec CAHN
AA	PATRIN	5MG/5ML	A 210764	001	Apr 10, 2020	Sep CAHN
AA		10MG/5ML	A 210764	002	Apr 10, 2020	Sep CAHN
>A> AA	WES PHARMA INC	5MG/5ML	A 210139	001	Oct 03, 2018	Dec CAHN
>A> AA		10MG/5ML	A 210139	002	Oct 03, 2018	Dec CAHN
TABLET;ORAL						
	RITALIN					
AB	+	SANDOZ	5MG	N 010187	003	Sep CAHN
AB	+		10MG	N 010187	006	Sep CAHN
AB	+		20MG	N 010187	010	Sep CAHN
TABLET, EXTENDED RELEASE;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE					
AB	ALKEM LABS LTD	18MG	A 214447	001	May 23, 2023	May NEWA
AB		27MG	A 214447	002	May 23, 2023	May NEWA
AB		36MG	A 214447	003	May 23, 2023	May NEWA
AB		54MG	A 214447	004	May 23, 2023	May NEWA
	@ AMNEAL PHARMS	18MG	A 207515	001	Feb 01, 2018	Jun DISC
	@	27MG	A 207515	002	Feb 01, 2018	Jun DISC
	@	36MG	A 207515	003	Feb 01, 2018	Jun DISC
	@	54MG	A 207515	004	Feb 01, 2018	Jun DISC
AB	OSMOTICA PHARM US	18MG	A 205327	001	Jul 28, 2017	Nov CAHN
AB		27MG	A 205327	002	Jul 28, 2017	Nov CAHN
AB		36MG	A 205327	003	Jul 28, 2017	Nov CAHN
AB		54MG	A 205327	004	Jul 28, 2017	Nov CAHN
AB	!	72MG	A 205327	005	Jul 28, 2017	Nov CAHN
AB	SUN PHARM INDUS INC	72MG	A 217229	001	Aug 25, 2023	Aug NEWA

METHYLPREDNISOLONE

	TABLET;ORAL					
	MEDROL					
+ PFIZER		2MG	N 011153	002		Apr CTEC
METHYLPREDNISOLONE						
@ CHARTWELL RX		2MG	A 209097	001	Feb 22, 2019	May CAHN
@		4MG	A 209097	002	Feb 22, 2019	May CAHN
@		8MG	A 209097	003	Feb 22, 2019	May CAHN
@		16MG	A 209097	004	Feb 22, 2019	May CAHN
@		32MG	A 209097	005	Feb 22, 2019	May CAHN

METHYLPREDNISOLONE ACETATE

	INJECTABLE;INJECTION					
	METHYLPREDNISOLONE ACETATE					
AB	AMNEAL	40MG/ML	A 216502	001	Nov 03, 2023	Oct NEWA
AB		80MG/ML	A 216502	002	Nov 03, 2023	Oct NEWA
AB	EUGIA PHARMA	40MG/ML	A 211930	001	Apr 13, 2023	Apr NEWA
AB		80MG/ML	A 211930	002	Apr 13, 2023	Apr NEWA
>D> AB	HONG KONG	40MG/ML	A 040557	001	Feb 23, 2005	Dec CAHN
AB		40MG/ML	A 040557	001	Feb 23, 2005	Sep CAHN
>D> AB		80MG/ML	A 040557	002	Feb 23, 2005	Dec CAHN
AB		80MG/ML	A 040557	002	Feb 23, 2005	Sep CAHN
>A> AB	MEITHEAL	40MG/ML	A 040557	001	Feb 23, 2005	Dec CAHN
>A> AB		80MG/ML	A 040557	002	Feb 23, 2005	Dec CAHN
AB	PAR STERILE PRODUCTS	40MG/ML	A 214297	001	Jan 21, 2022	Jun CMFD
AB	SLAYBACK PHARMA LLC	40MG/ML	A 214870	002	May 10, 2023	Apr NEWA

METOCLOPRAMIDE HYDROCHLORIDE

	SOLUTION;ORAL					
	METOCLOPRAMIDE HYDROCHLORIDE					
AA	! PHARM ASSOC	EQ 5MG BASE/5ML	A 072744	001	May 28, 1991	Jul CHRS
	@ PHARMOBEDIENT CNSLTG	EQ 5MG BASE/5ML	A 074703	001	Oct 31, 1997	Sep CAHN
	@ VISTAPHARM	EQ 5MG BASE/5ML	A 075051	001	Jan 26, 2001	Sep DISC
	@ XTTRIUM LABS INC	EQ 5MG BASE/5ML	A 074703	001	Oct 31, 1997	Jul DISC
AA	!	EQ 5MG BASE/5ML	A 074703	001	Oct 31, 1997	Jan CAHN
TABLET;ORAL						
	METOCLOPRAMIDE HYDROCHLORIDE					
>A>	@ AIPING PHARM INC	EQ 10MG BASE	A 072215	001	Jan 30, 1990	Dec CAHN

TABLET;ORAL METOCLOPRAMIDE HYDROCHLORIDE >D> @ CHARTWELL RX		EQ 10MG BASE	A072215	001	Jan 30, 1990	Dec CAHN
<u>METOLAZONE</u>						
	TABLET;ORAL METOLAZONE					
AB	AACE PHARMS @	2.5MG 2.5MG	A216216	001	Oct 25, 2022	Aug CMFD
AB	@	5MG	A216216	002	Oct 25, 2022	Aug CMFD
AB	@	5MG	A216216	002	Oct 25, 2022	Apr DISC
AB		10MG	A216216	003	Oct 25, 2022	Aug CMFD
AB	@	10MG	A216216	003	Oct 25, 2022	Apr DISC
AB	NE RX PHARMA	2.5MG	A216216	001	Oct 25, 2022	Sep CAHN
AB		5MG	A216216	002	Oct 25, 2022	Sep CAHN
AB		10MG	A216216	003	Oct 25, 2022	Sep CAHN
	MYKROX @ CHARTWELL MOLECULAR	0.5MG	N019532	001	Oct 30, 1987	Jul CAHN
<u>METOPROLOL SUCCINATE</u>						
	TABLET, EXTENDED RELEASE;ORAL METOPROLOL SUCCINATE					
AB	@ ACCORD HLTHCARE @ @ @	EQ 25MG TARTRATE EQ 50MG TARTRATE EQ 100MG TARTRATE EQ 200MG TARTRATE	A215637	001	Oct 18, 2022	Apr DISC
AB	GRANULES	EQ 25MG TARTRATE	A215637	002	Oct 18, 2022	Apr DISC
AB		EQ 25MG TARTRATE	A215637	003	Oct 18, 2022	Apr DISC
AB		EQ 200MG TARTRATE	A215637	004	Oct 18, 2022	Apr DISC
AB		EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Jul NEWA
AB		EQ 25MG TARTRATE	A216916	001	Jun 12, 2023	Jun NEWA
AB		EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Jul NEWA
AB		EQ 50MG TARTRATE	A216916	002	Jun 12, 2023	Jun NEWA
AB		EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Jul NEWA
AB		EQ 100MG TARTRATE	A216509	003	Jun 12, 2023	Jun NEWA
AB		EQ 200MG TARTRATE	A216916	003	Jun 12, 2023	Jun NEWA
AB		EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Jul NEWA
AB		EQ 200MG TARTRATE	A216916	004	Jun 12, 2023	Jun NEWA
AB	@ LUPIN	EQ 25MG TARTRATE	A209272	001	Aug 15, 2023	Aug DISC
AB		EQ 25MG TARTRATE	A209272	001	Aug 15, 2023	Aug NEWA
AB	@	EQ 50MG TARTRATE	A209272	002	Aug 15, 2023	Aug DISC
AB	@	EQ 50MG TARTRATE	A209272	002	Aug 15, 2023	Aug NEWA
AB	@	EQ 100MG TARTRATE	A209272	003	Aug 15, 2023	Aug DISC
AB	@	EQ 100MG TARTRATE	A209272	003	Aug 15, 2023	Aug NEWA
AB	@	EQ 200MG TARTRATE	A209272	004	Aug 15, 2023	Aug DISC
AB		EQ 200MG TARTRATE	A209272	004	Aug 15, 2023	Aug NEWA
<u>METOPROLOL TARTRATE</u>						
	INJECTABLE; INJECTION METOPROLOL TARTRATE					
AB	@ HOSPIRA	1MG/ML	A075160	001	Jul 06, 1998	Jun DISC
	TABLET;ORAL METOPROLOL TARTRATE					
>A> AB	AUROBINDO PHARMA	37.5MG	A077739	004	Dec 07, 2023	Dec NEWA
>A> AB		75MG	A077739	005	Dec 07, 2023	Dec NEWA
AB	RENATA	50MG	A074453	001	Apr 27, 1995	Nov CMFD
AB		100MG	A074453	002	Apr 27, 1995	Nov CMFD
	@ ZYDUS PHARMS	25MG	A212402	001	Apr 19, 2023	Oct DISC
AB		25MG	A212402	001	Apr 19, 2023	Apr NEWA
AB	@	50MG	A212402	002	Apr 19, 2023	Oct DISC
AB	@	50MG	A212402	002	Apr 19, 2023	Apr NEWA
AB	@	100MG	A212402	003	Apr 19, 2023	Oct DISC
AB		100MG	A212402	003	Apr 19, 2023	Apr NEWA
<u>METRONIDAZOLE</u>						
	CREAM;TOPICAL METRONIDAZOLE					
AB	ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Apr NEWA
	GEL;TOPICAL METRONIDAZOLE					
AB	@ CHARTWELL RX	1%	A090903	001	Jul 22, 2011	Oct CAHN
AB	COSETTE	1%	A216692	001	Jan 23, 2023	Jan NEWA
AB	@ TOLMAR	1%	A090903	001	Jul 22, 2011	Feb DISC
	GEL;VAGINAL METRONIDAZOLE					
AB	COSETTE	0.75%	A216323	001	Jul 12, 2023	Jun NEWA

	GEL;VAGINAL METRONIDAZOLE						
AB	@ ENCUBE	0.75% 0.75%		A077264	001	Oct 31, 2006	Mar CAHN
	INJECTABLE;INJECTION METRONIDAZOLE IN PLASTIC CONTAINER			A215610	001	Jun 16, 2023	Jun NEWA
AP	AMNEAL	500MG/100ML		A217665	001	May 24, 2023	Jun CMS1
	SUSPENSION;ORAL LIKMEZ						
	+! SAPTALIS PHARMS	500MG/5ML		N216755	001	Sep 22, 2023	Sep NEWA
	TABLET;ORAL FLAGYL						
	+ @ PFIZER	250MG		N012623	001		Oct DISC
	+ @	500MG		N012623	003		Oct DISC
	METRONIDAZOLE						
AB	ALEMBIC	250MG		A208681	001	Jun 20, 2017	Feb CAHN
AB		500MG		A208681	002	Jun 20, 2017	Feb CAHN
>D> AB	AMICI	250MG		A070772	001	Jul 16, 1986	Dec CAHN
>D> AB		500MG		A070772	002	Jul 16, 1986	Dec CAHN
AB	! AUROBINDO PHARMA LTD	500MG		A203974	002	May 29, 2015	Oct CHRS
>A> AB	INNOGENIX	250MG		A070772	001	Jul 16, 1986	Dec CAHN
>A> AB		500MG		A070772	002	Jul 16, 1986	Dec CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

	INJECTABLE;INJECTION METRONIDAZOLE IN PLASTIC CONTAINER						
AP	AMNEAL	500MG/100ML		A217665	001	May 24, 2023	May NEWA

MEXILETINE HYDROCHLORIDE

	CAPSULE;ORAL MEXILETINE HYDROCHLORIDE						
AB	CARNEGIE	150MG		A215315	001	Aug 26, 2022	Sep CAHN
AB		200MG		A215315	002	Aug 26, 2022	Sep CAHN
AB		250MG		A215315	003	Aug 26, 2022	Sep CAHN
AB	CHEMISTRY HLTH	150MG		A215876	001	Feb 27, 2023	Sep CAHN
AB		200MG		A215876	002	Feb 27, 2023	Sep CAHN
AB		250MG		A215876	003	Feb 27, 2023	Sep CAHN
AB	LEADING	150MG		A215876	001	Feb 27, 2023	Feb NEWA
AB		200MG		A215876	002	Feb 27, 2023	Feb NEWA
AB		250MG		A215876	003	Feb 27, 2023	Feb NEWA
AB	ZENARA	150MG		A215315	001	Aug 26, 2022	Feb CAHN
AB		200MG		A215315	002	Aug 26, 2022	Feb CAHN
AB		250MG		A215315	003	Aug 26, 2022	Feb CAHN

MICAFUNGIN SODIUM

	INJECTABLE;INTRAVENOUS MICAFUNGIN SODIUM						
AP	ZYDUS PHARMS	EQ 50MG BASE/VIAL		A215241	001	Oct 24, 2022	Aug CMFD
	@	EQ 50MG BASE/VIAL		A215241	001	Oct 24, 2022	Mar DISC
AP		EQ 100MG BASE/VIAL		A215241	002	Oct 24, 2022	Aug CMFD
	@	EQ 100MG BASE/VIAL		A215241	002	Oct 24, 2022	Mar DISC
	SOLUTION;INTRAVENOUS MICAFUNGIN IN SODIUM CHLORIDE 0.9%						
+!	BAXTER HLTHCARE CORP	EQ 50MG BASE/50ML (EQ 1MG BASE/ML)		N216142	001	Sep 29, 2023	Sep NEWA
+!		EQ 100MG BASE/100ML (EQ 1MG BASE/ML)		N216142	002	Sep 29, 2023	Sep NEWA
+!		EQ 150MG BASE/150ML (EQ 1MG BASE/ML)		N216142	003	Sep 29, 2023	Sep NEWA

MIDAZOLAM

	SOLUTION;INTRAVENOUS MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
AP	HIKMA	50MG/50ML (1MG/ML)		A216159	001	Apr 17, 2023	Apr NFTG
AP		100MG/100ML (1MG/ML)		A216159	002	Apr 17, 2023	Apr NFTG
AP	+! INFORLIFE	50MG/50ML (1MG/ML)		N211844	001	Mar 22, 2021	Apr CFTG
AP	+!	100MG/100ML (1MG/ML)		N211844	002	Mar 22, 2021	Apr CFTG

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	MICRO LABS	EQ 1MG BASE/ML	A217504	001	Aug 21, 2023	Aug NEWA
AP		EQ 5MG BASE/ML	A217504	002	Aug 21, 2023	Aug NEWA
>A>	@ PAI HOLDINGS	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Dec CAHN
>A>	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Dec CAHN
>A>	@	EQ 5MG BASE/ML	A078511	002	May 30, 2008	Dec CAHN
>A>	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Dec CAHN
>D>	@ RISING	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Sep CAHN
>D>	@ WOCKHARDT BIO AG	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Dec CAHN
>D>	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Dec CAHN
>D>	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Dec CAHN
>D>	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Dec CAHN
	MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE					
>D>	@ STERISCIENCE	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Dec CMFD
>A> AP		EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Dec CMFD
>D>	@	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Dec CMFD
>A> AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Dec CMFD
	MIDOZALAM HYDROCHLORIDE					
>D>	@ STERISCIENCE	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Dec CMFD
>A> AP		EQ 1MG BASE/ML	A090316	001	May 04, 2011	Dec CMFD
>D>	@	EQ 5MG BASE/ML	A090316	002	May 04, 2011	Dec CMFD
>A> AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Dec CMFD

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	MANKIND PHARMA	2.5MG	A217271	001	Nov 01, 2023	Oct NEWA
AB		5MG	A217271	002	Nov 01, 2023	Oct NEWA
AB		10MG	A217271	003	Nov 01, 2023	Oct NEWA
AB	NOVUGEN	2.5MG	A211973	001	Oct 17, 2023	Oct NEWA
AB		5MG	A211973	002	Oct 17, 2023	Oct NEWA
AB		10MG	A211973	003	Oct 17, 2023	Oct NEWA
>A> AB	THINQ PHARM-CRO PVT	2.5MG	A207613	001	Nov 02, 2018	Dec CAHN
>A> AB		5MG	A207613	002	Nov 02, 2018	Dec CAHN
>A> AB		10MG	A207613	003	Nov 02, 2018	Dec CAHN
>D> AB	UNIQUE	2.5MG	A207613	001	Nov 02, 2018	Dec CAHN
>D> AB		5MG	A207613	002	Nov 02, 2018	Dec CAHN
>D> AB		10MG	A207613	003	Nov 02, 2018	Dec CAHN

MIGLUSTAT

CAPSULE; ORAL

OPFOLDA

+! AMICUS THERAP US
YARGESA

AB EDENBRIDGE PHARMS

N215211	001	Sep 28, 2023	Sep NEWA
A209821	001	Aug 06, 2020	Jul CTNA

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+ ABBVIE
+
+!
+12.5MG
25MG
50MG
100MG

N022256	001	Jan 14, 2009	Jan CAHN
N022256	002	Jan 14, 2009	Jan CAHN
N022256	003	Jan 14, 2009	Jan CAHN
N022256	004	Jan 14, 2009	Jan CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP SHANDONG
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER
@ HOSPIRA
@EQ 1MG BASE/ML
EQ 20MG BASE/100ML (EQ 0.2MG
BASE/ML)
EQ 40MG BASE/200ML (EQ 0.2MG
BASE/ML)

A216373	001	Jan 23, 2023	Jan NEWA
A075885	001	May 28, 2002	Oct DISC
A075885	002	May 28, 2002	Oct DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

@ ALVOGEN
@
@EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE

A063067	003	Aug 14, 1990	Nov DISC
A063067	002	Sep 15, 1999	Nov DISC
A063067	001	Jul 31, 1990	Nov DISC

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

@ JOURNEY	EQ 45MG BASE	N 201922	001	Jul 11, 2012	Oct DISC
@	EQ 90MG BASE	N 201922	003	Jul 11, 2012	Oct DISC
@	EQ 135MG BASE	N 201922	005	Jul 11, 2012	Oct DISC

INJECTABLE; INJECTION

MINOCIN

+! REMPEX EQ 100MG BASE/VIAL

N 050444 001 May CTEC

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB ZYDUS PHARMS	EQ 55MG BASE	A 203553	002	Jun 16, 2023	Jun NEWA
AB	EQ 65MG BASE	A 203553	003	Jun 16, 2023	Jun NEWA
AB	EQ 115MG BASE	A 203553	007	Jun 16, 2023	Jun NEWA

MIRABEGRONTABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

@ ZYDUS PHARMS	25MG	A 209488	001	Sep 29, 2022	Mar DISC
@	50MG	A 209488	002	Sep 29, 2022	Mar DISC

MIRTAZAPINETABLET;ORAL

MIRTAZAPINE

AB PRASCO	7.5MG	A 216751	001	Jan 18, 2023	Jan NEWA
AB	15MG	A 216751	002	Jan 18, 2023	Jan NEWA
AB	30MG	A 216751	003	Jan 18, 2023	Jan NEWA
AB	45MG	A 216751	004	Jan 18, 2023	Jan NEWA
AB ! SUN PHARM IND S INC	7.5MG	A 076541	004	Apr 22, 2004	Oct CHRS
AB REMERON					
AB +! ORGANON	15MG	N 020415	001	Jun 14, 1996	Apr CAHN
AB +	30MG	N 020415	002	Jun 14, 1996	Apr CAHN
AB +	30MG	N 020415	002	Jun 14, 1996	May CAHN
+ @	45MG	N 020415	003	Mar 17, 1997	Apr CAHN
+ @	45MG	N 020415	003	Mar 17, 1997	May CAHN
AB TABLET, ORALLY DISINTEGRATING;ORAL					
AB REMERON SOLTAB					
AB +! ORGANON USA ORGANON	15MG	N 021208	001	Jan 12, 2001	May CAHN
AB +	30MG	N 021208	002	Jan 12, 2001	May CAHN
AB +	45MG	N 021208	003	Jan 12, 2001	May CAHN

MISOPROSTOLTABLET;ORAL

MISOPROSTOL

@ NOVEL LABS INC	0.1MG	A 091667	001	Jul 25, 2012	Feb DISC
@	0.2MG	A 091667	002	Jul 25, 2012	Feb DISC

MITOMYCININJECTABLE;INJECTION

MITOMYCIN

AP EUGIA PHARMA	5MG/VIAL	A 216732	001	Oct 30, 2023	Oct NEWA
AP	20MG/VIAL	A 216732	002	Oct 30, 2023	Oct NEWA
AP	40MG/VIAL	A 216732	003	Oct 30, 2023	Oct NEWA

MITOXANTRONE HYDROCHLORIDEINJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

>D> AP HONG KONG	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A 077356	001	Apr 11, 2006	Dec CAHN
AP	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A 077356	001	Apr 11, 2006	Sep CAHN
>D> AP	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A 077356	002	Apr 11, 2006	Dec CAHN
AP	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A 077356	002	Apr 11, 2006	Sep CAHN
>D> AP	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A 077356	003	Apr 11, 2006	Dec CAHN
AP	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A 077356	003	Apr 11, 2006	Sep CAHN
>A> AP MEITHEAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A 077356	001	Apr 11, 2006	Dec CAHN
>A> AP	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A 077356	002	Apr 11, 2006	Dec CAHN
>A> AP	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A 077356	003	Apr 11, 2006	Dec CAHN

MODAFINIL

TABLET;ORAL
PROVIGIL

AB + CEPHALON	100MG	N 020717 001 Dec 24, 1998 Jul CAHN
AB +!	200MG	N 020717 002 Dec 24, 1998 Jul CAHN

MOLINDONE HYDROCHLORIDE

CAPSULE;ORAL
MOBAN

>A> + @ CHARTWELL RX	5MG	N 017111 001 Dec CAHN
>A> + @	10MG	N 017111 002 Dec CAHN
>A> + @	25MG	N 017111 003 Dec CAHN
>D> + @ STRIDES PHARMA	5MG	N 017111 001 Dec CAHN
>D> + @	10MG	N 017111 002 Dec CAHN
>D> + @	25MG	N 017111 003 Dec CAHN

TABLET;ORAL
MOBAN

>A> + @ CHARTWELL RX	5MG	N 017111 004 Dec CAHN
>A> + @	10MG	N 017111 005 Dec CAHN
>A> + @	25MG	N 017111 006 Dec CAHN
>A> + @	50MG	N 017111 007 Dec CAHN
>A> + @	100MG	N 017111 008 Dec CAHN
>D> + @ STRIDES PHARMA	5MG	N 017111 004 Dec CAHN
>D> + @	10MG	N 017111 005 Dec CAHN
>D> + @	25MG	N 017111 006 Dec CAHN
>D> + @	50MG	N 017111 007 Dec CAHN
>D> + @	100MG	N 017111 008 Dec CAHN

MOMELOTINIB DIHYDROCHLORIDE

TABLET;ORAL
OJJAARA

+ GLAXOSMITHKLINE	EQ 100MG BASE	N 216873 001 Sep 15, 2023 Sep NEWA
+	EQ 150MG BASE	N 216873 002 Sep 15, 2023 Sep NEWA
+!	EQ 200MG BASE	N 216873 003 Sep 15, 2023 Sep NEWA

MOMETASONE FUROATE

LOTION;TOPICAL
MOMETASONE FUROATE

AB ! PADAGIS ISRAEL	0.1%	A 077180 001 Apr 06, 2005 Mar CHRS
---------------------	------	------------------------------------

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

AB CHARTWELL MOLECULAR	EQ 4MG BASE	A 207464 001 Dec 06, 2018 Jan CAHN
AB	EQ 5MG BASE	A 207464 002 Dec 06, 2018 Jan CAHN
AB RISING	EQ 4MG BASE	A 209011 001 Apr 18, 2017 Aug CAHN
AB	EQ 5MG BASE	A 209011 002 Apr 18, 2017 Aug CAHN
@ UNICHEM	EQ 4MG BASE	A 208621 001 Jul 02, 2018 Aug DISC
@	EQ 5MG BASE	A 208621 002 Jul 02, 2018 Aug DISC

MORPHINE SULFATE

INJECTABLE;INJECTION
MORPHINE SULFATE

AP HIKMA	2MG/ML	A 211452 001 Jan 12, 2023 Sep CAHN
AP	2MG/ML	A 211452 001 Jan 12, 2023 Jan NFTG
AP	4MG/ML	A 211452 002 Jan 12, 2023 Sep CAHN
AP	4MG/ML	A 211452 002 Jan 12, 2023 Jan NEWA
AP	8MG/ML	A 211452 003 Jan 12, 2023 Sep CAHN
AP	8MG/ML	A 211452 003 Jan 12, 2023 Jan NEWA
AP	10MG/ML	A 211452 004 Jan 12, 2023 Sep CAHN
AP	10MG/ML	A 211452 004 Jan 12, 2023 Jan NEWA
	15MG/ML	A 211452 005 Jan 12, 2023 Sep CAHN
	15MG/ML	A 211452 005 Jan 12, 2023 Jan NFTG
AP +! HOSPIRA INC	2MG/ML	N 202515 001 Nov 14, 2011 Jan CFTG

SOLUTION;ORAL
MORPHINE SULFATE

AA PHARM ASSOC	10MG/5ML	A 206573 002 Sep 12, 2023 Sep NEWA
----------------	----------	------------------------------------

TABLET;ORAL
MORPHINE SULFATE

AB SPECGX LLC	15MG	A 215194 001 Aug 21, 2023 Aug NEWA
---------------	------	------------------------------------

AB	30MG	A 215194 002 Aug 21, 2023 Aug NEWA
----	------	------------------------------------

TABLET, EXTENDED RELEASE;ORAL

MORPHABOND ER

+ @ OHMO LIFE	15MG	N206544	001	Oct 02, 2015	Jun CAHN
+ @	30MG	N206544	002	Oct 02, 2015	Jun CAHN
+ @	60MG	N206544	003	Oct 02, 2015	Jun CAHN
+ @	100MG	N206544	004	Oct 02, 2015	Jun CAHN

MOTIXAFORTIDE ACETATE

POWDER;SUBCUTANEOUS

APHEXDA

+! BIOLINERX LTD EQ 62MG BASE/VIAL

N217159 001 Sep 08, 2023 Sep NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

+ @ HARROW EYE EQ 0.5% BASE

N022428 001 Nov 19, 2010 Jun DISC

+! EQ 0.5% BASE

N022428 001 Nov 19, 2010 May CAHN

MOXIFLOXACIN HYDROCHLORIDE

@ AKORN EQ 0.5% BASE

A202916 001 Nov 09, 2017 Jan DISC

! LUPIN LTD EQ 0.5% BASE

A204079 001 May 28, 2015 Jun CHRS

EQ 0.5% BASE

A204079 001 May 28, 2015 Jun CTEC

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB CHARTWELL RX EQ 400MG BASE

A207285 001 Feb 13, 2017 Apr CAHN

AB HETERO LABS LTD V EQ 400MG BASE

A204836 001 Mar 02, 2023 Feb NEWA

@ TORRENT EQ 400MG BASE

A200160 001 Apr 03, 2014 Feb DISC

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

@ PADAGIS ISRAEL EQ 2% BASE

A212465 001 Aug 03, 2022 Oct DISC

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

>A> AB AUROBINDO PHARMA LTD 250MG

A217828 001 Jan 05, 2024 Dec NEWA

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB AIRIS PHARMA PVT LTD 200MG/ML

A213955 001 Sep 11, 2023 Sep NEWA

AB HETERO LABS LTD V 200MG/ML

A213955 001 Sep 11, 2023 Sep CAHN

AB STRIDES PHARMA 200MG/ML

A212634 001 Aug 29, 2023 Aug NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP BPI LABS 500MG/VIAL

A214283 001 Jun 01, 2023 May NEWA

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

AB AIRIS PHARMA PVT LTD EQ 180MG BASE

A217031 001 Nov 29, 2023 Nov NEWA

AB EQ 360MG BASE

A217031 002 Nov 29, 2023 Nov NEWA

NABUMETONE

TABLET;ORAL

NABUMETONE

@ AUROBINDO PHARMA USA 500MG

A090516 001 Jul 12, 2010 Apr CAHN

@ 750MG

A090516 002 Jul 12, 2010 Apr CAHN

NADOLOL

TABLET;ORAL

NADOLOL

AB ALEMBIC 20MG

A211763 001 Jun 02, 2023 May NEWA

AB 40MG

A211763 002 Jun 02, 2023 May NEWA

AB 80MG

A211763 003 Jun 02, 2023 May NEWA

@ HERITAGE PHARMA 20MG

A074229 001 Aug 30, 1996 Oct DISC

@ 40MG

A074229 002 Aug 30, 1996 Oct DISC

@ 80MG

A074255 001 Jan 24, 1996 Oct DISC

AB RK PHARMA 20MG

A212856 001 Sep 13, 2019 Jun CAHN

AB 40MG

A212856 002 Sep 13, 2019 Jun CAHN

AB 80MG

A212856 003 Sep 13, 2019 Jun CAHN

NAFCILLIN SODIUM

	INJECTABLE; INJECTION						
	NAFCILLIN SODIUM						
AP	! EUGIA PHARMA SPECLETS	EQ 1GM BASE/VIAL	A091613	001	Dec 26, 2012	Jan CHRS	
AP	!	EQ 2GM BASE/VIAL	A091613	002	Dec 26, 2012	Jan CHRS	
AP	!	EQ 10GM BASE/VIAL	A091614	001	Dec 26, 2012	Jan CHRS	
@	SANDOZ	EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984	Jan DISC	
@		EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986	Jan DISC	
@		EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984	Jan DISC	
@		EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986	Jan DISC	
@		EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Jan DISC	
AP	STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Oct CMFD	
AP		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Oct CMFD	

NAFTIFINE HYDROCHLORIDE

	CREAM; TOPICAL						
	NAFTIFINE HYDROCHLORIDE						
AB	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb CAHN	
	GEL; TOPICAL						
	NAFTIFINE HYDROCHLORIDE						
AB	AMNEAL	1%	A206165	001	Mar 20, 2019	Feb CAHN	
AB	TARO	2%	A208201	001	Apr 10, 2019	Mar CMFD	
	NAFTIN						
AB	+! SEBELA IRELAND LTD	2%	N204286	001	Jun 27, 2013	May CTEC	
	+!	2%	N204286	001	Jun 27, 2013	Feb CTEC	

NALMEFENE HYDROCHLORIDE

	SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS						
	NALMEFENE HYDROCHLORIDE						
	CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	Nov NFTG	
AP		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	Nov NEWA	
AP	! PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Nov NEWA	
	SPRAY; NASAL						
	OPVEE						
+!	INDIVIOR	EQ 2.7MG BASE/SPRAY	N217470	001	May 22, 2023	Jun CAHN	
+!	OPIANT PHARMS	EQ 2.7MG BASE/SPRAY	N217470	001	May 22, 2023	May NEWA	

NALOXEGOL OXALATE

	TABLET; ORAL						
	MOVANTIK						
+	VALINOR	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Feb CAHN	
+		EQ 25MG BASE	N204760	002	Sep 16, 2014	Feb CAHN	

NALOXONE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	NALOXONE HYDROCHLORIDE						
AP	BPI LABS	1MG/ML	A216977	001	Oct 06, 2023	Sep NEWA	
	@ CHARTWELL RX	0.4MG/ML	A207846	001	Dec 17, 2018	Sep CAHN	
AP	HIKMA	1MG/ML	A212300	001	Jun 10, 2022	Sep CAHN	
	SPRAY, METERED; NASAL						
	NALOXONE HYDROCHLORIDE						
	TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	Jul CTEC	
	REXTOVY						
+ @	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Oct DISC	
+		4MG/SPRAY	N208969	001	Mar 07, 2023	Jun CTNA	
+		4MG/SPRAY	N208969	001	Mar 07, 2023	Mar NEWA	

NAPHAZOLINE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC						
	NAPHAZOLINE HYDROCHLORIDE						
	@ RISING	0.1%	A083590	001		Sep CAHN	

NAPROXEN

	TABLET, DELAYED RELEASE; ORAL						
	NAPROXEN						
	@ AUROBINDO PHARMA USA	375MG	A075390	001	Apr 19, 2001	Apr CAHN	
	@	500MG	A075390	002	Apr 19, 2001	Apr CAHN	
AB	TULEX PHARMS INC	375MG	A216908	001	May 31, 2023	May NEWA	
AB		500MG	A216908	002	May 31, 2023	May NEWA	

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB	+	TWI PHARMS	EQ 375MG BASE	N020353	001	Jan 05, 1996	Nov CAHN
AB	+		EQ 500MG BASE	N020353	002	Jan 05, 1996	Nov CAHN
AB	+!		EQ 750MG BASE	N020353	003	Jan 05, 1996	Nov CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

+ @	GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763	002	Feb 10, 1998	Nov DISC
+ @		EQ 2.5MG BASE	N020763	001	Feb 10, 1998	Nov DISC
	NARATRIPTAN					
@	AUROBINDO PHARMA USA	EQ 1MG BASE	A202431	001	May 31, 2012	Apr CAHN
@		EQ 2.5MG BASE	A202431	002	May 31, 2012	Apr CAHN
AB	! HERITAGE PHARMS	EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Nov CHRS

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+!	HARROW EYE	5%	N050514	001		Oct CAHN
----	------------	----	---------	-----	--	----------

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

AB	BEXIMCO PHARMS USA	EQ 2.5MG BASE	A216568	001	Mar 30, 2023	Mar NEWA
AB		EQ 5MG BASE	A216568	002	Mar 30, 2023	Mar NEWA
AB		EQ 10MG BASE	A216568	003	Mar 30, 2023	Mar NEWA
AB		EQ 20MG BASE	A216568	004	Mar 30, 2023	Mar NEWA

NEDOSIRAN SODIUM

SOLUTION;INJECTION

RIVFLOZA

+!	NOVO	EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML)	N215842	001	Sep 29, 2023	Sep NEWA
+!		EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML)	N215842	002	Sep 29, 2023	Sep NEWA
+!		EQ 160MG BASE/ML (EQ 160MG BASE/ML)	N215842	003	Sep 29, 2023	Sep NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

@	AUROBINDO PHARMA USA	100MG	A076129	002	Sep 16, 2003	Apr CAHN
@		150MG	A076129	003	Sep 16, 2003	Apr CAHN
@		200MG	A076129	004	Sep 16, 2003	Apr CAHN
@		250MG	A076129	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE;INTRAVENOUS

ARRANON

AP	+! SANDOZ	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	May CAHN
AP	AMNEAL	250MG/50ML (5MG/ML)	A216346	001	Apr 04, 2023	Mar NEWA
>A>	AP GLAND PHARMA LTD	250MG/50ML (5MG/ML)	A212605	001	Jan 03, 2024	Dec NEWA
AP	SHORLA	250MG/50ML (5MG/ML)	A214809	001	Mar 03, 2023	Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

+!	EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	Nov NEWA
	NEOSTIGMINE METHYLSULFATE					
AP	EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	Oct NEWA
AP		10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	Oct NEWA
AP	HIKMA	5MG/10ML (0.5MG/ML)	A207042	001	Dec 28, 2015	May CAHN
AP		10MG/10ML (1MG/ML)	A207042	002	Dec 28, 2015	May CAHN
AP	SAGENT PHARMS INC	5MG/10ML (0.5MG/ML)	A216542	001	Feb 17, 2023	Feb NEWA
AP		10MG/10ML (1MG/ML)	A216542	002	Feb 17, 2023	Feb NEWA
AP	UMEDICA	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Sep CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Sep CAHN

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC
ILEVRO
+! HARROW EYE 0.3% N203491 001 Oct 16, 2012 May CAHN
NEVANAC
+! HARROW EYE 0.1% N021862 001 Aug 19, 2005 May CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS;OPHTHALMIC
RHOPRESSA
+! ALCON LABS INC EQ 0.02% BASE N208254 001 Dec 18, 2017 May CAHN

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE
@ AUROBINDO PHARMA 100MG A208616 001 Nov 23, 2016 Sep DISC
@ 400MG A207698 001 Feb 28, 2017 Sep DISC
VIRAMUNE XR
+ BOEHRINGER INGELHEIM 100MG N201152 002 Nov 08, 2012 Sep CTEC

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN
AB EYWA 500MG A213090 001 Aug 25, 2023 Aug NEWA
AB 750MG A213090 002 Aug 25, 2023 Aug NEWA
AB 1GM A213090 003 Aug 25, 2023 Aug NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL
NICARDIPINE HYDROCHLORIDE
AB BIONPHARMA 20MG A217555 001 May 03, 2023 Sep CAHN
AB 30MG A217555 002 May 03, 2023 Sep CAHN
AB SENORES PHARMS 20MG A215377 001 Jul 17, 2023 Jul NEWA
AB 30MG A215377 002 Jul 17, 2023 Jul NEWA
AB SQUARE PHARMS 20MG A217555 001 May 03, 2023 Apr NEWA
AB 30MG A217555 002 May 03, 2023 Apr NEWA

INJECTABLE;INJECTION
NICARDIPINE HYDROCHLORIDE
AP +! HIKMA INTL PHARMS 25MG/10ML (2.5MG/ML) N022276 001 Jul 24, 2008 Jun CTEC
AP MICRO LABS 25MG/10ML (2.5MG/ML) A216420 001 Jul 07, 2023 Jun NEWA
AP @ SUN PHARM 25MG/10ML (2.5MG/ML) N078405 001 Nov 17, 2009 Sep DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE
@ PHARMADAX INC 30MG A216019 001 Nov 18, 2022 Apr DISC
@ 60MG A216019 002 Nov 18, 2022 Apr DISC
@ VITRUVIAS 30MG A216019 001 Nov 18, 2022 Sep CAHN
@ 60MG A216019 002 Nov 18, 2022 Sep CAHN

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL
>A> NILOTINIB HYDROCHLORIDE
>A> AB APOTEX EQ 50MG BASE A203640 001 Jan 05, 2024 Dec NEWA
>A> AB EQ 150MG BASE A203640 002 Jan 05, 2024 Dec NEWA
>A> AB EQ 200MG BASE A203640 003 Jan 05, 2024 Dec NEWA

TASIGNA
>D> + NOVARTIS EQ 50MG BASE N022068 003 Mar 22, 2018 Dec CFTG
>A> AB + EQ 50MG BASE N022068 003 Mar 22, 2018 Dec CFTG
>D> + EQ 150MG BASE N022068 002 Jun 17, 2010 Dec CFTG
>A> AB + EQ 150MG BASE N022068 002 Jun 17, 2010 Dec CFTG
>D> +! EQ 200MG BASE N022068 001 Oct 29, 2007 Dec CFTG
>A> AB +! EQ 200MG BASE N022068 001 Oct 29, 2007 Dec CFTG

NIRAPARIB TOSYLATE

TABLET;ORAL
ZEJULA
+ GLAXOSMITHKLINE EQ 100MG BASE N214876 001 Apr 26, 2023 Apr NEWA
+ EQ 200MG BASE N214876 002 Apr 26, 2023 Apr NEWA
+! EQ 300MG BASE N214876 003 Apr 26, 2023 Apr NEWA

NIRMATRELVIR; RITONAVIR

TABLET;ORAL						
PAXLOVID (COPACKAGED)						
+ PFIZER	150MG;100MG		N 217188	001	May 25, 2023	May NEWA
+!	300MG;100MG		N 217188	002	May 25, 2023	May NEWA

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL						
OGSIVEO						
+! SPRINGWORKS	EQ 50MG BASE		N 217677	001	Nov 27, 2023	Nov NEWA

NISOLDIPIINE

TABLET, EXTENDED RELEASE;ORAL						
NISOLDIPIINE						
@ AMTA	8.5MG		A 216606	001	Apr 10, 2023	Sep DISC
	8.5MG		A 216606	001	Apr 10, 2023	Mar NEWA

NITISINONE

CAPSULE;ORAL						
NITISINONE						
AB ETON	2MG		A 216201	001	May 25, 2023	Oct CAHN
AB	5MG		A 216201	002	May 25, 2023	Oct CAHN
AB	10MG		A 216201	003	May 25, 2023	Oct CAHN
AB	20MG		A 216201	004	May 25, 2023	Oct CAHN
AB MEDUNIK	20MG		A 212390	004	Apr 27, 2023	Apr NEWA
AB ZENARA	2MG		A 216201	001	May 25, 2023	May NEWA
AB	5MG		A 216201	002	May 25, 2023	May NEWA
AB	10MG		A 216201	003	May 25, 2023	May NEWA
AB	20MG		A 216201	004	May 25, 2023	May NEWA

NITRIC OXIDE

GAS;INHALATION						
GENOSYL						
+! VERO BIOTECH INC	800PPM		N 202860	001	Dec 20, 2019	Jan CAHN
ULSPIRA						

AA AIRGAS THERAP 800PPM A 203144 001 Jul 27, 2023 Jul NEWA

NITROFURANTOIN

SUSPENSION;ORAL						
FURADANTIN						
AB + CASPER PHARMA LLC	25MG/5ML		N 009175	001		Jun CHRS
+!	50MG/5ML		N 009175	002	Jun 09, 2023	Jun NEWA
NITROFURANTOIN						
AB AMNEAL PHARMS	25MG/5ML		A 201679	001	May 11, 2011	Nov CMFD
AB AUROBINDO PHARMA	25MG/5ML		A 212607	001	May 11, 2023	May NEWA
AB NOVITIUM PHARMA	25MG/5ML		A 216385	001	Apr 14, 2023	Apr NEWA
TABLET;ORAL						
FURALAN						
@ CHARTWELL MOLECULAR	50MG		A 080017	001		Jul CAHN
@	100MG		A 080017	002		Jul CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL						
NITROFURANTOIN						
AB AUROBINDO PHARMA USA	50MG		A 074967	001	Jul 09, 1997	Apr CMFD
	100MG		A 074967	002	Jul 09, 1997	Apr CMFD
	100MG		A 077025	001	Aug 18, 2004	May CMFD
AB MANKIND PHARMA	25MG		A 217272	001	Mar 21, 2023	Mar NEWA
	50MG		A 217272	002	Mar 21, 2023	Mar NEWA
	100MG		A 217272	003	Mar 21, 2023	Mar NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL						
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)						
@ ALVOGEN	75MG;25MG		A 215002	001	Jul 20, 2022	Jan DISC
AB AUROBINDO PHARMA	75MG;25MG		A 209225	001	Mar 30, 2023	Mar NEWA
AB MANKIND PHARMA	75MG;25MG		A 217357	001	Jul 11, 2023	Jun NEWA
AB OMSAV PHARMA	75MG;25MG		A 217073	001	Nov 03, 2023	Oct NEWA

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

+!	BAXTER HLTHCARE	10MG/100ML	N019970	001	Dec 29, 1989	May CTEC
+!		20MG/100ML	N019970	002	Dec 29, 1989	May CTEC
+!		40MG/100ML	N019970	003	Dec 29, 1989	May CTEC
	OINTMENT; TRANSDERMAL					
	NITROGLYCERIN					
+!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	May CRLD
	TABLET; SUBLINGUAL					
	NITROGLYCERIN					
AB	AUROBINDO PHARMA	0.3MG	A217879	001	Oct 26, 2023	Oct NEWA
AB		0.4MG	A217879	002	Oct 26, 2023	Oct NEWA
AB		0.6MG	A217879	003	Oct 26, 2023	Oct NEWA
AB	MANKIND PHARMA	0.3MG	A217970	001	Dec 05, 2023	Nov NEWA
AB		0.4MG	A217970	002	Dec 05, 2023	Nov NEWA
AB		0.6MG	A217970	003	Dec 05, 2023	Nov NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	CAPLIN	EQ 1MG BASE/ML	A217575	001	Sep 15, 2023	Sep NEWA
>D> AP	HONG KONG	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	Dec CAHN
AP		EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	Oct CAHN
>A> AP	MEITHEAL	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	Dec CAHN
	SOLUTION; INTRAVENOUS					
	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE					
+ @	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	May CAHN
+ @		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	May CAHN
+ @		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	May CAHN
+ @	NEVAKAR INJECTABLES	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Apr DISC
+ @		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Apr DISC
+ @		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Apr DISC
	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE					
+!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	003	Nov 21, 2023	Nov NEWA

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	! PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000	Aug CTEC
AA	RUBICON	EQ 10MG BASE/5ML	A217731	001	Aug 15, 2023	Aug NEWA

NYSTATIN

OINTMENT; TOPICAL

NYSTATIN

@ TORRENT 100,000 UNITS/GM

A211838 001 Jan 28, 2019 Mar DISC

POWDER; TOPICAL

NYSTATIN

AT	BEOWULF ASSET	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Sep CAHN
----	---------------	------------------	---------	-----	--------------	----------

SUSPENSION; ORAL

NILSTAT

+ @ CHARTWELL MOLECULES 100,000 UNITS/ML

N050299 001 Apr CAHN

NYSTATIN

AA	MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Oct CAHN
	@ VISTAPHARM	100,000 UNITS/ML	A064142	001	Jun 25, 1998	Oct DISC
	@	100,000 UNITS/ML	A064142	002	Mar 07, 2011	Oct DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

@ TORRENT 100,000 UNITS/GM; 0.1%

A213142 001 Jul 14, 2020 Aug DISC

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	EPIC PHARMA LLC	100,000 UNITS/GM; 0.1%	A207217	001	Aug 04, 2017	Oct CAHN
	@ PAI HOLDINGS PHARM	100,000 UNITS/GM; 0.1%	A208287	001	Dec 30, 2016	Aug DISC

OBETICHOOLIC ACID

TABLET;ORAL

OBETICHOOLIC ACID

AB	@ APOTEX	5MG	A214862	001	May 30, 2023	Sep DISC
		5MG	A214862	001	May 30, 2023	May NFTG
AB	@	10MG	A214862	002	May 30, 2023	Sep DISC
		10MG	A214862	002	May 30, 2023	May NFTG
AB	@ LUPIN LTD	5MG	A214980	001	May 30, 2023	Oct DISC
		5MG	A214980	001	May 30, 2023	May NFTG
AB	@	10MG	A214980	002	May 30, 2023	Oct DISC
		10MG	A214980	002	May 30, 2023	May NFTG
AB	@ MSN	5MG	A215017	001	May 30, 2023	Jun DISC
		5MG	A215017	001	May 30, 2023	May NFTG
AB	@	10MG	A215017	002	May 30, 2023	Jun DISC
		10MG	A215017	002	May 30, 2023	May NFTG
	OCALIVA					
AB	+ INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	Oct CTEC
	+	5MG	N207999	001	May 27, 2016	May CFTG
	+!	10MG	N207999	002	May 27, 2016	Oct CTEC
AB	+!	10MG	N207999	002	May 27, 2016	May CFTG

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL

MYCAPSSA

>D>	+! AMRYT	EQ 20MG BASE	N208232	001	Jun 26, 2020	Dec CAHN
>A>	+! CHIESI	EQ 20MG BASE	N208232	001	Jun 26, 2020	Dec CAHN
	INJECTABLE;INJECTION					
	OCTREOTIDE ACETATE					
AP	GLAND PHARMA LTD	EQ 0.1MG BASE/ML	A216839	002	Jun 22, 2023	Jun NEWA
AP		EQ 0.2MG BASE/ML	A216807	001	Jun 13, 2023	Jun NEWA
AP		EQ 0.5MG BASE/ML	A216839	001	Jun 22, 2023	Jun NEWA
AP		EQ 1MG BASE/ML	A216807	002	Jun 13, 2023	Jun NEWA
>D> AP	HONG KONG	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	Dec CAHN
AP		EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	Oct CAHN
>D> AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	Dec CAHN
AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	Oct CAHN
>D> AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	Dec CAHN
AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	Oct CAHN
>D> AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	Dec CAHN
AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	Oct CAHN
>D> AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	Dec CAHN
AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	Oct CAHN
>D> AP		EQ 1MG BASE/ML	A075957	001	Oct 03, 2005	Dec CAHN
AP		EQ 1MG BASE/ML	A075957	001	Oct 03, 2005	Oct CAHN
>A> AP	MEITHEAL	EQ 0.05MG BASE/ML	A075957	002	Oct 03, 2005	Dec CAHN
>A> AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	Dec CAHN
>A> AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	Dec CAHN
>A> AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	Dec CAHN
>A> AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	Dec CAHN
AP	TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Nov NFTG
AP		EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Nov NFTG
AP		EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Nov NFTG
	SANDOSTATIN LAR					
AP	+ NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Nov CFTG
AP	+	EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Nov CFTG
AP	+!	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Nov CFTG

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	SENTISS	0.3%	A076407	001	Apr 15, 2008	Aug CAHN
	SOLUTION/DROPS;OTIC					
	OFLOXACIN					
>A> AT	CAPLIN	0.3%	A217903	001	Jan 05, 2024	Dec NEWA

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP	ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Mar NEWA
AP	+! CHEPLAPHARM	10MG/VIAL	N021253	001	Mar 29, 2004	Nov CAHN

TABLET;ORALOLANZAPINE

AB	CADILA PHARMS LTD	2.5MG	A210022	001	Feb 24, 2023	Feb NEWA
AB		5MG	A210022	002	Feb 24, 2023	Feb NEWA
AB		7.5MG	A210022	003	Feb 24, 2023	Feb NEWA
AB		10MG	A210022	004	Feb 24, 2023	Feb NEWA
AB		15MG	A210022	005	Feb 24, 2023	Feb NEWA
AB		20MG	A210022	006	Feb 24, 2023	Feb NEWA
	ZYPREXA					
AB	+ CHEPLAPHARM	2.5MG	N020592	001	Sep 30, 1996	Sep CAHN
AB	+!	5MG	N020592	002	Sep 30, 1996	Sep CAHN
AB	+	7.5MG	N020592	003	Sep 30, 1996	Sep CAHN
AB	+	10MG	N020592	004	Sep 30, 1996	Sep CAHN
AB	+	15MG	N020592	005	Sep 09, 1997	Sep CAHN
AB	+	20MG	N020592	006	Sep 09, 1997	Sep CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL					
	OLANZAPINE					
AB	HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Apr CMFD
AB		10MG	A206892	002	Dec 31, 2020	Apr CMFD
AB		15MG	A206892	003	Dec 31, 2020	Apr CMFD
AB		20MG	A206892	004	Dec 31, 2020	Apr CMFD
	@ ZYDUS PHARMS	5MG	A202889	001	Mar 09, 2023	Jul DISC
AB		5MG	A202889	001	Mar 09, 2023	Mar NEWA
AB	@	10MG	A202889	002	Mar 09, 2023	Jul DISC
AB	@	10MG	A202889	002	Mar 09, 2023	Mar NEWA
AB	@	15MG	A202889	003	Mar 09, 2023	Jul DISC
AB	@	15MG	A202889	003	Mar 09, 2023	Mar NEWA
AB	@	20MG	A202889	004	Mar 09, 2023	Jul DISC
AB		20MG	A202889	004	Mar 09, 2023	Mar NEWA
	ZYPREXA ZYDIS					
AB	+! CHEPLAPHARM	5MG	N021086	001	Apr 06, 2000	Sep CAHN
AB	+	10MG	N021086	002	Apr 06, 2000	Sep CAHN
AB	+	15MG	N021086	003	Apr 06, 2000	Sep CAHN
AB	+	20MG	N021086	004	Apr 06, 2000	Sep CAHN

OLANZAPINE PAMOATESUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ZYPREXA RELPREVV

+	CHEPLAPHARM	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009	Sep CAHN
+		EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009	Aug CAHN
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009	Sep CAHN
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009	Aug CAHN
+	!	EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009	Sep CAHN
+	!	EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009	Aug CAHN

OLMESARTAN MEDOXOMILTABLET;ORALOLMESARTAN MEDOXOMIL

AB	@ AMNEAL	5MG	A207480	001	Jul 11, 2023	Oct DISC
AB	@	5MG	A207480	001	Jul 11, 2023	Jun NEWA
AB		20MG	A207480	002	Jul 11, 2023	Oct DISC
AB	@	20MG	A207480	002	Jul 11, 2023	Jun NEWA
AB	@	40MG	A207480	003	Jul 11, 2023	Oct DISC
AB		40MG	A207480	003	Jul 11, 2023	Jun NEWA
AB	MSN	5MG	A217399	001	Jan 18, 2023	Jan NEWA
AB		20MG	A217399	002	Jan 18, 2023	Jan NEWA
AB		40MG	A217399	003	Jan 18, 2023	Jan NEWA
	@ TORRENT	5MG	A202375	001	Apr 24, 2017	Aug DISC
	@	20MG	A202375	002	Apr 24, 2017	Aug DISC
	@	40MG	A202375	003	Apr 24, 2017	Aug DISC

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMICOLOPATADINE HYDROCHLORIDE

AB	@ FLORIDA	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Nov CAHN
	SPRAY, METERED;NASAL					
	OLOPATADINE HYDROCHLORIDE					
AB	! AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	May CHRS
	PATANASE					
	+ @ NOVARTIS	0.665MG/SPRAY	N021861	001	Apr 15, 2008	May DISC

OMAVELOXOLONE

CAPSULE;ORAL
SKYCLARYS
+! REATA PHARMS 50MG N216718 001 Feb 28, 2023 Feb NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS
>A> AB SLAYBACK PHARMA LLC 1GM CONTAINS AT LEAST 900MG OF THE A211345 001 Dec 07, 2023 Dec NEWA
ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE
AB ANDA REPOSITORY 20MG;1.1GM A212587 001 Apr 30, 2020 Sep CAHN
AB 40MG;1.1GM A212587 002 Apr 30, 2020 Sep CAHN

OMIDENEPAK ISOPROPYL

SOLUTION;OPHTHALMIC
OMLONTI
+ @ SANTEN 0.002% N215092 001 Sep 22, 2022 May DISC
+ @ VISIOX PHARMA 0.002% N215092 001 Sep 22, 2022 Nov CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON
! CHARTWELL MOLECULES 1.6MG A077406 001 Dec 26, 2006 Mar CHRS
! 2.4MG A077406 002 Dec 26, 2006 Mar CHRS
AB IPCA LABS LTD 4MG A209389 001 Oct 30, 2023 Oct NEWA
AB 8MG A209389 002 Oct 30, 2023 Oct NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ZOFTRAN
+ @ SANDOZ EQ 2MG BASE/ML N020007 001 Jan 04, 1991 May CAHN
ZOFTRAN PRESERVATIVE FREE
+ @ SANDOZ EQ 2MG BASE/ML N020007 003 Dec 10, 1993 May CAHN
SOLUTION;ORAL
ONDANSETRON HYDROCHLORIDE
AA CHARTWELL MOLECULAR EQ 4MG BASE/5ML A091342 001 Jan 27, 2011 Jul CAHN
ZOFTRAN
+ @ SANDOZ EQ 4MG BASE/5ML N020605 001 Jan 24, 1997 May CAHN
TABLET;ORAL
ONDANSETRON HYDROCHLORIDE
@ CASI PHARMS INC EQ 4MG BASE A077517 001 Jun 25, 2007 Nov DISC
@ EQ 8MG BASE A077517 002 Jun 25, 2007 Nov DISC
! CHARTWELL MOLECULES EQ 24MG BASE A077303 004 Jun 25, 2007 Feb CTEC
ZOFTRAN
+ @ SANDOZ EQ 4MG BASE N020103 001 Dec 31, 1992 May CAHN
+ @ EQ 8MG BASE N020103 002 Dec 31, 1992 May CAHN
+ @ EQ 24MG BASE N020103 003 Aug 27, 1999 May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE
AB ! LUPIN 100MG A040284 001 Jun 19, 1998 Nov CHRS
AB RISING 100MG A040249 001 Jan 29, 1999 Jan CAHN
AB SANDOZ 100MG A040327 001 Feb 15, 2000 Nov CHRS

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE
@ ACCORD HLTHCARE EQ 30MG BASE A214726 001 Jul 25, 2022 Feb DISC
@ EQ 45MG BASE A214726 002 Jul 25, 2022 Feb DISC
@ EQ 75MG BASE A214726 003 Jul 25, 2022 Feb DISC
AB HAINAN POLY EQ 75MG BASE A218009 001 Nov 24, 2023 Nov NEWA
AB INVAGEN PHARMS EQ 30MG BASE A217467 001 Oct 03, 2023 Sep NEWA
AB EQ 45MG BASE A217467 002 Oct 03, 2023 Sep NEWA
AB EQ 75MG BASE A217467 003 Oct 03, 2023 Sep NEWA
AB SUNSHINE EQ 30MG BASE A212739 001 Mar 04, 2020 Jun CMFD

	CAPSULE;ORAL OSELTAMIVIR PHOSPHATE	EQ 45MG BASE EQ 75MG BASE	A212739 002 Mar 04, 2020 A212739 003 Mar 04, 2020	Jun CMFD Jun CMFD
AB	FOR SUSPENSION;ORAL OSELTAMIVIR PHOSPHATE	EQ 6MG BASE/ML EQ 6MG BASE/ML	A214949 001 Feb 28, 2022 A215538 001 Feb 14, 2023	Sep CAHN Feb NEWA
AB	@ CHEMISTRY HLTH EPIC PHARMA LLC			
	<u>OSILODROSTAT PHOSPHATE</u>			
	TABLET;ORAL ISTURISA + @ RECORDATI RARE	EQ 10MG BASE	N212801 003 Mar 06, 2020	Jul DISC
	<u>OXACILLIN SODIUM</u>			
	INJECTABLE;INJECTION OXACILLIN SODIUM @ PIRAMAL CRITICAL	EQ 10GM BASE/VIAL	A206760 001 Oct 26, 2017	Sep DISC
	<u>OXAPROZIN</u>			
	CAPSULE;ORAL COXANTO +! SOLUBIOMIX	300MG	N217927 001 Oct 20, 2023	Oct NEWA
	<u>OXCARBAZEPINE</u>			
	SUSPENSION;ORAL OXCARBAZEPINE			
AB	CHARTWELL RX	300MG/5ML	A212428 001 Jun 21, 2021	May CAHN
AB	HETERO LABS LTD III	300MG/5ML	A216749 001 Oct 20, 2023	Oct NEWA
>D> AB	HIKMA	300MG/5ML	A201193 001 Oct 03, 2012	Dec DISC
>A>	@	300MG/5ML	A201193 001 Oct 03, 2012	Dec DISC
AB	OAK TREE PHARMA	300MG/5ML	A211420 001 Jul 09, 2021	Aug CAHN
	@ RENEW PHARMS	300MG/5ML	A211420 001 Jul 09, 2021	Sep DISC
AB		300MG/5ML	A211420 001 Jul 09, 2021	Aug CAHN
	TABLET;ORAL OXCARBAZEPINE			
AB	ZYDUS	150MG	A211747 001 Jul 03, 2023	Jun NEWA
AB		300MG	A211747 002 Jul 03, 2023	Jun NEWA
AB		600MG	A211747 003 Jul 03, 2023	Jun NEWA
	TABLET, EXTENDED RELEASE;ORAL OXCARBAZEPINE			
AB	@ APOTEX	150MG	A213369 001 Jul 13, 2023	Sep DISC
AB		150MG	A213369 001 Jul 13, 2023	Jul NFTG
AB	@	300MG	A213369 002 Jul 13, 2023	Sep DISC
AB		300MG	A213369 002 Jul 13, 2023	Jul NFTG
AB	@	600MG	A213369 003 Jul 13, 2023	Sep DISC
AB		600MG	A213369 003 Jul 13, 2023	Jul NFTG
	OXTELLAR XR			
	+ SUPERNUS PHARMS	150MG	N202810 001 Oct 19, 2012	Sep CTEC
AB	+	150MG	N202810 001 Oct 19, 2012	Jul CFTG
	+	300MG	N202810 002 Oct 19, 2012	Sep CTEC
AB	+	300MG	N202810 002 Oct 19, 2012	Jul CFTG
	+!	600MG	N202810 003 Oct 19, 2012	Sep CTEC
AB	+!	600MG	N202810 003 Oct 19, 2012	Jul CFTG
	<u>OXYBUTYNIN CHLORIDE</u>			
	GEL;TRANSDERMAL GELNIQUE			
	+ @ ABBVIE	10% (100MG/PACKET)	N022204 001 Jan 27, 2009	Sep DISC
	+!	10% (100MG/PACKET)	N022204 001 Jan 27, 2009	Apr CAHN
	SYRUP;ORAL OXYBUTYNIN CHLORIDE			
AA	CHARTWELL RX	5MG/5ML	A075039 001 Jan 29, 1999	Mar CMFD
	@ PHARMOBEDIENT CNSLTG	5MG/5ML	A074868 001 Feb 12, 1997	Sep CAHN
	@ XTTRIUM LABS INC	5MG/5ML	A074868 001 Feb 12, 1997	Mar CAHN
	TABLET;ORAL OXYBUTYNIN CHLORIDE			
	! APPCO	2.5MG	A209025 002 Feb 07, 2023	Jan NFTG
	@ AVET LIFESCIENCES	5MG	A211682 001 May 10, 2019	Nov DISC
AB		5MG	A211682 001 May 10, 2019	Jun CTEC
	! RISING	2.5MG	A209025 002 Feb 07, 2023	Sep CAHN
AB		5MG	A209025 001 Dec 21, 2017	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL
DITROPAN XL

+ @ JANSSEN PHARMS	5MG	N 020897	001	Dec 16, 1998	Sep DISC
+ @	10MG	N 020897	002	Dec 16, 1998	Sep DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

>D> AA EYWA	5MG/5ML	A 207511	001	Nov 23, 2016	Dec CAHN
>D> AA	100MG/5ML	A 209897	001	Sep 06, 2017	Dec CAHN
>D> AA HIKMA	5MG/5ML	A 204037	001	Jul 15, 2013	Dec CHRS
>A> AA !	5MG/5ML	A 204037	001	Jul 15, 2013	Dec CHRS
	@ PHARMOBEDIENT CNSLTG	A 206456	001	Jun 16, 2015	Sep CAHN
>D> AA +! VI STAPHARM	5MG/5ML	N 201194	001	Jan 12, 2012	Dec DISC
>A> + @	5MG/5ML	N 201194	001	Jan 12, 2012	Dec DISC
	@	A 202537	001	Jul 30, 2012	Sep DISC
>A> AA WES PHARMA INC	100MG/5ML	A 207511	001	Nov 23, 2016	Dec CAHN
>A> AA	5MG/5ML	A 209897	001	Sep 06, 2017	Dec CAHN
	100MG/5ML				

TABLET;ORAL

OXAYDO

+ @ ZYLA	5MG	N 202080	001	Jun 17, 2011	Sep DISC
+ @	7.5MG	N 202080	002	Jun 17, 2011	Sep DISC

ROXYBOND

>D>	PROTEGA PHARMS	5MG	N 209777	001	Apr 20, 2017	Dec CAHN
>A>		5MG	N 209777	001	Apr 20, 2017	Dec CAHN
>D>		15MG	N 209777	002	Apr 20, 2017	Dec CAHN
>A>		15MG	N 209777	002	Apr 20, 2017	Dec CAHN
>D>		30MG	N 209777	003	Apr 20, 2017	Dec CAHN
>A>		30MG	N 209777	003	Apr 20, 2017	Dec CAHN

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

+ ! MAYNE PHARMA	1%	N 208552	001	Jan 18, 2017	Sep CAHN
------------------	----	----------	-----	--------------	----------

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

>D> AB SPECGX LLC	5MG	A 202321	001	Apr 25, 2013	Dec DISC
>A> @	5MG	A 202321	001	Apr 25, 2013	Dec DISC
>D> AB	10MG	A 202321	002	Apr 25, 2013	Dec DISC
>A> @	10MG	A 202321	002	Apr 25, 2013	Dec DISC

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

@ DASH PHARMS	6MG/ML	A 091540	001	Sep 29, 2011	Feb CAHN
---------------	--------	----------	-----	--------------	----------

POWDER;INTRAVENOUS

PACLITAXEL

+ ! AM REGENT	100MG/VIAL	N 211875	001	Jul 27, 2022	Apr CAHN
---------------	------------	----------	-----	--------------	----------

PALBOCICLIB

TABLET;ORAL

IBRANCE

AB + PFIZER	75MG	N 212436	001	Nov 01, 2019	Aug CFTG
AB +	100MG	N 212436	002	Nov 01, 2019	Aug CFTG
AB +!	125MG	N 212436	003	Nov 01, 2019	Aug CFTG
	PALBOCICLIB				
AB SYNTON PHARMS INC	75MG	A 215570	001	Aug 28, 2023	Aug NFTG
AB	100MG	A 215570	002	Aug 28, 2023	Aug NFTG
AB	125MG	A 215570	003	Aug 28, 2023	Aug NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB ASCENT PHARMS INC	1.5MG	A 216174	001	Aug 23, 2023	Aug NEWA
AB	3MG	A 216174	002	Aug 23, 2023	Aug NEWA
AB	6MG	A 216174	003	Aug 23, 2023	Aug NEWA
AB	9MG	A 216174	004	Aug 23, 2023	Aug NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	CHARTWELL RX	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A209287	001	Sep 19, 2018	Sep CAHN
	@ CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb DISC
	@ INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb DISC
AP	NANJING KING-FRIEND	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Aug NEWA
	@ NOVAST LABS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Sep CAHN
SOLUTION; INTRAVENOUS						
PALONOSETRON HYDROCHLORIDE						
>A>	@ AVYXA PHARMA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Dec CAHN
>A>	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Dec CAHN
>D>	@ DR REDDYS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Dec CAHN
>D>	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Dec CAHN
	@ HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Sep DISC

PALOVAROTENE

CAPSULE; ORAL

SOHONOS

+	IPSEN INC	1MG	N215559	001	Aug 16, 2023	Aug NEWA
+		1.5MG	N215559	002	Aug 16, 2023	Aug NEWA
+		2.5MG	N215559	003	Aug 16, 2023	Aug NEWA
+		5MG	N215559	004	Aug 16, 2023	Aug NEWA
+!		10MG	N215559	005	Aug 16, 2023	Aug NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP2	DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May CTEC
AP2		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May CTEC
AP1	+!	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	May CTEC
AP1	+!	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	May CTEC
AP2	HOSPIRA	30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	May CTEC
AP		30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	Apr CHRS
AP2		90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	May CTEC
AP		90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	Apr CHRS
AP2	MYLAN LABS LTD	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	May CTEC
AP2		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	May CTEC
AP1	SAGENT PHARMS INC	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May CTEC
AP1		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May CTEC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	AJANTA PHARMA LTD	EQ 40MG BASE	A217416	001	Feb 09, 2023	Feb NEWA
AB	ANNORA PHARMA	EQ 40MG BASE	A216139	001	Oct 27, 2023	Oct NEWA
AB	DEXCEL	EQ 40MG BASE	A216247	001	Jun 16, 2023	Jun NEWA
INJECTABLE; INTRAVENOUS						
PANTOPRAZOLE SODIUM						
AP	KNACK	EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	Sep CMFD
TABLET, DELAYED RELEASE; ORAL						
PANTOPRAZOLE SODIUM						
>A > AB	GRANULES	EQ 20MG BASE	A217282	001	Dec 11, 2023	Dec NEWA
>A > AB		EQ 40MG BASE	A217282	002	Dec 11, 2023	Dec NEWA

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

AA	! HERITAGE PHARMS	EQ 250MG BASE	A065173	001	Dec 14, 2007	Nov CTEC
	!	EQ 250MG BASE	A065173	001	Dec 14, 2007	Nov CHRS
	@ SUN PHARM INDNS INC	EQ 250MG BASE	A064171	001	Jun 30, 1997	Nov DISC

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

@ EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan CAHN	
@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan CAHN	
@	EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan CAHN	
>A> AB	PRINSTON INC	EQ 12.5MG BASE	A209748	001	Jan 04, 2024	Dec NEWA
>A> AB		EQ 25MG BASE	A209748	002	Jan 04, 2024	Dec NEWA

PAROXETINE MESYLATE

TABLET;ORAL

PEXEVA

+ @ SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	May DISC
+ @	EQ 20MG BASE	N021299	002	Jul 03, 2003	May DISC
+ @	EQ 30MG BASE	N021299	003	Jul 03, 2003	May DISC

PATIROMER SORBITEX CALCIUM

POWDER;ORAL

VELTASSA

+ VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Oct NEWA
----------------	--------------------	---------	-----	--------------	----------

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

PAZOPANIB HYDROCHLORIDE

AB	APOTEX	EQ 200MG BASE	A217713	001	Oct 19, 2023	Oct NEWA
AB	SUN PHARM	EQ 200MG BASE	A215837	001	Oct 19, 2023	Oct NFTG
AB	TEVA PHARMS INC	EQ 200MG BASE	A217517	001	Oct 19, 2023	Oct NEWA
	VOTRIENT					
AB	+! NOVARTIS	EQ 200MG BASE	N022465	001	Oct 19, 2009	Oct CFTG

PEGCETACOPLAN

SOLUTION;INTRAVITREAL

SYFOVRE

+! APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023	Feb NEWA
-------------------	-------------------------	---------	-----	--------------	----------

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

@ AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Jun DISC	
@	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Apr NEWA	
AP	MEITHEAL	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jun DISC
AP		EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan CAHN
AP		EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan CAHN
AP		EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan CAHN
AP		EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan CAHN
	@ MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar DISC
AP		EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar NEWA
>A> AP	PRINSTON INC	EQ 100MG BASE/VIAL	A216582	001	Dec 11, 2023	Dec NEWA
	SOLUTION;INTRAVENOUS					
	PEMETREXED					
+! SHILPA	EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023	May NEWA	
+!	EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023	May NEWA	
+!	EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023	May NEWA	
	PEMETREXED DISODIUM					
+! SANDOZ	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan CMS1	

PENCICLOVIR

CREAM;TOPICAL

PENCICLOVIR

AB	TORRENT	1%	A216981	001	Aug 07, 2023	Jul NEWA
----	---------	----	---------	-----	--------------	----------

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

PENTAMIDINE ISETHIONATE

AN	X-GEN PHARMS INC	300MG/VIAL	A206983	001	Jan 20, 2023	Jan NEWA
----	------------------	------------	---------	-----	--------------	----------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION
PENTOBARBITAL SODIUM

>A> AP	BPI LABS	50MG/ML	A206677	001	Nov 27, 2017	Dec CAHN
>D> AP	PRAZGEN PHARMS	50MG/ML	A206677	001	Nov 27, 2017	Dec CAHN
AP		50MG/ML	A206677	001	Nov 27, 2017	Jul CAHN

PERAMPANEL

SUSPENSION; ORAL
FYCOMPA

+! CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Feb CAHN
TABLET; ORAL					
FYCOMPA					
+ CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	Feb CAHN
+	4MG	N202834	002	Oct 22, 2012	Feb CAHN
+	6MG	N202834	003	Oct 22, 2012	Feb CAHN
+	8MG	N202834	004	Oct 22, 2012	Feb CAHN
+	10MG	N202834	005	Oct 22, 2012	Feb CAHN
+!	12MG	N202834	006	Oct 22, 2012	Feb CAHN

PERFLUOROHEXYLOCTANE

SOLUTION/DROPS; OPHTHALMIC
MIEBO

+! BAUSCH AND LOMB INC	1.338GM/ML	N216675	001	May 18, 2023	May NEWA
------------------------	------------	---------	-----	--------------	----------

PERFLUTREN

INJECTABLE; INTRAVENOUS
DEFINITY

+! LANTHEUS MEDCL	13.04MG/2ML (6.52MG/ML)	N021064	001	Jul 31, 2001	Nov CPOT
DEFINITY RT					
+! LANTHEUS MEDCL	13.04MG/2ML (6.52MG/ML)	N021064	002	Nov 17, 2020	Nov CPOT

PERMETHRIN

CREAM; TOPICAL
ELIMITE

AB	+ AUROBINDO PHARMA USA	5%	N019855	001	Aug 25, 1989	Oct CMFD
	PERMETHRIN					
AB	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jul NEWA

PEXIDARTINIB HYDROCHLORIDE

CAPSULE; ORAL
TURALIO

+ @ DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019	Jun DISC
------------------------	---------------	---------	-----	--------------	----------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

>D>	@ AUROBINDO PHARMA	10MG	A215600	001	May 08, 2023	Dec CMFD
>A> AB		10MG	A215600	001	May 08, 2023	Dec CMFD
	@	10MG	A215600	001	May 08, 2023	Nov DISC
AB		10MG	A215600	001	May 08, 2023	Apr NEWA
>D> AB	HIKMA	10MG	A201050	001	Jul 16, 2012	Dec DISC
>A>	@	10MG	A201050	001	Jul 16, 2012	Dec DISC
AB	RISING	10MG	A204551	001	Jun 20, 2023	Jun NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

@ LANNETT	15MG	A087022	002	Jan 20, 2012	Feb DISC
@	30MG	A087022	001	Feb 03, 1983	Feb DISC
@ SUN PHARM INDUSTRIES	30MG	A040525	001	Oct 23, 2003	Nov DISC

PHENTOLAMINE MESYLATE

SOLUTION; OPHTHALMIC
RYZUMVI

+! OCUPHIRE	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Sep NEWA
-------------	---------------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

IMMPHENТИV

+!	HIKMA	0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	May CAHN
+!		0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	Mar NEWA
+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	May CAHN
+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AVET LIFESCIENCES	10MG/ML (10MG/ML)	A209968	001	Feb 28, 2023	Feb NEWA
AP2	BE PHARMS	10MG/ML (10MG/ML)	A217521	001	Jun 26, 2023	Jun NEWA
AP2		50MG/5ML (10MG/ML)	A217521	002	Jun 26, 2023	Jun NEWA
AP2		100MG/10ML (10MG/ML)	A217521	003	Jun 26, 2023	Jun NEWA
AP2	+! HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	May CAHN
	+!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jun CTEC
AP2	+!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	May CAHN
AP2	+!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jun CTEC
AP2	+!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	May CAHN

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	+	AKORN	2.5%	N207926	001	Jan 15, 2015	Jul CHRS
AT	+		10%	N207926	002	Jan 15, 2015	Jul CHRS
AT	+	ALCON	2.5%	N207926	001	Jan 15, 2015	Jul CAHN
AT	+		10%	N207926	002	Jan 15, 2015	Jul CAHN
AT	!	MANKIND PHARMA	2.5%	A216859	001	Sep 29, 2022	Jul CHRS
AT	!		10%	A216496	001	Jan 11, 2023	Jul CHRS

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

@ XTTRIUM LABS INC	5MG/5ML; 6.25MG/5ML	A088897	001	Jan 04, 1985	Jan CAHN
--------------------	---------------------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

SPRAY, METERED; OPHTHALMIC

MYDCOMBI

+! EYENOVIA	2.5%; 1%	N215352	001	May 05, 2023	May NEWA
-------------	----------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

@ CHARTWELL MOLECULAR	30MG PROMPT	A080857	001		Jul CAHN
@	100MG PROMPT	A080857	002		Jul CAHN
EXTENDED PHENYTOIN SODIUM					
@ MYLAN	100MG EXTENDED	A040298	001	Dec 28, 1998	Mar DISC
@ UNICHEM	100MG EXTENDED	A213834	001	Oct 13, 2022	Apr DISC

PHYTONADIONE

TABLET; ORAL

PHYTONADIONE

AB	AGNITIO	5MG	A213336	001	Oct 12, 2023	Oct NEWA
AB	SCIEGEN PHARMS INC	5MG	A213329	001	Jul 28, 2023	Jul NEWA
AB	! ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb CHRS

PILOCARPINE

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

@ EPIC PHARMA LLC	5MG	N017431	001		Nov CAHN
OCUSERT PILO-40		N017548	001		Nov CAHN

@ EPIC PHARMA LLC

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

AT	+! SANDOZ	1%	N200890	001	Jun 22, 2010	Sep CAHN
AT	+!	2%	N200890	002	Jun 22, 2010	Sep CAHN
AT	+!	4%	N200890	003	Jun 22, 2010	Sep CAHN
	QLOSI					
+!	ORASIS PHARMS	0.4%	N217836	001	Oct 17, 2023	Oct NEWA
TABLET; ORAL						
PILOCARPINE HYDROCHLORIDE						
>D> AB	AMICI	5MG	A076963	001	Dec 22, 2004	Dec CAHN
>D> AB		7.5MG	A076963	002	Feb 27, 2007	Dec CAHN

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

>A> AB	INNOGENIX	5MG	A076963	001	Dec 22, 2004	Dec CAHN
>A> AB		7.5MG	A076963	002	Feb 27, 2007	Dec CAHN

PIOGLITAZONE HYDROCHLORIDETABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	@ ANDA REPOSITORY	EQ 15MG BASE	A078383	001	Mar 12, 2013	Sep CAHN
	@	EQ 30MG BASE	A078383	002	Mar 12, 2013	Sep CAHN
	@	EQ 45MG BASE	A078383	003	Mar 12, 2013	Sep CAHN
AB	CHARTWELL RX	EQ 15MG BASE	A076798	001	Oct 26, 2012	Nov CAHN
	@	EQ 15MG BASE	A078383	001	Mar 12, 2013	Nov CAHN
AB		EQ 30MG BASE	A076798	002	Oct 26, 2012	Nov CAHN
	@	EQ 30MG BASE	A078383	002	Mar 12, 2013	Nov CAHN
AB		EQ 45MG BASE	A076798	003	Oct 26, 2012	Nov CAHN
	@	EQ 45MG BASE	A078383	003	Mar 12, 2013	Nov CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	EUGIA PHARMA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Nov CTEC
		EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Nov CHRS
!		EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Oct NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023	Oct NEWA
AP	! SANDOZ	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Nov CHRS
AP	SHANDONG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Apr CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Apr CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Apr CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217243	001	Apr 14, 2023	Apr NEWA
	ZOSYN IN PLASTIC CONTAINER					
+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Mar CAHN
+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Mar CAHN
+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Mar CAHN

PIRFENIDONECAPSULE;ORAL

PIRFENIDONE

AB	@ APOTEX	267MG	A212687	001	Jun 09, 2023	Sep DISC
>D> AB	LUPIN LTD	267MG	A212687	001	Jun 09, 2023	Jun NEWA
>A>	@	267MG	A212404	001	Aug 28, 2023	Dec DISC
AB		267MG	A212404	001	Aug 28, 2023	Dec DISC
		267MG	A212404	001	Aug 28, 2023	Aug NEWA

TABLET;ORAL

PIRFENIDONE

AB	APOTEX	267MG	A212709	001	May 31, 2023	May NEWA
AB		801MG	A212709	002	May 31, 2023	May NEWA
>D> AB	LUPIN LTD	267MG	A212403	001	Aug 23, 2023	Dec DISC
>A>	@	267MG	A212403	001	Aug 23, 2023	Dec DISC
AB		267MG	A212403	001	Aug 23, 2023	Aug NEWA
>D> AB		801MG	A212403	002	Aug 23, 2023	Dec DISC
>A>	@	801MG	A212403	002	Aug 23, 2023	Dec DISC
AB		801MG	A212403	002	Aug 23, 2023	Aug NEWA

PIROXICAMCAPSULE;ORAL

PIROXICAM

>D> AB	HIKMA	10MG	A209256	001	Aug 11, 2017	Dec DISC
>A>	@	10MG	A209256	001	Aug 11, 2017	Dec DISC
>D> AB		20MG	A209256	002	Aug 11, 2017	Dec DISC
>A>	@	20MG	A209256	002	Aug 11, 2017	Dec DISC
AB	UNICHEM	10MG	A208340	001	Apr 13, 2017	Aug CTEC
AB		20MG	A208340	002	Apr 13, 2017	Aug CTEC

PIRTOBRUTINIB

TABLET;ORAL						
JAYPIRCA						
+ LOXO ONCOL	50MG		N216059	001	Jan 27, 2023	Jan NEWA
+!	100MG		N216059	002	Jan 27, 2023	Jan NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL						
PITAVASTATIN CALCIUM						
AB LUPIN LTD	EQ 1MG BASE		A206029	001	Nov 20, 2023	Nov NEWA
	EQ 2MG BASE		A206029	002	Nov 20, 2023	Nov NEWA
AB	EQ 4MG BASE		A206029	003	Nov 20, 2023	Nov NEWA
AB MYLAN	EQ 1MG BASE		A206070	001	Apr 04, 2019	Sep CMFD
AB	EQ 2MG BASE		A206070	002	Apr 04, 2019	Sep CMFD
AB	EQ 4MG BASE		A206070	003	Apr 04, 2019	Sep CMFD
AB ZYDUS PHARMS	EQ 1MG BASE		A206047	001	Feb 22, 2023	Feb NEWA
AB	EQ 2MG BASE		A206047	002	Feb 22, 2023	Feb NEWA
AB	EQ 4MG BASE		A206047	003	Feb 22, 2023	Feb NEWA

PLERIXAFOR

SOLUTION;SUBCUTANEOUS						
MOZOBIL						
AP +! GENZYME	24MG/1.2ML (20MG/ML)		N022311	001	Dec 15, 2008	Jul CFTG
PLERIXAFOR						
AP AMNEAL	24MG/1.2ML (20MG/ML)		A215334	001	Jul 24, 2023	Jul NFTG
AP DR REDDYS	24MG/1.2ML (20MG/ML)		A205182	001	Jul 24, 2023	Jul NFTG
AP EUGIA PHARMA	24MG/1.2ML (20MG/ML)		A213672	001	Jul 24, 2023	Jul NFTG
AP KINDOS	24MG/1.2ML (20MG/ML)		A215698	001	Jul 24, 2023	Jul NFTG
AP MSN	24MG/1.2ML (20MG/ML)		A211901	001	Jul 24, 2023	Jul NFTG
AP TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)		A205197	001	Jul 24, 2023	Jul NFTG
AP ZYDUS PHARMS	24MG/1.2ML (20MG/ML)		A208980	001	Jul 26, 2023	Jul NEWA

PODOFILOX

GEL;TOPICAL						
CONDYLOX						
AB +! ALLERGAN	0.5%		N020529	001	Mar 13, 1997	Nov CFTG
PODOFILOX						
AB PADAGIS US	0.5%		A211871	001	Nov 22, 2023	Nov NFTG

POLYMYXIN B SULFATE

INJECTABLE;INJECTION						
POLYMYXIN B SULFATE						
AP BEOWULF ASSET	EQ 500,000 UNITS BASE/VIAL		A063000	001	Sep 30, 1994	Sep CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC						
POLYTRIM						
+ @ ALLERGAN	10,000 UNITS/ML;EQ 1MG BASE/ML		N050567	001	Oct 20, 1988	Feb DISC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE						
AT ! SANDOZ	10,000 UNITS/ML;EQ 1MG BASE/ML		A064211	001	Apr 13, 1998	Feb CHRS

POMALIDOMIDE

CAPSULE;ORAL						
POMALYST						
+ BRISTOL	1MG		N204026	001	Feb 08, 2013	Jan CAHN
+	2MG		N204026	002	Feb 08, 2013	Jan CAHN
+	3MG		N204026	003	Feb 08, 2013	Jan CAHN
+!	4MG		N204026	004	Feb 08, 2013	Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL						
ICLUSIG						
+ TAKEDA PHARMS USA	EQ 15MG BASE		N203469	001	Dec 14, 2012	Sep CTEC
AB +	EQ 15MG BASE		N203469	001	Dec 14, 2012	Jul CFTG
+!	EQ 45MG BASE		N203469	002	Dec 14, 2012	Sep CTEC
AB +!	EQ 45MG BASE		N203469	002	Dec 14, 2012	Jul CFTG
PONATINIB HYDROCHLORIDE						
@ APOTEX	EQ 15MG BASE		A215893	001	Jul 14, 2023	Sep DISC
AB @	EQ 15MG BASE		A215893	001	Jul 14, 2023	Jul NFTG
AB EQ 45MG BASE			A215893	002	Jul 14, 2023	Sep DISC
AB EQ 45MG BASE			A215893	002	Jul 14, 2023	Jul NFTG

POSACONAZOLE

SOLUTION; INTRAVENOUS

POSACONAZOLE

>A>	AP	EUGIA PHARMA	300MG/16.7ML (18MG/ML)	A214842	001	Dec 26, 2023	Dec NEWA
>A>	AP	FRESENIUS KABI USA	300MG/16.7ML (18MG/ML)	A209983	001	Dec 26, 2023	Dec NEWA
>A>	AP	GLAND PHARMA LTD	300MG/16.7ML (18MG/ML)	A217553	001	Dec 26, 2023	Dec NEWA
>A>	AP	MYLAN LABS LTD	300MG/16.7ML (18MG/ML)	A211500	001	Dec 26, 2023	Dec NEWA

TABLET, DELAYED RELEASE; ORAL

POSACONAZOLE

@	ACTAVIS LABS FL INC	100MG	A207355	001	Nov 30, 2022	May DISC
AB	I 3 PHARMS	100MG	A216488	001	Aug 28, 2023	Aug NEWA
AB	WELDING	100MG	A216326	001	Jun 20, 2023	Jun NEWA
AB	WESTMINSTER PHARMS	100MG	A216326	001	Jun 20, 2023	Jul CAHN

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

AP	EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Feb CMFD
----	--------------	---------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

@	CHARTWELL MOLECULAR	8MEQ	A204210	001	Mar 28, 2016	Jul CAHN
@		10MEQ	A204210	002	Mar 28, 2016	Jul CAHN

FOR SOLUTION; ORAL

POKONZA

+	PHARMA RES SOFTWARE	10MEQ	N208019	002	Aug 25, 2023	Sep NEWA
---	---------------------	-------	---------	-----	--------------	----------

AA	GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jul CMFD
AA	NOVITIUM PHARMA	20MEQ	A212816	001	Jul 12, 2023	Jun NEWA
AA	+ PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Sep CHRS
AA	+!	40MEQ	N208019	003	Aug 25, 2023	Sep NEWA

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP	NEXUS PHARMS	2MEQ/ML	A217704	001	Aug 14, 2023	Aug NEWA
----	--------------	---------	---------	-----	--------------	----------

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA	ANDA REPOSITORY	20MEQ/15ML	A214892	001	Dec 30, 2022	Sep CAHN
AA		40MEQ/15ML	A214892	002	Dec 30, 2022	Sep CAHN
AA	BELCHER	20MEQ/15ML	A216156	001	Mar 07, 2023	Feb NEWA
AA		40MEQ/15ML	A216156	002	Mar 07, 2023	Feb NEWA
	@ STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022	May DISC

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

@	CHARTWELL RX	20MEQ	A210098	001	Apr 26, 2019	Oct CAHN
>A>	AB2	RISING	A217412	001	Dec 19, 2023	Dec NEWA
>A>	AB2		A217412	002	Dec 19, 2023	Dec NEWA
AB1	RUBICON	10MEQ	A216321	001	Jun 16, 2023	Jun NEWA
AB1		15MEQ	A216321	002	Jun 16, 2023	Jun NEWA
AB1		20MEQ	A216321	003	Jun 16, 2023	Jun NEWA
AB3	TWI PHARMS	10MEQ	A209688	001	Jan 12, 2018	Apr CAHN
AB3	!	20MEQ	A209688	002	Jan 12, 2018	Apr CAHN
AB3	! VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Feb CHRS

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS

POTASSIUM PHOSPHATES

AP	AM REGENT	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	A216274	001	Oct 02, 2023	Sep NFTG
AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	A216274	002	Oct 02, 2023	Sep NFTG
AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	A216274	003	Oct 02, 2023	Sep NFTG
AP	AMNEAL	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	A216344	001	Oct 10, 2023	Sep NEWA
AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	A216344	002	Oct 10, 2023	Sep NEWA
AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	A216344	003	Oct 10, 2023	Sep NEWA
AP	+! FRESENIUS KABI USA	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	N212832	001	Nov 26, 2019	Sep CFTG
AP	+	3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	N212832	002	Nov 26, 2019	Sep CFTG

SOLUTION; INTRAVENOUS
POTASSIUM PHOSPHATES

AP +! 11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML) N 212832 003 Nov 26, 2019 Sep CFTG

PRASUGREL HYDROCHLORIDE

TABLET; ORAL
PRASUGREL

AB	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Mar CTEC
AB	@ LUPIN LTD	EQ 10MG BASE	A205913	002	Jun 19, 2018	Mar CTEC
	@	EQ 5MG BASE	A205930	001	Jan 09, 2023	Feb DISC
		EQ 10MG BASE	A205930	002	Jan 09, 2023	Feb DISC
		PRASUGREL HYDROCHLORIDE				
AB	UNICHEM	EQ 5MG BASE	A213315	001	Aug 28, 2023	Aug NEWA
AB		EQ 10MG BASE	A213315	002	Aug 28, 2023	Aug NEWA

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVASTATIN SODIUM

AB	CHARTWELL RX	10MG	A077917	001	Jan 08, 2008	May CAHN
AB		20MG	A077917	002	Jan 08, 2008	May CAHN
AB		40MG	A077917	003	Jan 08, 2008	May CAHN
AB		80MG	A077917	004	Jan 08, 2008	May CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HYDROCHLORIDE

AB	ALEMBIC	EQ 1MG BASE	A217268	001	Mar 06, 2023	Feb NEWA
AB		EQ 2MG BASE	A217268	002	Mar 06, 2023	Feb NEWA
AB		EQ 5MG BASE	A217268	003	Mar 06, 2023	Feb NEWA
AB	AUROBINDO PHARMA LTD	EQ 1MG BASE	A213052	001	Mar 31, 2023	Mar NEWA
AB		EQ 2MG BASE	A213052	002	Mar 31, 2023	Mar NEWA
AB		EQ 5MG BASE	A213052	003	Mar 31, 2023	Mar NEWA
>A> AB	LANNETT CO INC	EQ 1MG BASE	A214083	001	Jan 03, 2024	Dec NEWA
>A> AB		EQ 2MG BASE	A214083	002	Jan 03, 2024	Dec NEWA
>A> AB		EQ 5MG BASE	A214083	003	Jan 03, 2024	Dec NEWA

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA	! CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun CHRS
AA	PHARM ASSOC	15MG/5ML	A040571	001	Aug 25, 2005	Sep CMFD
	@ PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Sep CAHN
	@ XTTRIUM LABS INC	15MG/5ML	A040313	001	Sep 10, 2003	Jul DISC
AA		15MG/5ML	A040313	001	Sep 10, 2003	Jan CAHN

TABLET; ORAL
PREDNISOLONE

AB	AUROBINDO PHARMA LTD	5MG	A215673	001	Mar 17, 2023	Mar NEWA
BX	CHARTWELL MOLECULAR	5MG	A080531	002		May CMFD
AB	+! WATSON LABS	5MG	A080354	001		Mar CTEC

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED

	@ HARROW EYE	0.125%	N 017468	001		Oct CAHN
	OMNIPRED					
AB	+! SANDOZ	1%	N 017469	001		Sep CAHN
	PRED FORTE					
AB	+! ABBVIE	1%	N 017011	001		Jan CAHN
	PRED MILD					
	+! ABBVIE	0.12%	N 017100	001		Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	EDENBRIDGE PHARMS	EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan NEWA
AA	! MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jan CTEC
AA	! PHARM ASSOC	EQ 15MG BASE/5ML	A076913	001	Apr 25, 2005	Jul CHRS
	@ PHARMOBEDIENT CNSLTG	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Sep CAHN
	@ XTTRIUM LABS INC	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jul DISC
AA		EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jan CAHN

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA ! EQ 15MG BASE/5ML A 076895 001 Oct 04, 2004 Jul DISC
AA ! EQ 15MG BASE/5ML A 076895 001 Oct 04, 2004 Jan CAHN

PREDNISONE

SOLUTION; ORAL

PREDNISONE

@ XTTRIUM LABS INC 5MG/5ML A089726 001 Aug 02, 1988 Jan CAHN

TABLET; ORAL

PREDNISONE

AB	GENEYORK PHARMS	2.5MG	A210525	004	Dec 07, 2018	Sep CMS1
AB		5MG	A210525	005	Dec 07, 2018	Sep CMS1
AB	GRANULATION TECH	5MG	A212629	001	Dec 05, 2023	Nov NEWA
AB		10MG	A212629	002	Dec 05, 2023	Nov NEWA
AB		20MG	A212629	003	Dec 05, 2023	Nov NEWA
AB +!	HIKMA	2.5MG	A087801	001	Apr 22, 1982	Jan CRLD
AB +!		5MG	A080352	001		Jan CRLD
AB +!		50MG	A084283	001		Jan CRLD
AB	JUBILANT CADISTA	2.5MG	A040362	004	Apr 17, 2023	Apr NEWA
AB		50MG	A040362	005	Apr 17, 2023	Apr NEWA

PREGABALIN

CAPSULE; ORAL

PREGABALIN

AB	@ ACI	25MG	A215755	001	Apr 26, 2023	Oct DISC
	@	25MG	A215755	001	Apr 26, 2023	Apr NEWA
AB	@	50MG	A215755	002	Apr 26, 2023	Oct DISC
	@	50MG	A215755	002	Apr 26, 2023	Apr NEWA
AB	@	75MG	A215755	003	Apr 26, 2023	Oct DISC
	@	75MG	A215755	003	Apr 26, 2023	Apr NEWA
AB	@	100MG	A215755	004	Apr 26, 2023	Oct DISC
	@	100MG	A215755	004	Apr 26, 2023	Apr NEWA
AB	@	150MG	A215755	005	Apr 26, 2023	Oct DISC
	@	150MG	A215755	005	Apr 26, 2023	Apr NEWA
AB	@	200MG	A215755	006	Apr 26, 2023	Oct DISC
	@	200MG	A215755	006	Apr 26, 2023	Apr NEWA
AB	@	225MG	A215755	007	Apr 26, 2023	Oct DISC
	@	225MG	A215755	007	Apr 26, 2023	Apr NEWA
AB	@	300MG	A215755	008	Apr 26, 2023	Oct DISC
	@	300MG	A215755	008	Apr 26, 2023	Apr NEWA
AB	ADAPTIS	25MG	A216197	001	Jul 18, 2022	Sep CAHN
		50MG	A216197	002	Jul 18, 2022	Sep CAHN
AB		75MG	A216197	003	Jul 18, 2022	Sep CAHN
AB		100MG	A216197	004	Jul 18, 2022	Sep CAHN
AB		150MG	A216197	005	Jul 18, 2022	Sep CAHN
AB		200MG	A216197	006	Jul 18, 2022	Sep CAHN
AB		225MG	A216197	007	Jul 18, 2022	Sep CAHN
AB		300MG	A216197	008	Jul 18, 2022	Sep CAHN
AB	AUROBINDO PHARMA	25MG	A205321	001	Mar 29, 2023	Mar NEWA
		50MG	A205321	002	Mar 29, 2023	Mar NEWA
AB		75MG	A205321	003	Mar 29, 2023	Mar NEWA
AB		100MG	A205321	004	Mar 29, 2023	Mar NEWA
AB		150MG	A205321	005	Mar 29, 2023	Mar NEWA
AB		200MG	A205321	006	Mar 29, 2023	Mar NEWA
AB		225MG	A205321	007	Mar 29, 2023	Mar NEWA
AB		300MG	A205321	008	Mar 29, 2023	Mar NEWA
AB	CHARTWELL RX	50MG	A212865	001	Mar 20, 2020	Mar CAHN
		75MG	A212865	002	Mar 20, 2020	Mar CAHN
AB		100MG	A212865	003	Mar 20, 2020	Mar CAHN
AB		150MG	A212865	004	Mar 20, 2020	Mar CAHN
AB	CREEKWOOD PHARMS	25MG	A213423	001	Mar 23, 2020	Aug CAHN
		50MG	A213423	002	Mar 23, 2020	Aug CAHN
AB		75MG	A213423	003	Mar 23, 2020	Aug CAHN
AB		100MG	A213423	004	Mar 23, 2020	Aug CAHN
AB		150MG	A213423	005	Mar 23, 2020	Aug CAHN
AB		200MG	A213423	006	Mar 23, 2020	Aug CAHN
AB		225MG	A213423	007	Mar 23, 2020	Aug CAHN
AB		300MG	A213423	008	Mar 23, 2020	Aug CAHN
AB	YILING	75MG	A210891	001	Sep 30, 2019	Mar CAHN
		300MG	A210891	002	Sep 30, 2019	Mar CAHN
AB	ZYDUS PHARMS	25MG	A206752	001	Dec 09, 2022	May DISC
		50MG	A206752	002	Dec 09, 2022	May DISC

CAPSULE;ORAL
PREGABALIN

@		75MG	A206752	003	Dec 09, 2022	May DISC
@		100MG	A206752	004	Dec 09, 2022	May DISC
@		150MG	A206752	005	Dec 09, 2022	May DISC
@		200MG	A206752	006	Dec 09, 2022	May DISC
@		225MG	A206752	007	Dec 09, 2022	May DISC
@		300MG	A206752	008	Dec 09, 2022	May DISC

SOLUTION;ORAL
PREGABALIN

AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Jan CAHN
	TABLET, EXTENDED RELEASE;ORAL PREGABALIN					

AB	EPIC PHARMA LLC	82.5MG	A214496	001	Jun 01, 2023	Aug CAHN
AB		165MG	A214496	002	Jun 01, 2023	Aug CAHN
AB		330MG	A214496	003	Jun 01, 2023	Aug CAHN
	SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022	May DISC
	@	165MG	A215675	002	Sep 14, 2022	May DISC
	@	330MG	A215675	003	Sep 14, 2022	May DISC
AB	SINOATHERAPEUTICS INC	82.5MG	A214496	001	Jun 01, 2023	May NEWA
AB		165MG	A214496	002	Jun 01, 2023	May NEWA
AB		330MG	A214496	003	Jun 01, 2023	May NEWA
	ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022	Jan DISC
	@	165MG	A215577	002	Aug 26, 2022	Jan DISC
	@	330MG	A215577	003	Aug 26, 2022	Jan DISC

PRIMIDONE

	TABLET;ORAL PRIMIDONE RUBICON	125MG	A214896	003	Dec 28, 2022	May CTEC
--	-------------------------------------	-------	---------	-----	--------------	----------

PROBENECID

	TABLET;ORAL PROBENECID RISING	500MG	A217020	001	Nov 20, 2023	Nov NEWA
--	-------------------------------------	-------	---------	-----	--------------	----------

PROCAINAMIDE HYDROCHLORIDE

	INJECTABLE;INJECTION PROCAINAMIDE HYDROCHLORIDE HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986	Feb CTEC
--	---	----------	---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATE

	INJECTABLE;INJECTION PROCHLORPERAZINE EDISYLATE HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Sep CAHN
	SAGENT	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jul CAHN

PROCHLORPERAZINE MALEATE

	TABLET;ORAL PROCHLORPERAZINE MALEATE AMNEAL	EQ 5MG BASE	A216598	001	Apr 17, 2023	Apr NEWA
		EQ 10MG BASE	A216598	002	Apr 17, 2023	Apr NEWA
	BIONPHARMA	EQ 5MG BASE	A217478	001	Apr 04, 2023	Mar NEWA
		EQ 10MG BASE	A217478	002	Apr 04, 2023	Mar NEWA
	GLENMARK PHARMS LTD	EQ 5MG BASE	A216595	001	Mar 17, 2023	Mar NEWA
		EQ 10MG BASE	A216595	002	Mar 17, 2023	Mar NEWA

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

>D> BX	SOFGEN PHARMS	100MG	A200456	001	Sep 28, 2012	Dec CTEC
>A> AB		100MG	A200456	001	Sep 28, 2012	Dec CTEC
>D> BX		200MG	A200456	002	Sep 28, 2012	Dec CTEC
>A> AB		200MG	A200456	002	Sep 28, 2012	Dec CTEC

INJECTABLE;INJECTION
PROGESTERONE

AO	ACCORD HLTHCARE	50MG/ML	A217707	001	Nov 21, 2023	Nov NEWA
----	-----------------	---------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA	@ AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Jun DISC
	CHARTWELL RX	6.25MG/5ML	A040026	001	Sep 25, 1998	Sep CAHN
	@ PHARM ASSOC	6.25MG/5ML	A040643	001	Apr 26, 2006	Sep DISC
	TABLET; ORAL					
	PROMETHAZINE HYDROCHLORIDE					
>D> AB	@ AUROBINDO PHARMA USA	12.5MG	A091054	001	Aug 30, 2011	Apr CAHN
>A>	@	25MG	A091054	002	Aug 30, 2011	Apr CAHN
>D> AB		50MG	A091054	003	Aug 30, 2011	Apr CAHN
>A>	SUN PHARM INDNS INC	12.5MG	A040863	001	Dec 30, 2008	Dec DISC
>A>	@	25MG	A040863	001	Dec 30, 2008	Dec DISC
>D> AB		50MG	A040863	002	Dec 30, 2008	Dec DISC
>A>	@	50MG	A040863	002	Dec 30, 2008	Dec DISC
>D> AB		50MG	A040863	003	Dec 30, 2008	Dec DISC
>A>	@	50MG	A040863	003	Dec 30, 2008	Dec DISC

PROPAFENONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
PROPAFENONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	225MG	A213096	001	Feb 21, 2023	Feb NEWA
AB		325MG	A213096	002	Feb 21, 2023	Feb NEWA
AB		425MG	A213096	003	Feb 21, 2023	Feb NEWA
AB	SCIINOPHARM TAIWAN	225MG	A212928	001	Jun 18, 2020	Sep CAHN
AB		325MG	A212928	002	Jun 18, 2020	Sep CAHN
AB		425MG	A212928	003	Jun 18, 2020	Sep CAHN
AB	! STRIDES PHARMA RYTHMOL SR	425MG	A078540	003	Oct 18, 2010	Nov CHRS
	+ @ GLAXOSMITHKLINE LLC	225MG	N021416	001	Sep 04, 2003	Nov DISC
	+ @	325MG	N021416	002	Sep 04, 2003	Nov DISC
	+ @	425MG	N021416	003	Sep 04, 2003	Nov DISC

PROPARACAINe HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PROPARACAINe HYDROCHLORIDE

AT	! BAUSCH AND LOMB	0.5%	A040074	001	Sep 29, 1995	Jul CHRS
----	-------------------	------	---------	-----	--------------	----------

PROPOFOLINJECTABLE; INJECTION
PROPOFOL

AB	AVET LIFESCIENCES	10MG/ML	A206408	001	Oct 12, 2021	Jan CAHN
	@ WATSON LABS INC	10MG/ML	A205307	001	Dec 22, 2015	Oct DISC

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

>D> AB	AMICI	10MG	A070322	002	Oct 22, 1985	Dec CAHN
AB		10MG	A070322	002	Oct 22, 1985	Sep CAHN
>D> AB		20MG	A070322	003	Oct 22, 1985	Dec CAHN
AB		20MG	A070322	003	Oct 22, 1985	Sep CAHN
>D> AB		40MG	A070322	004	Oct 22, 1985	Dec CAHN
AB		40MG	A070322	004	Oct 22, 1985	Sep CAHN
>D> AB		60MG	A070322	005	Sep 24, 1986	Dec CAHN
AB		60MG	A070322	005	Sep 24, 1986	Sep CAHN
>D> AB		80MG	A070322	001	Aug 04, 1986	Dec CAHN
AB		80MG	A070322	001	Aug 04, 1986	Sep CAHN
AB	! IMPAX LABS INC	80MG	A071976	001	Apr 06, 1988	Jun CHRS
>A> AB	INNOGENIX	10MG	A070322	002	Oct 22, 1985	Dec CAHN
>A> AB		20MG	A070322	003	Oct 22, 1985	Dec CAHN
>A> AB		40MG	A070322	004	Oct 22, 1985	Dec CAHN
>A> AB		60MG	A070322	005	Sep 24, 1986	Dec CAHN
>A> AB		80MG	A070322	001	Aug 04, 1986	Dec CAHN
AB	WATSON LABS	80MG	A070178	001	May 13, 1986	Jun CHRS

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

AB	+! DAVA PHARMS INC	50MG	N006188	001		Apr CTEC
AB	MACLEODS PHARMS LTD	50MG	A208867	001	May 10, 2023	Apr NEWA

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

PYRIDOSTIGMINE BROMIDE

AA	MSN	60MG/5ML	A216512	001	Sep 21, 2023	Sep NEWA
AA	RISING	60MG/5ML	A208797	001	Jan 09, 2020	Sep CAHN

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

AB	+! TILDE SCIENCES	25MG	N008578	001	Oct	CAHN
----	-------------------	------	---------	-----	-----	------

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

@ AUROBINDO PHARMA USA 324MG

A202581 001 Dec 14, 2012 May CAHN

QUIZARTINIB DIHYDROCHLORIDE

TABLET;ORAL

VANFLYTA

+ DAIICHI SANKYO INC

EQ 17.7MG BASE

N216993 001 Jul 20, 2023 Jul NEWA

+!

EQ 26.5MG BASE

N216993 002 Jul 20, 2023 Jul NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

AB	AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Jun NEWA
AB	INNOGENIX	8MG	A215435	001	Aug 24, 2022	May CMFD
	@	8MG	A215435	001	Aug 24, 2022	Mar DISC
AB		8MG	A215435	001	Aug 24, 2022	Jan CAHN
AB	MICRO LABS	8MG	A215243	001	Feb 09, 2023	Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB	COREPHARMA	1.25MG	A079116	001	Jun 20, 2008	Feb CAHN
AB		2.5MG	A079116	002	Jun 20, 2008	Feb CAHN
AB		5MG	A079116	003	Jun 20, 2008	Feb CAHN
AB		10MG	A079116	004	Jun 20, 2008	Feb CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

@ HIKMA	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	May DISC
@	EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	May DISC
@ ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May DISC
ZANTAC					
+ @ PAI HOLDINGS PHARM	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	May DISC
SYRUP;ORAL					
RANITIDINE HYDROCHLORIDE					
@ EPIC PHARMA LLC	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	Oct CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

>D>	+ @ GILEAD	500MG	N021526	002	Jan 27, 2006	Dec CAHN
	+ @	500MG	N021526	002	Jan 27, 2006	Jan DISC
>D>	+ @	1GM	N021526	001	Feb 12, 2007	Dec CAHN
	+ @	1GM	N021526	001	Feb 12, 2007	Jan DISC
>A>	+ @ MENARINI INTL	500MG	N021526	002	Jan 27, 2006	Dec CAHN
>A>	+ @	1GM	N021526	001	Feb 12, 2007	Dec CAHN
	RANOLAZINE					
AB	NOVAST LABS	500MG	A210668	001	Sep 27, 2023	Sep NEWA
AB		1GM	A210668	002	Sep 27, 2023	Sep NEWA
AB	PIRAMAL HLTHCARE UK	500MG	A213085	001	Jul 25, 2023	Jul NEWA
AB		1GM	A213085	002	Jul 25, 2023	Jul NEWA
AB	RISING	500MG	A212889	001	Jan 28, 2021	Aug CAHN
AB		1GM	A212889	002	Jan 28, 2021	Aug CAHN
AB	! SUN PHARM	1GM	A211707	002	May 28, 2019	Jan CHRS
>D>	@ UNICHEM	500MG	A213083	001	Mar 16, 2023	Dec CMFD
>A> AB		500MG	A213083	001	Mar 16, 2023	Dec CMFD
	@	500MG	A213083	001	Mar 16, 2023	Sep DISC

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AB		500MG	A213083	001	Mar 16, 2023	Mar NEWA
>D>	@	1GM	A213083	002	Mar 16, 2023	Dec CMFD
>A> AB		1GM	A213083	002	Mar 16, 2023	Dec CMFD
	@	1GM	A213083	002	Mar 16, 2023	Sep DISC
AB		1GM	A213083	002	Mar 16, 2023	Mar NEWA

RASAGILINE MESYLATE

	TABLET;ORAL					
	RASAGILINE MESYLATE					
>A>	@ CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Dec CAHN
>A>	@	EQ 1MG BASE	A201942	002	Nov 18, 2021	Dec CAHN
>D>	@ DR REDDYS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Dec CAHN
>D>	@	EQ 1MG BASE	A201942	002	Nov 18, 2021	Dec CAHN

REGADENOSON

	SOLUTION;INTRAVENOUS					
	REGADENOSON					
AP	BAXTER HLTHCARE CORP	0.4MG/5ML (0.08MG/ML)	A217455	001	May 23, 2023	May NEWA
AP	HIKMA	0.4MG/5ML (0.08MG/ML)	A215827	001	Feb 02, 2023	Jan NEWA
AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Apr CMFD

RELUGOLIX

	TABLET;ORAL					
	ORGOVYX					
+!	SUMITOMO PHARMA	120MG	N214621	001	Dec 18, 2020	Nov CAHN

REPAGLINIDE

	TABLET;ORAL					
	REPAGLINIDE					
	@ KENTON	0.5MG	A091517	001	Apr 24, 2015	Oct CAHN
	@	1MG	A091517	002	Apr 24, 2015	Oct CAHN
	@	2MG	A091517	003	Apr 24, 2015	Oct CAHN
AB	MACLEODS PHARMS LTD	0.5MG	A207209	001	Mar 22, 2023	Mar NEWA
AB		1MG	A207209	002	Mar 22, 2023	Mar NEWA
AB		2MG	A207209	003	Mar 22, 2023	Mar NEWA

REPOTRECTINIB

	CAPSULE;ORAL					
	AUGTYRO					
+!	BRISTOL	40MG	N218213	001	Nov 15, 2023	Nov NEWA

REZAFUNGIN ACETATE

	POWDER;INTRAVENOUS					
	REZZAYO					
+!	CIDARA THERAPS	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Mar NEWA

RIBOFLAVIN 5'-PHOSPHATE

	SOLUTION/DROPS;OPHTHALMIC					
	PHOTREXA					
+!	GLAUKOS	0.146%	N203324	001	Apr 15, 2016	Jun CAIN
	PHOTREXA VISCOSUS IN DEXTRAN 20%					
+!	GLAUKOS	0.146%	N203324	002	Apr 15, 2016	Jun CAIN

RIFAMPIN

	CAPSULE;ORAL					
	RIFAMPIN					
AB	HIKMA	150MG	A065028	001	Mar 14, 2001	Sep CAHN
AB		300MG	A065028	002	Mar 14, 2001	Sep CAHN
	INJECTABLE;INJECTION					
	RIFAMPIN					
AP	EPIC PHARMA LLC	600MG/VIAL	A065502	001	Sep 21, 2010	Sep CAHN

RIMANTADINE HYDROCHLORIDE

	TABLET;ORAL					
	FLUMADINE					
+ @	SUN PHARM INDs INC	100MG	N019649	001	Sep 17, 1993	Nov DISC
	RIMANTADINE HYDROCHLORIDE					
! !	IMPAK LABS	100MG	A076132	001	Aug 30, 2002	Nov CTEC
AB	!	100MG	A076132	001	Aug 30, 2002	Nov CHRS

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+! PFIZER

EQ 75MG BASE

N212728 001 Feb 27, 2020 Feb CAHN

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

@ HARROW EYE

1%

N020474 001 Dec 30, 1994 Oct CAHN

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

+! SHANDONG LUYE 12.5MG
+! 25MG
+! 37.5MG
+! 50MGN212849 001 Jan 13, 2023 Jan NEWA
N212849 002 Jan 13, 2023 Jan NEWA
N212849 003 Jan 13, 2023 Jan NEWA
N212849 004 Jan 13, 2023 Jan NEWAINJECTABLE;INTRAMUSCULAR
RISPERDAL CONSTA>D> + JANSSEN PHARMS 12.5MG/VIAL
>A> AP + 12.5MG/VIAL
>D> +! 25MG/VIAL
>A> AP +! 25MG/VIAL
>D> + 37.5MG/VIAL
>A> AP + 37.5MG/VIAL
>D> + 50MG/VIAL
>A> AP + 50MG/VIALN021346 004 Apr 12, 2007 Dec CFTG
N021346 004 Apr 12, 2007 Dec CFTG
N021346 001 Oct 29, 2003 Dec CFTG
N021346 001 Oct 29, 2003 Dec CFTG
N021346 002 Oct 29, 2003 Dec CFTG
N021346 002 Oct 29, 2003 Dec CFTG
N021346 003 Oct 29, 2003 Dec CFTG
N021346 003 Oct 29, 2003 Dec CFTG

>A> RISPERIDONE

>A> AP TEVA PHARMS USA INC 12.5MG/VIAL
>A> AP 25MG/VIAL
>A> AP 37.5MG/VIAL
>A> AP 50MG/VIALA214068 001 Dec 05, 2023 Dec NFTG
A214068 002 Dec 05, 2023 Dec NFTG
A214068 003 Dec 05, 2023 Dec NFTG
A214068 004 Dec 05, 2023 Dec NFTGSUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
UZEDY+ TEVA 50MG/0.14ML (50MG/0.14ML)
+ 75MG/0.21ML (75MG/0.21ML)
+ 100MG/0.28ML (100MG/0.28ML)
+ 125MG/0.35ML (125MG/0.35ML)
+ 150MG/0.42ML (150MG/0.42ML)
+ 200MG/0.56ML (200MG/0.56ML)
+! 250MG/0.7ML (250MG/0.7ML)N213586 001 Apr 28, 2023 Apr NEWA
N213586 002 Apr 28, 2023 Apr NEWA
N213586 003 Apr 28, 2023 Apr NEWA
N213586 004 Apr 28, 2023 Apr NEWA
N213586 005 Apr 28, 2023 Apr NEWA
N213586 006 Apr 28, 2023 Apr NEWA
N213586 007 Apr 28, 2023 Apr NEWA

TABLET;ORAL

RISPERIDONE

@ DASH PHARMS 0.25MG
@ 0.5MG
@ 1MG
@ 2MG
@ 3MG
@ 4MGA076288 001 Sep 15, 2008 Feb CAHN
A076288 002 Sep 15, 2008 Feb CAHN
A076288 003 Sep 15, 2008 Feb CAHN
A076288 004 Sep 15, 2008 Feb CAHN
A076288 005 Sep 15, 2008 Feb CAHN
A076288 006 Sep 15, 2008 Feb CAHNAB WESTMINSTER PHARMS 0.25MG
AB 0.5MG
AB 1MG
AB 2MG
AB 3MG
AB 4MGA078707 001 Dec 29, 2008 Aug CAHN
A078707 002 Dec 29, 2008 Aug CAHN
A078707 003 Dec 29, 2008 Aug CAHN
A078707 004 Dec 29, 2008 Aug CAHN
A078707 005 Dec 29, 2008 Aug CAHN
A078707 006 Dec 29, 2008 Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@ DASH PHARMS 0.25MG
@ 0.5MG
@ 1MG
@ 2MG
@ 3MG
@ 4MGA091537 006 Feb 12, 2013 Feb CAHN
A091537 001 Mar 30, 2011 Feb CAHN
A091537 002 Mar 30, 2011 Feb CAHN
A091537 003 Mar 30, 2011 Feb CAHN
A091537 004 Mar 30, 2011 Feb CAHN
A091537 005 Mar 30, 2011 Feb CAHNRITLEGITINIB TOSYLATE

CAPSULE;ORAL

LITFULO

+! PFIZER

EQ 50MG BASE

N215830 001 Jun 23, 2023 Jun NEWA

RITONAVIR

SOLUTION;ORAL

NORVIR

+ @ ABBVIE

80MG/ML

N020659 001 Mar 01, 1996 Feb DISC

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
EXELONAB + SANDOZ 4.6MG/24HR
AB +! 9.5MG/24HR
AB + 13.3MG/24HRN022083 001 Jul 06, 2007 Sep CAHN
N022083 002 Jul 06, 2007 Sep CAHN
N022083 005 Aug 31, 2012 Sep CAHNRIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

+! GENSCO EQ 10MG BASE
+! INTELGENX CORP EQ 10MG BASEN205394 001 Apr 14, 2023 Sep CAHN
N205394 001 Apr 14, 2023 Apr NEWA

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB CHARTWELL RX EQ 5MG BASE
AB EQ 10MG BASE
AB CREEKWOOD PHARMS EQ 5MG BASE
AB EQ 10MG BASEA077526 001 Mar 26, 2013 May CAHN
A077526 002 Mar 26, 2013 May CAHN
A202047 001 Dec 31, 2012 Aug CAHN
A202047 002 Dec 31, 2012 Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

@ UNICHEM EQ 5MG BASE
@ EQ 10MG BASEA207835 001 Mar 07, 2017 Oct DISC
A207835 002 Mar 07, 2017 Oct DISCROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP CAPLIN 50MG/5ML (10MG/ML)
AP 100MG/10ML (10MG/ML)
AP HIKMA 50MG/5ML (10MG/ML)
AP HONG KONG 50MG/5ML (10MG/ML)
AP 100MG/10ML (10MG/ML)
AP MEITHEAL 50MG/5ML (10MG/ML)
AP 100MG/10ML (10MG/ML)A216234 001 Mar 02, 2023 Feb NEWA
A216234 002 Mar 02, 2023 Feb NEWA
A217034 001 May 24, 2023 May NEWA
A213453 001 May 08, 2023 Apr NEWA
A213453 002 May 08, 2023 Apr NEWA
A213453 001 May 08, 2023 Aug CAHN
A213453 002 May 08, 2023 Aug CAHNROFLUMILAST

FOAM;TOPICAL

>A> ZORYVE

>A> +! ARCUTIS 0.3%

N217242 001 Dec 15, 2023 Dec NEWA

TABLET;ORAL

ROFLUMILAST

AB ALKEM LABS LTD 250MCG
AB 500MCG
AB AUROBINDO PHARMA LTD 500MCG
AB BRECKENRIDGE 250MCG
AB HETERO LABS LTD III 250MCG
AB MICRO LABS 250MCG
AB STRIDES PHARMA 250MCG
@ TORRENT 500MCG
AB ZYDUS PHARMS 250MCGA212490 001 Apr 18, 2023 Apr NEWA
A212490 002 Apr 18, 2023 Apr NEWA
A213298 001 Apr 17, 2023 Apr NEWA
A208236 002 Oct 19, 2023 Oct NEWA
A208213 002 Apr 18, 2023 Apr NEWA
A208180 002 Apr 18, 2023 Apr NEWA
A208247 002 Jun 20, 2023 Jun NEWA
A208272 001 Aug 06, 2018 Oct DISC
A208303 002 Apr 18, 2023 Apr NEWAROMIDEPSTIN

POWDER;INTRAVENOUS

ISTODAX

AP +! BRISTOL-MYERS 10MG/VIAL

N022393 001 Nov 05, 2009 Jul CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB CHARTWELL RX EQ 0.25MG BASE
AB EQ 0.5MG BASE
AB EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 3MG BASE
AB EQ 4MG BASE
AB EQ 5MG BASE
@ MYLAN EQ 0.25MG BASEA079050 001 May 29, 2008 Jun CAHN
A079050 002 May 29, 2008 Jun CAHN
A079050 003 May 29, 2008 Jun CAHN
A079050 004 May 29, 2008 Jun CAHN
A079050 005 May 29, 2008 Jun CAHN
A079050 006 May 29, 2008 Jun CAHN
A079050 007 May 29, 2008 Jun CAHN
A078881 001 May 05, 2008 May DISC

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

EQ	0.5MG BASE	A078881	002	May 05, 2008	May DISC
EQ	1MG BASE	A078881	003	May 05, 2008	May DISC
EQ	2MG BASE	A078881	004	May 05, 2008	May DISC
EQ	3MG BASE	A078881	005	May 05, 2008	May DISC
EQ	4MG BASE	A078881	006	May 05, 2008	May DISC
EQ	5MG BASE	A078881	007	May 19, 2008	Mar DISC

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 2MG BASE	A 091395	001	Aug 27, 2012	Jun CAHN
AB		EQ 4MG BASE	A 091395	002	Aug 27, 2012	Jun CAHN
AB		EQ 6MG BASE	A 091395	003	Aug 27, 2012	Jun CAHN
AB		EQ 8MG BASE	A 091395	004	Aug 27, 2012	Jun CAHN
AB		EQ 12MG BASE	A 091395	005	Aug 27, 2012	Jun CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb NEWA
AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb NEWA
AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb NEWA
AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb NEWA
AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A206091	001	Oct 26, 2023	Oct NEWA
AP		400MG/200ML (2MG/ML)	A206091	002	Oct 26, 2023	Oct NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

+ @ WOODWARD EQ 2MG BASE N021071 002 May 25, 1999 Jun DISC
+ @ EQ 4MG BASE N021071 003 May 25, 1999 Jun DISC

ROUVASTATIN CALCIUM

CAPSULE; ORAL

EZATTOR

>D>	+	SUN PHARM	EQ 5MG BASE	N208647	001	Dec 18, 2018	Dec DISC
>A>	+	@	EQ 5MG BASE	N208647	001	Dec 18, 2018	Dec DISC
>D>	+		EQ 10MG BASE	N208647	002	Dec 18, 2018	Dec DISC
>A>	+	@	EQ 10MG BASE	N208647	002	Dec 18, 2018	Dec DISC
>D>	+		EQ 20MG BASE	N208647	003	Dec 18, 2018	Dec DISC
>A>	+	@	EQ 20MG BASE	N208647	003	Dec 18, 2018	Dec DISC
>D>	+	!	EQ 40MG BASE	N208647	004	Dec 18, 2018	Dec DISC
>A>	+	@	EQ 40MG BASE	N208647	004	Dec 18, 2018	Dec DISC

TABLET; ORAL

ROUVASTATIN CALCIUM

AB	UMEDICA	EQ 5MG BASE	A207626	001	Apr 09, 2019	Jul CMFD
AB		EQ 10MG BASE	A207626	002	Apr 09, 2019	Jul CMFD
AB		EQ 20MG BASE	A207626	003	Apr 09, 2019	Jul CMFD
AB		EQ 40MG BASE	A207626	004	Apr 09, 2019	Jul CMFD

RUCAPARIB CAMSYLATE

TABLET: ORAL

RUBRACA

+ ZR PHARMA EQ 200MG BASE N209115 001 Dec 19, 2016 May CAHN
+ EQ 250MG BASE N209115 003 May 01, 2017 May CAHN
+! EQ 300MG BASE N209115 002 Dec 19, 2016 May CAHN

RUFINAMIDE

SUSPENSION; ORAL

RUFINAMIDE

AB	CHARTWELL RX	40MG/ML	A214009	001	Nov 07, 2022	May CAHN
AB	HETERO LABS LTD III	40MG/ML	A216841	001	Dec 05, 2023	Nov NEWA
TABLET;ORAL						
RUFINAMIDE						
AB	AUROBINDO PHARMA	200MG	A217230	001	Jun 16, 2023	Jun NEWA
AB		400MG	A217230	002	Jun 16, 2023	Jun NEWA
AB	MICRO LABS	200MG	A216688	001	May 15, 2023	May NEWA
AB		400MG	A216688	002	May 15, 2023	May NEWA

SAFINAMIDE MESYLATE

	TABLET;ORAL						
	XADAGO						
AB	+ MDD US	EQ 50MG BASE		N207145	001	Mar 21, 2017	Jun CTEC
AB	+ !	EQ 50MG BASE		N207145	001	Mar 21, 2017	Jun CFTG
AB	+ !	EQ 100MG BASE		N207145	002	Mar 21, 2017	Jun CTEC
		EQ 100MG BASE		N207145	002	Mar 21, 2017	Jun CFTG

SAXAGLIPTIN HYDROCHLORIDE

	TABLET;ORAL						
	ONGLYZA						
AB	+ @ ASTRAZENECA AB	EQ 2.5MG BASE		N022350	001	Jul 31, 2009	Oct DISC
AB	+ !	EQ 2.5MG BASE		N022350	001	Jul 31, 2009	Jul CFTG
AB	+ @	EQ 5MG BASE		N022350	002	Jul 31, 2009	Oct DISC
AB	+ !	EQ 5MG BASE		N022350	002	Jul 31, 2009	Jul CFTG
	SAXAGLIPTIN						
AB	AMNEAL	EQ 2.5MG BASE		A205941	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE		A205941	002	Jul 31, 2023	Jul NFTG
AB	AUROBINDO PHARMA	EQ 2.5MG BASE		A205972	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE		A205972	002	Jul 31, 2023	Jul NFTG
AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE		A205994	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE		A205994	002	Jul 31, 2023	Jul NFTG
AB	MYLAN	EQ 2.5MG BASE		A205980	001	Jul 31, 2023	Jul NFTG
AB	!	EQ 5MG BASE		A205980	002	Jul 31, 2023	Oct CHRS
AB		EQ 5MG BASE		A205980	002	Jul 31, 2023	Jul NFTG
AB	SUN PHARM	EQ 2.5MG BASE		A206078	001	Jul 31, 2023	Jul NFTG
AB		EQ 5MG BASE		A206078	002	Jul 31, 2023	Jul NFTG

SELEGILINE HYDROCHLORIDE

	TABLET;ORAL						
	SELEGILINE HYDROCHLORIDE						
@	BAYSHORE PHARMS LLC	5MG		A074912	001	Apr 30, 1998	Sep CAHN
@	DASH PHARMS NATCO	5MG		A074866	001	Nov 26, 1997	Mar CAHN

SELENIUM SULFIDE

	LOTION/SHAMPOO;TOPICAL						
	SELENIUM SULFIDE						
@	PHARMOBEDIENT CNSLTG	2.5%		A088228	001	Sep 01, 1983	Sep CAHN
@	XTTRIUM LABS INC	2.5%		A088228	001	Sep 01, 1983	Mar CAHN

SELEXIPAG

	TABLET;ORAL						
	SELEXIPAG						
AB	ALEMBIC	0.2MG		A214414	001	Oct 11, 2023	Sep NEWA
AB		0.4MG		A214414	002	Oct 11, 2023	Sep NEWA
AB		0.6MG		A214414	003	Oct 11, 2023	Sep NEWA
AB		0.8MG		A214414	004	Oct 11, 2023	Sep NEWA
AB		1.4MG		A214414	005	Oct 11, 2023	Sep NEWA
AB		1.6MG		A214414	006	Oct 11, 2023	Sep NEWA
	ZYDUS	0.2MG		A214302	001	Dec 21, 2022	May DISC
		0.4MG		A214302	002	Dec 21, 2022	May DISC
		0.6MG		A214302	003	Dec 21, 2022	May DISC
		0.8MG		A214302	004	Dec 21, 2022	May DISC
		1MG		A214302	005	Dec 21, 2022	May DISC
		1.2MG		A214302	006	Dec 21, 2022	May DISC
		1.4MG		A214302	007	Dec 21, 2022	May DISC
		1.6MG		A214302	008	Dec 21, 2022	May DISC
	UPTRAVI						
AB	+ ACTELION	0.2MG		N207947	001	Dec 21, 2015	Sep CTEC
		0.2MG		N207947	001	Dec 21, 2015	May CTEC
AB	+ !	0.4MG		N207947	002	Dec 21, 2015	Sep CTEC
		0.4MG		N207947	002	Dec 21, 2015	May CTEC
AB	+ !	0.6MG		N207947	003	Dec 21, 2015	Sep CTEC
		0.6MG		N207947	003	Dec 21, 2015	May CTEC
AB	+ !	0.8MG		N207947	004	Dec 21, 2015	Sep CTEC
		0.8MG		N207947	004	Dec 21, 2015	May CTEC
		1MG		N207947	005	Dec 21, 2015	May CTEC
		1.2MG		N207947	006	Dec 21, 2015	May CTEC
AB	+ !	1.4MG		N207947	007	Dec 21, 2015	Sep CTEC
		1.4MG		N207947	007	Dec 21, 2015	May CTEC
AB	+ !	1.6MG		N207947	008	Dec 21, 2015	Sep CTEC
		1.6MG		N207947	008	Dec 21, 2015	May CTEC

SERTACONAZOLE NITRATE

CREAM;TOPICAL

ERTACZO

+! LACER PHARMA

2%

N021385 001 Dec 10, 2003 Aug CAHN

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL

SERTRALINE HYDROCHLORIDE

+! ALMATICA

EQ 150MG BASE

N215133 001 Oct 04, 2021 Nov CHRS

+

EQ 200MG BASE

N215133 002 Oct 04, 2021 Nov CHRS

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB HERITAGE PHARMA AVET EQ 25MG BASE

A076465 001 Aug 11, 2006 Mar CMFD

AB EQ 50MG BASE

A076465 002 Aug 11, 2006 Mar CMFD

AB EQ 100MG BASE

A076465 003 Aug 11, 2006 Mar CMFD

@ ZYDUS

EQ 25MG BASE

A077106 001 Feb 06, 2007 May CAHN

@

EQ 50MG BASE

A077106 002 Feb 06, 2007 May CAHN

@

EQ 100MG BASE

A077106 003 Feb 06, 2007 May CAHN

SETMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

IMCIVREE

+! RHYTHM

EQ 10MG BASE/ML (EQ 10MG BASE/ML)

N213793 001 Nov 25, 2020 Aug CPOT

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB CHARTWELL RX 800MG/PACKET

A217319 001 Mar 02, 2023 Aug CAHN

AB 2.4GM/PACKET

A217319 002 Mar 02, 2023 Aug CAHN

AB HANGZHOU ANPRIME 800MG/PACKET

A217319 001 Mar 02, 2023 Feb NEWA

AB 2.4GM/PACKET

A217319 002 Mar 02, 2023 Feb NEWA

AB STRIDES PHARMA 800MG/PACKET

A211917 001 Sep 08, 2023 Sep NEWA

AB 2.4GM/PACKET

A211917 002 Sep 08, 2023 Sep NEWA

TABLET;ORAL

SEVELAMER CARBONATE

AB MACLEODS PHARMS LTD 800MG

A206100 001 Apr 19, 2023 Apr NEWA

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

AB AUROBINDO PHARMA LTD 400MG

A212599 001 Jul 11, 2023 Jun NEWA

AB 800MG

A212599 002 Jul 11, 2023 Jun NEWA

AB MACLEODS PHARMS LTD 400MG

A206883 001 May 26, 2023 May NEWA

AB 800MG

A206883 002 May 26, 2023 May NEWA

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

AN SHANDONG 100%

A214382 001 Aug 18, 2023 Aug NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB GRANULES EQ 10MG BASE/ML

A214556 001 Dec 01, 2023 Nov NEWA

SUSPENSION;ORAL

LIQREV

+! CMP DEV LLC EQ 10MG BASE/ML

N214952 001 Apr 28, 2023 Apr NEWA

TABLET;ORAL

SILDENAFIL CITRATE

AB CADILA PHARMS LTD EQ 25MG BASE

A218045 001 Nov 28, 2023 Nov NEWA

AB EQ 50MG BASE

A218045 002 Nov 28, 2023 Nov NEWA

AB EQ 100MG BASE

A218045 003 Nov 28, 2023 Nov NEWA

AB MACLEODS PHARMS LTD EQ 25MG BASE

A202255 001 Apr 19, 2023 Apr NEWA

AB EQ 50MG BASE

A202255 002 Apr 19, 2023 Apr NEWA

AB EQ 100MG BASE

A202255 003 Apr 19, 2023 Apr NEWA

AB NOVITIUM PHARMA EQ 25MG BASE

A216383 001 Aug 29, 2023 Aug NEWA

AB EQ 50MG BASE

A216383 002 Aug 29, 2023 Aug NEWA

AB EQ 100MG BASE

A216383 003 Aug 29, 2023 Aug NEWA

SILODOSIN

	CAPSULE;ORAL SILODOSIN						
AB	CREEKWOOD PHARMS @	4MG 4MG	A213230	001	Jan 03, 2022	Nov CMFD	
AB		8MG	A213230	002	Jan 03, 2022	Sep CAHN	
	@	8MG	A213230	002	Jan 03, 2022	Nov CMFD	
	@ ZYDUS PHARMS	4MG	A204816	001	Dec 08, 2022	Sep CAHN	
	@	8MG	A204816	002	Dec 08, 2022	May DISC	

SIMVASTATIN

	TABLET;ORAL SIMVASTATIN						
AB	INVAGEN PHARMS	10MG	A206557	001	Nov 13, 2017	Nov CAHN	
AB		20MG	A206557	002	Nov 13, 2017	Sep CAHN	
AB		40MG	A206557	003	Nov 13, 2017	Nov CAHN	
AB		80MG	A206557	004	Nov 13, 2017	Nov CAHN	
	@ WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	Sep DISC	
	@	10MG	A076685	002	Dec 20, 2006	Sep DISC	
	@	20MG	A076685	003	Dec 20, 2006	Sep DISC	
	@	40MG	A076685	004	Dec 20, 2006	Sep DISC	
	@	80MG	A076685	005	Dec 20, 2006	Sep DISC	

SIPONIMOD

	TABLET;ORAL MAYZENT						
+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CAIN	
+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CAIN	
+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	May CAIN	

SIROLIMUS

	SOLUTION;ORAL SIROLIMUS						
AA	MSN	1MG/ML	A216728	001	Jan 19, 2023	Jan NEWA	
	TABLET;ORAL SIROLIMUS						
AB	ZYDUS PHARMS	1MG	A201676	001	Feb 15, 2023	Feb NEWA	
AB		2MG	A201676	002	Feb 15, 2023	Feb NEWA	

SITAGLIPTIN

	TABLET;ORAL ZITUPIO						
+	ZYDUS	25MG	N211566	001	Oct 18, 2023	Oct NEWA	
+		50MG	N211566	002	Oct 18, 2023	Oct NEWA	
+!		100MG	N211566	003	Oct 18, 2023	Oct NEWA	

SODIUM ACETATE

	INJECTABLE;INJECTION SODIUM ACETATE						
AP	FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017	Aug CTEC	
AP	MILLA PHARMS	4MEQ/ML	A214805	002	Aug 25, 2023	Aug NEWA	

SODIUM BENZOATE; SODIUM PHENYLACETATE

	SOLUTION;INTRAVENOUS SODIUM PHENYLACETATE AND SODIUM BENZOATE						
AP	+! MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021	Jul CFTG	
AP	NAVINTA LLC	10%;10% (2GM/20ML; 2GM/20ML)	A217526	001	Jul 14, 2023	Jul NFTG	

SODIUM BICARBONATE

	INJECTABLE;INJECTION SODIUM BICARBONATE						
AP	OMNIVIUM PHARMS	1MEQ/ML	A216364	001	Jun 15, 2023	Jun NEWA	
AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Jun NEWA	

SODIUM CHLORIDE

	INJECTABLE;INJECTION SODIUM CHLORIDE 0.9%						
+	B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Mar CPOT	
+	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	+ @ LIEBEL-FLARSHEIM	450MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Mar CPOT	
		1.125GM/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Mar CPOT	

INJECTABLE; INJECTION		SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC	OUTPUT USE	
+ @	ICU MEDICAL INC	9MG/ML	N 019217	001 Jul 13, 1984 Jun CTNA
		SODIUM CHLORIDE 23.4%		
AP	FRESENIUS KABI USA	234MG/ML	A 212248	001 Apr 28, 2021 Jun CTEC
AP		234MG/ML	A 217796	001 Jul 11, 2023 Jun NEWA
SOLUTION; INJECTION		BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
@	ABRAXIS PHARM	9MG/ML	A 088909	001 Feb 07, 1985 Jun CDFR
@		90MG/10ML (9MG/ML)	A 088909	002 May 15, 1985 Jun CMS1
@		270MG/30ML (9MG/ML)	A 088909	001 Feb 07, 1985 Jun CPOT
AP	FRESENIUS KABI USA	9MG/ML	A 088911	001 Feb 07, 1985 Jun CDFR
AP		90MG/10ML (9MG/ML)	A 088911	002 May 17, 1985 Jun CMS1
AP		270MG/30ML (9MG/ML)	A 088911	001 Feb 07, 1985 Jun CPOT
AP	+! HOSPIRA	9MG/ML	N 018800	001 Oct 29, 1982 Jun CDFR
AP	+!	90MG/10ML (9MG/ML)	N 018800	001 Oct 29, 1982 Jun CPOT
AP	+!	180MG/20ML (9MG/ML)	N 018800	002 Oct 29, 1982 Jun CMS1
AP	+!	270MG/30ML (9MG/ML)	N 018800	003 Oct 29, 1982 Jun CMS1
		SODIUM CHLORIDE 0.9%		
+ @	B BRAUN	9MG/ML	N 019635	005 Aug 08, 2016 Jun CDFR
+ @		90MG/10ML (9MG/ML)	N 019635	005 Aug 08, 2016 Jun CPOT
	HIKMA	9MG/ML	A 201833	001 Sep 24, 2013 Jun CDFR
AP		9MG/ML	A 201850	001 Jan 20, 2012 Jun CDFR
		18MG/2ML (9MG/ML)	A 201833	001 Sep 24, 2013 Jun CPOT
AP		90MG/10ML (9MG/ML)	A 201833	002 Jan 07, 2015 Jun CMS1
AP		90MG/10ML (9MG/ML)	A 201850	001 Jan 20, 2012 Jun CPOT
AP	NEXUS PHARMS	90MG/10ML (9MG/ML)	A 217535	001 Aug 23, 2023 Aug NEWA
AP		180MG/20ML (9MG/ML)	A 217535	002 Aug 23, 2023 Aug NEWA
AP	SPECTRA MDCL DEVICES	9MG/ML	A 206171	001 Jul 21, 2017 Jun CDFR
AP		45MG/5ML (9MG/ML)	A 206171	001 Jul 21, 2017 Jun CPOT
AP		90MG/10ML (9MG/ML)	A 206171	002 Jul 21, 2017 Jun CMS1
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
@	ABBOTT	9MG/ML	N 019218	001 Jul 13, 1984 Jun CDFR
@		90MG/10ML (9MG/ML)	N 019218	001 Jul 13, 1984 Jun CPOT
@		180MG/20ML (9MG/ML)	N 019218	002 Apr 30, 1985 Jun CMS1
AP	+! BAXTER HLTHCARE	9MG/ML	N 016677	004 Oct 30, 1985 Jun CDFR
AP	+ @	9MG/ML	N 020178	002 Dec 07, 1992 Jun CDFR
	+!	225MG/25ML (9MG/ML)	N 016677	004 Oct 30, 1985 Jun CTEC
AP	+!	225MG/25ML (9MG/ML)	N 016677	004 Oct 30, 1985 Jun CPOT
AP	+!	450MG/50ML (9MG/ML)	N 016677	003 Jun CMS1
AP	+ @	450MG/50ML (9MG/ML)	N 020178	002 Dec 07, 1992 Jun CPOT
AP	+!	900MG/100ML	N 016677	001 Jun CDFR
AP	+!	900MG/100ML	N 020178	001 Dec 07, 1992 Jun CDFR
AP	+ ! FRESENIUS KABI USA	9MG/ML	A 088912	001 Jan 10, 1985 Jun CDFR
	+ !	18MG/2ML (9MG/ML)	A 088912	004 Nov 29, 1985 Jun CMS1
AP	+ !	90MG/10ML (9MG/ML)	A 088912	001 Jan 10, 1985 Jun CPOT
AP	+ !	180MG/20ML (9MG/ML)	A 088912	002 Jan 10, 1985 Jun CMS1
AP	+ !	270MG/30ML (9MG/ML)	A 088912	003 Jan 10, 1985 Jun CMS1
AP	+! HOSPIRA	90MG/10ML (9MG/ML)	N 018803	001 Oct 29, 1982 Jun CPOT
AP	+!	9MG/ML	N 018803	001 Oct 29, 1982 Jun CDFR
AP	+ @	9MG/ML	N 019465	002 Jul 15, 1985 Jun CDFR
	+ @	18MG/2ML (9MG/ML)	N 018803	004 Jan 22, 2015 Jun CMS1
	+ @	27MG/3ML (9MG/ML)	N 018803	005 Jan 22, 2015 Jun CMS1
	+ @	45MG/5ML (9MG/ML)	N 018803	006 Jan 22, 2015 Jun CMS1
AP	+!	180MG/20ML (9MG/ML)	N 018803	002 Oct 29, 1982 Jun CMS1
AP	+!	450MG/50ML (9MG/ML)	N 018803	003 Oct 29, 1982 Jun CMS1
AP	+ @	450MG/50ML (9MG/ML)	N 019465	002 Jul 15, 1985 Jun CPOT
AP	+!	900MG/100ML	N 019465	001 Jul 15, 1985 Jun CDFR
+ @	ICU MEDICAL INC	45MG/5ML (9MG/ML)	N 019217	002 Nov 18, 1998 Jun CMS1
+ @		90MG/10ML (9MG/ML)	N 019217	003 Nov 18, 1998 Jun CMS1
+ @		360MG/40ML (9MG/ML)	N 019217	004 Apr 01, 1999 Jun CMS1
@	JUBILANT CADISTA	9MG/ML	A 203352	001 May 18, 2016 Jun CDFR
@		27MG/3ML (9MG/ML)	A 203352	002 May 18, 2016 Jun CMS1
@		90MG/10ML (9MG/ML)	A 203352	001 May 18, 2016 Jun CPOT
@	MILES	450MG/50ML (9MG/ML)	N 018502	002 Jun CMS1
@		900MG/100ML	N 018502	001 Jun CDFR
AP	NEPHRON	9MG/ML	A 211968	001 Apr 23, 2020 Jun CDFR
AP		450MG/50ML (9MG/ML)	A 211968	001 Apr 23, 2020 Jun CPOT
AP		900MG/100ML	A 211968	002 Apr 23, 2020 Jun CMS1
AP	+! TARO	9MG/ML	A 077407	001 Aug 11, 2006 Jun CDFR
AP	+!	45MG/5ML (9MG/ML)	A 077407	001 Aug 11, 2006 Jun CPOT
AP	+!	90MG/10ML (9MG/ML)	A 077407	002 Aug 11, 2006 Jun CMS1

SOLUTION; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE
 + @ ICU MEDICAL INC 9MG/ML N 019217 001 Jul 13, 1984 Jun CDFR
 + @ 90MG/10ML (9MG/ML) N 019217 001 Jul 13, 1984 Jun CPOT

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

>D> AP SHERTECH LABS LLC 10-200mCi/ML A 204315 001 Sep 22, 2014 Dec DISC
 >A> @ 10-200mCi/ML A 204315 001 Sep 22, 2014 Dec DISC

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
SODIUM NITROPRUSSIDE
@ CHARTWELL RX 25MG/ML

AP MYLAN 25MG/ML A 209834 001 Jun 26, 2018 Sep CAHN
 @ VIRTUS 25MG/ML A 209584 001 Aug 10, 2018 Sep CAHN

SODIUM OXYBATE

FOR SUSPENSION, EXTENDED RELEASE; ORAL
LUMRYZ
+! AVADEL CNS 4.5GM/PACKET
+ 4.5GM/PACKET
+ 6GM/PACKET
+ 7.5GM/PACKET
+ 9GM/PACKET

N 214755 001 May 01, 2023 Jun CHRS
 N 214755 001 May 01, 2023 May NEWA
 N 214755 002 May 01, 2023 May NEWA
 N 214755 003 May 01, 2023 May NEWA
 N 214755 004 May 01, 2023 May NEWA

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL

AB +! HORIZON THERAP US 3GM/TEASPOONFUL N 020573 001 Apr 30, 1996 Jan CAHN
 TABLET; ORAL
BUPHENYL

AB +! HORIZON THERAP US 500MG N 020572 001 May 13, 1996 Jan CAHN

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE
! NOVEL LABS INC 0.398GM;1.102GM A 079247 001 Dec 30, 2011 Jul CTEC
 AB ! 0.398GM;1.102GM A 079247 001 Dec 30, 2011 Jul CHRS
 OSMOPREP
+ @ SALIX PHARMS 0.398GM;1.102GM N 021892 001 Mar 16, 2006 Jul DISC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
SODIUM PHOSPHATES
AP ! FRESENIUS KABI USA 142MG/ML;276MG/ML

A 209997 001 Mar 30, 2022 Mar CHRS

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA UPSHER SMITH LABS 453.6GM/BOT

A 090313 001 Dec 21, 2011 Sep CAHN

SOLIFENACIN SUCCINATE

TABLET; ORAL
SOLIFENACIN SUCCINATE

AB	CHARTWELL RX	5MG	A 210582	001	May 20, 2019	May CAHN
AB		10MG	A 210582	002	May 20, 2019	May CAHN
	@ CIPLA	5MG	A 209839	001	May 20, 2019	Jul DISC
	@	10MG	A 209839	002	May 20, 2019	Jul DISC
>D> AB	LANNETT CO INC	5MG	A 211622	001	Jun 06, 2023	Dec DISC
>A>	@	5MG	A 211622	001	Jun 06, 2023	Dec DISC
AB		5MG	A 211622	001	Jun 06, 2023	May NEWA
>D> AB		10MG	A 211622	002	Jun 06, 2023	Dec DISC
>A>	@	10MG	A 211622	002	Jun 06, 2023	Dec DISC
AB		10MG	A 211622	002	Jun 06, 2023	May NEWA
AB	RISING	5MG	A 211423	001	Dec 11, 2019	Aug CAHN
AB		10MG	A 211423	002	Dec 11, 2019	Aug CAHN

SORAFENIB TOSYLATE

TABLET;ORAL

SORAFENIB TOSYLATE

AB TORRENT EQ 200MG BASE A217095 001 Apr 12, 2023 Mar NEWA

SOTAGLIFLOZIN

TABLET;ORAL

INPEFA

+ LEXICON PHARMS INC 200MG N216203 001 May 26, 2023 May NEWA
+! 400MG N216203 002 May 26, 2023 May NEWASOTALOL HYDROCHLORIDE

TABLET;ORAL

SORINE

AB AIPING PHARM INC 80MG A075500 001 Apr 27, 2001 Oct CAHN
AB 120MG A075500 004 Apr 27, 2001 Oct CAHN
AB 160MG A075500 002 Apr 27, 2001 Oct CAHN
AB 240MG A075500 003 Apr 27, 2001 Oct CAHN

SOTALOL HYDROCHLORIDE

AB AUROBINDO PHARMA USA 80MG A077616 001 Feb 07, 2007 Jul CMFD
AB 120MG A077616 002 Feb 07, 2007 Jul CMFD
AB 160MG A077616 003 Feb 07, 2007 Jul CMFD
@ NATCO PHARMA USA 80MG A075237 001 May 01, 2000 Aug CAHN
@ 120MG A075237 002 May 01, 2000 Aug CAHN
@ 160MG A075237 003 May 01, 2000 Aug CAHN
@ 240MG A075237 004 May 01, 2000 Aug CAHNSOTORASIB

TABLET;ORAL

LUMAKRAS

+ AMGEN INC 120MG N214665 001 May 28, 2021 Mar CHRS
+! 320MG N214665 002 Jan 20, 2023 Mar CHRS
+ 320MG N214665 002 Jan 20, 2023 Feb NEWASOYBEAN OIL

INJECTABLE;INJECTION

INTRALIPID 10%

+ @ FRESENIUS 10% N017643 001 Nov DISC
NUTRILIPID 10%
+! B BRAUN 10% N019531 001 May 28, 1993 Nov CTECSPARENTEAN

TABLET;ORAL

FILSPARI

+ TRAVERE 200MG N216403 001 Feb 17, 2023 Feb NEWA
+! 400MG N216403 002 Feb 17, 2023 Feb NEWASPIRONOLACTONE

SUSPENSION;ORAL

CAROSPIR

AB +! CMP DEV LLC 25MG/5ML N209478 001 Aug 04, 2017 Aug CFTG
SPIRONOLACTONE
AB AMNEAL 25MG/5ML A215572 001 Sep 05, 2023 Aug NFTGSTERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP AM REGENT 100% (10ML) A217341 001 Aug 29, 2023 Aug NEWA
AP 100% (20ML) A217341 002 Aug 29, 2023 Aug NEWA
AP HIKMA 100% A212735 001 Jan 31, 2023 Jan NEWA
AP +! HOSPIRA 100% (20ML) N018801 003 Oct 27, 1982 Jun CFTG
+ @ 100% (5.2ML) N018801 006 May 02, 2023 Jun DISC
+! 100% (5.2ML) N018801 006 May 02, 2023 May NEWASUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

>D> @ BE PHARMS 20MG/ML A216003 001 Feb 07, 2022 Dec CMFD
>A> AP 20MG/ML A216003 001 Feb 07, 2022 Dec CMFD
@ BRECKENRIDGE 20MG/ML A212638 001 Oct 09, 2019 Apr DISC
AP EUGIA PHARMA 20MG/ML A217808 001 Oct 16, 2023 Oct NEWA

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

AP	@ MANKIND PHARMA	20MG/ML	A216127	001	Feb 02, 2023	Aug DISC
AP		20MG/ML	A216127	001	Feb 02, 2023	Jan NEWA
AP	UMEDICA	20MG/ML	A211625	001	May 19, 2020	Sep CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	ZYDUS LIFESCIENCES	1GM	A215705	001	May 03, 2023	Apr NEWA
----	--------------------	-----	---------	-----	--------------	----------

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE

AP	+! RISING	EQ 0.05MG BASE/ML	N019050	001	May 04, 1984	Sep CAHN
	TABLET; SUBLINGUAL DSUVIA					
	+! VERTICAL PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018	Apr CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

AP	+ MSD SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul CAHN
AP	+!	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jul CAHN
AP	+ ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jun CFTG
AP	+!	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jun CFTG
	SUGAMMADEX SODIUM					
AP	ASPIRO	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214337	001	Jun 09, 2023	Jun NFTG
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214337	002	Jun 09, 2023	Jun NFTG
AP	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Sep NEWA
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Sep NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10

+ @ ALLERGAN	10%	A080028	001		Nov DISC
@ AKORN	10%	A040215	001	May 25, 1999	Jan DISC
@ EPIC PHARMA LLC	30%	A040216	001	May 25, 1999	Sep CAHN

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

>A>	@ CHARTWELL MOLECULAR	500MG	A080084	001		Dec CAHN
>D>	@ LANNETT	500MG	A080084	001		Dec CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	CHARTWELL MOLECULAR	200MG/5ML; 40MG/5ML	A077785	001	Jan 24, 2007	Jul CAHN
----	---------------------	---------------------	---------	-----	--------------	----------

SULINDAC

TABLET; ORAL

SULINDAC

@ CHARTWELL RX	150MG	A072712	001	Aug 30, 1991	Jan CAHN
@	200MG	A072713	001	Aug 30, 1991	Jan CAHN

SUMATRIPTAN

SPRAY; NASAL

TOSYMRA

+! TONIX MEDS	10MG/SPRAY	N210884	001	Jan 25, 2019	Jul CAHN
---------------	------------	---------	-----	--------------	----------

	TABLET;ORAL Tadalafil				
AB2		20MG		A212515 001 Jun 06, 2023	May NEWA
	<u>TALAZOPARIB TOSYLATE</u>				
	CAPSULE;ORAL Talzenna				
+ !	Pfizer	EQ 0.1MG BASE		N211651 005 Jun 20, 2023	Jul NEWA
+ !		EQ 0.35MG BASE		N211651 006 Jun 20, 2023	Jul NEWA
	<u>TAMOXIFEN CITRATE</u>				
	SOLUTION;ORAL Soltamox				
+ !	Mayne Pharma Commrcl	EQ 20MG BASE/10ML		N021807 001 Oct 29, 2005	Feb CAHN
	<u>TAMSULOSIN HYDROCHLORIDE</u>				
	CAPSULE;ORAL Tamsulosin Hydrochloride				
AB	@ Ascent Pharms Inc Chartwell Rx	0.4MG 0.4MG		A214730 001 May 04, 2022 A211885 001 Oct 17, 2019	Sep CAHN Sep CAHN
	<u>TASIMELTEON</u>				
	CAPSULE;ORAL Tasimelteon				
AB	Apotex	20MG		A211607 001 Dec 20, 2022	Jan CAHN
AB	MSN	20MG		A211654 001 Jan 12, 2023	Jan NEWA
	<u>TAVABOROLE</u>				
	SOLUTION;TOPICAL Tavaborole				
AB	ZyDus Lifesciences	5%		A212294 001 Apr 10, 2023	Mar NEWA
	<u>TAZAROTENE</u>				
	GEL;TOPICAL Tazarotene				
AB	Padagis Israel	0.05%		A213079 001 Apr 25, 2023	Apr NEWA
AB		0.1%		A213079 002 Apr 25, 2023	Apr NEWA
AB	Solaris Pharma Corp	0.05%		A213644 001 Mar 20, 2023	Mar NEWA
AB		0.1%		A213644 002 Mar 20, 2023	Mar NEWA
	<u>TECHNETIUM TC-99M LABELED CARBON</u>				
	AEROSOL;INHALATION Technegas Kit				
+ !	CycloMedica	N/A		N022335 001 Sep 29, 2023	Sep NEWA
	<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>				
	POWDER;INTRAVENOUS Technetium TC 99m Mertiatide Kit				
+ !	Jubilant Draximage	N/A		N216820 001 Jan 30, 2023	Jan NEWA
	<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>				
	SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC RadioGenix System				
+ !	Northstar Medical	30-1153mCi/GENERATOR		N202158 001 Feb 08, 2018	Oct DISC
	<u>TECHNETIUM TC-99M SULFUR COLLOID KIT</u>				
	SOLUTION;INJECTION, ORAL An-Sulfur Colloid				
AP	+ ! Sun Pharm Inds Inc	N/A		N017858 001	Nov CFTG
	Technetium TC-99m Sulfur Colloid Kit				
AP	Jubilant	N/A		A213516 001 Nov 09, 2023	Nov NFTG
	<u>TELMISARTAN</u>				
	TABLET;ORAL Telmisartan				
AB	Chartwell Rx	20MG		A078710 001 Jan 08, 2014	May CAHN
AB		40MG		A078710 002 Jan 08, 2014	May CAHN
AB		80MG		A078710 003 Jan 08, 2014	May CAHN

TEMAZEPAM

CAPSULE;ORAL							
TEMAZEPAM							
AB ALKEM LABS LTD	7.5MG		A217875	001	Aug 24, 2023	Aug NEWA	
AB	15MG		A217875	002	Aug 24, 2023	Aug NEWA	
AB	22.5MG		A217875	003	Aug 24, 2023	Aug NEWA	
AB	30MG		A217875	004	Aug 24, 2023	Aug NEWA	
@ SUN PHARM INDUSTRIES	22.5MG		A071175	002	Sep 14, 2009	Nov DISC	

TEMOZOLOMIDE

CAPSULE;ORAL							
TEMOZOLOMIDE							
@ CHARTWELL MOLECULAR	5MG		A203898	001	Feb 10, 2016	Jul CAHN	
@	20MG		A203898	002	Feb 10, 2016	Jul CAHN	
@	100MG		A203898	003	Feb 10, 2016	Jul CAHN	
@	140MG		A203898	004	Feb 10, 2016	Jul CAHN	
@	180MG		A203898	005	Feb 10, 2016	Jul CAHN	
@	250MG		A203898	006	Feb 10, 2016	Jul CAHN	
@ HERITAGE	5MG		A078879	001	Mar 01, 2010	Aug DISC	
@	20MG		A078879	002	Mar 01, 2010	Aug DISC	
@	100MG		A078879	003	Mar 01, 2010	Aug DISC	
@	140MG		A078879	005	Mar 01, 2010	Aug DISC	
@	180MG		A078879	006	Mar 01, 2010	Aug DISC	
@	250MG		A078879	004	Mar 01, 2010	Aug DISC	

TENAPANOR HYDROCHLORIDE

TABLET;ORAL							
XPHOZAH							
+ ARDELYX INC	EQ 10MG BASE		N213931	001	Oct 17, 2023	Oct NEWA	
+	EQ 20MG BASE		N213931	002	Oct 17, 2023	Oct NEWA	
+	EQ 30MG BASE		N213931	003	Oct 17, 2023	Oct NEWA	

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL							
TENOFOVIR ALAFENAMIDE							
AB LUPIN LTD	EQ 25MG BASE		A214226	001	Mar 30, 2023	Mar NFTG	
VEMLIDY							
AB +! GILEAD SCIENCES INC	EQ 25MG BASE		N208464	001	Nov 10, 2016	Mar CFTG	

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL							
TENOFOVIR DISOPROXIL FUMARATE							
@ CASI PHARMS INC	300MG		A209550	001	Feb 26, 2018	Nov DISC	
AB REYOUNG	300MG		A211337	001	Mar 02, 2023	Aug CAHN	
AB REYOUNG PHARM	300MG		A211337	001	Mar 02, 2023	Feb NEWA	

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL							
TERAZOSIN HYDROCHLORIDE							
@ BIONPHARMA	EQ 1MG BASE		A075667	001	Jul 28, 2000	Apr CAHN	
@	EQ 2MG BASE		A075667	002	Jul 28, 2000	Apr CAHN	
@	EQ 5MG BASE		A075667	003	Jul 28, 2000	Apr CAHN	
@	EQ 10MG BASE		A075667	004	Jul 28, 2000	Apr CAHN	
TABLET;ORAL							
TERAZOSIN HYDROCHLORIDE							
@ CHARTWELL RX	EQ 1MG BASE		A074657	001	Apr 28, 2000	May CAHN	
@	EQ 2MG BASE		A074657	002	Apr 28, 2000	May CAHN	
@	EQ 5MG BASE		A074657	003	Apr 28, 2000	May CAHN	
@	EQ 10MG BASE		A074657	004	Apr 28, 2000	May CAHN	

TERIFLUNOMIDE

TABLET;ORAL							
TERIFLUNOMIDE							
AB AMNEAL PHARMS CO	7MG		A209613	001	Sep 28, 2018	Feb CMFD	
AB	14MG		A209613	002	Sep 28, 2018	Feb CMFD	
AB APOTEX	7MG		A209601	001	Nov 02, 2018	Jan CMFD	
AB	14MG		A209601	002	Nov 02, 2018	Jan CMFD	
AB AUROBINDO PHARMA	7MG		A209638	001	Oct 26, 2018	Jan CMFD	
AB	14MG		A209638	002	Oct 26, 2018	Jan CMFD	
AB BIOCON PHARMA	7MG		A209639	001	Mar 13, 2023	Mar NEWA	
AB	14MG		A209639	002	Mar 13, 2023	Mar NEWA	

TABLET;ORALTERIFLUNOMIDE

AB	HETERO LABS LTD V	7MG	A209598	001	Mar 13, 2023	Mar NEWA
AB		14MG	A209598	002	Mar 13, 2023	Mar NEWA
AB	MSN	7MG	A209623	001	Apr 24, 2019	Feb CMFD
AB		14MG	A209623	002	Apr 24, 2019	Feb CMFD
AB	MYLAN	7MG	A209702	001	Feb 28, 2020	Feb CMFD
AB		14MG	A209702	002	Feb 28, 2020	Feb CMFD
AB	NATCO	7MG	A209555	001	May 15, 2023	May NEWA
AB		14MG	A209555	002	May 15, 2023	May NEWA
AB	SOLA PHARMS	7MG	A209677	002	Sep 28, 2023	Sep NEWA
AB		14MG	A209677	001	Jun 17, 2020	Feb CMFD
AB	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Feb CMFD
AB		14MG	A209700	002	Sep 04, 2018	Feb CMFD
AB	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	Jan CMFD
AB		14MG	A209668	002	Nov 30, 2018	Jan CMFD

TERIPARATIDESOLUTION;SUBCUTANEOUS
FORTEO

AP	+! LILLY TERIPARATIDE	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Nov CFTG
AP	APOTEX	0.6MG/2.4ML (0.25MG/ML)	A211097	001	Nov 16, 2023	Nov NFTG
AP	TEVA PHARMS USA	0.6MG/2.4ML (0.25MG/ML)	A208569	001	Nov 16, 2023	Nov NFTG

TESTOSTERONEGEL, METERED;NASAL
NATESTO

+!	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CHRS
+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CRLD
	GEL, METERED;TRANSDERMAL ANDROGEL					
AB	+! BESINS HLTHCARE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Feb CAHN
+ @		12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Feb CAHN
	TESTOSTERONE					
AB	ENCUBE	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Jan CAHN

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

AO	EUGIA PHARMA	100MG/ML	A211817	001	Oct 20, 2023	Oct NEWA
AO		200MG/ML	A211817	002	Oct 20, 2023	Oct NEWA
AO	XIROMED	100MG/ML	A215351	001	Apr 13, 2023	Mar NEWA
AO		200MG/ML	A215351	002	Apr 13, 2023	Mar NEWA

TETRABENAZINETABLET;ORAL
TETRABENAZINE

AB	CHARTWELL RX	12.5MG	A210544	001	Apr 20, 2018	May CAHN
AB		25MG	A210544	002	Apr 20, 2018	May CAHN
@	SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan DISC
@		25MG	A206129	002	Aug 17, 2015	Jan DISC

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
ACHROMYCIN V

+ @ AVET		250MG	N050278	003		Sep DISC
+ @		500MG	N050278	001		Sep DISC
	TETRACYCLINE HYDROCHLORIDE					
AB	! AMNEAL PHARMS NY	500MG	A210674	002	Sep 18, 2018	Sep CHRS
@ AUROBINDO PHARMA USA	250MG		A060783	001		Apr CAHN
@	500MG		A060783	002		Apr CAHN

THALIDOMIDECAPSULE;ORAL
THALIDOMIDE

AB	@ NATCO	150MG	A213267	001	Apr 27, 2023	Oct DISC
	THALOMID		A213267	001	Apr 27, 2023	Apr NFTG
+ BRISTOL-MYERS		50MG	N020785	001	Jul 16, 1998	Sep CAHN
+		100MG	N020785	002	Jan 17, 2003	Sep CAHN
+		150MG	N020785	004	Jan 10, 2007	Oct CTEC

CAPSULE;ORAL
THALOMID

AB	+	150MG	N 020785	004	Jan 10, 2007	Sep CAHN
	+!	200MG	N 020785	003	Jan 17, 2003	Sep CAHN
AB	+	CELGENE	N 020785	004	Jan 10, 2007	Apr CFTG

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201
+! CURIUM 1mCi/ML
+ @ LANTHEUS MEDCL 1mCi/ML

N 018150	001	Aug CTEC
N 017806	001	Aug DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL
THEO-24

AUXILIUM PHARMS LLC	100MG	A 087943	002	Aug 22, 1983	Oct CMS1
	300MG	A 087943	003	Aug 22, 1983	Oct CMS1
!	400MG	A 087943	004	Feb 28, 1992	Oct CMS1

INJECTABLE;INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER
+ @ B BRAUN 40MG/100ML
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER
+ @ B BRAUN 80MG/100ML
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER
+ @ B BRAUN 160MG/100ML
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER
+ @ B BRAUN 320MG/100ML

N 019826	001	Aug 14, 1992	Oct DISC
N 019826	002	Aug 14, 1992	Oct DISC
N 019826	003	Aug 14, 1992	Oct DISC
N 019826	006	Aug 14, 1992	Oct DISC

TABLET, EXTENDED RELEASE;ORAL
THEO-DUR

>D>	@ SCHERING	100MG	A 085328	001	Dec CRLD
>A>	+ @	100MG	A 085328	001	Dec CRLD

THEOCHRON

NOSTRUM PHARMS LLC	100MG	A 087400	003	Feb 21, 1985	Aug CMFD
	200MG	A 087400	004	Feb 21, 1985	Aug CMFD

AB		300MG	A 087400	002	Jan 11, 1983	Aug CMFD
AB		450MG	A 087400	005	Aug 09, 2023	Aug NEWA

THEOPHYLLINE

AB	AMNEAL	300MG	A 216276	001	Mar 20, 2023	Mar NEWA
AB		450MG	A 216276	002	Mar 20, 2023	Mar NEWA
AB	ANNORA PHARMA	300MG	A 217422	001	Sep 08, 2023	Sep NEWA
AB		450MG	A 217422	002	Sep 08, 2023	Sep NEWA
AB	BIONPHARMA	300MG	A 216300	001	Apr 26, 2023	Apr NEWA
AB		450MG	A 216300	002	Apr 26, 2023	Apr NEWA
AB	HARMAN FINOCHEM	300MG	A 214806	001	Oct 24, 2023	Oct NEWA
AB		450MG	A 214806	002	Oct 24, 2023	Oct NEWA
AB	LEADING	300MG	A 214950	001	Jan 30, 2023	Jan NEWA
AB		450MG	A 214950	002	Jan 30, 2023	Jan NEWA
AB	RHODES PHARMS	300MG	A 214113	001	May 11, 2023	May NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A 215692	001	Mar 06, 2023	Feb NEWA
AP	DR REDDYS	100MG/ML	A 080571	001		Mar CMFD
	!	200MG/ML	A 080571	002		Mar CMFD

THIOGUANINE

TABLET;ORAL
THIOGUANINE
+! WAYLIS THERAP 40MG

N 012429	001	Sep CAHN
----------	-----	----------

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE
@ CHARTWELL RX 10MG
@ 15MG
@ 25MG
@ 50MG
@ 100MG
@ 150MG
@ 200MG

A 088131	001	Aug 30, 1983	Jan CAHN
A 088132	001	Aug 30, 1983	Jan CAHN
A 088133	001	Aug 30, 1983	Jan CAHN
A 088134	001	Aug 30, 1983	Jan CAHN
A 088135	001	Nov 20, 1984	Jan CAHN
A 088136	001	Sep 17, 1986	Jan CAHN
A 088137	001	Sep 17, 1986	Jan CAHN

THIOTEPHA

INJECTABLE; INJECTION

THIOTEPHA

AP	PENN LIFE	15MG/VIAL	A208242	001	Jan 10, 2020	May CAHN
	POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL					
	THIOTEPHA					
AP	HIKMA	100MG/VIAL	A211755	001	Sep 05, 2023	Aug NEWA
>A> AP	KINDOS	15MG/VIAL	A216037	001	Dec 26, 2023	Dec NEWA
>A> AP		100MG/VIAL	A216037	002	Dec 26, 2023	Dec NEWA

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

AB	RISING	1MG	A071093	002	Jun 23, 1987	Feb CAHN
AB		2MG	A071093	003	Jun 23, 1987	Feb CAHN
AB		5MG	A071093	004	Jun 23, 1987	Feb CAHN
AB		10MG	A071093	001	Jun 23, 1987	Feb CAHN

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AB	ALKEM LABS LTD	90MG	A208567	001	Apr 21, 2023	Apr NEWA
----	----------------	------	---------	-----	--------------	----------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

! APOTEX	250MG	A075089	001	Jul 01, 1999	Sep CHRS
	250MG	A075089	001	Jul 01, 1999	Sep CTEC
@ TEVA	250MG	A075149	001	Aug 20, 1999	Sep DISC

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+! THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Jan CTEC
+!	EQ 0.5% BASE	N020439	002	Mar 31, 1995	Jan CTEC
TIMOLOL					
@ AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Jan DISC
@	EQ 0.5% BASE	A205309	002	Sep 30, 2016	Jan DISC
@ EPIC PHARMA LLC	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Oct CAHN
@	EQ 0.5% BASE	A205309	002	Sep 30, 2016	Oct CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	EUGIA PHARMA	EQ 0.5% BASE	A213540	001	Mar 23, 2023	Mar NEWA
AB	GLAND PHARMA LTD	EQ 0.5% BASE	A214645	002	Feb 14, 2023	Feb NEWA

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

@ AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Jan DISC
AT1 MICRO LABS	EQ 0.25% BASE	A217343	001	May 26, 2023	May NEWA
AT1	EQ 0.5% BASE	A217343	002	May 26, 2023	May NEWA
AT3 SENTISS PHARMA	EQ 0.5% BASE	A217195	001	May 08, 2023	Apr NEWA

TABLET; ORAL

TIMOLOL MALEATE

AB RISING	5MG	A207556	001	May 02, 2019	Aug CAHN
AB	10MG	A207556	002	May 02, 2019	Aug CAHN
AB	20MG	A207556	003	May 02, 2019	Aug CAHN

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

AB CHARTWELL RX	250MG	A202044	001	Apr 30, 2012	Apr CAHN
AB	500MG	A202044	002	Apr 30, 2012	Apr CAHN
>A> AB THINQ PHARM-CRO PVT	250MG	A202489	001	Oct 09, 2013	Dec CAHN
>A> AB	500MG	A202489	002	Oct 09, 2013	Dec CAHN
>D> AB UNIQUE	250MG	A202489	001	Oct 09, 2013	Dec CAHN
>D> AB	500MG	A202489	002	Oct 09, 2013	Dec CAHN

TIOPRONIN

	TABLET, DELAYED RELEASE;ORAL THIOLA EC						
AB	+ MISSION PHARMACAL	100MG	N 211843	001	Jun 28, 2019	Apr	CTEC
AB	+!	300MG	N 211843	002	Jun 28, 2019	Aug	CTEC
AB	+ MISSION PHARMACAL CO	100MG	N 211843	001	Jun 28, 2019	Feb	CFTG
	+!	300MG	N 211843	002	Jun 28, 2019	Apr	CTEC
AB	+!	300MG	N 211843	002	Jun 28, 2019	Feb	CFTG
	TIOPRONIN						
AB	AMNEAL	300MG	A 216278	001	Aug 15, 2023	Aug	NEWA
	@ PAR PHARM	100MG	A 217219	001	Feb 24, 2023	Apr	DISC
AB		100MG	A 217219	001	Feb 24, 2023	Feb	NFTG
	@	300MG	A 217219	002	Feb 24, 2023	Apr	DISC
AB		300MG	A 217219	002	Feb 24, 2023	Feb	NFTG

TIOTROPIUM BROMIDE

	POWDER;INHALATION SPIRIVA						
AB	+! BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N 021395	001	Jan 30, 2004	Jun	CFTG
	TIOTROPIUM BROMIDE						
AB	LUPIN	EQ 0.018MG BASE/INH	A 211287	001	Jun 20, 2023	Jun	NFTG

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

	TABLET;ORAL LONSURF						
AB	+ TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N 207981	001	Sep 22, 2015	Jun	CFTG
AB	+!	EQ 8.19MG BASE;20MG	N 207981	002	Sep 22, 2015	Jun	CFTG
	TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE						
AB	NATCO	EQ 6.14MG BASE;15MG	A 214008	001	Jun 13, 2023	Jun	NFTG
AB		EQ 8.19MG BASE;20MG	A 214008	002	Jun 13, 2023	Jun	NFTG

TIROFIBAN HYDROCHLORIDE

	SOLUTION;INTRAVENOUS AGGRASTAT						
AP	+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N 020913	002	May 17, 2002	Jan	CFTG
	TIROFIBAN HYDROCHLORIDE						
AP	EUGIA PHARMA	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A 216379	001	May 01, 2023	Apr	NEWA
AP		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A 216379	002	May 01, 2023	Apr	NEWA

TIRZEPATIDE

	SOLUTION;SUBCUTANEOUS ZEPBOUND						
	+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N 217806	001	Nov 08, 2023	Nov	NEWA
	+!	5MG/0.5ML (5MG/0.5ML)	N 217806	002	Nov 08, 2023	Nov	NEWA
	+!	7.5MG/0.5ML (7.5MG/0.5ML)	N 217806	003	Nov 08, 2023	Nov	NEWA
	+!	10MG/0.5ML (10MG/0.5ML)	N 217806	004	Nov 08, 2023	Nov	NEWA
	+!	12.5MG/0.5ML (12.5MG/0.5ML)	N 217806	005	Nov 08, 2023	Nov	NEWA
	+!	15MG/0.5ML (15MG/0.5ML)	N 217806	006	Nov 08, 2023	Nov	NEWA

TIZANIDINE HYDROCHLORIDE

	CAPSULE;ORAL ZANAFLEX						
AB	+ LEGACY PHARMA USA	EQ 2MG BASE	N 021447	001	Aug 29, 2002	Jul	CAHN
AB	+	EQ 4MG BASE	N 021447	002	Aug 29, 2002	Jul	CAHN
AB	+!	EQ 6MG BASE	N 021447	003	Aug 29, 2002	Jul	CAHN
	TABLET;ORAL						
	TIZANIDINE HYDROCHLORIDE						
	@ AUROBINDO PHARMA USA	EQ 2MG BASE	A 076282	001	Dec 16, 2003	Apr	CAHN
	@	EQ 4MG BASE	A 076282	002	Dec 16, 2003	Apr	CAHN
	ZANAFLEX						
	+ @ LEGACY PHARMA USA	EQ 2MG BASE	N 020397	002	Feb 04, 2000	Jul	CAHN
AB	+!	EQ 4MG BASE	N 020397	001	Nov 27, 1996	Jul	CAHN

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

AN	MANKIND PHARMA	300MG/5ML	A214478	001	Jun 30, 2023	Jun NEWA
AN	MICRO LABS	300MG/5ML	A217344	001	Jul 27, 2023	Jul NEWA
<u>SOLUTION/DROPS; OPHTHALMIC</u>						
AKTOB						
	@ AKORN	0.3%	A064096	001	Jan 31, 1996	Feb DISC
	@ EPIC PHARMA LLC	0.3%	A064096	001	Jan 31, 1996	Nov CAHN
	TOBRAMYCIN					
AT	CHARTWELL RX	0.3%	A065026	001	Sep 11, 2001	Oct CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	@ EPIC PHARMA LLC	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014	Oct CAHN
AP	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Jun NEWA
AP	! FRESENIUS KABI USA	EQ 10MG BASE/ML	A065122	001	Nov 29, 2002	Sep CHRS
AP	HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jan NEWA
	@ HOSPIRA	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Sep DISC
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@ HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990	Sep DISC
	@	EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993	Sep DISC
	@	EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990	Sep DISC

TOFACITINIB CITRATE

SOLUTION; ORAL

TOFACITINIB CITRATE

AA	SLAYBACK PHARMA LLC	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Sep NFTG
AA	XELJANZ					
AA	+! PFIZER	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	Sep CFTG
	+!	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	Aug CPOT
TABLET; ORAL						
	TOFACITINIB CITRATE					
AB	@ MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar DISC
		EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar NFTG
AB	@ ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Sep DISC
		EQ 5MG BASE	A209829	001	Mar 13, 2023	Mar NEWA
XELJANZ						
	+ PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Sep CTEC
AB	+	EQ 5MG BASE	N203214	001	Nov 06, 2012	Mar CFTG

TOFERSEN

SOLUTION; INTRATHECAL

QALSODY

+! BIOGEN MA

100MG/15ML (6.7MG/ML)

N215887 001 Apr 25, 2023 Apr NEWA

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

RISING

EQ 400MG BASE

A073393 001 May 27, 1993 Jul CMFD

TABLET; ORAL

TOLMETIN SODIUM

! RISING

EQ 600MG BASE

A074473 001 Aug 30, 1994 May CMFD

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

AB	ELYSIUM	1MG	A210775	001	Dec 30, 2019	Sep CAHN
AB		2MG	A210775	002	Dec 30, 2019	Sep CAHN

TOLVAPTA

TABLET; ORAL

TOLVAPTA

AB	MSN	15MG	A216949	001	Jun 21, 2023	Jun NEWA
AB		30MG	A216949	002	Jun 21, 2023	Jun NEWA

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB	AUROBINDO PHARMA LTD	15MG	A215449	001	Sep 27, 2023	Sep NEWA
AB		25MG	A215449	002	Sep 27, 2023	Sep NEWA
AB	TWI PHARMS	15MG	A217694	001	Dec 05, 2023	Nov NEWA
AB		25MG	A217694	002	Dec 05, 2023	Nov NEWA
	© WATSON LABS	15MG	A077868	001	Apr 15, 2009	Sep DISC
	©	25MG	A077868	002	Apr 15, 2009	Sep DISC
	CAPSULE, EXTENDED RELEASE;ORAL					
	TOPIRAMATE					
AB1	ACTAVIS LABS FL	25MG	A206210	001	Mar 10, 2023	Mar NEWA
AB1		50MG	A206210	002	Mar 10, 2023	Mar NEWA
AB1		100MG	A206210	003	Mar 10, 2023	Mar NEWA
AB1		200MG	A206210	004	Mar 10, 2023	Mar NEWA
AB1	AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Aug NEWA
AB1		50MG	A215663	002	Aug 15, 2023	Aug NEWA
AB1		100MG	A215663	003	Aug 15, 2023	Aug NEWA
AB1		200MG	A215663	004	Aug 15, 2023	Aug NEWA
AB1	ALKEM LABS LTD	25MG	A217248	001	Jun 20, 2023	Jun NEWA
AB1		50MG	A217248	002	Jun 20, 2023	Jun NEWA
AB1		100MG	A217248	003	Jun 20, 2023	Jun NEWA
AB1		200MG	A217248	004	Jun 20, 2023	Jun NEWA
AB1	DR REDDYS	25MG	A217231	001	Nov 17, 2023	Nov NEWA
AB1		50MG	A217231	002	Nov 17, 2023	Nov NEWA
AB1		100MG	A217231	003	Nov 17, 2023	Nov NEWA
AB1		200MG	A217231	004	Nov 17, 2023	Nov NEWA
AB1	PAR PHARM	25MG	A205976	002	May 04, 2023	Apr NEWA
AB1		50MG	A205976	003	May 04, 2023	Apr NEWA
AB1		100MG	A205976	004	May 04, 2023	Apr NEWA
AB1		200MG	A205976	001	Mar 01, 2023	Feb NEWA
AB1	ZYDUS	25MG	A207382	001	Nov 24, 2017	Jan CAHN
AB2		25MG	A208949	001	Nov 29, 2022	Jan CAHN
AB1		50MG	A207382	002	Nov 24, 2017	Jan CAHN
AB2		50MG	A208949	002	Nov 29, 2022	Jan CAHN
AB1		100MG	A207382	003	Nov 24, 2017	Jan CAHN
AB2		100MG	A208949	003	Nov 29, 2022	Jan CAHN
AB2		150MG	A208949	004	Nov 29, 2022	Jan CAHN
AB1		200MG	A207382	004	Oct 30, 2023	Oct NEWA
AB2		200MG	A208949	005	Nov 29, 2022	Jan CAHN
	© ZYDUS PHARMS	200MG	A216167	001	Feb 09, 2023	Aug DISC
AB1		200MG	A216167	001	Feb 09, 2023	Jan NFTG
	TROKENDI XR					
AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan CFTG
	TABLET;ORAL					
	TOPIRAMATE					
	© TEVA	25MG	A076317	001	Mar 27, 2009	Sep DISC
	©	50MG	A076317	002	Mar 27, 2009	Sep DISC
	©	100MG	A076317	003	Mar 27, 2009	Sep DISC
	©	200MG	A076317	004	Mar 27, 2009	Sep DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

+ SANDOZ

EQ 0.25MG BASE

N020981

001 Oct 11, 2007

May CAHN

+!

EQ 1MG BASE

N020981

002 Oct 11, 2007

May CAHN

INJECTABLE;INJECTION

HYCAMTIN

AP +! SANDOZ

EQ 4MG BASE/VIAL

N020671

001 May 28, 1996

May CAHN

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

>D> AP © DASH PHARMS

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A206074

001 Nov 24, 2017

Mar CAHN

HONG KONG

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N022453

001 Dec 20, 2012

Dec CAHN

AP

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N022453

001 Dec 20, 2012

Oct CAHN

>A> AP MEITHEAL

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N022453

001 Dec 20, 2012

Dec CAHN

TORSEMIDE

TABLET;ORAL							
SOAANZ							
+ @ SARFE PHARMS	20MG		N213218	001	Jun 14, 2021	Jun	DISC
+ @	60MG		N213218	002	Jun 14, 2021	Jun	DISC
TORSEMIDE							
@ TEVA	5MG		A076110	001	May 14, 2002	Sep	DISC
@	10MG		A076110	002	May 14, 2002	Sep	DISC
@	20MG		A076110	003	May 14, 2002	Sep	DISC
@	100MG		A076110	004	May 14, 2002	Sep	DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL							
TRAMADOL HYDROCHLORIDE							
@ PLIVA	50MG		A075982	001	Jul 01, 2002	Sep	DISC
RUBICON	25MG		A208708	003	Nov 27, 2023	Nov	NFTG
TABLET, EXTENDED RELEASE;ORAL							
TRAMADOL HYDROCHLORIDE							
@ ACTAVIS ELIZABETH	100MG		A091609	001	Jun 27, 2012	Sep	DISC
@	200MG		A091609	002	Jun 27, 2012	Sep	DISC
@	300MG		A091609	003	Jun 27, 2012	Sep	DISC
! SUN PHARM	100MG		A091607	001	Dec 30, 2011	Sep	CTEC
>D>	200MG		A091607	002	Dec 30, 2011	Dec	DISC
>A>	@		A091607	002	Dec 30, 2011	Dec	DISC
	200MG		A091607	002	Dec 30, 2011	Sep	CTEC
	300MG		A091607	003	Dec 30, 2011	Sep	CTEC

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION;ORAL							
MEKINIST							
+! NOVARTIS	EQ 0.05MG BASE/ML		N217513	001	Mar 16, 2023	Mar	NEWA

TRANDOLAPRIL

TABLET;ORAL							
TRANDOLAPRIL							
@ TEVA PHARMS	1MG		A077489	001	Dec 12, 2006	Sep	DISC
@	2MG		A077489	002	Dec 12, 2006	Sep	DISC
@	4MG		A077489	003	Dec 12, 2006	Sep	DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION							
TRANEXAMIC ACID							
@ CHARTWELL RX	100MG/ML		A202755	001	Feb 25, 2016	Sep	CAHN
AP EPIC PHARMA LLC	100MG/ML		A202373	001	Nov 17, 2011	Oct	CAHN
@ VIRTUS	100MG/ML		A202755	001	Feb 25, 2016	Sep	CAHN
SOLUTION;INTRAVENOUS							
TRANEXAMIC ACID							
AP AMNEAL	1GM/100ML (10MG/ML)		A217155	001	Oct 16, 2023	Oct	NFTG
AP +! EXELA PHARMA	1GM/100ML (10MG/ML)		N212020	001	Apr 15, 2019	Oct	CFTG
TABLET;ORAL							
TRANEXAMIC ACID							
>D> @ AUROBINDO PHARMA USA	650MG		A205133	001	Sep 21, 2015	Dec	CMFD
>A> AB	650MG		A205133	001	Sep 21, 2015	Dec	CMFD

TRAVOPROST

IMPLANT;INTRACAMERAL							
IDOSE TR							
>A> +! GLAUkos	75MCG		N218010	001	Dec 13, 2023	Dec	NEWA
SOLUTION/DROPS;OPHTHALMIC							
TRAVATAN Z							
AT +! SANDOZ	0.004%		N021994	001	Sep 21, 2006	Sep	CAHN

TRAZODONE HYDROCHLORIDE

TABLET;ORAL							
TRAZODONE HYDROCHLORIDE							
AB AUROBINDO PHARMA	50MG		A204852	001	Feb 05, 2020	Jan	CAHN
AB	100MG		A204852	002	Feb 05, 2020	Jan	CAHN
AB	150MG		A204852	003	Feb 05, 2020	Jan	CAHN
AB	300MG		A204852	004	Feb 05, 2020	Jan	CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS REMODULIN							
+!	UNITED THERAP	0.1MG/ML	N 021272	006	Sep 28, 2023	Oct	NEWA
+!		0.2MG/ML	N 021272	007	Sep 28, 2023	Oct	NEWA
+!		0.4MG/ML	N 021272	008	Sep 28, 2023	Oct	NEWA
TREPROSTINIL							
AP	DR REDDYS	1MG/ML	A 210214	001	May 22, 2020	Feb	CMFD
AP		2.5MG/ML	A 210214	002	May 22, 2020	Feb	CMFD
AP		5MG/ML	A 210214	003	May 22, 2020	Feb	CMFD
AP		10MG/ML	A 210214	004	May 22, 2020	Feb	CMFD

TRETINOIN

CREAM;TOPICAL RETIN-A							
AB	+! BAUSCH	0.025%	N 019049	001	Sep 16, 1988	Jan	CAHN
	GEL;TOPICAL AVITA						
	@ MYLAN	0.025%	N 020400	001	Jan 29, 1998	May	DISC
	RETIN-A MICRO						
>A>	+! BAUSCH	0.04%	N 020475	002	May 10, 2002	Dec	CAHN
>A>	+!	0.1%	N 020475	001	Feb 07, 1997	Dec	CAHN
>D>	+! VALEANT INTL	0.04%	N 020475	002	May 10, 2002	Dec	CAHN
>D>	+!	0.1%	N 020475	001	Feb 07, 1997	Dec	CAHN
	RETIN-A-MICRO						
>A>	+! BAUSCH	0.06%	N 020475	004	Oct 23, 2017	Dec	CAHN
>A> AB	+!	0.08%	N 020475	003	Jan 28, 2014	Dec	CAHN
>D>	+! VALEANT INTL	0.06%	N 020475	004	Oct 23, 2017	Dec	CAHN
>D> AB	+!	0.08%	N 020475	003	Jan 28, 2014	Dec	CAHN
AB	+!	0.08%	N 020475	003	Jan 28, 2014	Aug	CFTG
	TRETINOIN MICROSPHERE						
AB	ENCUBE	0.08%	A 215609	001	Aug 22, 2023	Aug	NFTG

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL TRIAMCINOLONE ACETONIDE							
AT	CHARTWELL RX	0.025%	A 208763	001	Feb 01, 2017	May	CAHN
AT		0.1%	A 208763	002	Feb 01, 2017	May	CAHN
AT		0.5%	A 208763	003	Feb 01, 2017	May	CAHN
AT	ENCUBE	0.1%	A 208848	001	Sep 18, 2017	Oct	CAHN
	INJECTABLE;INTRAVITREAL TRIESENCE						
>A>	+! HARROW EYE	40MG/ML (40MG/ML)	N 022048	001	Nov 29, 2007	Dec	CAHN
>D>	+! NOVARTIS	40MG/ML (40MG/ML)	N 022048	001	Nov 29, 2007	Dec	CAHN
	LOTION;TOPICAL TRIAMCINOLONE ACETONIDE						
AT	EPIC PHARMA LLC	0.025%	A 202374	001	May 08, 2013	Oct	CAHN
AT		0.1%	A 202374	002	May 08, 2013	Oct	CAHN
	@ PAI HOLDINGS PHARM	0.025%	A 204608	001	Jul 07, 2016	Aug	DISC
	@	0.1%	A 204606	001	Jul 07, 2016	Aug	DISC
	OINTMENT;TOPICAL TRIAMCINOLONE ACETONIDE						
AT	CHARTWELL RX	0.05%	A 214532	001	Jan 27, 2023	May	CAHN
AT		0.1%	A 207365	001	Oct 12, 2018	Apr	CAHN
AT	! ENCUBE	0.05%	A 212384	001	Nov 29, 2019	Nov	CHRS
AT		0.1%	A 205373	001	May 13, 2016	Oct	CAHN
AT	GLASSHOUSE PHARMS	0.05%	A 214532	001	Jan 27, 2023	Jan	NEWA
AT	MACLEODS PHARMS LTD	0.05%	A 216625	001	Aug 18, 2023	Aug	NEWA
	@ PAI HOLDINGS PHARM	0.5%	A 208590	001	Mar 03, 2017	Aug	DISC
	TRIANEX						
	@ CMP PHARMA INC	0.05%	A 089595	001	Mar 23, 1995	Nov	DISC
	SPRAY;TOPICAL KENALOG						
	+ @ SUN PHARM INDs INC	0.147MG/GM	N 012104	001		Jun	DISC
	TRIAMCINOLONE ACETONIDE						
AT	! PADAGIS ISRAEL	0.147MG/GM	A 205782	001	Apr 13, 2015	Jun	CHRS

TRIAMTERENE

CAPSULE;ORAL				
TRIAMTERENE				
@ EYWA	50MG	A214768	001	Jul 06, 2022
@	100MG	A214768	002	Jul 06, 2022

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL				
TRIENTINE HYDROCHLORIDE				
AB MSN	250MG	A211134	001	May 22, 2019
AB RISING	500MG	A212238	002	Sep 22, 2023

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL				
TRIMETHOBENZAMIDE HYDROCHLORIDE				
AB AVET LIFESCIENCES	300MG	A205950	001	Nov 21, 2023

TROFINETIDE

SOLUTION;ORAL				
DAYBUE				
+! ACADIA PHARMS INC	200MG/ML	N217026	001	Mar 10, 2023

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC				
TROPICACYL				
AT EPIC PHARMA LLC	0.5%	A040314	001	Sep 29, 2000

TROSPiUM CHLORIDE

TABLET;ORAL				
TROSPiUM CHLORIDE				
AB CHARTWELL RX	20MG	A215781	001	Feb 16, 2022

UBROGEPANT

TABLET;ORAL				
UBREILVY				
+ ABBVIE	50MG	N211765	001	Dec 23, 2019
+!	100MG	N211765	002	Dec 23, 2019

UREA, C-14

CAPSULE;ORAL				
PYTEST KIT				
+ @ AVENT	1uCi	N020617	002	May 09, 1997

URIDINE TRIACETATE

GRANULE;ORAL				
VISTOGARD				
+! BTG INTL	10GM/PACKET	N208159	001	Dec 11, 2015
XURIDEN				
+! BTG INTL	2GM/PACKET	N208169	001	Sep 04, 2015

URSODIOL

CAPSULE;ORAL				
URSODIOL				
@ MYLAN	300MG	A090530	001	Feb 17, 2010
AB RK PHARMA	300MG	A214329	001	Jul 28, 2021
@ TEVA PHARMS	300MG	A075592	001	May 25, 2000
AB VGYAAN	300MG	A214329	001	Jul 28, 2021

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL				
VALACYCLOVIR HYDROCHLORIDE				
AB ADAPTIS	EQ 500MG BASE	A079012	001	May 24, 2010
AB	EQ 1GM BASE	A079012	002	May 24, 2010
AB CHARTWELL RX	EQ 500MG BASE	A090216	001	May 24, 2010
AB	EQ 1GM BASE	A090216	002	May 24, 2010
AB YAMPA	EQ 500MG BASE	A079012	001	May 24, 2010
AB	EQ 1GM BASE	A079012	002	May 24, 2010

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	+! CHEPLAPHARM	50MG/ML	N 022257	001	Aug 28, 2009	Mar CAHN
AB	APPCCO	50MG/ML	A 216317	001	Apr 11, 2023	Mar NEWA
	TABLET;ORAL					
	VALCYTE					
AB	+! CHEPLAPHARM	EQ 450MG BASE	N 021304	001	Mar 29, 2001	Mar CAHN
	VALGANCICLOVIR HYDROCHLORIDE					
	@ CIPLA	EQ 450MG BASE	A 209672	001	Nov 09, 2018	Aug DISC

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

AP	SAGENT	EQ 100MG BASE/ML	A 076295	001	Nov 14, 2002	Aug CAHN
----	--------	------------------	----------	-----	--------------	----------

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

>D>	@ ANI PHARMS	250MG/5ML	A 073178	001	Aug 25, 1992	Dec CMFD
>A> AA		250MG/5ML	A 073178	001	Aug 25, 1992	Dec CMFD
AA	HIKMA	250MG/5ML	A 074060	001	Jan 13, 1995	Sep CAHN
	@ PHARMOBEDIENT CNSLTG	250MG/5ML	A 070868	001	Jul 01, 1986	Sep CAHN
	@ XTTRIUM LABS INC	250MG/5ML	A 070868	001	Jul 01, 1986	Mar CAHN

VALSARTAN

SOLUTION;ORAL

VALSARTAN

! NOVITIUM PHARMA

20MG/5ML

A 214102 001 Nov 02, 2021 Jan CHRS

TABLET;ORAL

VALSARTAN

@ IVAX PHARMS

40MG

A 077530 001 Jan 04, 2016 Sep DISC

@

80MG

A 077530 002 Jan 04, 2016 Sep DISC

@

160MG

A 077530 003 Jan 04, 2016 Sep DISC

@

320MG

A 077530 004 Jan 04, 2016 Sep DISC

VAMOROLONE

SUSPENSION;ORAL

AGAMREE

+! CATALYST PHARMS

40MG/ML

N 215239 001 Oct 26, 2023 Oct CAHN

+! SANTHERA PHARMS

40MG/ML

N 215239 001 Oct 26, 2023 Oct NEWA

VANCOMYCIN

SOLUTION;INTRAVENOUS, ORAL

VANCOMYCIN

+ @ XELLIA PHARMS APS

5GM/100ML (50MG/ML)

N 213895 001 Aug 26, 2021 Oct DISC

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB	PAI HOLDINGS PHARM	EQ 125MG BASE	A 065478	001	Apr 09, 2012	Oct CAHN
AB		EQ 250MG BASE	A 065478	002	Apr 09, 2012	Oct CAHN
	@ WATSON LABS	EQ 125MG BASE	A 065510	001	Apr 09, 2012	Sep DISC
	@	EQ 250MG BASE	A 065510	002	Apr 09, 2012	Sep DISC
	FOR SOLUTION;ORAL					

VANCOCIN HYDROCHLORIDE

AA	! ANI PHARMS	EQ 250MG BASE/5ML	A 061667	002	Jul 13, 1983	Jun CTEC
	VANCOMYCIN HYDROCHLORIDE					
AA	AMNEAL	EQ 250MG BASE/5ML	A 215338	001	Jun 23, 2023	Jun NEWA
	INJECTABLE;INJECTION					
	VANCOMYCIN HYDROCHLORIDE					

AP	GLAND PHARMA LTD	EQ 5GM BASE/VIAL	A 205694	003	Jun 06, 2023	May NEWA
AP		EQ 10GM BASE/VIAL	A 205694	004	Jun 06, 2023	May NEWA
AP	HIKMA	EQ 1GM BASE/VIAL	A 203300	002	Aug 11, 2020	Jan CMFD
	POWDER;INTRAVENOUS					

AP	EUGIA PHARMA	EQ 1.25GM BASE/VIAL	A 217401	001	Aug 04, 2023	Jul NEWA
AP		EQ 1.5GM BASE/VIAL	A 217401	002	Aug 04, 2023	Jul NEWA
AP	HIKMA	EQ 1.25GM BASE/VIAL	A 217489	001	Jun 29, 2023	Jun NFTG

POWDER; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

AP		EQ 1.5GM BASE/VIAL	A217489	002	Jun 29, 2023	Jun NFTG
AP	+! MYLAN LABS LTD	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018	Jun CFTG
AP	+!	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018	Jun CFTG
		POWDER; INTRAVENOUS, ORAL				
		VANCOMYCIN HYDROCHLORIDE				
+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan NEWA
+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan NEWA
+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan NEWA
+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan NEWA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL
VARDENAFIL HYDROCHLORIDE

>D>	@ AMNEAL PHARMS CO	EQ 5MG BASE	A210738	001	Oct 31, 2018	Dec CAHN
>D>	@	EQ 10MG BASE	A210738	002	Oct 31, 2018	Dec CAHN
>D>	@	EQ 20MG BASE	A210738	003	Oct 31, 2018	Dec CAHN
>A>	@ STEVENS J	EQ 5MG BASE	A210738	001	Oct 31, 2018	Dec CAHN
>A>	@	EQ 10MG BASE	A210738	002	Oct 31, 2018	Dec CAHN
>A>	@	EQ 20MG BASE	A210738	003	Oct 31, 2018	Dec CAHN

VARENICLINE TARTRATE

TABLET; ORAL
VARENICLINE TARTRATE

AB	ALKEM LABS LTD	EQ 0.5MG BASE	A214557	001	Aug 23, 2023	Aug NEWA
AB		EQ 1MG BASE	A214557	002	Aug 23, 2023	Aug NEWA
AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan NEWA
AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan NEWA
AB	HETERO LABS LTD III	EQ 0.5MG BASE	A214571	001	Oct 23, 2023	Oct NEWA
AB		EQ 1MG BASE	A214571	002	Oct 23, 2023	Oct NEWA
AB	LEADING PHARMA	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Sep CAHN
AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Sep CAHN
AB	LUPIN LTD	EQ 0.5MG BASE	A211862	001	Dec 04, 2023	Nov NEWA
AB		EQ 1MG BASE	A211862	002	Dec 04, 2023	Nov NEWA
AB	MANKIND PHARMA	EQ 0.5MG BASE	A214255	001	Aug 01, 2023	Jul NEWA
AB		EQ 1MG BASE	A214255	002	Aug 01, 2023	Jul NEWA
AB	MEDLEY PHARMS	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Jul NEWA
AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Jul NEWA
AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan CTEC
AB	ZYDUS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun CAHN
AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun CAHN
AB	ZYDUS PHARMS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun NEWA
AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS
VASOPRESSIN

AP	+! AM REGENT	200UNITS/10ML (20UNITS/ML)	N212593	002	Jun 09, 2023	Jul NEWA
AP	CIPILA	20UNITS/100ML (0.2UNITS/ML)	A217987	001	Dec 06, 2023	Nov NFTG
AP	FRESENIUS KABI USA	20UNITS/ML (20UNITS/ML) VASOPRESSIN IN SODIUM CHLORIDE 0.9%	A213206	001	May 26, 2023	May NEWA
+!	BAXTER HLTHCARE CORP	20UNITS/100ML (0.2UNITS/ML)	N217569	001	Sep 29, 2023	Sep NEWA
+!		40UNITS/100ML (0.4UNITS/ML)	N217569	002	Sep 29, 2023	Sep NEWA
		VASOSTRICT				
AP	+! PAR STERILE PRODUCTS	20UNITS/100ML (0.2UNITS/ML)	N204485	005	Apr 21, 2021	Nov CFTG
>D>	+!	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Dec DISC
>A>	+ @	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Dec DISC
+!		50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Apr NEWA
>D>	+!	60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Dec DISC
>A>	+ @	60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Dec DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

>D> AP	HONG KONG	10MG/VIAL	A074688	001	Aug 25, 1999	Dec CAHN
AP		10MG/VIAL	A074688	001	Aug 25, 1999	Oct CAHN
>D> AP		20MG/VIAL	A074688	002	Aug 25, 1999	Dec CAHN
AP		20MG/VIAL	A074688	002	Aug 25, 1999	Oct CAHN
>A> AP	MEITHEAL	10MG/VIAL	A074688	001	Aug 25, 1999	Dec CAHN
>A> AP		20MG/VIAL	A074688	002	Aug 25, 1999	Dec CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	GRANULES	EQ 37.5MG BASE	A217390	001	May 18, 2023	May NEWA
AB		EQ 75MG BASE	A217390	002	May 18, 2023	May NEWA
AB		EQ 150MG BASE	A217390	003	May 18, 2023	May NEWA
AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	Mar NEWA
AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	Mar NEWA
AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	Mar NEWA
@	TORRENT	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	Aug DISC
@		EQ 75MG BASE	A090899	002	Jun 01, 2011	Aug DISC
@		EQ 150MG BASE	A090899	003	Jun 01, 2011	Aug DISC
TABLET;ORAL						
VENLAFAXINE HYDROCHLORIDE						
@	CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL						
VENLAFAXINE HYDROCHLORIDE						
AB	AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023	Mar NEWA
AB		EQ 75MG BASE	A214691	002	Apr 12, 2023	Mar NEWA
AB		EQ 150MG BASE	A214691	003	Apr 12, 2023	Mar NEWA
AB		EQ 225MG BASE	A214691	004	Apr 12, 2023	Mar NEWA
AB	OSMOTICA PHARM US	EQ 37.5MG BASE	N022104	001	May 20, 2008	Nov CAHN
AB	+	EQ 75MG BASE	N022104	002	May 20, 2008	Nov CAHN
AB	+!	EQ 150MG BASE	N022104	003	May 20, 2008	Nov CAHN
AB	+	EQ 225MG BASE	N022104	004	May 20, 2008	Nov CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

+	@ PFIZER	120MG	N019152	003	Mar 06, 1991	Mar DISC
+	@	240MG	N019152	001	Dec 16, 1986	Mar DISC

VERAPAMIL HYDROCHLORIDE

AB	CADILA PHARMS LTD	120MG	A206173	003	Nov 14, 2022	Mar NEWA
AB	! GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Mar CHRS
AB	!	240MG	A078906	001	Sep 17, 2009	Mar CHRS
@	IVAX SUB TEVA PHARMS	120MG	A073568	002	Oct 10, 1997	Sep DISC
@		180MG	A074330	001	Jan 31, 1994	Sep DISC
@		240MG	A073568	001	Jul 31, 1992	Sep DISC
>D> AB	SUN PHARM IND'S INC	120MG	A090529	001	Dec 30, 2011	Dec DISC
>A>	@	120MG	A090529	001	Dec 30, 2011	Dec DISC
>D> AB		180MG	A090529	002	Dec 30, 2011	Dec DISC
>A>	@	180MG	A090529	002	Dec 30, 2011	Dec DISC
>D> AB		240MG	A090529	003	Dec 30, 2011	Dec DISC
>A>	@	240MG	A090529	003	Dec 30, 2011	Dec DISC

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

@	ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020	Mar DISC
@	CHARTWELL RX	500MG/PACKET	A211790	001	Mar 10, 2022	May CAHN
>D> AA	PYROS PHARMS	500MG/PACKET	A214961	001	Jun 24, 2022	Dec CTNA
AA	@ ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Jul DISC
>A>	VIGPODER	500MG/PACKET	A214671	001	Mar 02, 2023	Feb NEWA
>A> AA	PYROS PHARMS	500MG/PACKET	A214961	001	Jun 24, 2022	Dec CTNA
TABLET;ORAL						
VIGABATRIN						
AB	PROPEL PHARMA	500MG	A215519	001	Apr 28, 2023	Apr NEWA
AB	UPSHER SMITH LABS	500MG	A214749	001	Jun 29, 2023	Sep CAHN
AB	ZENARA	500MG	A214749	001	Jun 29, 2023	Jun NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB	+! ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan CAHN
AB	+	20MG	N022567	002	Jan 21, 2011	Jan CAHN
AB	+	40MG	N022567	003	Jan 21, 2011	Jan CAHN

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB	APOTEX	10MG	A208228	001	Jul 07, 2023	Jun NEWA
AB		20MG	A208228	002	Jul 07, 2023	Jun NEWA
AB		40MG	A208228	003	Jul 07, 2023	Jun NEWA

VINCRISTINE SULFATE

INJECTABLE;INJECTION

VINCRISTINE SULFATE PFS

! HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Sep CTEC
@ TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Sep DISC

VONOPRAZAN FUMARATE

TABLET;ORAL

VOQUEZNA

+ PHATHOM

+!

EQ 10MG BASE

EQ 20MG BASE

N215151	001	Nov 01, 2023	Nov NEWA
N215151	002	Nov 01, 2023	Nov NEWA

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

>A> AB	HAINAN POLY	200MG/5ML	A216805	001	Jan 02, 2024	Dec NEWA
	INJECTABLE;INTRAVENOUS					
	VORICONAZOLE					
AP	@ EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Aug DISC
AP		200MG/VIAL	A212162	001	Feb 02, 2023	Jan NEWA
AP	SLATE RUN PHARMA	200MG/VIAL	A211661	001	Nov 30, 2018	Sep CAHN
AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Mar NEWA
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar CDFR
	TABLET;ORAL					
	VORICONAZOLE					
AB	CHARTWELL RX	50MG	A207371	001	May 24, 2016	Apr CAHN
AB		200MG	A207371	002	May 24, 2016	Apr CAHN
AB	EPIC PHARMA LLC	50MG	A207049	001	Sep 07, 2016	Nov CAHN
AB		200MG	A207049	002	Sep 07, 2016	Nov CAHN

VUTRISIRAN SODIUM

SOLUTION;SUBCUTANEOUS

AMVUTTRA

+! ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
+!	25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb CAIN

WARFARIN SODIUM

TABLET;ORAL

WARFARIN SODIUM

@ AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004	May CAHN
@	2MG	A040415	002	Sep 27, 2004	May CAHN
@	2.5MG	A040415	003	Sep 29, 2004	May CAHN
@	3MG	A040415	004	Sep 27, 2004	May CAHN
@	4MG	A040415	005	Sep 27, 2004	May CAHN
@	5MG	A040415	006	Sep 27, 2004	May CAHN
@	6MG	A040415	007	Sep 27, 2004	May CAHN
@	7.5MG	A040415	008	Sep 27, 2004	May CAHN
@	10MG	A040415	009	Sep 27, 2004	May CAHN

XENON XE-129 HYPERPOLARIZED

GAS;INHALATION

XENOVIEW

+! POLAREAN	N/A	N214375	001	Dec 23, 2022	Jan NEWA
-------------	-----	---------	-----	--------------	----------

ZAFIRLUKAST

TABLET;ORAL

ZAFIRLUKAST

AB	AUROBINDO PHARMA	10MG	A213163	001	Nov 27, 2023	Nov NEWA
AB		20MG	A213163	002	Nov 27, 2023	Nov NEWA

ZAVEGEPAINT HYDROCHLORIDE

SPRAY, METERED;NASAL

ZAVZPRET

+! PFIZER

EQ 10MG BASE/SPRAY

N216386 001 Mar 09, 2023 Mar NEWA

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB	AIZANT	600MG	A211390	001	Oct 23, 2020	Aug CAHN
AB	! RISING	600MG	A204929	001	Mar 17, 2017	Jan CHRS

ZILUCOPLAN SODIUM

SOLUTION;SUBCUTANEOUS

ZILBRYSQ

+! UCB INC	EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML)	N216834	001	Oct 17, 2023	Oct NEWA
+!	EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML)	N216834	002	Oct 17, 2023	Oct NEWA
+!	EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML)	N216834	003	Oct 17, 2023	Oct NEWA

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

AP	FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022	May CAIN
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022	May CAIN
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022	May CAIN
AP	GLAND PHARMA LTD	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216249	003	Sep 01, 2023	Aug NEWA
AP	ZYDUS PHARMS	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217074	003	Aug 22, 2023	Aug NEWA
AP		EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217074	001	Aug 22, 2023	Aug NEWA
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217074	002	Aug 22, 2023	Aug NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

RECLAST

AP	+! SANDOZ	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	May CAHN
>D> AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Dec CHRS
>A> AP	!	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Dec CHRS
ZOLEDRONIC ACID						
AP	AVET LIFESCIENCES	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Sep CMFD
	@ BRECKENRIDGE	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep DISC
AP	CHARTWELL RX	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Aug CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Aug CAHN
>D> AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Dec CHRS
>A> AP	!	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Dec CHRS
AP	HONG KONG	EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	May NEWA
AP	+! INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Nov CHRS
AP	+	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jul CRLD
	@ INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Jun DISC
AP	MEITHEAL	EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	Aug CAHN
	@ NOVAST LABS	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Sep CAHN
AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Jul CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Jul CAHN
>D>	ZOMETA					
>D> AP	+! NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Dec DISC
>A>	+ @	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Dec DISC
>D> AP	+!	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Dec DISC
>A>	+ @	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Dec DISC

ZOLMITRIPTAN

SPRAY;NASAL

ZOMIG

AB	+ AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Jan CAHN
AB	+!	5MG/SPRAY	N021450	004	Sep 30, 2003	Jan CAHN

TABLET;ORAL

ZOLMITRIPTAN

AB	! AJANTA PHARMA LTD	5MG	A204041	002	May 20, 2016	Jun CHRS
>D>	@ MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Dec CAHN
>D>	@	5MG	A203186	002	May 14, 2013	Dec CAHN
>A>	@ NATCO PHARMA USA	2.5MG	A203186	001	May 14, 2013	Dec CAHN
>A>	@	5MG	A203186	002	May 14, 2013	Dec CAHN

TABLET;ORAL

ZOMIG

+ @ IPR	2.5MG
+ @	5MG

N 020768	001	Nov 25, 1997	Jun DISC
N 020768	002	Nov 25, 1997	Jun DISC

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

AB ! ZYDUS PHARMS USA INC	5MG	A 202890	002	May 15, 2013	Jun CHRS
ZOMIG-ZMT					
+ @ ASTRAZENECA	2.5MG	N 021231	001	Feb 13, 2001	Jun DISC
+ @	5MG	N 021231	002	Sep 17, 2001	Jun DISC

ZOLPIDEM TARTRATE

CAPSULE;ORAL

ZOLPIDEM TARTRATE

+! ALMATICHA	7.5MG
--------------	-------

N 215721	001	May 09, 2023	May NEWA
----------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

@ ACTAVIS LABS FL INC	6.25MG	A 090153	001	Mar 25, 2013	Sep DISC
@	12.5MG	A 090153	002	Mar 25, 2013	Sep DISC
@ ANCHEN PHARMS	6.25MG	A 078148	002	Apr 14, 2011	May DISC
@	12.5MG	A 078148	001	Dec 03, 2010	May DISC
@ BRECKENRIDGE	6.25MG	A 213592	001	Jun 04, 2020	Aug DISC
@	12.5MG	A 213592	002	Jun 04, 2020	Aug DISC

ZURANOLONE

CAPSULE;ORAL

ZURZUVAE

+ BIOGEN INC	20MG	N 217369	001	Oct 31, 2023	Oct NEWA
+	25MG	N 217369	002	Oct 31, 2023	Oct NEWA
+!	30MG	N 217369	003	Oct 31, 2023	Oct NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE RELIEF)

+! GLAXOSMITHKLINE CONS 250MG;250MG;65MG

N020802 001 Jan 14, 1998 Apr CTNA

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

BIONPHARMA 250MG;125MG

GRANULES 250MG;125MG

L PERRIGO CO 250MG;125MG

MARKSANS PHARMA 250MG;125MG

A216999 001 Aug 01, 2023 Jul NEWA

A216592 001 Jul 13, 2023 Jul NEWA

A214836 001 Feb 28, 2023 Feb NEWA

A216994 001 Jul 10, 2023 Jun NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

>D> EUGIA PHARMA 0.25%

A210659 001 Jun 23, 2023 Dec DISC

>A> @ 0.25%

A210659 001 Jun 23, 2023 Dec DISC

0.25%

A210659 001 Jun 23, 2023 Jun NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

@ PERRIGO R AND D 800MG;10MG;165MG

A204782 001 Aug 29, 2016 Aug DISC

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ APOTEX 10MG

A207235 001 Aug 12, 2016 Aug DISC

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D> SUN PHARM 10MG

A090142 002 Aug 30, 2011 Dec DISC

>A> @ 10MG

A090142 002 Aug 30, 2011 Dec DISC

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> SUN PHARM 10MG

A090142 004 Aug 30, 2011 Dec DISC

>A> @ 10MG

A090142 004 Aug 30, 2011 Dec DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD 5MG;120MG

A212409 001 Mar 08, 2023 Sep DISC

5MG;120MG

A212409 001 Mar 08, 2023 Feb NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

+! 3M HEALTH CARE 2%;70%

N208288 001 Aug 08, 2018 Mar CTNA

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ IVAX SUB TEVA PHARMS 200MG

A075345 001 Jun 16, 1999 Sep DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

DR REDDYS 30MG;600MG

A217340 001 Aug 01, 2023 Jul NEWA

60MG;1.2GM

A217340 002 Aug 01, 2023 Jul NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

COREPHARMA 25MG;220MG

A211830 001 Aug 22, 2019 Feb CAHN

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

TARO

10%

A214454 001 Oct 26, 2023 Oct NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

ANDA REPOSITORY

EQ 20MG BASE

GUARDIAN DRUG

EQ 20MG BASE

A216149 001 Mar 15, 2023 Sep CAHN

A216149 001 Mar 15, 2023 Mar NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

MARKSANS PHARMA

10MG

20MG

A217543 001 Mar 08, 2023 Feb NEWA

A217543 002 Mar 08, 2023 Feb NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

FEXOFENADINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 30MG/5ML

A213466 001 May 23, 2023 May NEWA

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 30MG

A202039 001 Nov 19, 2014 Oct CAHN

AUROBINDO PHARMA USA 30MG

A202039 001 Nov 19, 2014 Apr CAHN

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 60MG

A202039 002 Nov 19, 2014 Oct CAHN

180MG

A202039 003 Nov 19, 2014 Oct CAHN

AUROBINDO PHARMA USA 60MG

A202039 002 Nov 19, 2014 Apr CAHN

180MG

A202039 003 Nov 19, 2014 Apr CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

MARKSANS PHARMA

600MG

1.2GM

A217780 001 Aug 21, 2023 Aug NEWA

A217780 002 Aug 21, 2023 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ GRANULES

600MG;60MG

A216082 001 Aug 22, 2022 Feb DISC

@

1.2GM;120MG

A216082 002 Aug 22, 2022 Feb DISC

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM SALT

A215777 001 Sep 14, 2023 Sep NEWA

SUSPENSION;ORAL

IBUPROFEN

@ ARISE

100MG/5ML

A200457 001 Aug 18, 2011 Jun DISC

SUSPENSION/DROPS;ORAL

IBUPROFEN

TARO

40MG/ML

A217261 001 Aug 08, 2023 Jul NEWA

TABLET;ORAL

IBUPROFEN

@ OHM

200MG

A071163 001 Jul 15, 1986 Nov DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD 200MG;30MG

200MG;30MG

A213565 001 Mar 10, 2023 Sep DISC

A213565 001 Mar 10, 2023 Mar NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

SENTISSL

EQ 0.025% BASE

A077958 001 Jul 26, 2007 Aug CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
 LANSOPRAZOLE
 @ MYLAN 15MG A203187 001 Jun 01, 2016 Aug DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
 @ GRANULES 2MG;125MG A215981 001 Aug 29, 2022 Feb DISC

LORATADINE

CAPSULE;ORAL LORATADINE @ AUROBINDO PHARMA	10MG	A211900 001 Mar 24, 2023	Sep DISC
	10MG	A211900 001 Mar 24, 2023	Mar NEWA
TABLET;ORAL LORATADINE GUARDIAN DRUG	10MG	A207569 001 Mar 12, 2019	Sep CAHN
HETERO LABS LTD V	10MG	A211718 001 Jul 28, 2023	Jul NEWA

MINOXIDIL

SOLUTION;TOPICAL MINOXIDIL (FOR MEN) AUROBINDO PHARMA LTD 2%	A074767 001 Feb 28, 1997	Sep CAHN
MINOXIDIL EXTRA STRENGTH (FOR MEN) AUROBINDO PHARMA LTD 5%	A075438 001 Feb 27, 2003	Sep CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL MOMETASONE FUROATE @ AMNEAL	0.05MG/SPRAY	A217460 001 Jun 14, 2023	Sep DISC
	0.05MG/SPRAY	A217460 001 Jun 14, 2023	Jun NFTG

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL NALOXONE HYDROCHLORIDE PADAGIS ISRAEL	4MG/SPRAY	A211951 001 Jun 21, 2022	Jul CMKT
NARCAN +! EMERGENT	4MG/SPRAY	N208411 001 Nov 18, 2015	Mar CMKT
RIVIVE +! HARM REDUCTION THERP	3MG/SPRAY	N217722 001 Jul 28, 2023	Jul NEWA

NAPROXEN SODIUM

CAPSULE;ORAL NAPROXEN SODIUM @ STRIDES PHARMA	EQ 200MG BASE	A215472 001 Aug 17, 2022	Feb DISC
---	---------------	--------------------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL NICOTINE POLACRILEX @ FERTIN PHARMA	EQ 4MG BASE	A214354 001 Dec 21, 2022	Jun DISC
---	-------------	--------------------------	----------

NORGESTREL

TABLET;ORAL OPILL + @ LABORATOIRE HRA	0.075MG	N017031 001	Jul CMKT
---	---------	-------------	----------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC OLOPATADINE HYDROCHLORIDE @ AKORN	EQ 0.1% BASE	A204532 001 Jan 10, 2017	Jan DISC
@	EQ 0.2% BASE	A204723 001 Dec 05, 2017	Jan DISC
@ BAUSCH AND LOMB INC	EQ 0.2% BASE	A206087 001 Dec 05, 2017	Dec CAHN
@ CIPLA	EQ 0.2% BASE	A206087 001 Dec 05, 2017	Dec CAHN

>A>
>D>

OMEПRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEПRAZOLE MAGNESIUM

@ AUROBINDO PHARMA LTD EQ 20MG BASE
EQ 20MG BASEA213201 001 Apr 28, 2023 Oct DISC
A213201 001 Apr 28, 2023 Apr NEWAOMEПRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEПRAZOLE AND SODIUM BICARBONATE

AUROBINDO PHARMA 20MG;1.1GM
ZYDUS 20MG;1.1GMA204923 001 Nov 07, 2016 Jun CAHN
A203345 001 Mar 16, 2018 May CAHNPOLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

ELYSIUM 17GM/SCOOPFUL

A202071 001 Dec 28, 2012 Sep CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D> THINQ PHARM-CRO PVT EQ 150MG BASE
>A> @ EQ 150MG BASEA210228 001 Aug 30, 2019 Dec DISC
A210228 001 Aug 30, 2019 Dec DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2023

NO DECEMBER 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	8129385	Oct 05, 2027	DS DP		M-294	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP		NPP	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11680942	Jan 10, 2040	U-3322		I-907	Dec 19, 2025
	11782041	Apr 30, 2038	DP U-2009			
	11782041	Apr 30, 2038	DP U-3543			
	8748382	Oct 03, 2027	U-2009			
	8748382	Oct 03, 2027	U-3543			
	RE49444	Apr 28, 2031	U-2009			
	RE49444	Apr 28, 2031	U-3543			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11091459	Mar 27, 2038	DS DP		NP	Aug 11, 2026
	11207311	Jul 28, 2037		U-2830		
	11673877	Mar 27, 2038	DS DP			
	8071579	Aug 12, 2027		U-2830		
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027		U-2830		
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031		U-2830		
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11091459	Mar 27, 2038	DS DP		NP	Aug 11, 2026
	11207311	Jul 28, 2037		U-2830		
	11673877	Mar 27, 2038	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	8071579	Aug 12, 2027		U-2830		
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027		U-2830		
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031		U-2830		
<u>ABROCITINIB - CIBINOO</u>						
N 213871 001					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 002					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 003					NPP	Feb 09, 2026
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	11771696	Jan 21, 2035		U-3710		
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	11771696	Jan 21, 2035		U-3710		
<u>ACETAMINOPHEN; IBUPROFEN - COMBOGESIC</u>						
N 209471 001	10532036	Sep 22, 2025		U-3553		
	11197830	Feb 27, 2039	DP	U-3553		
	11534407	Feb 27, 2039	DP	U-3553		
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11213498	Jan 14, 2036	DP		NP	Oct 17, 2026
	11389416	Jul 17, 2035	DP			
	11446266	Oct 26, 2031		U-3744		
	11446266	Oct 26, 2031		U-3745		
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001					NCE	Dec 12, 2027
					ODE-352	Dec 12, 2029
<u>ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CAPTREO</u>						
N 216632 001	10220049	Jun 03, 2029	DP	U-3713		
	10624918	Jun 03, 2029		U-3713		
	11389467	Dec 28, 2040	DP	U-3713		
	8288434	Aug 05, 2029	DP	U-3713		
	9561208	Jun 03, 2029	DP	U-3713		
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030		U-3509		
					NP	Jan 10, 2026
<u>ALENDRONATE SODIUM - ALENDRONATE SODIUM</u>						
A 214512 001					CGT	Nov 20, 2023
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-300	Jul 27, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u> N 203414 002					M-300	Jul 27, 2026
<u>ALPELISIB - PIORAY</u> N 212526 001	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIORAY</u> N 212526 002	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIORAY</u> N 212526 003	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - VIJOICE</u> N 215039 001	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u> N 215039 002	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u> N 215039 003	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u> N 020965 001	11571478	Jan 12, 2038	U-3163			
	11690914	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u> N 208081 001	11540981	Feb 07, 2028	DP			
<u>AMLODIPINE BENZOATE - KATERZIA</u> N 211340 001	11701326	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIQVA</u> N 214439 001	11723866	Feb 24, 2041	DP U-3309			
	11723866	Feb 24, 2041	DP U-3310			
	11723866	Feb 24, 2041	DP U-3311			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u> N 213004 001					NP GAIN	Nov 01, 2022 Nov 01, 2027
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR</u> N 208147 001	11590228	Sep 07, 2036	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5</u> N 210526 001	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10</u> N 210526 002	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15</u> N 210526 003	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20</u> N 210526 004	11590081	Sep 24, 2038	DP U-3538			
<u>AMPICILLIN/AMPICILLIN TRIHYDRATE - AMPICILLIN TRIHYDRATE</u> A 216554 001					>A> CGT	Jun 03, 2024
<u>AMPICILLIN/AMPICILLIN TRIHYDRATE - AMPICILLIN TRIHYDRATE</u> A 216554 002					>A> CGT	Jun 03, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	11559559	Dec 18, 2034	U-3514			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	10052314	Sep 23, 2033	U-2381	Y		
	10052314	Sep 23, 2033	U-2382	Y		
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	RE49353	Sep 23, 2033	U-2381			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
<u>APREMILAST - OTEZLA</u>						
N 205437 001				M-299		Jul 20, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 002				M-299		Jul 20, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 003				M-299		Jul 20, 2026
<u>APREPITANT - CINVANTI</u>						
N 209296 001	11744800	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	11744800	Sep 18, 2035	DP U-3690			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 001	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 001	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 002	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
<u>ASENAPINE - SECUADO</u>						
N 212268 001 >A> 11813364		Sep 22, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 002 >A> 11813364		Sep 22, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 003 >A> 11813364		Sep 22, 2033	DP			
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ASPIRIN - VAZALORE</u>						
N 203697 002	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ATOGEPANT - OULIPTA</u>						
N 215206 001	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPANT - OULIPTA</u>						
N 215206 002	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPANT - OULIPTA</u>						
N 215206 003	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11369567	Jun 07, 2037	DP			
	11654106	Jun 07, 2037	DP U-3612			
	11654106	Jun 07, 2037	DP U-3613			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	10947544	Feb 14, 2025	DS	U-3673		
	11273171	Jul 11, 2034		U-3673		
	11491176	Jul 11, 2034		U-3673		
	7538211	Feb 14, 2025	DS			
	7579456	Feb 14, 2025	DS			
	7803931	Feb 14, 2025	DS			
	8236773	Nov 11, 2026		U-3673		
	9617546	Feb 14, 2025	DS	U-3673		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11603356	May 29, 2041	DS DP U-3558			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001				ODE-434	ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002				ODE-434	ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003				ODE-434	ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004 >A> 11827642	9200002 9200002 9944651 9944651 9994575 9994575	Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034	DS DP U-3506 DS DP U-3168 DS DP U-3506 DS DP U-3168 DS DP U-3506 DS DP U-3168	I-912 ODE-434	May 22, 2026 May 22, 2030	
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005				ODE-434	ODE-434	May 22, 2030
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001				NPP	NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001				ODE-399	ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120 001 11571436		May 14, 2029	DP			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002 11571436		May 14, 2029	DP			
<u>BACLOFEN - BACLOFEN</u>						
A 217252 001				PC	PC	Dec 16, 2023
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001 11654124		Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002 11654124		Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003 11654124		Jul 29, 2039	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001 11806555	9737469	Nov 02, 2031	U-3500			
		Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002 11806555	9737469	Nov 02, 2031	U-3500			
		Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003 11806555	9737469	Nov 02, 2031	U-3500			
		Nov 02, 2031	U-3500			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
	11793953	Jan 26, 2038	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
	11793953	Jan 26, 2038	DP			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	>A> 9908845	Sep 05, 2034	DS DP U-3201			
	>A> 9908845	Sep 05, 2034	DS DP U-3780			
	>A> 9969689	Sep 05, 2034	DS DP U-3201			
	>A> 9969689	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11613511	Jun 19, 2040	DS			
	11760714	Jun 19, 2040	DP			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	11613511	Jun 19, 2040	DS			
	11744816	Mar 14, 2036		U-3692		
	11760714	Jun 19, 2040	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - BEIRAPZO</u>						
N 205580 001	>A> 11844783	Jan 28, 2031	U-1542			
	>A> 11844783	Jan 28, 2031	U-1971			
	>A> 11844783	Jan 28, 2031	U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	>A> 11844783	Jan 28, 2031	U-1542			
	>A> 11844783	Jan 28, 2031	U-1971			
	>A> 11844783	Jan 28, 2031	U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA</u>						
N 212209 001	>A> 11844784	Jul 29, 2042	DP			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11541026	Feb 19, 2040	U-3356			
	11628155	Dec 27, 2040	U-3356			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 208683 001				PC		Mar 30, 2024
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11618733	Nov 01, 2039	U-3300			
	11708333	Mar 09, 2035	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11618733	Nov 01, 2039	U-3300			
	11708333	Mar 09, 2035	U-3300			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001	11696919	Mar 18, 2039	DP			
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	11744802	Nov 08, 2036	DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	10005761	Aug 27, 2030	U-2331		>A> I-928	Oct 11, 2026
	10005761	Aug 27, 2030	U-3737			
	7777050	Mar 13, 2024	DS DP			
	9314464	Jul 04, 2031	U-2332			
	9314464	Jul 04, 2031	U-3737			
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE - BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE</u>						
A 217511 001					CGT	Dec 29, 2023
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			ODE-444	Sep 26, 2030
	7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3708		PED	Mar 26, 2031
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			ODE-444	Sep 26, 2030
	7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3708		PED	Mar 26, 2031
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	11103497	Feb 28, 2034	U-3216	I-923	Sep 26, 2026	
	11103497	Feb 28, 2034	U-3217	ODE-163	Dec 19, 2024	
	11103497*PED	Aug 28, 2034		ODE-444	Sep 26, 2030	
	7417148	Dec 11, 2025	U-1283	PED	Jun 19, 2025	
	7417148	Dec 11, 2025	U-3707	PED	Mar 26, 2027	
	7417148	Dec 11, 2025	U-3708	PED	Mar 26, 2031	
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	11103497	Feb 28, 2034	U-3216	I-923	Sep 26, 2026	
	11103497	Feb 28, 2034	U-3217	ODE-163	Dec 19, 2024	
	11103497*PED	Aug 28, 2034		ODE-444	Sep 26, 2030	
	7417148	Dec 11, 2025	U-1283	PED	Jun 19, 2025	
	7417148	Dec 11, 2025	U-3707	PED	Mar 26, 2027	
	7417148	Dec 11, 2025	U-3708	PED	Mar 26, 2031	
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 217729 001	11103497	Feb 28, 2034	U-3216	NP	Sep 26, 2026	
	11103497	Feb 28, 2034	U-3217	ODE-444	Sep 26, 2030	
	11103497*PED	Aug 28, 2034		PED	Mar 26, 2027	
	7417148	Dec 11, 2025	U-3707	PED	Mar 26, 2031	
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS DP			
	RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 217729 002	11103497	Feb 28, 2034	U-3216	NP	Sep 26, 2026	
	11103497	Feb 28, 2034	U-3217	ODE-444	Sep 26, 2030	
	11103497*PED	Aug 28, 2034		PED	Mar 26, 2027	
	7417148	Dec 11, 2025	U-3707	PED	Mar 26, 2031	
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS DP			
	RE42376*PED	Oct 13, 2024				
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	11590209	Apr 29, 2041	U-3539			
<u>BREXIPRAZOLE - REXULTI</u>						
N 205422 001				I-913	May 10, 2026	
<u>BREXIPRAZOLE - REXULTI</u>						
N 205422 002				I-913	May 10, 2026	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 003					I-913	May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 004					I-913	May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 005					I-913	May 10, 2026
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 006					I-913	May 10, 2026
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	11596600	Jul 27, 2029	U-2222			
	>A> 11833245	Jul 27, 2029	U-2222			
<u>BRINZOLAMIDE - BRINZOLAMIDE</u>						
A 211914 001					CGT	Apr 07, 2024
<u>BUDESONIDE - BUDESONIDE</u>						
A 215328 001					CGT	Oct 24, 2023
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					ODE-389	Dec 15, 2028
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 001	10716753	May 28, 2030	DP U-3203			
	9415009	May 28, 2030	U-3203			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	11331442	Oct 05, 2038	DP			
	>A> 11833292	Oct 05, 2038	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	>A> 11819574	Jan 22, 2041	DP U-3250			
	11819575	Jan 22, 2041	DP U-3250			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	>A> 11819574	Jan 22, 2041	DP U-3250			
	11819575	Jan 22, 2041	DP U-3250			
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	11771624	Jan 12, 2041	U-3724			
<u>BUPIVACAINE HYDROCHLORIDE - XARACOLL</u>						
N 209511 001	11746141	Jan 09, 2033	DP			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	>A> 11844837	Apr 21, 2036	U-3417			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	>A> 11844837	Apr 21, 2036	U-3417			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	>A> 11844837	Apr 21, 2036	U-3417			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	>A> 11844837	Apr 21, 2036	U-3417			
<u>BUPRENORPHINE - SUBLOCade</u>						
N 209819 001	>A> 11839611	Nov 06, 2035	U-3111			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCade</u>						
N 209819 002 >A> 11839611		Nov 06, 2035		U-3111		
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	11596627	Nov 05, 2034	U-3419			
	11617728	Nov 05, 2034	U-3419			
	11617747	Nov 05, 2034	U-3563			
	11717518	Jan 20, 2043	U-3419			
	11730706	Jan 23, 2043	U-3419			
	11752144	Feb 23, 2043	U-3419			
	11779579	Nov 05, 2034	U-3419			
>A>	11839612	Mar 02, 2043	U-3419			
>A>	11844797	Apr 20, 2043	U-3778			
CALCIFEDIOL - RAYALDEE						
N 208010 001	11801253	Sep 07, 2030	DP U-3721			
	11801253	Sep 07, 2030	DP U-3722			
	11801253	Sep 07, 2030	DP U-3723			
CALCIUM GLUCONATE - CALCIUM GLUCONATE						
A 216541 001					CGT	Apr 30, 2024
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
A 217174 001					CGT	Mar 10, 2024
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
A 217174 002					CGT	Mar 10, 2024
CALCIUM GLUCONATE - CALCIUM GLUCONATE						
A 217689 001					CGT	Apr 17, 2024
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	11554102	Jan 11, 2033	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 001	11576894	Jul 06, 2030	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	11576894	Jul 06, 2030	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003	11576894	Jul 06, 2030	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004	11576894	Jul 06, 2030	DP			
CANNABIDIOL - EPIDIOLEX						
N 210365 001	11633369	Jun 17, 2035	DP U-2780		M-270	Oct 20, 2026
	11633369	Jun 17, 2035	DP U-2781			
	11633369	Jun 17, 2035	DP U-3071			
	11701330	Jun 17, 2035	U-2780			
	11701330	Jun 17, 2035	U-2781			
	11766411	Jun 17, 2035	U-2781			
CANTHARIDIN - YCANTH						
N 212905 001	11052064	May 28, 2035	DP U-3663			
	11052064	May 28, 2035	DP U-3665			
	11147790	Aug 22, 2038	DP U-3663			
	11147790	Aug 22, 2038	DP U-3664			
CAPIVASERTIB - TRUQAP						
N 218197 001	>A> 10039766	Apr 16, 2033	U-3762		>A> NCE	Nov 16, 2028
	>A> 10059714	Oct 10, 2028	DS DP			
	>A> 10654855	Oct 10, 2028	U-3762			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CAPIVASETIB - TRUQAP</u>						
N 218197 001	>A> 11760760	Oct 10, 2028		U-3762		
	>A> 8101623	Mar 10, 2030	DS DP	U-3762		
	>A> 8809336	Oct 25, 2025		U-3762		
	>A> 9006430	Oct 25, 2025		DP		
	>A> 9487525	Apr 16, 2033	DS DP			
<u>CAPIVASETIB - TRUQAP</u>						
N 218197 002	>A> 10039766	Apr 16, 2033		U-3762		
	>A> 10059714	Oct 10, 2028	DS DP		>A> NCE	Nov 16, 2028
	>A> 10654855	Oct 10, 2028		U-3762		
	>A> 11760760	Oct 10, 2028		U-3762		
	>A> 8101623	Mar 10, 2030	DS DP	U-3762		
	>A> 8809336	Oct 25, 2025		U-3762		
	>A> 9006430	Oct 25, 2025		DP		
	>A> 9487525	Apr 16, 2033	DS DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040		DP		
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11439613	Mar 28, 2039		U-3557		
	>A> 11819485	Mar 28, 2039		U-3557		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP	U-1750	I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP	U-2543		
	7737142	Sep 17, 2029	DS DP	U-2544		
	7737142	Sep 17, 2029	DS DP	U-2545		
	7737142	Sep 17, 2029	DS DP	U-3503		
	RE47350	Jul 16, 2029		U-1750		
	RE47350	Jul 16, 2029		U-2543		
	RE47350	Jul 16, 2029		U-2544		
	RE47350	Jul 16, 2029		U-2545		
	RE47350	Jul 16, 2029		U-3503		
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110	Jul 16, 2029		U-3503		
	RE49302	Jul 16, 2029		U-2543		
	RE49302	Jul 16, 2029		U-2544		
	RE49302	Jul 16, 2029		U-2545		
	RE49302	Jul 16, 2029		U-3503		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP	U-1750	I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP	U-2543		
	7737142	Sep 17, 2029	DS DP	U-2544		
	7737142	Sep 17, 2029	DS DP	U-2545		
	7737142	Sep 17, 2029	DS DP	U-3503		
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110	Jul 16, 2029		U-3503		
	RE49302	Jul 16, 2029		U-2543		
	RE49302	Jul 16, 2029		U-2544		
	RE49302	Jul 16, 2029		U-2545		
	RE49302	Jul 16, 2029		U-3503		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029		U-2543	I-904	Dec 16, 2025
	RE49302	Jul 16, 2029		U-2544		
	RE49302	Jul 16, 2029		U-2545		
	RE49302	Jul 16, 2029		U-3503		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 001	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 002	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 003	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 004	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 005	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 006	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S</u>						
N 208288 001					M-292	Jan 20, 2026
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2024	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001 >A>	8143240	Jan 12, 2025	U-2942			
	8865690	Jul 24, 2024	U-2942			
	9211295	Jul 24, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11597699	Oct 05, 2026	U-3554		ODE-416	Oct 28, 2029
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001	10016407	Feb 07, 2037	U-2225			
	10016407	Feb 07, 2037	U-2226			
	10016407	Feb 07, 2037	U-2329			
	10149843	Feb 07, 2037	U-2478			
	10149843	Feb 07, 2037	U-2479			
	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-3014			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001	10420760	Feb 07, 2037	U-2478			
	10857095	Feb 07, 2037	U-3014			
	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-2478			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-3680			
	11040032	Feb 07, 2037	DP			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
	9867815	Feb 07, 2037	U-2329			
<u>COLCHICINE - COLCHICINE</u>						
A 208678 001					PC	Apr 29, 2024
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	Dec 31, 2034	U-3642			
	10206891	Jan 22, 2035	U-3641			
	10265281	Jan 22, 2035	U-3639			
	10842762	Jan 22, 2035	U-3640			
	11026899	Jan 22, 2035	U-3639			
	11026900	Jan 22, 2035	U-3639			
	11026901	Jan 22, 2035	U-3638			
	9744144	Jan 22, 2035	U-3643			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001					D-191	Apr 03, 2026
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 217581 001	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N 217581 002	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N 217581 003	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N 217581 003	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11786548	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11786548	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003	11786548	Jul 01, 2041	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735 003	9662342	Jun 26, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 001	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 002	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 003	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	11612658	Jan 27, 2026	U-3560		NP	Jun 23, 2024
<u>CYCLOSPORINE - VEVYE</u>						
N 217469 001	10813976	Sep 22, 2037	DP		NP	May 30, 2026
	11154513	Nov 20, 2038	DP U-1900			
	11413323	Oct 11, 2039	U-3627			
	8614178	Dec 13, 2030	DP			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149			
	10028912	Oct 15, 2032	DP U-3150			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034	I-908		Mar 16, 2026	
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP		ODE-428	Mar 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8703781	Oct 15, 2030	DS DP U-3565			
	8835443	Jun 10, 2025	U-3565			
DALBAVANCIN HYDROCHLORIDE - DALVANCE						
N 021883 001	6900175	May 23, 2028		U-3499		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					M-298	May 08, 2026
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002 >A> 11826376		Jul 18, 2039	U-3766		M-298	May 08, 2026
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 001	11759497	Aug 28, 2038	DP			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 002	11759497	Aug 28, 2038	DP			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	8975254	Mar 25, 2033	DS DP U-2605			
<u>DARUNAVIR - DARUNAVIR</u>						
A 202073 002					PC	Nov 28, 2023
<u>DASATINIB - PHYRAGO</u>						
N 216099 001 >A> 11202778		Jan 22, 2041	U-3770			
>A> 11202778		Jan 22, 2041	U-3771			
>A> 11202778		Jan 22, 2041	U-3772			
>A> 11298356		Jan 22, 2041	DP			
>A> 11324745		Jan 22, 2041	U-3767			
>A> 11324745		Jan 22, 2041	U-3768			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099 001	>A> 11324745	Jan 22, 2041	U-3769			
<u>DASATINIB - PHYRAGO</u>						
N 216099 002	>A> 11202778	Jan 22, 2041	U-3770			
	>A> 11202778	Jan 22, 2041	U-3771			
	>A> 11202778	Jan 22, 2041	U-3772			
	>A> 11298356	Jan 22, 2041	DP			
	>A> 11324745	Jan 22, 2041	U-3767			
	>A> 11324745	Jan 22, 2041	U-3768			
	>A> 11324745	Jan 22, 2041	U-3769			
<u>DASATINIB - PHYRAGO</u>						
N 216099 003	>A> 11202778	Jan 22, 2041	U-3770			
	>A> 11202778	Jan 22, 2041	U-3771			
	>A> 11202778	Jan 22, 2041	U-3772			
	>A> 11298356	Jan 22, 2041	DP			
	>A> 11324745	Jan 22, 2041	U-3767			
	>A> 11324745	Jan 22, 2041	U-3768			
	>A> 11324745	Jan 22, 2041	U-3769			
<u>DASATINIB - PHYRAGO</u>						
N 216099 004	>A> 11202778	Jan 22, 2041	U-3770			
	>A> 11202778	Jan 22, 2041	U-3771			
	>A> 11202778	Jan 22, 2041	U-3772			
	>A> 11298356	Jan 22, 2041	DP			
	>A> 11324745	Jan 22, 2041	U-3767			
	>A> 11324745	Jan 22, 2041	U-3768			
	>A> 11324745	Jan 22, 2041	U-3769			
<u>DASATINIB - PHYRAGO</u>						
N 216099 005	>A> 11202778	Jan 22, 2041	U-3770			
	>A> 11202778	Jan 22, 2041	U-3771			
	>A> 11202778	Jan 22, 2041	U-3772			
	>A> 11298356	Jan 22, 2041	DP			
	>A> 11324745	Jan 22, 2041	U-3767			
	>A> 11324745	Jan 22, 2041	U-3768			
	>A> 11324745	Jan 22, 2041	U-3769			
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	>A> 11202778	Jan 22, 2041	U-3770			
	>A> 11202778	Jan 22, 2041	U-3771			
	>A> 11202778	Jan 22, 2041	U-3772			
	>A> 11298356	Jan 22, 2041	DP			
	>A> 11324745	Jan 22, 2041	U-3767			
	>A> 11324745	Jan 22, 2041	U-3768			
	>A> 11324745	Jan 22, 2041	U-3769			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	11795204	Jan 06, 2034	U-3752			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	11795204	Jan 06, 2034	U-3752			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001				ODE-417	Apr 30, 2028	
				ODE-420	Apr 30, 2028	
				ODE-421	Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002				ODE-417	Apr 30, 2028	
				ODE-420	Apr 30, 2028	
				ODE-421	Apr 30, 2028	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001					ODE-417 ODE-418 ODE-419	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002					ODE-417 ODE-418 ODE-419	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	11723874	Oct 25, 2038	U-3083		ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11746348	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	11766468	Apr 27, 2032	U-1978			
>A>	11826397	Apr 27, 2032	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	11766468	Apr 27, 2032	U-1978			
>A>	11826397	Apr 27, 2032	U-1978			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
>A>	11666566	Sep 18, 2033	DP			
>A>	11666566*PED	Mar 18, 2034				
>A>	11813232	Mar 15, 2038	DP			
>A>	11813232*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
>A>	11666566	Sep 18, 2033	DP			
>A>	11666566*PED	Mar 18, 2034				
>A>	11813232	Mar 15, 2038	DP			
>A>	11813232*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
>A>	11666566	Sep 18, 2033	DP			
>A>	11666566*PED	Mar 18, 2034				
>A>	11813232	Mar 15, 2038	DP			
>A>	11813232*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
>A>	11813232	Mar 15, 2038	DP			
>A>	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
>A>	11813232	Mar 15, 2038	DP			
>A>	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
>A>	11813232	Mar 15, 2038	DP			
>A>	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXAMETHASONE - DEXAMETHASONE</u>						
A 217695 003				CGT		Apr 29, 2024
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001				NPP		Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002				NPP		Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003				NPP		Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004				NPP		Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 005				NPP		Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
	11786508	Dec 29, 2037	U-3698			
	11806334	Jan 12, 2043	U-3725			
>A>	11839604	Dec 29, 2037	U-3756			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
	11786508	Dec 29, 2037	U-3698			
	11806334	Jan 12, 2043	U-3725			
>A>	11839604	Dec 29, 2037	U-3756			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	11559501	Jan 06, 2042	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	11793786	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	11793786	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	11793786	Mar 27, 2029	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 001	10398785	Mar 14, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 002	10398785	Mar 14, 2036	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 003	10398785	Mar 14, 2036	DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
<u>DOXE PIN HYDROCHLORIDE - DOXE PIN HYDROCHLORIDE</u>						
A 215408 001				CGT		Aug 16, 2023
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11793760	Jun 17, 2036	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
	11617751	Jul 17, 2030	DP U-3573			
	11617751	Jul 17, 2030	DP U-3574			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
<u>DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)</u>						
N 216974 001	10376499	Nov 17, 2035	DP U-2840		NCE	May 23, 2028
	9309245	Apr 02, 2033	DS		GAIN	May 23, 2033
	9623014	Apr 02, 2033		U-2840		
	9968593	Nov 17, 2035	DP U-2840			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11826352	Nov 01, 2039	DP			
<u>EDETAE CALCIUM DISODIUM - EDETAE CALCIUM DISODIUM</u>						
A 216435 001					CGT	Jan 08, 2024
<u>EFINAConazole - JUBLIA</u>						
N 203567 001	11654139	Oct 02, 2034		U-1969		
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	10071066	Oct 10, 2034		U-3524		
	10385008	Jan 05, 2038	DS DP		NCE	Jan 27, 2028
	10420734	Oct 10, 2034		U-3524		
	10745343	Jan 05, 2038		U-3523		
	11779552	Oct 10, 2034		U-3524		
>A>	11819480	Nov 29, 2036		U-3523		
	7612114	Aug 18, 2026	DS DP	U-3523		
	8399520	Dec 25, 2024	DS DP	U-3523		
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	10071066	Oct 10, 2034		U-3524		
	10385008	Jan 05, 2038	DS DP		NCE	Jan 27, 2028
	10420734	Oct 10, 2034		U-3524		
	10745343	Jan 05, 2038		U-3523		
	11779552	Oct 10, 2034		U-3524		
>A>	11819480	Nov 29, 2036		U-3523		
	7612114	Aug 18, 2026	DS DP	U-3523		
	8399520	Dec 25, 2024	DS DP	U-3523		
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040		U-3654		
	11690854	Apr 19, 2038		U-3653		
	11707464	Mar 14, 2034		U-3672		
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040		U-3654		
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040		U-3655		
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029		U-3525		
	11578062	Mar 25, 2031	DP	U-3544		
	11639347	Apr 09, 2027	DS DP	U-3587		
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11564916	Aug 13, 2029		U-3525		
	11578062	Mar 25, 2031	DP	U-3544		
	11639347	Apr 09, 2027	DS DP	U-3587		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	11752106	Feb 27, 2033	DP U-3696			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	11752106	Feb 27, 2033	DP U-3696			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-869	Aug 18, 2024
	10258637*PED	Oct 03, 2034			I-922	Sep 21, 2026
	11090323	Apr 03, 2034	U-3191		M-82	Feb 24, 2025
	11090323*PED	Oct 03, 2034			NPP	Jun 20, 2026
	11666590	Apr 03, 2034	U-3691		PED	Aug 24, 2025
>A>	11813275	Apr 03, 2034	U-3759		PED	Dec 20, 2026
>A>	11813275	Apr 03, 2034	U-3760			
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11813275	Apr 03, 2034	U-3759			
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11813275	Apr 03, 2034	U-3759			
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11813275	Apr 03, 2034	U-3759			
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11813275	Apr 03, 2034	U-3759			
>A>	11833166	Apr 03, 2034	U-3776			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002 >A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
>A>	11833166	Apr 03, 2034	U-3776			
>A>	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001				>A> I-928	Oct 11, 2026	
				ODE-445	Oct 11, 2030	
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		>A> I-928	Oct 11, 2026
	10005761	Aug 27, 2030	U-2802		ODE-445	Oct 11, 2030
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	8501758	Aug 27, 2030	DS DP			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	RE49556	Feb 27, 2030	DS DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001				>A> NPP ODE-448	Oct 20, 2026 Oct 20, 2030	
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002				>A> NPP ODE-448	Oct 20, 2026 Oct 20, 2030	
<u>ENTRECTINIB - ROZLYTREK</u>						
N 218550 001				NCE NP ODE-448	Aug 15, 2024 Oct 20, 2026 Oct 20, 2030	
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	>A> 8183274	Aug 24, 2026	U-1281		>A> I-926	Nov 17, 2026
	>A> 8183274	Aug 24, 2026	U-1588			
	>A> 8183274	Aug 24, 2026	U-2345			
	>A> 8183274	Aug 24, 2026	U-2708			
	>A> 8183274	Aug 24, 2026	U-3763			
	>A> 9126941	May 15, 2026	U-1588			
	>A> 9126941	May 15, 2026	U-2345			
	>A> 9126941	May 15, 2026	U-2708			
	>A> 9126941	May 15, 2026	U-3763			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	>A> 11839689	Sep 11, 2033	DP		>A> I-926	Nov 17, 2026
	>A> 8183274	Aug 24, 2026	U-2345			
	>A> 8183274	Aug 24, 2026	U-2708			
	>A> 8183274	Aug 24, 2026	U-3763			
	>A> 9126941	May 15, 2026	U-2345			
	>A> 9126941	May 15, 2026	U-2708			
	>A> 9126941	May 15, 2026	U-3763			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	>A> 11839689	Sep 11, 2033	DP		>A> I-926	Nov 17, 2026
	>A> 8183274	Aug 24, 2026	U-2345			
	>A> 8183274	Aug 24, 2026	U-2708			
	>A> 8183274	Aug 24, 2026	U-3763			
	>A> 9126941	May 15, 2026	U-2345			
	>A> 9126941	May 15, 2026	U-2708			
	>A> 9126941	May 15, 2026	U-3763			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11571398	May 16, 2040		U-3183		
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040	U-3183			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	11590286	Dec 12, 2026		DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	11590286	Dec 12, 2026	DP			
	>A> 11771830	Dec 21, 2037	DP U-2980			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	11590286	Dec 12, 2026	DP			
>A> 11771830						
Dec 21, 2037						
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 001	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 002	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 003	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 004	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 005	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	11578044	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	11578044	Oct 19, 2037	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036		U-3065		
	11684620	Feb 09, 2036		U-3066		
	11684620	Feb 09, 2036		U-3067		
	8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036		U-3065		
	11684620	Feb 09, 2036		U-3066		
	11684620	Feb 09, 2036		U-3067		
	8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036		U-3065		
	11684620	Feb 09, 2036		U-3066		
	11684620	Feb 09, 2036		U-3067		
	8895601	Apr 12, 2033	DS DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002					NPP	May 12, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021365 001					NPP	May 12, 2026
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11793812	May 03, 2038	U-2360		M-289	Jan 27, 2026
	11795178	Sep 27, 2033	DS DP			
>A>	7300935	Jan 28, 2025	DS			
>A>	8058280	Jan 28, 2025	DS			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11793819	Nov 21, 2032	U-2439			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11793819	Nov 21, 2032	U-2439			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	10301262	Jun 21, 2036	DS DP		NCE	Oct 12, 2028
	10676435	Jun 21, 2036	U-3731			
	11007175	Jan 06, 2036	U-3730			
	11091435	Jun 21, 2036	DS DP			
	8580841	Mar 05, 2030	DS DP			
	9126932	Jul 22, 2029	U-3732			
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	7528143	Nov 16, 2031	DS DP			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	>A> 11759440	Aug 02, 2037	U-3694		ODE-393	Mar 25, 2029
	>A> 11759440*PED	Feb 02, 2038			PED	Sep 25, 2029
	>A> 11786487	Aug 02, 2037	U-3733			
	>A> 11786487*PED	Feb 02, 2038				
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP	U-3312		
	11590097	Oct 20, 2023	DS DP	U-3313		
	7754702	Feb 15, 2028		U-2555		
	7754702	Feb 15, 2028		U-2556		
	7754702	Feb 15, 2028		U-2557		
	7754702	Feb 15, 2028		U-3312		
	7754702	Feb 15, 2028		U-3313		
	7754702	Feb 15, 2028		U-3314		
	7754702	Feb 15, 2028		U-3636		
	8895612	Jan 08, 2027		U-1620		
	8895612	Jan 08, 2027		U-3050		
	8895612	Jan 08, 2027		U-3051		
	8895612	Jan 08, 2027		U-3115		
	8895612	Jan 08, 2027		U-3116		
	8895612	Jan 08, 2027		U-3315		
	8895612	Jan 08, 2027		U-3316		
	8895612	Jan 08, 2027		U-3635		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP	U-3312		
	11590097	Oct 20, 2023	DS DP	U-3313		
	7754702	Feb 15, 2028		U-2555		
	7754702	Feb 15, 2028		U-2556		
	7754702	Feb 15, 2028		U-2557		
	7754702	Feb 15, 2028		U-3312		
	7754702	Feb 15, 2028		U-3313		
	7754702	Feb 15, 2028		U-3314		
	7754702	Feb 15, 2028		U-3636		
	8895612	Jan 08, 2027		U-1620		
	8895612	Jan 08, 2027		U-3050		
	8895612	Jan 08, 2027		U-3051		
	8895612	Jan 08, 2027		U-3115		
	8895612	Jan 08, 2027		U-3116		
	8895612	Jan 08, 2027		U-3315		
	8895612	Jan 08, 2027		U-3316		
	8895612	Jan 08, 2027		U-3635		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP	U-3312		
	11590097	Oct 20, 2023	DS DP	U-3313		
	7754702	Feb 15, 2028		U-3312		
	7754702	Feb 15, 2028		U-3313		
	7754702	Feb 15, 2028		U-3314		
	7754702	Feb 15, 2028		U-3636		
	8895612	Jan 08, 2027		U-3115		
	8895612	Jan 08, 2027		U-3116		
	8895612	Jan 08, 2027		U-3315		
	8895612	Jan 08, 2027		U-3316		
	8895612	Jan 08, 2027		U-3635		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP	U-3312		
	11590097	Oct 20, 2023	DS DP	U-3313		
	7754702	Feb 15, 2028		U-3312		
	7754702	Feb 15, 2028		U-3313		
	7754702	Feb 15, 2028		U-3314		
	7754702	Feb 15, 2028		U-3636		
	8895612	Jan 08, 2027		U-3115		
	8895612	Jan 08, 2027		U-3116		
	8895612	Jan 08, 2027		U-3315		
	8895612	Jan 08, 2027		U-3316		
	8895612	Jan 08, 2027		U-3635		
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11633489	Jun 22, 2036		U-3594		
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11633489	Jun 22, 2036		U-3594		
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11633489	Jun 22, 2036		U-3594		
<u>FEZOLINETANT - VEOZAH</u>						
N 216578 001	10836768	Mar 28, 2034		U-3621		
	8871761	Apr 04, 2031	DS			
	9422299	Mar 28, 2034	DS DP	U-3622		
	9987274	Mar 28, 2034		U-3622		
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 001	8932557	May 26, 2032	DS			
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 002	8932557	May 26, 2032	DS			
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 003	8932557	May 26, 2032	DS			
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 004	8932557	May 26, 2032	DS			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	11413360	Nov 22, 2038	DS	U-3614		
	11413360	Nov 22, 2038	DS	U-3615		
<u>FLUORESCIN SODIUM - FLUORESCEIN SODIUM</u>						
A 215709 001					CGT	Apr 21, 2024
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8746242	Oct 11, 2030		DP		
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030		DP		
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027		DP		
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	8113199	Oct 23, 2027		DP		M-290 Mar 01, 2026
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028		DP		
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030		DP		
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030		DP		
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027		DP		
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	7439393	May 21, 2025	DS DP U-2127			
	7439393	May 21, 2025	DS DP U-2957			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-2954			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 002	7439393	May 21, 2025	DS DP U-2957			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-2954			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	11116721	Feb 26, 2029	DP U-1401		NPP	May 13, 2026
	11116721	Feb 26, 2029	DP U-1691		PED	Nov 13, 2026
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1401			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1424			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8511304	Jun 14, 2027	DP U-1691			
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	11116721	Feb 26, 2029	DP U-1691			
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1691			
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 003	11116721	Feb 26, 2029	DP U-3623		NS	May 13, 2026
	11116721*PED	Aug 26, 2029			PED	Nov 13, 2026
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	8522778	Apr 20, 2024	DP			
<u>FOSAPREPITANT DIMEGLUMINE - FOCINVEZ</u>						
N 216686 001	11065265	Jan 11, 2039	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001 >A> 7449458		Sep 04, 2031	DS			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002 >A> 7449458		Sep 04, 2031	DS			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001	10519142	Sep 07, 2035	DS DP U-3753			
	11046674	Sep 07, 2035	U-3753			
	7829574	May 09, 2028	DS DP			
	8212033	May 09, 2028	U-3753			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002	10519142	Sep 07, 2035	DS DP U-3753			
	11046674	Sep 07, 2035	U-3753			
	7829574	May 09, 2028	DS DP			
	8212033	May 09, 2028	U-3753			
<u>FUTIBATINIB - LYTGOBI</u>						
N 214801 001 >A> 11833151		Nov 05, 2039	DP		ODE-410	Sep 30, 2029
<u>GADOBUTROL - GADOBUTROL</u>						
A 216081 001					CGT	Apr 29, 2024
<u>GADOBUTROL - GADOBUTROL</u>						
A 216081 002					CGT	Apr 29, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	11590246	Jan 17, 2040	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 001	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 002	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 003	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 004	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	9133461	Nov 30, 2033	DS DP U-2672			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 214874 001					CGT	Apr 15, 2024
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOOPEN</u>						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOOPEN</u>						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE KIT</u>						
N 212097 005	11590205	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	>A> 11839656	Nov 02, 2031		U-2625		
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11648256	Jun 06, 2036	DP	U-2625		
	11679115	Jun 06, 2036	DP	U-2625		
	>A> 11839656	Nov 02, 2031		U-2625		
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001	>A> 11738120	Apr 15, 2042	DS	DP		
	>A> 7696182	May 16, 2025	DS	DP	U-3774	
	>A> 8541393	Nov 02, 2024	DS	DP	U-3774	
	>A> 9339036	Nov 02, 2024	DS	DP		
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002	>A> 11738120	Apr 15, 2042	DS	DP		
	>A> 7696182	May 16, 2025	DS	DP	U-3774	
	>A> 8541393	Nov 02, 2024	DS	DP	U-3774	
	>A> 9339036	Nov 02, 2024	DS	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	>A> 11844865	Feb 13, 2025		DP	U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	>A> 11844865	Feb 13, 2025		DP	U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	>A> 11844865	Feb 13, 2025		DP	U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	>A> 11844865	Feb 13, 2025		DP	U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	>A> 11844865	Feb 13, 2025		DP	U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	>A> 11844865	Feb 13, 2025		DP	U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	>A> 11844865	Feb 13, 2025		DP	U-1556	
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 006	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 007	>A> 9248229	Mar 12, 2034	DP			
	>A> 9731082	Apr 23, 2032	DP			
<u>IBREXAFUNGERP CITRATE - BREXAFAFEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10478439	Jun 03, 2031	U-1650		ODE-109	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE-117	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE-152	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 02, 2025
	10478439	Jun 03, 2031	U-2665		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10478439	Jun 03, 2031	U-1650	ODE*	Mar 04, 2023	
	10478439	Jun 03, 2031	U-1684	ODE*	May 06, 2023	
	10478439	Jun 03, 2031	U-1946	ODE*	Aug 02, 2024	
	10478439	Jun 03, 2031	U-2241	ODE-405	Aug 24, 2029	
	10478439	Jun 03, 2031	U-2242	PED	Feb 24, 2030	
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
IBRUTINIB - IMBRUVICA						
N 210563 002	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10106548	Jun 03, 2033	DS DP		ODE-405	Aug 24, 2029
	10106548*PED	Dec 03, 2033			PED	Feb 24, 2030
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034		U-3422		
	9795604*PED	Apr 24, 2035				
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	11806400	Mar 16, 2032		U-3746		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003	11806400	Mar 16, 2032		U-3746		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11717504	Apr 29, 2030		U-3669		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11717504	Apr 29, 2030		U-3669		
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP	U-3652		
	10131907	Aug 24, 2028	DS DP	U-3652		
	10266825	Nov 04, 2023		U-3652		
	10851377	Aug 25, 2036		U-3652		
	11078485	Nov 04, 2023	DS	U-3652		
	8106022	Dec 12, 2029	DS DP	U-3652		
	8222222	Dec 29, 2027		U-3652		
	8809292	May 10, 2027	DS DP	U-3652		
	8828956	Dec 04, 2028	DS DP	U-3652		
	9370582	Dec 04, 2028	DS DP	U-3652		
	9708610	Jan 01, 2024	DS DP	U-3652		
<u>INDIGOTINDISULFONATE SODIUM - BLUDIGO</u>						
N 216264 001 >A> 11845867		Nov 25, 2036	DS			
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001	11712320	Jul 14, 2039	DP		I-911	Jun 05, 2026
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 216184 001					CGT	Jan 30, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001 >A> 11603363		May 25, 2041	DS DP			
>A> 9682968		Jul 14, 2034	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	10206879	Sep 14, 2027	DP		NCE	Mar 06, 2020
	10206879*PED	Mar 14, 2028			ODE-305	Mar 06, 2022
	10603280	Sep 14, 2027	DP		ODE-90	Mar 06, 2022
	10603280*PED	Mar 14, 2028			PED	Sep 06, 2020
	6812238	Oct 31, 2025	DS		PED	Sep 06, 2022
	6812238*PED	May 01, 2026			PED	Sep 06, 2022
					GAIN	Sep 06, 2025
					GAIN	Sep 06, 2027
					GAIN	Sep 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002	10206879	Sep 14, 2027	DP		NCE	Mar 06, 2020
	10206879*PED	Mar 14, 2028			ODE*	Mar 06, 2022
	10603280	Sep 14, 2027	DP		PED	Sep 06, 2020
	10603280*PED	Mar 14, 2028			PED	Sep 06, 2022
	6812238	Oct 31, 2025	DS		GAIN	Sep 06, 2025
	6812238*PED	May 01, 2026			GAIN	Sep 06, 2027
					GAIN	Sep 06, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238 6812238*PED	Oct 31, 2025 May 01, 2026	DS		NCE ODE-305 ODE-90 PED PED PED GAIN GAIN GAIN	Mar 06, 2020 Mar 06, 2022 Mar 06, 2022 Sep 06, 2020 Sep 06, 2022 Sep 06, 2022 Sep 06, 2025 Sep 06, 2027 Sep 06, 2027
<u>ISTRADERFYLLINE - NOURIANZ</u>						
N 022075 001	7727993	Jan 28, 2028	DP U-2623			
<u>ISTRADERFYLLINE - NOURIANZ</u>						
N 022075 002	7727993	Jan 28, 2028	DP U-2623			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	11564916	Aug 13, 2029	U-3530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11564916 11752106	Aug 13, 2029 Feb 27, 2033	U-3528 DP U-3697		ODE-435	May 03, 2030
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11564916 11752106	Aug 13, 2029 Feb 27, 2033	U-3528 DP U-3697		ODE-435	May 03, 2030
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11564916 11752106	Aug 13, 2029 Feb 27, 2033	U-3528 DP U-3697		ODE-435	May 03, 2030
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10272046 10646481 11147770 11564916 11752106 7495103 8324242 8354427 8410274 8629162 8754224 8883206 9670163	Feb 27, 2033 Aug 13, 2029 Feb 27, 2033 Aug 13, 2029 Feb 27, 2033 May 20, 2027 Aug 05, 2027 Jul 06, 2026 Dec 28, 2026 Jun 24, 2025 Dec 28, 2026 Feb 27, 2033 Dec 28, 2026	DP U-3605 DP DP U-3604 U-3603 DP U-3697 DS DP U-3609 U-3608 DP U-3607 DS DP DP DP U-3606		NPP ODE-435	May 03, 2026 May 03, 2030
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10272046 10646481 11147770 11564916 11752106 7495103 8324242 8354427 8410274 8629162 8754224 8883206 9670163	Feb 27, 2033 Aug 13, 2029 Feb 27, 2033 Aug 13, 2029 Feb 27, 2033 May 20, 2027 Aug 05, 2027 Jul 06, 2026 Dec 28, 2026 Jun 24, 2025 Dec 28, 2026 Feb 27, 2033 Dec 28, 2026	DP U-3605 DP DP U-3604 U-3603 DP U-3697 DS DP U-3609 U-3608 DP U-3607 DS DP DP DP U-3606		NPP ODE-435	May 03, 2026 May 03, 2030
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916 11578062 11639347	Aug 13, 2029 Mar 25, 2031 Apr 09, 2027	U-3527 DP U-3545 DS DP U-2569			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10980788	Jun 07, 2039	U-3112		I-924	Oct 24, 2026
	10980788	Jun 07, 2039	U-3113		ODE-447	Oct 24, 2030
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	10980788	Jun 07, 2039	U-3743			
	11667673	Jan 18, 2033	U-3742			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9474779	Aug 19, 2033	DS DP U-3742			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-3742			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001				D-188		Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002				D-188		Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003				D-188		Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004				D-188		Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001				D-188		Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001				D-188		Apr 28, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11191766	Apr 04, 2037	U-2471			
	11484535	Apr 04, 2037	U-2470			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Feb 17, 2028	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Feb 17, 2028	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	7423050	Feb 17, 2028	DS DP U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11618748	Jan 27, 2030	U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001				ODE*		Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002				ODE*		Apr 07, 2024
				ODE*		Aug 28, 2026
				PED		Oct 07, 2024
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001				M-293		Apr 20, 2026
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002				M-293		Apr 20, 2026
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
<u>LENIOLISIB PHOSPHATE - JOENJA</u>						
N 217759 001	8653092	Feb 19, 2032	DS DP		NCE	Mar 24, 2028
					ODE-430	Mar 24, 2030
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	11090386	Feb 23, 2036	U-3519			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	11090386	Feb 23, 2036	U-3519			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 001				D-189 I-916 ODE-423	Aug 02, 2026 Jun 05, 2026 Jun 05, 2030	
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 002				D-189 I-916 ODE-423	Aug 02, 2026 Jun 05, 2026 Jun 05, 2030	
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 001				D-189 I-916 ODE-423	Aug 02, 2026 Jun 05, 2026 Jun 05, 2030	
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 002				D-189 I-916 ODE-423	Aug 02, 2026 Jun 05, 2026 Jun 05, 2030	
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT</u>						
N 020263 009	8921326 9617303	Feb 05, 2031 Mar 22, 2028	DP U-3611		NS	Apr 14, 2026
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	11717555	Jan 01, 2039	DP			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001					ODE-385	Dec 30, 2028
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 001	11541012	Mar 25, 2039	DP			
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 002	11541012	Mar 25, 2039	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11628088	Feb 07, 2027	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	11571328	Sep 07, 2040	DP		I-917	Jun 29, 2026
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11628088	Feb 07, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	>A> 11241382	Sep 17, 2039		U-3757		
	>A> 11241382	Sep 17, 2039		U-3758		
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	11786455	May 10, 2031		DP	U-2267	
	11793766	May 10, 2031			U-2267	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	11786455 11793766	May 10, 2031 May 10, 2031	DP U-2267 U-2267			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001					I-921	Jun 12, 2026
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10702576 10702576 7304036 7304036 8110553 8110553 8933030 8933030 9708371 9708371	Aug 11, 2031 Aug 11, 2031 Aug 30, 2026 Aug 30, 2026 Jan 28, 2024 Jan 28, 2024 Feb 17, 2031 Feb 17, 2031 Aug 16, 2033 Aug 16, 2033	U-1516 U-3644 DS DP U-1516 DS DP U-3644 U-1516 U-3644 DP U-1516 DP U-3644 DP U-1516 DP U-3644		I-921	Jun 12, 2026
<u>LINAGLIPITIN - TRADJENTA</u>						
N 201280 001	10034877 10034877*PED 11033552 11033552*PED 7407955 7407955*PED 8673927 8673927*PED 8846695 8846695*PED 8853156 8853156*PED 8883805 8883805*PED 9486526 9486526*PED	Aug 05, 2029 Feb 05, 2030 May 04, 2027 Nov 04, 2027 May 02, 2025 Nov 02, 2025 May 04, 2027 Nov 04, 2027 Jun 04, 2030 Dec 04, 2030 Mar 05, 2031 Sep 05, 2031 Nov 26, 2025 May 26, 2026 Aug 05, 2029 Feb 05, 2030	U-2347 DP DS DP U-1503 U-1503 U-1503 DP U-1642 DP DP U-1915		M-295 PED	Jun 20, 2026 Dec 20, 2026
<u>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10022379 10022379*PED 10973827 10973827*PED 7407955 7407955*PED 8673927 8673927*PED 8846695 8846695*PED 8883805 8883805*PED 9155705 9155705*PED 9415016 9415016*PED	Apr 02, 2029 Oct 02, 2029 Apr 02, 2029 Oct 02, 2029 May 02, 2025 Nov 02, 2025 May 04, 2027 Nov 04, 2027 Jun 04, 2030 Dec 04, 2030 Nov 26, 2025 May 26, 2026 May 21, 2030 Nov 21, 2030 Apr 02, 2029 Oct 02, 2029	U-2339 DP DS DP U-1503 U-1503 DP DP DP DP DP DP DP DP DP DP		M-295 PED	Jun 20, 2026 Dec 20, 2026
<u>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10022379 10022379*PED 10973827 10973827*PED 7407955 7407955*PED 8673927 8673927*PED 8846695 8846695*PED 8883805 8883805*PED	Apr 02, 2029 Oct 02, 2029 Apr 02, 2029 Oct 02, 2029 May 02, 2025 Nov 02, 2025 May 04, 2027 Nov 04, 2027 Jun 04, 2030 Dec 04, 2030 Nov 26, 2025 May 26, 2026	U-2339 DP DS DP U-1503 U-1503 DP		M-295 PED	Jun 20, 2026 Dec 20, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
<u>LISINOPRIL - QBRELIS</u>						
N 208401 001	11771733	Nov 06, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LITHIUM CITRATE - LITHIUM CITRATE</u>						
A 218036 001					CGT	Mar 18, 2024
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	8828356	Oct 17, 2024	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	8828356	Oct 17, 2024	U-3070			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	11534395	Jan 26, 2036	DP U-2764			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11642317	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11596599	May 03, 2033	U-2985			
	11642317	May 03, 2033	DP			
<u>LOTILANER - XDEMVY</u>						
N 217603 001	10835517	Dec 14, 2038	U-3674		NCE	Jul 24, 2028
	11197847	Dec 14, 2038	U-3674			
	11690826	Dec 14, 2038	U-3674			
	11690827	Dec 14, 2038	U-3674			
	11752137	Dec 14, 2038	DP			
	8383659	Jan 17, 2030	DS DP			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001					ODE-415	Oct 06, 2029
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
>A>	9168258	May 27, 2029	DP			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	7763615	Dec 13, 2029	DS DP U-2836			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001				NP		Jun 15, 2026
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135 001	11638697	Aug 04, 2037	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001				NPP		Mar 13, 2026
				ODE-429		Mar 13, 2030
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	11684632	Jan 04, 2032	U-3650		ODE-388	Nov 23, 2028
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001				M-297		Jun 15, 2026
				ODE-398		Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002				M-297		Jun 15, 2026
				ODE-398		Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003				M-297		Jun 15, 2026
				ODE-398		Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004				M-297		Jun 15, 2026
				ODE-398		Apr 28, 2029
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	6992207	Jun 25, 2024	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - HEPZATO</u>						
N 201848 001	10098997	Nov 07, 2032	DP		NP	Aug 14, 2026
	10195334	Jan 16, 2033	DP		ODE-438	Aug 14, 2030
	10369264	Nov 07, 2032	DP			
	10569004	Nov 07, 2032	U-3680			
	10569004	Nov 07, 2032	U-3683			
	11083831	Dec 30, 2032	DP			
	11241522	Nov 07, 2032	DP			
	11633528	Nov 07, 2032	U-3675			
>A>	11833286	Dec 30, 2032	DP			
	9314561	Feb 07, 2034	DP			
	9707331	Sep 17, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
MELPHALAN HYDROCHLORIDE - MELPHALAN HYDROCHLORIDE						
N 217110 001	10537520	Jun 29, 2036	DP			
METHOTREXATE - OTREXUP						
N 204824 001	11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 002	11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 003	11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 004	11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 005	11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 006	11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 007	11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 008	11684723	Mar 10, 2029	DP			
METHOTREXATE - JYLAMVO						
N 212479 001	11129833	Oct 28, 2035	DP			
	11771701	Oct 29, 2034	DP U-3700			
	11771701	Oct 29, 2034	DP U-3701			
	11771701	Oct 29, 2034	DP U-3702			
	11771701	Oct 29, 2034	DP U-3703			
	11771701	Oct 29, 2034	DP U-3704			
METHSUXIMIDE - METHSUXIMIDE						
A 217213 001					CGT	Oct 28, 2023
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 001	11633389	Aug 14, 2033	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 002	11633389	Aug 14, 2033	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 003	11633389	Aug 14, 2033	DP			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI						
N 209388 001	11628150	Dec 22, 2029	DP U-2843			
	11813231	Dec 22, 2029	DP U-2843			
METRONIDAZOLE - LIKMEZ						
N 216755 001	11541035	Oct 04, 2039	DP			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
A 216159 001					PC	Jan 02, 2024
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
A 216159 002					PC	Jan 02, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	11612593	May 30, 2038	DS			
	11612594	May 30, 2038	DS			
	11622962	Mar 17, 2039	DS			
	11633387	May 30, 2038	DS			
	11633388	Mar 25, 2039	U-2371			
	11642334	Feb 20, 2039	U-2371			
	11666564	May 30, 2038	U-2371			
	11786516	May 30, 2038	DS			
>A>	11813255	May 30, 2038	U-2371			
>A>	11826360	Feb 16, 2039	DS			
>A>	11833164	Jan 11, 2042	U-2371			
MIGLUSTAT - OPFOLDA						
N 215211 001	10208299	Sep 30, 2035	DS DP	U-3726	NP	Sep 28, 2026
	10512677	Mar 07, 2033		U-3726		
	10857212	Aug 12, 2037		U-3726		
	10961522	Sep 30, 2035		U-3726		
	11278599	Mar 07, 2033		U-3726		
	11278601	Dec 29, 2036	DP	U-3726		
	11753632	Sep 30, 2035		U-3726		
MIRABEGRON - MYRBETRIO						
N 202611 001	10842780	Sep 28, 2029	DP	U-2996		
	10842780	Sep 28, 2029	DP	U-3670		
	10842780*PED	Mar 28, 2030				
	11707451	Sep 28, 2029		U-2996		
	11707451	Sep 28, 2029		U-3670		
	11707451*PED	Mar 28, 2030				
MIRABEGRON - MYRBETRIO						
N 202611 002	10842780	Sep 28, 2029	DP	U-2996		
	10842780	Sep 28, 2029	DP	U-3670		
	10842780*PED	Mar 28, 2030				
	11707451	Sep 28, 2029		U-2996		
	11707451	Sep 28, 2029		U-3670		
	11707451*PED	Mar 28, 2030				
MITAPIVAT SULFATE - PYRUKYND						
N 216196 001	11793806	Apr 12, 2033		U-3320	ODE-392	Feb 17, 2029
	RE49582	Feb 24, 2031	DS DP			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 002	11793806	Apr 12, 2033		U-3320	ODE-392	Feb 17, 2029
	RE49582	Feb 24, 2031	DS DP			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 003	11793806	Apr 12, 2033		U-3320	ODE-392	Feb 17, 2029
	RE49582	Feb 24, 2031	DS DP			
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 001	8486941	Jan 03, 2030	DS DP	U-1201	NCE	Sep 15, 2028
	9809559	Jun 11, 2035		U-1201	ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP	U-1201		
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 002	8486941	Jan 03, 2030	DS DP	U-1201	NCE	Sep 15, 2028
	9809559	Jun 11, 2035		U-1201	ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP	U-1201		
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 003	8486941	Jan 03, 2030	DS DP	U-1201	NCE	Sep 15, 2028
	9809559	Jun 11, 2035		U-1201	ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP	U-1201		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	11679210	Sep 03, 2038	DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11590095	Mar 18, 2036	U-1384			
<u>MOTIXAFORTIDE ACETATE - APHEXA</u>						
N 217159 001				NCE ODE-442	Sep 08, 2028 Sep 08, 2030	
<u>NALMEFENE HYDROCHLORIDE - OPVEE</u>						
N 217470 001	11458091	Jul 10, 2038	DP U-3630		NP	May 22, 2026
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	11590286	Dec 12, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - REXTOVY</u>						
N 208969 001					NP	Mar 07, 2026
<u>NALOXONE HYDROCHLORIDE - AUTOINJECTOR</u>						
N 209862 001	11590286	Dec 12, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	11617713	Aug 26, 2034	DP U-3110			
	11628139	Aug 26, 2034	DP U-3110			
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001	11571518	Jun 14, 2041	DP U-3515			
	11571518	Jun 14, 2041	DP U-3516			
	11571518	Jun 14, 2041	DP U-3517			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	11590286	Dec 12, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11020343	May 11, 2032	U-3671			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		ODE-443	Sep 29, 2030
	11053502	Oct 29, 2035	DS DP			
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			
	11661604	Oct 12, 2038	DS DP U-3709			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		ODE-443	Sep 29, 2030
	11053502	Oct 29, 2035	DS DP			
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			
	11661604	Oct 12, 2038	DS DP U-3709			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		ODE-443	Sep 29, 2030
	11053502	Oct 29, 2035	DS DP			
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			
	11661604	Oct 12, 2038	DS DP U-3709			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11618748	Jan 27, 2030		U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	11559523	Nov 18, 2030		DP U-3522		
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE</u>						
A 215377 001					CGT	Mar 20, 2024
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE</u>						
A 215377 002					CGT	Mar 20, 2024
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	11547758	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	11547758	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	11547758	Apr 18, 2027		U-1029		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11806338	Apr 16, 2038		DP		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	10105323	Jun 04, 2029	DP		ODE-261	Sep 06, 2026
	10105323*PED	Dec 04, 2029			PED	Mar 06, 2027
	10154990	Jan 08, 2026	U-2620			
	10154990*PED	Jul 08, 2026				
	6762180	Oct 01, 2025	DS DP			
	6762180*PED	Apr 01, 2026				
	9907756	Jun 07, 2029	DP			
	9907756*PED	Dec 07, 2029				
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10105323	Jun 04, 2029	DP		ODE-261	Sep 06, 2026
	10105323*PED	Dec 04, 2029			PED	Mar 06, 2027
	10154990	Jan 08, 2026	U-2620			
	10154990*PED	Jul 08, 2026				
	6762180	Oct 01, 2025	DS DP			
	6762180*PED	Apr 01, 2026				
	9907756	Jun 07, 2029	DP			
	9907756*PED	Dec 07, 2029				
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 002	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027		U-2655		
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031		U-2655		
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 003	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP	U-3646		
	11673877	Mar 27, 2038	DP	U-3647		
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027		U-2655		
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027		U-2655		
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031		U-2655		
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)						
N 217188 001	11351149	Aug 05, 2041	DS DP	U-3629	NCE	May 25, 2028
	11541034	Oct 31, 2041		U-3629		
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)						
N 217188 002					NCE	May 25, 2028
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 001	10590087	Aug 09, 2039	DS			
	10710966	Aug 09, 2039	DS	U-3754		
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
>A>	11844780	Sep 08, 2042	DP	U-3754		
>A>	11845732	Aug 09, 2039	DS	U-3754		
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
NITRIC OXIDE - GENOSYL						
N 202860 001	11511252	Sep 21, 2029	DP			
	11554241	Aug 18, 2025		U-3037		
	11672938	Jul 22, 2040		U-3037		
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 001	11602508	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 002	11602508	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 003	11602508	Jan 30, 2038	DP			
NORGESTREL - OPILL						
N 017031 001					RTO	Jul 13, 2026
ODEVIXIBAT - BYLVAY						
N 215498 001	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186	I-918	Jun 13, 2026	
	10011633	Nov 08, 2031	U-3187	ODE-436	Jun 13, 2030	
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031		U-3734		
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11633396	Oct 07, 2029	DP		I-914	May 31, 2026
	8071579	Aug 12, 2027		U-2480		
	8071579	Aug 12, 2027		U-2482		
	8071579	Aug 12, 2027		U-2483		
	8071579	Aug 12, 2027		U-2716		
	8071579	Aug 12, 2027		U-2819		
	8071579	Aug 12, 2027		U-2820		
	8071579	Aug 12, 2027		U-2821		
	8071579	Aug 12, 2027		U-2822		
	8071579	Aug 12, 2027		U-2823		
	8071579	Aug 12, 2027		U-2824		
	8071579	Aug 12, 2027		U-2832		
	8071579	Aug 12, 2027		U-2833		
	8071579	Aug 12, 2027		U-3333		
	8071579	Aug 12, 2027		U-3631		
	8071579	Aug 12, 2027		U-3695		
	8143241	Aug 12, 2027		U-2480		
	8143241	Aug 12, 2027		U-2482		
	8143241	Aug 12, 2027		U-2483		
	8143241	Aug 12, 2027		U-2716		
	8143241	Aug 12, 2027		U-2819		
	8143241	Aug 12, 2027		U-2820		
	8143241	Aug 12, 2027		U-2821		
	8143241	Aug 12, 2027		U-2822		
	8143241	Aug 12, 2027		U-2823		
	8143241	Aug 12, 2027		U-2824		
	8143241	Aug 12, 2027		U-2832		
	8143241	Aug 12, 2027		U-2833		
	8143241	Aug 12, 2027		U-3333		
	8143241	Aug 12, 2027		U-3631		
	8143241	Aug 12, 2027		U-3695		
	8859562	Aug 04, 2031		U-2101		
	8859562	Aug 04, 2031		U-2103		
	8859562	Aug 04, 2031		U-2480		
	8859562	Aug 04, 2031		U-2482		
	8859562	Aug 04, 2031		U-2483		
	8859562	Aug 04, 2031		U-2716		
	8859562	Aug 04, 2031		U-2819		
	8859562	Aug 04, 2031		U-2820		
	8859562	Aug 04, 2031		U-2821		
	8859562	Aug 04, 2031		U-2822		
	8859562	Aug 04, 2031		U-2823		
	8859562	Aug 04, 2031		U-2824		
	8859562	Aug 04, 2031		U-2832		
	8859562	Aug 04, 2031		U-2833		
	8859562	Aug 04, 2031		U-3333		
	8859562	Aug 04, 2031		U-3631		
	8859562	Aug 04, 2031		U-3695		
	8912187	Mar 12, 2024		U-2480		
	8912187	Mar 12, 2024		U-2482		
	8912187	Mar 12, 2024		U-2483		
	8912187	Mar 12, 2024		U-2819		
	8912187	Mar 12, 2024		U-2820		
	8912187	Mar 12, 2024		U-2821		
	8912187	Mar 12, 2024		U-2822		
	8912187	Mar 12, 2024		U-2823		
	8912187	Mar 12, 2024		U-2824		
	8912187	Mar 12, 2024		U-3333		
	8912187	Mar 12, 2024		U-3695		
	9169235	Mar 12, 2024		U-2832		
	9169235	Mar 12, 2024		U-2833		
	9169235	Mar 12, 2024		U-3631		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11633396	Oct 07, 2029	DP		I-914	May 31, 2026
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8071579	Aug 12, 2027	U-3695			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-3695			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	8859562	Aug 04, 2031	U-3695			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
	8912187	Mar 12, 2024	U-3631			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	11723905	Nov 12, 2039	DP		NCE	Dec 01, 2027
	11738018	Jul 17, 2039	U-3684		ODE-413	Dec 01, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2024	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2024	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP</u>						
N 213593 001	11633478	Jul 16, 2039	DP			
	11771686	Mar 01, 2040	U-623			
<u>OMIDENEPAK ISOPROPYL - OMLONTI</u>						
N 215092 001	11666563	Jul 16, 2039	U-3454			
	11793798	Jan 08, 2035	DP U-3454			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	11701343	Dec 16, 2039	U-2849			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 001	11680050	Sep 30, 2038	DS DP U-2774			
	11680050	Sep 30, 2038	DS DP U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 002	11680050	Sep 30, 2038	DS DP U-2774			
	11680050	Sep 30, 2038	DS DP U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 003	11680050	Sep 30, 2038	DS DP U-2774			
	11680050	Sep 30, 2038	DS DP U-3740			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001					ODE-397	Feb 28, 2029
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001					I-905	Dec 16, 2025
					ODE-390	Nov 29, 2028
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	11065250	Aug 19, 2036	DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	11065250	Aug 19, 2036	DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	11065250	Aug 19, 2036	DP			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11666697	Nov 24, 2041	U-3626			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11666697	Nov 24, 2041	U-3626			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676	ODE-439		Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676	ODE-439		Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676	ODE-439		Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676	ODE-439		Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001					NPP	Oct 02, 2026
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002					NPP	Oct 02, 2026
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003					NPP	Oct 02, 2026
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 004	10485821	Mar 30, 2024	U-1766		NS	Oct 02, 2026
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS	U-1766		
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11661441	Jan 13, 2033	DS	U-3124	M-288	Feb 08, 2026
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS	U-3540		
	11292815	Nov 15, 2033	DS	DP U-3540		
	11661441	Jan 13, 2033	DS	U-3540		
	7888323	Dec 04, 2027	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027		U-3540		
	8168584	Apr 07, 2027		U-3542		
	9056076	Oct 25, 2026		U-3540		
	9169307	Nov 18, 2027	DS	U-3541		
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	11793813	Feb 19, 2036		DP		
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 001	11147817	Mar 26, 2035		DP		
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 002	11147817	Mar 26, 2035		DP		
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 003	11147817	Mar 26, 2035		DP		
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	11628162	Aug 30, 2040		U-3568		
	11628162	Aug 30, 2040		U-3569		
	11628162	Aug 30, 2040		U-3570		
	11628162	Aug 30, 2040		U-3571		
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	11628162	Aug 30, 2040		U-3568		
	11628162	Aug 30, 2040		U-3569		
	11628162	Aug 30, 2040		U-3570		
	11628162	Aug 30, 2040		U-3571		
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	11628162	Aug 30, 2040		U-3568		
	11628162	Aug 30, 2040		U-3569		
	11628162	Aug 30, 2040		U-3570		
	11628162	Aug 30, 2040		U-3571		
<u>PENCICLOVIR - PENCICLOVIR</u>						
A 216981 001					CGT	Feb 28, 2024
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2024	DS DP	U-106		
	6949571	Jun 08, 2024	DS DP	U-2088		
	6949571	Jun 08, 2024	DS DP	U-2089		
	6949571	Jun 08, 2024	DS DP	U-2428		
	6949571	Jun 08, 2024	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2024	DS DP	U-106		
	6949571	Jun 08, 2024	DS DP	U-2088		
	6949571	Jun 08, 2024	DS DP	U-2089		
	6949571	Jun 08, 2024	DS DP	U-2428		
	6949571	Jun 08, 2024	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2024	DS DP	U-106		
	6949571	Jun 08, 2024	DS DP	U-2088		
	6949571	Jun 08, 2024	DS DP	U-2089		
	6949571	Jun 08, 2024	DS DP	U-2428		
	6949571	Jun 08, 2024	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2024	DS DP	U-106		
	6949571	Jun 08, 2024	DS DP	U-2088		
	6949571	Jun 08, 2024	DS DP	U-2089		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERFLUOROHEXYLOCTANE - MIEBO</u>						
N 216675 001	10058615	Sep 12, 2033	U-1900		NCE	May 18, 2028
	10369117	Sep 12, 2033	U-1900			
	10449164	Sep 12, 2033	U-1900			
	10507132	Jun 21, 2037	U-1900			
	10576154	Sep 12, 2033	U-1900			
	11357738	Sep 29, 2036	DP			
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001 >A> 11857683		Apr 07, 2042	DP U-3779		ODE-414	Nov 17, 2029
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	7229630	Jul 31, 2023	DP			
	7575757	Jul 31, 2023	DP			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001					NP	Sep 25, 2026
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496 001					CGT	Jul 17, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPHENТИV</u>						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV</u>						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	10839960	Jul 15, 2031	U-3685		NP	May 05, 2026
	11398306	Jul 15, 2031	U-3685			
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
<u>PILOCARPINE HYDROCHLORIDE - QLOSI</u>						
N 217836 001	10639297	Aug 18, 2037	DP U-3741		NP	Oct 17, 2026
	11129812	Aug 18, 2037	U-3741			
	9867810	Aug 18, 2037	DP U-3741			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	>A> 10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	>A> 10464905	Dec 16, 2036	U-3761			
	>A> 10695323	Dec 16, 2036	DS DP U-3518			
	>A> 10695323	Dec 16, 2036	DS DP U-3761			
	>A> 10918622	Dec 16, 2036	U-3518			
	>A> 10918622	Dec 16, 2036	U-3761			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	>A> 10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	>A> 10464905	Dec 16, 2036	U-3761			
	>A> 10695323	Dec 16, 2036	DS DP U-3518			
	>A> 10695323	Dec 16, 2036	DS DP U-3761			
	>A> 10918622	Dec 16, 2036	U-3518			
	>A> 10918622	Dec 16, 2036	U-3761			
<u>PITAVASTATIN CALCIUM - PITAVASTATIN CALCIUM</u>						
A 206015 001					PC	Feb 19, 2024
<u>PITAVASTATIN CALCIUM - PITAVASTATIN CALCIUM</u>						
A 206015 002					PC	Feb 19, 2024
<u>PITAVASTATIN CALCIUM - PITAVASTATIN CALCIUM</u>						
A 206015 003					PC	Feb 19, 2024
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001 >A> 11834521		Jun 05, 2034	DP			
<u>PODOFILOX - PODOFILOX</u>						
A 211871 001				>A> CGT		Jun 10, 2024
<u>POSACONAZOLE - POSACONAZOLE</u>						
A 208768 001					PC	Dec 26, 2023
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
A 217704 001					CGT	Mar 11, 2024
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
A 216274 001					CGT	Apr 13, 2024
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
A 216274 002					CGT	Apr 10, 2024
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
A 216274 003					CGT	Apr 10, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	10030005	Nov 01, 2036	DS DP U-2952			
	10030005	Nov 01, 2036	DS DP U-3002			
<u>PREDNISOLONE - PREDNISOLONE</u>						
A 215673 001					CGT	Nov 18, 2023
<u>QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA</u>						
N 216993 001	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
	7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	8129374	Mar 16, 2027	U-3661			
	8357690	Feb 26, 2031	U-3661			
	8557810	Mar 16, 2027	DP			
	8836218	Mar 23, 2030	U-3661			
	8865710	Aug 15, 2029	DP			
	8883783	Mar 16, 2027	DS			
	9555040	May 14, 2030	U-3661			
	9585892	Mar 16, 2027	U-3661			
	9675549	Sep 30, 2033	DP			
<u>QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA</u>						
N 216993 002	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
	7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	8129374	Mar 16, 2027	U-3661			
	8357690	Feb 26, 2031	U-3661			
	8557810	Mar 16, 2027	DP			
	8836218	Mar 23, 2030	U-3661			
	8865710	Aug 15, 2029	DP			
	8883783	Mar 16, 2027	DS			
	9555040	May 14, 2030	U-3661			
	9585892	Mar 16, 2027	U-3661			
	9675549	Sep 30, 2033	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	8771733	Jun 02, 2030	DS DP U-257			
	8852632	Jan 28, 2028	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	11583526	Sep 29, 2037	U-3020			
	11795178	Sep 27, 2033	DS DP			
>A>	7300935	Jan 28, 2025	DS			
>A>	8058280	Jan 28, 2025	DS DP			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001					M-301	Jul 13, 2026
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002					M-301	Jul 13, 2026
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	>A> 10294242	Jul 05, 2036	DS			
	>A> 11452725	Jul 24, 2036	U-3755			
	>A> 9714258	Jan 23, 2035	DS DP			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11691948	Jul 14, 2030	DP			
	>A> 11858898	Jul 14, 2030	DS DP U-2440			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566	ODE-426		Mar 22, 2030
	11654196	Mar 02, 2032	DS DP U-3566	GAIN		Mar 22, 2033
	11712459	Mar 15, 2037	DP U-3566	GAIN		Mar 22, 2035
>A>	11819533	Jul 11, 2038	DS DP U-3566			
	8722619	Mar 02, 2032	DS DP U-3566			
	9526835	Mar 14, 2033	DS DP U-3566			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	11564912	Feb 26, 2029	U-3511			
	11564912	Feb 26, 2029	U-3512			
	11779571	Feb 26, 2029	U-3706			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Mar 09, 2030	DS DP U-2718			
	8314117	Mar 09, 2030	DS DP U-3142			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040	U-3537			
	11612591	Dec 30, 2040	DP			
	11779572	Oct 06, 2042	U-3714			
	11793795	Dec 30, 2040	DP			
	11801237	Dec 30, 2040	DP U-3219			
	11813251	Aug 12, 2040	U-3750			
>A>	11844788	Dec 30, 2040	DP			
>A>	11850240	Dec 30, 2040	DP			
>A>	11850241	Dec 30, 2040	DP			
	8461179	May 15, 2034	DS DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11534444	Oct 04, 2038	U-1943	M-270	Oct 03, 2026	
>A>	11827646	Jan 25, 2036	U-1943	ODE-400	May 27, 2029	
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	11712475	Feb 13, 2028	U-3135			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	11712475	Feb 13, 2028	U-3135			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RYKINDO						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - UZEDY						
N 213586 001	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 002	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 003	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 004	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 005	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 006	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 006	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 007	10736965	Jan 12, 2025	DP		NP	
	8221778	Nov 12, 2027	DP U-543			Apr 28, 2026
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RITLECITINIB TOSYLATE - LITFULO						
N 215830 001	9617258	Dec 03, 2034	DS DP		NCE	
RIZATRIPTAN BENZOATE - RIZAFILM						
N 205394 001	9301948	Jul 30, 2034	DS DP			
ROFLUMILAST - ZORYVE						
N 215985 001	11129818	Aug 25, 2037	U-3408		NPP	
	11129818	Aug 25, 2037	U-3712			Oct 05, 2026
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3748			
	9907788	Jun 07, 2037	U-3408			
	9907788	Jun 07, 2037	U-3712			
ROFLUMILAST - ZORYVE						
N 217242 001	>A> 10940142	Jun 07, 2037	DP			
	>A> 11129818	Aug 25, 2037	U-3773			
	>A> 11707454	Dec 03, 2041	U-3773			
	>A> 11793796	Jun 07, 2037	DP			
	>A> 11819496	Jun 07, 2037	U-3773			
	>A> 9884050	Jun 07, 2037	DP			
	>A> 9907788	Jun 07, 2037	U-3773			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			
	11602536	May 05, 2041	U-3550			
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205941 001				PC		Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205941 002				PC		Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205972 001				PC		Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205972 002				PC		Jan 27, 2024
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
	11684607	Sep 16, 2035	DP U-2583			
	11684607	Sep 16, 2035	DP U-3169			
	11684607	Sep 16, 2035	DP U-3270			
	11684607	Sep 16, 2035	DP U-3302			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			
<u>SEPERCATINIB - RETEVMO</u>						
N 213246 001				ODE-409	Sep 21, 2029	
				ODE-412	Sep 21, 2029	
<u>SEPERCATINIB - RETEVMO</u>						
N 213246 002				ODE-409	Sep 21, 2029	
				ODE-412	Sep 21, 2029	
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001 >A> 11813246		Mar 26, 2029	DP			
	7425637	Mar 13, 2024	DS			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002 >A> 11813246		Mar 26, 2029	DP			
	7425637	Mar 13, 2024	DS			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	11752198	Aug 24, 2038	DP U-3162		NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	11752198	Aug 24, 2038	DP U-3162		NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	11752198	Aug 24, 2038	DP U-3162		NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	11752198	Aug 24, 2038	DP U-3162		D-190 NPP	Jul 21, 2026 Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	11752198	Aug 24, 2038	DP U-3162		NPP	Dec 23, 2025
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					ODE-402	Jun 16, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	11337979	Dec 24, 2038	DP U-3582			
	11464778	Dec 24, 2038	DP U-3582			
	11759468	Dec 24, 2038	DP U-3582			
<u>SINCALIDE - SINCALIDE</u>						
N 210850 001	11737983	Apr 20, 2038	DP U-3482			
	11737983	Apr 20, 2038	DP U-3689			
<u>SIROLIMUS - FYARRO</u>						
N 213312 001					ODE-386	Nov 22, 2028
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001					ODE-391	Mar 22, 2029
<u>SITAGLIPTIN - ZITUVIO</u>						
N 211566 001 >A> 10925871		Feb 25, 2035	DP			
<u>SITAGLIPTIN - ZITUVIO</u>						
N 211566 002 >A> 10925871		Feb 25, 2035	DP			
<u>SITAGLIPTIN - ZITUVIO</u>						
N 211566 003 >A> 10925871		Feb 25, 2035	DP			
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE - SODIUM PHENYLACETATE AND SODIUM BENZOATE</u>						
A 217526 001					CGT	Mar 17, 2024
<u>SODIUM CHLORIDE - SODIUM CHLORIDE 23.4%</u>						
A 217796 001					CGT	Jan 23, 2024
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	11753301	Feb 10, 2030	DS DP U-3681			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
>A>	11839597	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP	U-3580		
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11826335	Jul 21, 2037	U-3751			
>A>	11839597	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP	U-3580		
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
>A>	11839597	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP	U-3580		
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
>A>	11839597	Jul 21, 2037	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	11583542	Jul 27, 2040	DP		ODE-411	Sep 29, 2029
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	11753301	Feb 10, 2030	DS DP U-3682			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	10596190	Jan 05, 2038	U-3443	Y	ODE-384	Sep 20, 2029
	11617793	Jul 01, 2039	DP			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	11738044	Oct 14, 2035	U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	11738044	Oct 14, 2035	U-2312			
<u>SOFOBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	11707479	Jan 30, 2034	DP U-1470			
	11707479*PED	Jul 30, 2034				
<u>SOFOBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	11707479	Jan 30, 2034	DP U-1470			
	11707479*PED	Jul 30, 2034				
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001					NP	May 26, 2023
					W	Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			
	11779554	Dec 30, 2042	U-3693			
	11793776	Dec 30, 2042	U-3693			
>A>	11839598	Mar 19, 2040	U-3765			
>A>	11839599	Mar 19, 2040	U-3764			
>A>	11850226	Mar 19, 2040	U-3775			
>A>	11850227	Mar 19, 2040	U-3775			
>A>	11850228	Mar 19, 2040	U-3775			
	8440715	Jun 11, 2031	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			
	11779554	Dec 30, 2042	U-3693			
	11793776	Dec 30, 2042	U-3693			
>A>	11839598	Mar 19, 2040	U-3765			
>A>	11839599	Mar 19, 2040	U-3764			
>A>	11850226	Mar 19, 2040	U-3775			
>A>	11850227	Mar 19, 2040	U-3775			
>A>	11850228	Mar 19, 2040	U-3775			
	8440715	Jun 11, 2031	U-2548			
<u>SOTAGLIFLOZIN - INPEFA</u>						
N 216203 001	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
<u>SOTAGLIFLOZIN - INPEFA</u>						
N 216203 002	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 14, 2038	U-2769			
	10512620	Aug 14, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
	11696902	Aug 14, 2038	U-2769			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	>A> 11850222	Nov 19, 2034	U-2096			
	>A> 11850222	Nov 19, 2034	U-2494			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11426404	Sep 15, 2040	U-3306			
	>A> 11827635	May 20, 2040	DS DP U-3306			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE-352	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	>A> 11827635	May 20, 2040	DS DP U-3306			
<u>SPARENTEAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
<u>SPARENTEAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001					ODE-403	Jul 14, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002					ODE-403	Jul 14, 2029
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	11672738	Feb 02, 2038	DP			
	11676691	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					M-291	Jan 22, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					M-291	Jan 22, 2024
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	11723869	May 15, 2039	DP U-3666			
	11723869	May 15, 2039	DP U-3667			
	11723869	May 15, 2039	DP U-3668			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	11571531	Feb 23, 2026	U-1809			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11666576	Dec 24, 2038	DP U-3397			
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Dec 19, 2024	DS DP			
	7214696	Dec 19, 2024	U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Dec 19, 2024	DS DP			
	7214696	Dec 19, 2024	U-2524			
	8653119	Dec 19, 2023	U-2524			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	11744828	Dec 02, 2035	U-2582			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10780088	Jul 27, 2029	U-3651		I-920	Jun 20, 2026
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 003	10780088	Jul 27, 2029	U-3651		I-920	Jun 20, 2026
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 005	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 006	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP	Jul 03, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP	Jul 03, 2026
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP	Jul 03, 2026
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001					NPP	Jul 03, 2026
<u>TAPINAROF - VTAMA</u>						
N 215272 001	11590088	Nov 13, 2039		U-2625		
	11597692	Nov 13, 2038	DS DP			
	11612573	May 19, 2036		U-2625		
	11617724	May 19, 2036	DP			
	11622945	May 19, 2036	DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033		U-2149		
	11633377	Jan 25, 2033		U-3003		
	11759446	Feb 21, 2041		U-3003		
	11760740	Feb 12, 2035	DS DP			
	11786502	Oct 10, 2034		U-3007		
	11786502	Oct 10, 2034		U-3739		
>A>	11833130	Jan 25, 2033		U-2149		
>A>	11833130	Jan 25, 2033		U-3003		
>A>	11850229	Jan 25, 2033		U-3342		
>A>	11850229	Jan 25, 2033		U-3343		
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033		U-3003		
	11759446	Feb 21, 2041		U-3003		
	11760740	Feb 12, 2035	DS DP			
	11786502	Oct 10, 2034		U-3007		
>A>	11833130	Jan 25, 2033		U-3003		
>A>	11850229	Jan 25, 2033		U-3342		
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	11679116	Jun 06, 2036	DP			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	8410088	Jan 23, 2034	DS DP			
<u>TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT</u>						
N 022335 001					NP	Sep 29, 2026
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - TECHNETIUM TC-99M SULFUR COLLOID KIT</u>						
A 213516 001				>A> CGT		Jun 01, 2024
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	10272079	Apr 10, 2034		U-3736	NCE	Sep 12, 2024
	10272079	Apr 10, 2034		U-381	NP	Oct 17, 2026
	10940146	Apr 10, 2034		U-3736		
	10940146	Apr 10, 2034		U-381		
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	10272079	Apr 10, 2034		U-3736	NCE	Sep 12, 2024
	10272079	Apr 10, 2034		U-381	NP	Oct 17, 2026
	10940146	Apr 10, 2034		U-3736		
	10940146	Apr 10, 2034		U-381		
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	10272079	Apr 10, 2034	U-3736		NCE	Sep 12, 2024
	10272079	Apr 10, 2034	U-381		NP	Oct 17, 2026
	10940146	Apr 10, 2034	U-3736			
	10940146	Apr 10, 2034	U-381			
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	10272079	Apr 10, 2034	U-3736		NCE	Sep 12, 2024
	10272079	Apr 10, 2034	U-381		NP	Oct 17, 2026
	10940146	Apr 10, 2034	U-3736			
	10940146	Apr 10, 2034	U-381			
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700 001					PC	Sep 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710 002					PC	Sep 08, 2023
<u>TERIPARATIDE - FORTEO</u>						
N 021318 001					M-302	Nov 16, 2023
<u>TERIPARATIDE - FORTEO</u>						
N 021318 002					M-302	Nov 16, 2023
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u>						
N 022231 001	10335452	Apr 05, 2037	U-3711		ODE-406	Sep 14, 2029
<u>TESTOSTERONE CYTIONATE - TESTOSTERONE CYPTIONATE</u>						
N 216318 001	11642355	Mar 25, 2039	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11771646	Apr 10, 2034	DP			
	11813435	Feb 25, 2035	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11771646	Apr 10, 2034	DP			
	11813435	Feb 25, 2035	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11771646	Apr 10, 2034	DP			
	11813435	Feb 25, 2035	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	11559530	Nov 28, 2037	U-1500			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10456399	Feb 03, 2037	U-3657			
	10456399	Feb 03, 2037	U-3658			
	10960004	Feb 03, 2037	U-3657			
	10960004	Feb 03, 2037	U-3658			
	9943537	Sep 05, 2034	U-3659			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	RE46284	Sep 22, 2029		U-1751		
	RE46284	Sep 22, 2029		U-2503		
	RE46284	Sep 22, 2029		U-3656		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10456399	Feb 03, 2037		U-3657		
	10456399	Feb 03, 2037		U-3658		
	10960004	Feb 03, 2037		U-3657		
	10960004	Feb 03, 2037		U-3658		
	9943537	Sep 05, 2034		U-3659		
	RE46284	Sep 22, 2029		U-1751		
	RE46284	Sep 22, 2029		U-2503		
	RE46284	Sep 22, 2029		U-3656		
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2024	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2024	DS DP U-3100			
<u>TOFERSEN - QALSODY</u>						
N 215887 001	10385341	Apr 01, 2035	DS DP		NCE	Apr 25, 2028
	10669546	Apr 01, 2035		U-3575	ODE-432	Apr 25, 2030
	10968453	Apr 01, 2035		U-3575		
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11633374	Aug 21, 2040	DP			
	>A> 11826343	Aug 21, 2040	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11633374	Aug 21, 2040	DP			
>A> 11826343 Aug 21, 2040 DP						
<u>TRAMADOL HYDROCHLORIDE - QDOLO</u>						
N 214044 001	11752103	Sep 01, 2040	DP U-3197			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	8703781	Oct 15, 2030	DS DP U-3564		ODE-428	Mar 16, 2030
	8835443	Jun 10, 2025	U-3564			
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 217155 001					CGT	Apr 16, 2024
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001	>A> 10206813	Oct 17, 2030	DP			
	>A> 11426306	Oct 17, 2030	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 006	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - REMODULIN						
N 021272 007	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
	9199908	May 24, 2024		U-1771		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 008	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
	9199908	May 24, 2024		U-1771		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO						
N 022387 001	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042		U-3749		
TREPROSTINIL - TYVASO DPI						
N 214324 001	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042		U-3749		
TREPROSTINIL - TYVASO DPI						
N 214324 002	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042		U-3749		
TREPROSTINIL - TYVASO DPI						
N 214324 003	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042		U-3749		
TREPROSTINIL - TYVASO DPI						
N 214324 004	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042		U-3749		
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	11723887	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 002	11723887	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 003	11723887	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	11723887	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 005	11723887	Dec 15, 2028	DS			
TRETINOIN - TRETINOIN MICROSPHERE						
A 215609 001					CGT	Mar 06, 2024
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR						
N 215760 001					ODE-401	Apr 28, 2029
TRIFAROTENE - AKLIEF						
N 211527 001	7807708	Jul 19, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001	8697748	Apr 28, 2029	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
	11717523	Mar 14, 2034	U-3678			
	11717523	Mar 14, 2034	U-3679			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	9212204	Jan 27, 2032	U-3556		ODE-425	Mar 10, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11717515	Dec 22, 2041	U-3677			
	8912210	Dec 23, 2033	DS DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	8912210	Dec 23, 2033	DS DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	7439393	May 21, 2025	DS DP U-1476			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1476			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371		I-919	May 18, 2026
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11767326	Oct 17, 2036	U-3298			
	11773105	Oct 17, 2036	DS DP			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11780847	Oct 17, 2036	DP			
	11780848	Oct 17, 2036	U-3371			
	11787815	Oct 17, 2036	DP			
	11795175	Oct 17, 2036	U-3255			
	8962629	Jan 15, 2031	DS	U-3255		
	8962629	Jan 15, 2031	DS	U-3275		
	8962629	Jan 15, 2031	DS	U-3341		
	8962629	Jan 15, 2031	DS	U-3371		
	8962629	Jan 15, 2031	DS	U-3624		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371		I-919	May 18, 2026
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11767326	Oct 17, 2036	U-3298			
	11773105	Oct 17, 2036	DS DP			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11780847	Oct 17, 2036	DP			
	11780848	Oct 17, 2036	U-3371			
	11787815	Oct 17, 2036	DP			
	11795175	Oct 17, 2036	U-3255			
	8962629	Jan 15, 2031	DS	U-3255		
	8962629	Jan 15, 2031	DS	U-3275		
	8962629	Jan 15, 2031	DS	U-3341		
	8962629	Jan 15, 2031	DS	U-3371		
	8962629	Jan 15, 2031	DS	U-3624		
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298		I-919	May 18, 2026
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11767326	Oct 17, 2036	U-3298			
	11773105	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS	U-3341		
	8962629	Jan 15, 2031	DS	U-3624		
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	11564922	Mar 09, 2038	U-3624		I-919	May 18, 2026
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11773105	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS	U-3341		
	8962629	Jan 15, 2031	DS	U-3624		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055		ODE-440	Aug 18, 2030
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8357697	Nov 08, 2027	U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10065952	Oct 28, 2036	DS DP U-1995	I-925	Aug 18, 2026	
	10065952	Oct 28, 2036	DS DP U-3055	ODE-440	Aug 18, 2030	
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995	I-925	Aug 18, 2026	
	10065952	Oct 28, 2036	DS DP U-3055	ODE-440	Aug 18, 2030	
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	10857161	May 28, 2029	DP U-3747	NCE	Oct 26, 2028	
	11382922	Jul 16, 2040	DS DP	ODE-450	Oct 26, 2030	
	11471471	Mar 17, 2040	U-3747			
	11690853	Jun 29, 2036	U-3747			
>A>	11833159	May 28, 2029	DP			
	8334279	May 28, 2029	U-3747			
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 214913 001				PC	Feb 25, 2024	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 214913 002					PC	Feb 25, 2024
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					CGT	Dec 20, 2023
A 215338 001					CGT	Feb 12, 2024
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					CGT	Feb 12, 2024
A 217489 001					CGT	Feb 12, 2024
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>					DP	
N 208910 001	11638692	Mar 13, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>					DP	
N 208910 002	11638692	Mar 13, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					DP	
N 211962 001	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					DP	
N 211962 002	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					DP	
N 211962 003	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					DP	
N 211962 004	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					DP	
N 211962 005	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					DP	
N 211962 006	11628200	Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>					DP	
N 211962 007	11628200	Nov 06, 2035		DP		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	10010575	Jan 30, 2035		U-1857		
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035		U-1857		
	9925234	Jan 30, 2035		U-1857		
	9962422	Jan 30, 2035		U-1857		
	9968649	Jan 30, 2035		U-1857		
	9974827	Jan 30, 2035		U-1857		
	9981006	Jan 30, 2035		U-1857		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	11590128	Sep 06, 2033		U-3548		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	11590128	Sep 06, 2033		U-3548		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11590128	Sep 06, 2033		U-3548		
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	11622991	Dec 07, 2037		U-3056		
	7332472	Oct 17, 2024	DS DP	U-3056		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001	7977488 9186411	Aug 11, 2028 Aug 11, 2030	DS DP		>A> NCE >A> NP	May 03, 2027 Nov 01, 2026
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002	7977488 9186411	Aug 11, 2028 Aug 11, 2030	DS DP		>A> NCE >A> NP	May 03, 2027 Nov 01, 2026
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	11458134 11458134*PED 7144884 7144884*PED 8722684 8722684*PED 8969355 8969355*PED 9125908 9125908*PED 9125909 9125909*PED 9125910 9125910*PED 9227946 9227946*PED 9278096 9278096*PED 9861630 9861630*PED	Jun 15, 2027 Dec 15, 2027 Jun 17, 2026 Dec 17, 2026 Jun 30, 2031 Dec 30, 2031 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 U-1668 U-1668 U-2309 U-2309 U-2309 U-2309 U-2309 U-2309 U-2436 U-2436 U-1668 U-1668	DP U-3463 DS DP U-1439 DS DP DP		M-232 PED	Aug 23, 2026 Feb 23, 2027
N 204447 002	11458134 11458134*PED 7144884 7144884*PED 8722684 8722684*PED 8969355 8969355*PED 9125908 9125908*PED 9125909 9125909*PED 9125910 9125910*PED 9227946 9227946*PED 9278096 9278096*PED 9861630 9861630*PED	Jun 15, 2027 Dec 15, 2027 Jun 17, 2026 Dec 17, 2026 Jun 30, 2031 Dec 30, 2031 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 U-1668 U-1668 U-2309 U-2309 U-2309 U-2309 U-2309 U-2309 U-2436 U-2436 U-1668 U-1668	DP U-3463 DS DP U-1439 DS DP DP		M-232 PED	Aug 23, 2026 Feb 23, 2027
N 204447 003	11458134 11458134*PED 7144884 7144884*PED 8722684 8722684*PED 8969355 8969355*PED 9125908 9125908*PED 9125909 9125909*PED 9125910 9125910*PED 9227946	Jun 15, 2027 Dec 15, 2027 Jun 17, 2026 Dec 17, 2026 Jun 30, 2031 Dec 30, 2031 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 Dec 15, 2027 Jun 15, 2027 U-1668 U-1668 U-2309 U-2309 U-2309 U-2309 U-2309 U-2309 U-2436 U-2436 U-1668 U-1668	DP U-3463 DS DP U-1439 DS DP DP		M-232 PED	Aug 23, 2026 Feb 23, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032		U-2436		
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027		U-1668		
	9861630*PED	Dec 15, 2027				
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	11458134	Jun 15, 2027	DP	U-3463	M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS	DP U-1439		
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS	DP		
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027		U-1668		
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027		U-2309		
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027		U-2309		
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027		U-2309		
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027		U-1668		
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032		U-2436		
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027		U-1668		
	9861630*PED	Dec 15, 2027				
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001					NPP	Oct 20, 2026
					ODE-387	Nov 19, 2028
					ODE-449	Oct 20, 2030
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002					NPP	Oct 20, 2026
					ODE-387	Nov 19, 2028
					ODE-449	Oct 20, 2030
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003					NPP	Oct 20, 2026
					ODE-387	Nov 19, 2028
					ODE-449	Oct 20, 2030
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002					NCE	Nov 25, 2024
					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE-394	Dec 17, 2028
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					ODE-212	Jun 13, 2029
<u>XENON XE-129 HYPERPOLARIZED - XENOVIEW</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
<u>ZANUBRUTINIB - BRUKINS</u>						
N 213217 001	10570139	Apr 22, 2034		U-1745	I-817	Jan 19, 2026
	10570139	Apr 22, 2034		U-2145	ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034		U-2537		
	10570139	Apr 22, 2034		U-2666		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	7220862	Jan 21, 2024	DS DP		NCE	Mar 09, 2028
	7314883	Dec 05, 2023	U-3555			
	8481546	Oct 07, 2031	DS DP U-3555			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
	10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
	10435438	Jun 12, 2035	DS U-3735			
	10562934	Jun 12, 2035	DS			
	10835574	Jun 12, 2035	DP			
	11014965	Jun 12, 2035	DS U-3735			
	11535650	Jun 12, 2035	DP			
	11752190	Jun 12, 2035	DP U-3735			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
	10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
	10435438	Jun 12, 2035	DS U-3735			
	10562934	Jun 12, 2035	DS			
	10835574	Jun 12, 2035	DP			
	11014965	Jun 12, 2035	DS U-3735			
	11535650	Jun 12, 2035	DP			
	11752190	Jun 12, 2035	DP U-3735			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
	10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
	10435438	Jun 12, 2035	DS U-3735			
	10562934	Jun 12, 2035	DS			
	10835574	Jun 12, 2035	DP			
	11014965	Jun 12, 2035	DS U-3735			
	11535650	Jun 12, 2035	DP			
	11752190	Jun 12, 2035	DP U-3735			
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216145 001					CGT	Aug 14, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
	10342810	Apr 17, 2034	U-2552			
	11236121	Aug 23, 2037	DS			
	9512165	Apr 17, 2034	DS DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
	10342810	Apr 17, 2034	U-2552			
	11236121	Aug 23, 2037	DS			
	9512165	Apr 17, 2034	DS DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
	10342810	Apr 17, 2034	U-2552			
	11236121	Aug 23, 2037	DS			
	9512165	Apr 17, 2034	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm